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ABSTRACT 
 
The Epstein-Barr virus (EBV)-encoded RNAs (EBERs) are abundantly expressed in all EBV-
associated malignancies, although the precise mechanisms by which EBV is able to achieve 
such high levels of EBER expression have not been fully determined. Abundant EBER 
expression has previously been demonstrated to be important for the oncogenic potential of 
the EBERs to be realised in epithelial cells. This study aimed to elucidate further how EBV 
achieves abundant EBER expression. Firstly, experimental analysis focussed on the possible 
direct correlation between EBV genomic copy number and levels of EBER expression. These 
initial experiments revealed that no direct link between EBV genomic copy number and levels 
of EBER expression was evident, suggesting that EBV may be influencing the cellular 
environment. Previously, EBV has been demonstrated to induce a variety of cellular EBER-
associated transcription factors, and the remainder of the study focussed on determining the 
role of EBV nuclear antigen 1 (EBNA1) in inducing changes to the cellular environment to 
allow high levels of EBER expression. EBNA1 was found to induce the transcription of 
cellular RNA polymerase (pol) II and pol III transcription factors associated with EBER 
expression and levels of the cellular transcripts transcribed by the EBER-transcribing pol III 
were increased. Cell systems were generated which allowed EBNA1 to be expressed 
transiently in EBER-expressing cells, with such expression resulting in increased EBER 
expression, demonstrating directly that EBNA1 is able to increase levels of EBER expression. 
EBNA1 promoter binding studies were conducted, revealing EBNA1 to be present at the 
promoter regions of transcriptionally induced genes, affording mechanistic insight into 
EBNA1’s mode of action. The results of this study prove significant not only in determining 
how EBV expresses such high levels of EBERs, but also in that EBNA1 is shown to influence 
several cellular factors directly implicated in oncogenesis.  
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Introduction 
Chapter 1 – Introduction 
 
1.0 The Biology of Cancer 
Although cancer as a disease was recognised several thousand years ago, it was not until the 
19th century that scientific oncology was born. An historical perspective of cancer is 
succinctly provided by several interesting review articles (Kardinal and Yarbro 1979; 
Diamandopoulos 1996). In the past quarter of a century, cancer research has advanced hugely 
and at a rapid rate, generating a complex and diverse body of evidence demonstrating that 
dynamic changes to the genome are responsible for the disease.  Two classes of cancer gene 
have been identified through their alteration (mutation) in cells and the oncogenic phenotypes 
these mutations elicit in vitro (Bishop et al. 1996); proto-oncogenes possessing a dominant 
gain of function, and tumour suppressor genes with a recessive loss of function. Evidence 
suggests that tumourigenesis is a multistep process, determined by genetic and environmental 
factors, that reflects the progressive alterations that drive the transformation of normal human 
cells into malignant derivative cells (Hanahan and Weinberg 2000). For the transformation 
into a malignant cell, it has been proposed that any normal cell must evolve six “hallmarks” 
of cancer, or acquired capabilities (in addition to genomic instability which represents the 
means that enables the 6 biological endpoints to be reached), namely: 1) self-sufficiency in 
growth signals; 2) insensitivity to anti-growth signals; 3) evasion of apoptosis; 4) limitless 
replicative potential (immortalisation); 5) sustained angiogenesis; 6) tissue invasion and 
metastasis (Hanahan and Weinberg 2000). Each of these novel capabilities acquired during 
tumour development breaches one or more of the multitude of anticancer mechanisms 
possessed by cells and tissues. As such the evolution of these traits is a long and cumulative 
process, with only cells that develop each of the capabilities reaching their full malignant 
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potential. The dynamic and complex nature of the process explains, at least in part, how more 
than 100 distinct types of human cancer may have developed, and why cancer is relatively 
rare during a human lifetime.   
1.1 Viruses and Cancer 
Oncogenic viruses are of huge importance in cancer research for two main reasons. Firstly, 
current estimates suggest viruses are involved in 15% to 20% of human cancers worldwide 
(Javier and Butel 2008), with this proportion likely to be significantly increased over the 21st 
century, given the years of research usually required for the viral causation of a given human 
cancer to be widely accepted (Butel 2000; Pagano et al. 2004). A large number of these 
cancer causative infections may in future be prevented through immunisation, a trend which is 
sure to grow beyond the current vaccination for hepatitis B virus (HBV) and human 
papillomaviruses (HPVs). Secondly, experimental analysis of tumour viruses has provided 
more general illumination of cancer, with many oncogenes and tumour suppressor genes first 
identified through studies of tumour viruses.  
Tumour viruses can be subdivided, based upon whether an RNA or DNA genome is packaged 
into the infectious virus particle, into two categories; the RNA tumour viruses and DNA 
tumour viruses (Javier and Butel 2008). 
1.2 RNA Tumour Viruses 
Hepatitis C Virus (HCV) is a single stranded RNA virus of the Hepacivirus genus in the 
Flaviviridae family. It infects approximately 2% of the worldwide population and is the only 
positive-stranded RNA virus among human oncogenic viruses. Persistent infection with HCV 
is associated with hepatitis, cirrhosis, hepatic steatosis, and hepatocellular carcinoma (HCC) 
(Saito et al. 1990; Alter 1995; Lauer and Walker 2001; Poynard et al. 2003; Pawlotsky 2004). 
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Among patients infected with HCV, it is almost exclusively those with cirrhosis who develop 
HCC, and while it is currently thought that this major risk factor for malignant progression 
plays a key role in HCV-induced carcinogenesis, precise underlying mechanisms are yet to be 
elucidated fully (Fattovich et al. 2004). Multiple viral and cellular factors are likely to be 
involved, along with viral and environmental cofactors such as HBV infection and excessive 
alcohol consumption. Interestingly, HCV has been shown to cause genome instability, 
suggesting a mutator function for certain HCV proteins (Smirnova et al. 2006).  
 
Human T-cell leukaemia virus type 1 (HTLV-1) was the first reported tumourigenic human 
retrovirus, first isolated from cultured human T-lymphoma cells in 1980 (Poiesz et al. 1980). 
Over several subsequent years, a rapid accumulation of evidence linking HTLV-1 with adult 
T-cell leukaemia (ATL) occurred (Levine 1991). HTLV-1 remains the only human retrovirus 
linked directly to a specific malignancy (Javier and Butel 2008), despite retroviral association 
with a variety of animal tumours. Contrary to typical animal retrovirus mechanisms, HTLV-1 
does not cause cancer through transactivation of cellular proto-oncogenes or insertional 
mutagenesis of tumour suppressor genes. The viral Tax gene is the major oncogenic 
determinant of HTLV-1 (Matsuoka and Jeang 2007), and also encodes a protein essential for 
viral replication. Tax modulates expression of viral genes though the viral long terminal 
repeats (LTRs), and also induces dysregulation of multiple cellular transcriptional signalling 
pathways including activator protein 1 (AP-1) (Iwai et al. 2001; Peloponese and Jeang 2006), 
nuclear factor kappa B (NF-κB) (Chu et al. 1998; Sun and Ballard 1999), and cyclic AMP 
response element-binding protein (CREB) (Zhao and Giam 1992; Franklin et al. 1993; Kwok 
et al. 1996). Tax does not bind to promoter or enhancer sequences directly, but interacts with 
cellular transcriptional co-activators (Bex et al. 1998; Harrod et al. 1998; Scoggin et al. 2001). 
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Tat, a homologue of Tax in human immunodeficiency virus 1 (HIV-1), plays an important 
role in the pathogenesis of Kaposi’s sarcoma (Blattner 1999). 
Recently, Xenotropic murine leukemia virus-related virus (XMRV) has been described. A 
gamma retrovirus, XMRV was discovered in tumours from prostate cancer patients (Urisman 
et al. 2006), and although it is unclear whether XMRV is causally associated with prostate 
cancer, it may contribute to tumourigenesis through an indirect mechanism.  
1.3 DNA Tumour Viruses 
Human DNA tumour viruses are a diverse group consisting of viruses that vary in terms of 
structure, replication strategy and genome organisation, with some causing malignancies in 
their natural hosts (e.g. HBV, Epstein-Barr virus (EBV), HPV and Kaposi's sarcoma-
associated herpesvirus (KSHV)), and others possessing transforming properties in cultured 
cells and heterologous animal models (e.g. human adenoviruses). DNA tumour virus 
oncogenes are often of viral rather than cellular origin, and are required for viral replication 
(Damania 2007). Analysis of DNA tumour virus oncoproteins has provided insight into viral 
mechanisms controlling mammalian cell growth. Although extensive description of each 
tumourigenic mechanism of individual DNA tumour viruses is beyond the scope of this 
thesis, key examples are discussed below. 
 
Certain cellular tumour suppressors are targeted by evolutionarily distinct DNA tumour 
viruses using diverse mechanisms, highlighting the importance of these regulators in both the 
viral life-cycle and tumourigenesis. Two of the most significant and best described cellular 
tumour suppressors affected by infection of cells by DNA tumour viruses are p53 and 
retinoblastoma protein (Rb). Cellular tumour suppressor gene p53 was discovered through its 
association with the large tumour (T) antigen of Simian Virus 40 (SV40) (Lane and Crawford 
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1979; Linzer and Levine 1979). A variety of cellular stress stimuli induce activation and 
accumulation of p53, which in its role as a sequence-specific transcription factor regulates 
several important cellular factors (Braithwaite and Prives 2006) which control cell cycle, 
senescence, apoptosis and DNA damage. SV40 large T antigen, along with adenovirus E1B-
55K protein and HPV protein E6, binds to and inactivates p53, opening a temporal window 
for virus replication, before a p53-mediated cellular anti-viral response is initiated by viral 
infection.  
 
The Rb tumour suppressor gene was identified in the mid 1980s (Friend et al. 1986; Lee et al. 
1987) and subsequently associations were established between Rb and adenovirus E1A 
protein, SV40 large T antigen, HPV E7 protein  and polyomavirus large T antigen which lead 
to aberrant cell cycle control (DeCaprio et al. 1988; Whyte et al. 1988; Dyson et al. 1989). 
Binding of these viral oncoproteins to Rb results in the disruption of cellular complexes 
containing the transcription factor E2F, with release of E2F accompanied by the progression 
of the cell cycle from G1 to S-phase and DNA synthesis. Active E2F that has been aberrantly 
freed by viral oncoprotein binding to Rb leads to unscheduled cellular proliferation of 
quiescent cells. Adenovirus, SV40 and HPV16 infected cells are associated with increased 
levels of free E2F and loss of cell cycle-dependent E2F regulation (Chellappan et al. 1992). 
Human herpesviruses are also known to modulate Rb function during infection, and this topic 
has been recently reviewed by Hume and Kalejta (2009). That dysregulation of the Rb/E2F 
pathway occurs in the majority of human tumours (Weinberg 1995) demonstrates the vast 
significance of DNA tumour viruses in cellular pathways important in tumourigenesis. 
 
Immune evasion by DNA tumour viruses also plays a role in their tumourigenic pathogenesis. 
For example, down-regulation of major histocompatibility class-I expression by E1A of 
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adenovirus type 12 and the KSHV encoded proteins K3 and K5 (Guan et al. 2008; 
McLaughlin-Drubin and Munger 2008) has been demonstrated to play a role in the 
pathogenesis of these tumour viruses. Further, evasion of cytotoxic T lymphocytes (CTLs) by 
adenoviruses, KSHV and EBV means cells infected by these viruses are not killed in a CTL-
dependent manner while EBV also encodes a homologue of interleukin 10 (vIL-10) which 
may be capable of suppressing cytotoxic T-cells (Marshall et al. 2004). 
 
The listed mechanisms of DNA tumour virus function and viral oncogenes given above are by 
no means exhaustive, with further examples given throughout this thesis. Additionally, 
viruses other than those described have been implicated in human tumourigenesis. For 
example, Torque teno virus, a single-stranded circular DNA virus of the Circoviridae family, 
is associated with a number of human cancers (de Villiers et al. 2002) and Merkel cell 
polyomavirus is frequently found to be integrated in cells prior to tumour development in 
Merkel cell carcinoma, a rare but a highly aggressive neuro-endocrine carcinoma of the skin 
(Becker et al. 2009).  
 
Further examples of tumour viruses and their mechanisms have been subject to recent review 
by Mclaughlin-Drubin and Munger (2008). 
 
1.4 Human Herpesviruses 
 The taxonomy of herpesviruses has been updated by the International Committee on 
Taxonomy of Viruses (ICTV). The former family Herpesviridae has been split into three 
families, which have been incorporated into the new order Herpesvirales (Davidson et al. 
2009). The revised family Herpesviridae retains the mammal, bird, and reptile viruses; the 
new family Alloherpesviridae incorporates the fish and frog viruses; the new family 
Malacoherpesviridae contains a bivalve virus.  Although there are over 100 characterised 
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members of the Herpesviridae family, only eight herpesviruses are routinely isolated from 
humans; Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV-2), 
Varicella-zoster virus (VZV), EBV, Cytomegalovirus (CMV), Human herpesvirus 6 (HHV-
6), Human herpesvirus 7 (HHV-7) and Kaposi sarcoma-associated herpesvirus (KSHV) 
(reviewed by Whitley 2006). 
 
Four significant biological properties are shared by all human herpesviruses (Roizman and 
Pellett 2001): 1) Unique enzymes are encoded. These structurally diverse enzymes provide 
unique sites for inhibition by antiviral agents. 2) Viral DNA synthesis and assembly, and 
capsid assembly, are initiated in the nucleus. 3) Cell death accompanies release of progeny 
virus from infected cells. 4) Latent infection is established that is indicative of the tissue 
tropism of each family member. 
 
Herpesviruses contain double stranded DNA, varying from 120 to 250kb in length, located at 
the central core, which is surrounded by a capsid in which 162 capsomers are arranged in 
icosapentahedral symmetry. The viral tegument adheres tightly to the outside of the capsid, 
with a lipid bilayer derived from host cell membranes loosely surrounding the capsid and 
tegument. Finally an envelope, consisting of cellular polyamines and lipids, and viral 
glycoproteins, coats herpesvirus virions. 
 
Herpesviruses are grouped into subfamilies which identify evolutionary relatedness and 
summarise the unique properties of each member. Members of the Alphaherpesviridae have 
an extremely short (hours) replicative cycle, destroy the host cell and replicate in a wide 
variety of host tissues. These viruses have a propensity to replicate in neuronal tissue, 
meaning latent infection is established in sensory nerve ganglia. The alphaherpesvirus 
subfamily consists of HSV-1, HSV-2, and VZV.   
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Members of the Betaherpesviridae infect a restricted host range, and have long (days) 
replicative cycles, with slowly progressing infection in culture. Infection is characterised by 
the formation of giant multinucleated cells. Latent infections are established in secretory 
glands, cells of the reticuloendothelial system (phagocytic cells) and the kidneys. 
Betaherpesviruses include CMV, HHV-6 and HHV-7. 
The Gammaherpesviridae include EBV and KSHV. Subfamily members are lymphotrophic, 
possessing the most limited limited host range of the Herpesviridae, and are characterised as 
having oncogenic potential. Some gammaherpesvirus subfamily members including murine 
gammaherpesvirus 68 and EBV possess dual tissue tropism, replicating in the respiratory and 
oropharyngeal epithelium respectively, before establishing latent infection in B-cells. 
Gammaherpesviruses can be further sub-categorised into the lymphocryptoviruses (gamma-1-
herpesviruses) and rhadinoviruses (gamma-2-herpesviruses). Lymphocryptoviruses include 
EBV, rhesus lymphocryptovirus, and herpesvirus papio of baboons, while gamma-2-
herpesviruses include KSHV, herpesvirus saimiri virus of squirrel monkeys and the murid 
herpesvirus MHV-68. This thesis will focus on the gamma-1-herpesvirus EBV. 
1.5 Epstein-Barr Virus 
Epstein-Barr Virus was the first reported human tumour virus. In the 1950s, a British surgeon, 
Denis Burkitt, working in East Africa was the first to describe the childhood tumour now 
known as Burkitt’s lymphoma (BL) (Burkitt 1958).  Strikingly, cases of the disease were 
found to follow closely the African malarial belt, leading Burkitt to suspect that a virus, 
perhaps transmitted by an arthropod vector, might be the etiologic agent for the novel 
childhood tumour (Burkitt 1962). In 1965, Tony Epstein, Yvonne Barr and colleagues were 
successful in establishing  BL-derived cell lines, and in the visualisation by electron 
microscopy of herpesvirus-like particles from a small percentage of cells (Epstein et al. 1965). 
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This virus was subsequently shown to be antigenically and biologically distinct from other 
known human herpesviruses (Henle and Henle 1966) and was named EBV. 
Seroepidemiologic studies showed a worldwide distribution for EBV in human populations, 
with over 90% of adults testing positive for serum antibodies to EBV, and the proposed role 
of EBV in Burkitt’s lymphoma was initially met with scepticism (Epstein 2001), although 
overwhelming evidence now supports the concept of EBV playing a central role in African 
BL (Pagano et al. 2004). Serological studies also identified EBV as the etiological agent of 
infectious mononucleosis (IM), and demonstrated that EBV infection was a common feature 
of another malignancy, undifferentiated nasopharyngeal carcinoma (NPC) (Henle et al. 1968; 
zur Hausen et al. 1970). The transformation potential of EBV was confirmed almost 
concurrently by demonstration of the ability of the virus to transform resting B-cells in vitro 
(Henle et al. 1967; Pope et al. 1968), leading to EBV being characterised as the first human 
tumour virus. Subsequent studies have implicated EBV in other malignancies including 
Hodgkin’s lymphoma (HL), lymphoproliferative disorders in the immunocompromised, T-
cell lymphomas and gastric carcinoma (GC). EBV and its role in oncogenesis have been 
reviewed extensively (Young and Murray 2003; Thompson and Kurzrock 2004; Young and 
Rickinson 2004), and will be discussed more fully later in this chapter. 
The EBV particle shares features common to all human herpesviruses, with the outer 
envelope studded with viral glycoproteins used for attachment to host cells, fusion and 
subsequent entry. EBV preferentially infects B lymphocytes by binding the major viral 
envelope glycoprotein gp350 to the CD21 receptor on the surface of B-cells, and through the 
binding of glycoprotein gp42 to human leukocyte antigen class II molecules as a co-receptor 
(Nemerow et al. 1987; Borza and Hutt-Fletcher 2002).  
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The DNA genome extracted from virus particles is a double-stranded linear molecule of 
around 172kb. EBV was the first herpesvirus to be completely cloned and sequenced (Baer et 
al. 1984), with the prototype EBV strain B95-8 being obtained from patients with IM and 
passaged in marmoset leucocytes. The EBV genome is not a unique structure, with genomes 
containing a variable number of terminal repeats (TR) of 538 nucleotides in length, a short 
unique region of about 15 kb, and a long unique region of around 150kb in size. These 
regions are separated by varying number (5-12) of internal tandem repeats (each repeat unit 
being 3072bp in length), known as internal repeat (IR)-1. EBV also contains other smaller 
repeated sequences including IR2 and IR4. IR2 is 125 nucleotides long and is proximal to the 
left end of the long unique region. IR4 (102 nucleotides long) shows homology with IR2 and 
is located towards the right end of the long unique region. Additionally, a distinct repeating 
sequence (IR3) is located within the coding region for EBNA1 and consists of around 45 
copies of the tandemly repeated sequence GGGGCAGGAGCAGGA, which encodes an array 
of alanine and glycine residues, giving rise to its alternative name of the ‘Gly/Ala repeat’ 
region. The EBV genome organisation is shown schematically in Figure 1.1. The EBV 
genome was sequenced from an EBV DNA BamHI fragment-cloned library (Baer et al. 
1984), and as such open reading frames (ORFs), genes and sites for transcription or RNA 
processing are often referenced to specific BamHI fragments named according to size, with 
‘A’ being the largest, through to the smaller ‘Z’. Lowercase letters indicate the smallest 
fragments and a summary of the BamHI fragments is presented in Figure 1.1B. Although the 
EBV DNA genome is linear, following infection terminal repeats are known to fuse, resulting 
in intracellular viral DNA being predominantly episomal and circular. However, the presence 
of integrants in early passage cell lines suggests that in vivo integration of EBV DNA occurs, 
a suggestion supported by evidence reporting the observation of integrated EBV genomes in 
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Figure 1.1 – A) General organisation of EBV DNA, adapted from Arrand (1998). U1 and U2 
are the unique sequence regions of the genome which are interspersed with four internal 
repeat regions (IR1-4) and flanked by terminal repeats (TR).  
B) Adapted from Young and Rickinson (2004). Location of open reading frames for the EBV 
latent proteins on the BamHI restriction-endonuclease map of the prototype B95.8 EBV 
genome. The BamHI fragments are named according to size, with ‘A’ being the largest, 
through to the smaller ‘Z’. Lowercase letters indicate the smallest fragments. Notably, the 
LMP2 proteins (not marked on this map) are produced from mRNAs that splice across the 
terminal repeats (TRs) in the circularized EBV genome. This region is referred to as Nhet, to 
denote the heterogeneity in this region due to the variable number of TRs in different virus 
isolates and in different clones of EBV-infected cells.  
C) Adapted from Young and Rickinson (2004). Location and transcription of the EBV latent 
genes on the double-stranded viral DNA episome. The origin of plasmid replication (OriP) is 
shown in orange and the large green solid arrows represent exons encoding each of the latent 
proteins with arrows indicating the direction in which the genes encoding these proteins are 
transcribed. The long outer green arrow represents EBV transcription during latency III (Lat 
III), in which all the EBNAs are transcribed from either the Cp or Wp promoter while the 
inner, shorter red arrow represents the EBNA1 transcript, which originates from the Qp 
promoter during Lat I and Lat II.  
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NPC tumour biopsies (Kripalani-Joshi and Law 1994). Integration of DNA has been 
implicated in carcinogenesis (e.g. HBV and HPV) although it is unclear whether integration 
of viral DNA is required for EBV-associated neoplasia, as the majority of EBV DNA found in 
tumour cells is episomal.   
 
1.5.1 EBV infection in vitro 
EBV has the unique ability to transform resting B-cells into permanent, latently infected 
lymphoblastoid cell lines (LCLs). This in vitro system has provided an invaluable model of 
the lymphomagenic potential of the virus. Each cell in an LCL carries multiple 
extrachromosomal copies of the viral episome and constitutively expresses a limited set of 
latent viral gene products: six nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and -LP);  three 
latent membrane proteins (LMPs 1, 2A and 2B); the BamHI-A transcripts (BARTs); two 
small non-polyadenylated RNAs (EBERs) and viral microRNAs (miRNAs) (Thompson and 
Kurzrock 2004; Young and Rickinson 2004). This ‘growth programme’ pattern of gene 
expression is referred to as latency III and mimics what occurs in vivo upon infection of 
naïve, and possibly, memory B-cells. Patterns of EBV latent gene expression are discussed 
more fully in the subsequent section, 1.5.4. 
 
LCLs show high levels of expression of the B-cell activation markers CD23, CD30, CD39 
and CD70, and of the cell-adhesion molecules lymphocyte-function-associated antigens 1 and 
3, and intercellular cell-adhesion molecule 1 (Rowe et al. 1987; Kieff and Rickinson 2001). 
Usually on resting B-cells, such markers are expressed at extremely low level or are absent, 
but transient induction of these markers to high levels can occur following activation into 
short-term growth by mitogenic or antigenic stimulation. This indicates that EBV-induced 
immortalisation can be elicited through the activation of the same cellular pathways that drive 
14 
 
Introduction 
B-cell proliferation in a physiological setting (Young and Rickinson 2004). The role of 
individual EBV latent genes in the in vitro transformation of B-cells has been investigated 
through the use of recombinant forms of EBV lacking single latent genes. Such studies have 
confirmed the absolute requirement for LMP1 and EBNA2 in transformation, and have 
highlighted crucial roles for EBNA3, EBNA-LP, and EBNA1 (Kieff and Rickinson 2001). 
 
Although EBV infection of resting B-cells is usually tightly latent, a small number of cells 
within an LCL population will be undergoing spontaneous reactivation and lytic replication at 
any one time. Lytic replication can also be induced by the treatment of cells with chemical 
activators or cross-linking of the B-cell receptor (Shimizu et al. 1996; Feederle et al. 2000). 
Such stimulation results in the induction of lytic transactivators BZLF1 and BRLF1, through 
activation of transcription factors such as AP-1. These lytic transactivators subsequently 
mediate a switch from viral latency to classic herpesvirus lytic replication, which is observed 
to be almost identical in B-cells and epithelial cells despite the reported differences in latent 
infection in vitro (Feederle et al. 2000). 
 
Examination of the early events following in vitro infection of primary epithelial cells and cell 
lines has been problematic for researchers, given that epithelial cells do not express cell 
surface molecule CD21 and, as such, are generally refractory to infection with EBV. 
Transfection of CD21 into epithelial lines has been utilised to allow the efficient infection of 
epithelial cells, with abortive lytic infection resulting (Li et al. 1992; Knox et al. 1996), a 
finding in contrast to the outcome of EBV-infection of CD21 expressing B-lymphocytes in 
vitro. However, some rare clones retaining EBV have previously been isolated by limiting 
dilution cloning (Knox et al. 1996) and by utilising recombinant EBV, thus allowing drug 
resistance selection of EBV-positive clones (Imai et al. 1995). The EBV-positive clones 
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which were generated in such experiments displayed a latency I or II type gene expression, 
similar to the EBV expression in the malignant cells of undifferentiated NPC. 
Recently, a system has been developed in which EBV is efficiently delivered into epithelial 
cells by a process which involves the transfer from the surface of virus-loaded resting B 
cells (Shannon-Lowe et al. 2006). This system has been utilised to demonstrate that B-cell 
and epithelial cell types support different patterns of transcription, and that other differences 
between in vitro EBV-infection of B-cells and epithelial cells are apparent (Shannon-Lowe et 
al. 2009). For example, whereas infection of B cells with one or two copies of EBV results in 
rapid amplification of the viral genome to >20 copies per cell, such amplification was not 
observed after infection of primary epithelial cells or undifferentiated epithelial lines in this 
study. Furthermore, in epithelial cells, EBNA1 expression was detected in less than 50% of 
EBER-expressing cells, with the EBV genome subsequently being lost during prolonged 
culture. Such data highlight the influence of the host cell on the outcome of EBV infection 
with regard to genome expression, amplification, and maintenance. 
 
1.5.2 EBV primary infection  
Transmission of EBV from host to host is via saliva, with most children in the developing 
world becoming infected early in life, in most instances through familial contact (Gratama et 
al. 1990). However in the Western world, primary infection is often delayed, with the virus 
subsequently being acquired in adolescence or young adulthood, often resulting in IM. EBV 
induced IM is a self-limiting infection characterised by fever, malaise, lymphadenopathy and 
hepatosplenomegaly (Slots et al. 2006). In acute infection of B-lymphocytes, EBV expresses 
a protein complement that results in cell proliferation. In healthy individuals, this produces an 
EBV-specific CTL response, accounting for an ensuing fall in infected B-cells, with the 
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adaptive immune response eventually controlling primary infection. As such, EBV becomes 
latent and persists within memory B-cells for the lifetime of the carrier (Babcock et al. 1998), 
although periodic lytic reactivation of EBV occurs at mucosal sites and shedding of virus can 
be detected in healthy EBV carriers (Babcock et al. 1998; Ikuta et al. 2000).  
 
The precise life cycle of EBV in vivo is still incompletely defined. EBV, transmitted by 
infected saliva, transits (through an unknown mechanism) the epithelium of tonsillar crypts 
before infecting naïve B-cells in underlying tissue (Thorley-Lawson 2005). This infection 
results in the expression of the EBV transforming growth programme (latency III) as 
observed in the transformation of resting B-cells in vitro (Babcock et al. 2000). Following the 
attachment of EBV to CD21 molecules on the surface of naïve B-cells, cellular CD21 
becomes cross-linked, initiating an activation signal that prepares the cell for EBV infection. 
The tyrosine kinase lck is activated by EBV binding to CD21 and calcium is mobilised 
(Gordon et al. 1986; Cheung and Dosch 1991). An increase in mRNA synthesis follows, 
along with blast transformation, surface CD23 expression, homotypic cell adhesion and 
interleukin (IL)-6 production (Tanner et al. 1987; Alfieri et al. 1991; Tanner et al. 1996), 
before viral genome uncoating and delivery to the nucleus. Here, circularisation of viral DNA 
occurs, before a cascade of events is launched by gene expression from the viral W promoter 
(Wp). This cascade results in expression of all six nuclear antigens along with the three 
LMPs, with EBNA-LP and EBNA2 being the first detectable EBV proteins following 
infection (Hennessy and Kieff 1985; Sung et al. 1991). 24-48 hours post-infection, 
transcription shifts from Wp to the C promoter (Cp). EBNAs are then transcribed (from Cp) 
from the same transcriptional unit which is around 100kb in length, ending at the 3’ end of the 
EBNA1-encoding gene. Initially, the switch from Wp to Cp expression was thought to 
coincide with an expansion of splicing patterns to allow expression of EBNA1 and EBNA-
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3A, -3B, and -3C, although this splicing pattern is now known to precede the switch in 
promoter usage (Puglielli et al. 1997). Indeed, data suggest that these downstream EBNAs are 
involved in the regulation of Cp activation (Reisman and Sugden 1986; Radkov et al. 1997; 
Yoo et al. 1997). Further, each EBNA protein is involved in other transcriptional control 
processes, and EBNAs are known to participate in the activation of LMP expression, along 
with the induction of several cellular genes. Expression of viral gene products has the 
capacity to activate B-cells and drive their proliferation in the absence of antigenic 
stimulation. Activated lymphoblasts transit to a follicle and subsequently enter germinal 
centre reactions. During this transit down-regulation of EBNA2 occurs, with EBV adopting a 
more restricted pattern of gene expression (latency II) confined to EBNA1, LMP1, LMP2A, 
the EBERs and BARTs (Babcock et al. 2000).  
 
1.5.3 EBV latency states 
The analysis of a number of different EBV-positive cell lines, and of several EBV-associated 
malignancies, has led to the definition of four latency programmes in which the patterns of 
viral gene expression are distinct. These patterns of latent gene expression result from 
differential viral promoter activity, in addition to influences from host cellular factors, and are 
outlined below: 
 
Latency 0 - proposed to occur in circulating memory B-lymphocytes. Expression of all EBV 
latent gene products is absent, with the possible exception of LMP2A and the EBERs.  
Latency I - characterised by BL, where expression is limited to the EBER and BART RNAs, 
with EBNA1 expression being driven from the Qp promoter.  Expression of all of the other 
EBNAs, LMP1 and LMP2 is not observed. 
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Latency II - characterised by NPC and EBV-positive HL.  In addition to the expression of the 
EBERs, BART RNAs and Qp-driven EBNA1, LMP1 and LMP2 are detected to varying 
degrees.  No expression of all other EBNAs is observed. 
Latency III – characterised by LCLs (as outlined above) and post-transplant 
lymphoproliferative disease (PTLD). The full spectrum of latent gene products is expressed, 
including all six EBNA genes spliced from a single poly-cistronic transcript driven from the 
Cp/Wp promoter. Expression of all three latent membrane proteins, the EBERs, and the 
BART RNAs is also observed.  
 
Whilst the outlined forms of viral latency are useful in defining distinct viral gene expression 
patterns, they are subject to variability.  EBV gene expression is a dynamic process in vivo, 
with the virus often adapting itself to the cellular environment in which it infects, leading to 
subsequent changes in latent gene expression over time, if necessary. In vitro observations of 
drifting patterns of latent gene expression (Rowe et al. 1992) and atypical gene expression 
patterns in BL cells (Kelly et al. 2002) support the idea of EBV gene expression being a 
highly dynamic process.   
 
1.5.4 EBV persistence in vivo 
Following antigen stimulation, activated naïve B-cells enter the germinal centre before 
undergoing rounds of rapid proliferation. This process is associated with isotype switching 
and somatic hypermutation of immunoglobulin genes. During this process cells which show 
greatest avidity for antigen are actively selected, with cells showing weaker antigen binding 
undergoing apoptosis. Actively selected surviving cells leave the germinal centre as either 
memory cells or differentiated plasma cells. The process requires survival signals provided by 
T helper cells through CD40 ligand stimulation in addition to antigenic activation. It has been 
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proposed that down-regulation of EBNA2 is essential for differentiation of EBV infected 
naïve B-cells. LMP1 and LMP2A provide essential survival signals which may increase the 
probability and frequency of EBV infected cells reaching the memory cell pool (Thorley-
Lawson 2001) with LMP1 mimicking the constitutively active CD40 receptor and LMP2A 
being a viral homologue of the B-cell receptor, providing cell survival signals. These viral 
signals replace the usual requirement for high-affinity binding to antigen (Young and 
Rickinson 2004).   
 
Contrary to the proposed model of EBV infection and persistence described above, some 
reports have revealed that IM tonsil sections show no down-regulation of EBNA2 in memory 
B-cells (Kurth et al. 2000). Taking this evidence into account, it is theorised that EBV may 
gain access to the memory compartment through the direct infection memory B-cells, 
resulting in latency III gene expression and resultant expansion of latently infected cells. 
Down-regulation or shut off of EBV gene expression may subsequently occur in order to 
allow EBV infected memory cells to evade CTL-mediated killing (Kurth et al. 2000). 
Alternatively, it is possible that EBV may directly infect memory cells during primary 
infection, however such direct infection of memory cells by EBV in healthy carriers has never 
been detected (Babcock et al. 2000). 
Although the precise mechanism of EBV-infection of the pool of memory B-cells has yet to 
be elucidated, subsequent events are better characterised. After entry into the peripheral 
circulation, EBV gene expression is repressed with EBV-infected memory B-lymphocytes 
displaying a latency 0 transcription programme (Babcock et al. 1999). Latency 0 has been 
proposed to occur in circulating memory B-lymphocytes with the absence of expression of all 
EBV latent gene products (with the possible exception of LMP2A and the EBERs) enabling 
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the avoidance of host immune detection and EBV persistence within the B-lymphocyte 
compartment (Babcock et al. 1998; Thorley-Lawson 2005).  Upon the occasional division of 
the memory B-lymphocytes in which EBV persists, a type I latency programme is adopted by 
EBV, where EBNA1 is expressed, thus ensuring equal segregation of the viral genome 
(Thorley-Lawson and Gross 2004). EBV is also thought to change its pattern of gene 
expression on occasions where resting memory B-lymphocytes re-enter the tonsil from the 
peripheral circulation.  Survival of antigen-specific memory B-lymphocytes requires an intact 
functional B-cell receptor (BCR) and it is postulated that unknown signals induce the 
adoption of latency II, resulting in the re-expression of LMP1 and LMP2. LMP2 is then able 
to provide the required BCR signal to ensure the survival of cells in the memory population 
(Thorley-Lawson 2001). 
 
For the maintenance of EBV in the general population, the virus must intermittently replicate 
and be shed into saliva for host to host transmission to occur. EBV is reactivated into lytic 
replication by signals that induce terminal differentiation of B-lymphocytes into plasma cells, 
resulting in the release of infectious virions (Laichalk and Thorley-Lawson 2005).  Given the 
migration of antibody-secreting plasma cells into mucosal epithelium, virions would be 
released onto the mucosal surface, in the case of tonsil, directly into saliva (Thorley-Lawson 
2005).   
EBV infection of epithelial cells in vivo remains poorly elucidated in comparison with in vivo 
EBV-infection of B-lymphocytes. Initial studies revealed the presence of EBV in 
desquamated oropharyngeal epithelial cells of patients with acute IM (Sixbey et al. 1984), and 
recent data have successfully detected EBV DNA, mRNA and protein in a small subset of 
epithelial cells derived from healthy EBV-positive donors (Pegtel et al. 2004). However, other 
data contradict these findings (Hudnall et al. 2005; Karajannis et al. 1997; Niedobitek et al. 
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1997), leaving the question of the importance EBV-infection of epithelial cells in EBV 
persistence open to debate. 
 
1.5.5 EBV Strain Variation 
Given the high prevalence of EBV infection across the world’s population, potential for huge 
evolutionary variation of the virus exists. Analysis of EBV DNA from a large variety of 
sources has revealed that despite this potential, all strains of EBV are closely related, though 
two of the best characterised strains, the prototypic B95-8, and P3HR-1, are variants which 
possess significant deletions within their DNA sequence. B95-8 has a deletion of around 12.5 
kb, encompassing IR4. P3HR-1 has a deletion of the EBNA2 region. DNA homology of EBV 
isolates correlates well with antigenic similarity on the envelopes of various strains, and the 
fact that no distinct serotypes have been reported. Although expected minor inter-isolate 
differences exist, the notion of disease-specific subtypes is not favoured.  
In spite of the overall similarity between EBV isolates two distinct EBV types, EBV-1 and 
EBV-2, have been defined on the basis of specific sequence variation in the EBNA2 gene 
(Dillner et al. 1985; Hennessy and Kieff 1985; Mueller-Lantzsch et al. 1985; Rymo et al. 
1985). This variation results in antigenically distinct forms of EBNA2, and subsequently type 
specific differences have been demonstrated to extend to EBNA3A, EBNA3B, EBNA3C, 
EBNA-LP and the EBERs (Rickinson et al. 1987; Arrand et al. 1989; Sample et al. 1990; 
McCann et al. 2001). EBV-1 has been demonstrated to be more efficient in the in vitro 
transformation of resting B-cells, with EBV-1 transformants proliferating more rapidly, 
reaching higher saturation densities and showing less dependence on cell concentration than 
EBV-2 transformants (Rickinson et al. 1987; Cohen et al. 1989). Despite variation in a 
number of EBV genes being reported between EBV-1 and EBV-2, EBNA2 variation has been 
shown to be sufficient to mediate such effects (Cohen et al. 1989; Tomkinson and Kieff 
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1992). However, both EBV-1 and EBV-2 appear to contribute to the pathogenesis of BL and 
NPC with equal efficiency, and the specific divergence at genetic loci seems to be confined to 
latent genes as proteins associated with productive infection show much greater conservation 
(Arrand 1998).  
 
1.6 EBV-associated diseases 
 
In addition to IM, the acute, self-limiting disease associated with primary EBV infection, the 
virus is implicated in the aetiology of several different lymphoid and epithelial malignancies. 
Characteristics of these malignancies, and the role of EBV in each, are outlined in this 
section.  
 
1.6.1 EBV-associated B-cell lymphomas 
1.6.1.1 Burkitt’s lymphoma 
Burkitt’s lymphoma is a particularly aggressive lymphoma, the hallmark of which is a 
chromosomal translocation between chromosome 8 and either chromosomes 14, 2, or 22 
(Dalla-Favera et al. 1982; Taub et al. 1982; Leder et al. 1983). Because of this translocation, 
the oncogene c-myc (chromosome 8) is juxtaposed to the immunoglobulin heavy-chain 
(chromosome 14) or light-chain genes (chromosomes 2 or 22), with this aberrant 
configuration resulting in dysregulation of c-myc expression. The relationship between EBV, 
Burkitt’s lymphoma, and the c-myc translocation is complicated by the existence of two types 
of Burkitt’s lymphoma: endemic and nonendemic. EBV is present in all cases of endemic BL 
(Young and Rickinson 2004; Bornkamm 2009), the high-incidence form of the tumour that 
affects children in areas of Africa and New Guinea in which malaria is holoendemic , and in 
up to 85% of cases in areas of intermediate incidence such as Brazil and North Africa (where 
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schistosomiasis may play an aetiological role, similar to malaria, in EBV associated BL) 
(Araujo et al. 1996). However, in low-incidence sporadic tumours (nonendemic BL) that are 
seen in children in the developed world, only 15% EBV positivity is observed. Although a c-
myc translocation occurs in both endemic and nonendemic BL, the breakpoints within the 
genes involved, and presumably the mechanism mediating juxtaposition, vary between the 
types of BL (Baumforth et al. 1999). 
The role of EBV in BL is strongly supported by observations of the Akata BL cell line. Akata 
subcultures that lose EBV show decreased growth and an inability to induce tumours in mice 
(Shimizu et al. 1994), with reinfection of such subcultures with EBV re-establishing the 
malignant phenotype (Komano et al. 1998). However, the primary importance of c-Myc 
deregulation as the key factor in BL pathogenesis is widely accepted, given data produced 
from a range of experimental systems (Polack et al. 1996; Kovalchuk et al. 2000). In addition, 
mutations to the p53 pathway and the retinoblastoma-like tumour suppressor are further 
common features of BL (Lindstrom and Wiman 2002). Irrespective of EBV status, the 
phenotype of BL cells is strikingly similar to that of germinal centroblasts, with the detection 
of ongoing Ig-gene mutation in tumour cells supporting the suggestion that they are of 
germinal centre origin. The crucial c-Myc translocation is also likely to have occurred through 
error in the somatic hypermutation process (Young and Rickinson 2004), with the 
juxtaposition of c-myc next to one of the three immunoglobulin enhancers shown to result in 
deregulated c-myc expression (Klein et al. 2007). 
Monoclonal EBV is consistently detected in the cell populations of BL biopsies suggesting 
that infection occurs prior to the malignant outgrowth of the tumour (Neri et al. 1991). The 
majority of EBV-positive BL tumours show a highly restricted latency I form of infection at 
presentation, with viral antigen expression limited to that of EBNA1 (Rowe et al. 1987; Kelly 
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et al. 2002) meaning that EBV’s method of contribution to the pathogenesis of BL remains a 
matter of speculation, given that the EBV antigens required for B-cell immortalisation in vitro 
are not expressed in BL cells in vivo. The virus may play an initiating role in which growth-
transforming B-cell infections establish a pool of target cells that are at risk of a subsequent c-
myc translocation, and this process has been successfully modelled in vitro (Polack et al. 
1996). However, this study highlighted the apparent incompatibility of the EBV latency III-
driven and c-myc-driven growth programmes in B-cells (Pajic et al. 2001), indicating that the 
progression to BL can occur only if the EBV programme is suppressed. The strength of 
selection against full expression of viral latent genes is illustrated by a subset of BLs in which 
the transcriptional features of latency III are retained, but the deletion of the EBNA2 gene of 
viral genomes has occurred, ablating conventional B-cell transforming capability (Kelly et al. 
2002). However, despite the apparent incompatibility of EBV latency III and c-Myc growth 
programmes, recent data suggest that c-Myc transcriptional regulation is an active effector in 
EBV latency III growth programme (Faumont et al. 2009a).  
It is possible that EBV might contribute to BL pathogenesis through the latency I-active genes 
themselves, with EBNA1 an obvious candidate, and experiments in which EBNA1 function 
was blocked in EBV-positive BL cell lines demonstrated that EBNA1 promotes cell survival 
(Kennedy et al. 2003). However, as subsequently discussed (Section 1.7.7), EBNA1’s 
oncogenicity in mouse transgene assays (Wilson et al. 1996), and its contribution to in vitro 
B-cell transformation, remains controversial. Other observations in Akata BL cell lines that 
suggest the involvement of latency I gene products in BL pathogenesis include increased 
survival (and therefore viral persistence), mediated either by virus-induced downregulation of 
c-myc expression in low serum (Ruf et al. 1999), upregulation of the TCL1 oncogene (Kiss et 
al. 2003), or through the EBER-mediated induction of IL-10 (Takada and Nanbo 2001). 
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EBERs have also been demonstrated to upregulate BCL-2 expression, induce colony 
formation in soft agar, and induce tumours in nude transgenic mice (Komano et al. 1999; 
Kitagawa et al. 2000; Ruf et al. 2000), features reminiscent of EBV infected Akata cells 
relative to their negative counterparts (Komano et al. 1998). Although the wider relevance of 
these effects beyond the Akata Burkitt’s lymphoma model system remains to be determined, 
and Akata BL cells have been observed to behave differently from other BL lines in culture 
(Shimizu et al. 1994; Shimizu et al. 1996), a proportion of the described effects of EBERs in 
Akata BL cells have also been observed in other BL lines such as BJAB, Daudi and Mutu 
(Yamamoto et al. 2000; Nanbo et al. 2002). Holoendemic malaria and HIV infection are 
associated with marked increases in tumour incidence. Both agents are able to act as chromic 
stimuli of the B-cell system, with HIV infection also resulting in persistent generalised 
lymphadenopathy that is characterised by exaggerated germinal centre activity. Such 
increased activity is proposed to enhance the chances of productive c-Myc translocations 
occurring (Young and Rickinson 2004). Both agents also disturb the balance between host 
cells and EBV, probably increasing the numbers of EBV-infected B-cells that are at risk of 
being recruited into germinal-centre reactions (Araujo et al. 1999). Despite the observed lack 
of consistent association of EBV with non-endemic BL, EBV is proposed to play a role in the 
pathogenesis of this sporadic form of BL. Such proposals are based upon the observation of 
rearranged EBV genomes in tumour biopsies. Rearranged genomes may consequently express 
BZLF1 (the lytic transactivator), resulting in loss of the virus. Further, any replicating virus 
may not be detected by EBER in situ hybridisation as EBER expression is downregulated 
during lytic replication (Greifenegger et al. 1998). As such, EBV may play a “hit and run” 
role in the development of nonendemic BL (Young and Murray 2003). 
 
26 
 
Introduction 
1.6.1.2 Hodgkin’s lymphoma (HL) 
Although the morphology of the pathognomonic Reed-Sternberg cells of HL was described 
over a century ago, it was not until recently that their origin from B lymphocytes was 
recognised. The demonstration that a proportion of cases of HL harbour EBV and that its 
genome is monoclonal in these tumours suggests that the virus contributes to the development 
of HL in some cases. HL is a complex granuloma where the clonal malignant Hodgkin/Reed-
Sternberg (HRS) cells represent less than 2% of the tumour mass surrounded by a complex 
infiltrate of T- and B-cells, macrophages, eosinophils and plasma cells. The appearance of the 
non-malignant infiltrate distinguishes the nodular sclerosing (NS), mixed cellularity (MC), 
rarer lymphocyte depleted (LD), and a newly defined entity known as ‘‘lymphocyte rich 
classical’’ subtypes of HL (Kapatai and Murray 2007). In the developed world, EBV can be 
detected in 40-50% of HL cases within the HRS cells as a monoclonal population (Staudt 
2000; Klein et al. 2007). This figure includes most MC and LD cases but only a minority of 
the NS tumours that make up the peak of HL incidence that is seen in the third decade of life 
in the developed world, and that first raised the issue of an infectious aetiology. In the 
developing world, HL appears to show an even higher overall association with EBV (Chang 
et al. 1993; Weinreb et al. 1996). The increased EBV positivity in HL in underdeveloped 
countries may be due to the existence of an underlying immunosuppression, similar to that 
observed for endemic BL, a theory supported by the higher EBV-positive rates in HL from 
HIV-infected patients (Uccini et al. 1990). Alternatively, the timing of EBV infection (which 
often occurs earlier in life in developing countries) might also be important (Kapatai and 
Murray 2007). 
The existence of HL tumours in the absence of EBV infection presents the possibility that, 
when present, EBV is simply a ‘passenger’. However, the chance of HL arising in an EBV-
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positive cell by chance is slight, given that infected cells normally make up a small fraction of 
the total B-cell pool (Laichalk et al. 2002). Further, in EBV-positive tumours, the viral 
genome is present in each HRS cell, and exhibits a latency II pattern of gene expression 
(Deacon et al. 1993). Levels of LMP1 in HL appear extremely high indicating that this 
particular viral protein may play a pivotal role in the tumourigenic phenotype (Deacon et al. 
1993), although whether EBV is able to contribute to the malignant phenotype at the time of 
tumour presentation is more difficult to determine, given that there are no EBV-positive HRS 
cell lines available as in vitro models that retain a latency II pattern of gene expression. 
HRS cells show many characteristics of LMP1-induced phenotypic changes (Section 1.7.3), 
including the strong activation of NF-κB (and its associated downstream effects). 
Intriguingly, HRS cells of EBV-negative HL also show a similar phenotype, which, in a 
proportion of cases at least, seems to have been induced through the inactivation of inhibitor 
of IκBα (the physiological regulator of NF-κB activity), or through the amplification of the 
REL gene (which encodes an NF-κB family member (Kuppers 2002). That EBV-positive and 
EBV-negative tumours achieve this same endpoint by biologically distinct mechanisms 
indicates the importance of NF-κB deregulation in the pathogenesis of HL. Manipulation of 
HRS cells from tumour biopsies has demonstrated that these cells contain clonal 
rearrangements in their immunoglobulin genes, with DNA sequencing demonstrating a high 
level of crippling somatic mutations in the rearranged segments. Such data indicate that the 
HRS cell progenitor is derived from a germinal centre B-cell, rescued from apoptosis  
(Kanzler et al. 1996). EBV has been found to rescue BCR-negative germinal centre B-cells 
from apoptosis (Chaganti et al. 2005), most likely through LMP1 mimicking of CD40 which 
binds the CD40L on T-cells, thus inducing B-cell proliferation and survival. Further, LMP2A 
(also expressed as part of the latency II pattern of gene expression seen in HL) is a viral 
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homologue of the cellular BCR, and may provide tonic signalling in the absence of receptor 
cross-linking (Caldwell et al. 2000). Therefore, EBV may play a direct role in the 
development of HL by preventing apoptosis of the HRS progenitor in the absence of antigenic 
stimulation.  
1.6.1.3 Lymphoproliferative disease in immunosuppressed individuals 
The lymphoproliferations that arise following immunosuppression for transplant surgery are 
collectively known as PTLDs. Similar tumours are observed in other immunocompromised 
patients with certain forms of inherited immunodeficiency syndromes, such as X-linked 
lymphoproliferative syndrome and Wiscott–Aldrich syndrome, and in AIDS patients.  
PTLDs are often of B-cell origin, and T-cells are required for the development of PTLD-like 
tumours in severe combined immunodeficient (SCID) mice, which suggests an important role 
for T-cell help in the growth of B-cell-derived PTLDs (Johannessen et al. 2000). Most cases 
of PTLD are EBV positive, and show a latency III pattern of gene expression (Young et al. 
1989), appearing to represent an in vivo counterpart for the in vitro LCL model system, and 
therefore by implication PTLDs are likely to be primarily driven by EBV, with a decrease in 
chemotherapy usually being sufficient to induce regression (Timms et al. 2003). However, 
other patterns of EBV latent gene expression are sometimes observed in PTLDs, and EBV-
negative forms of PTLDs have also been described. AIDS-related lymphoproliferative 
disorders are another group of heterogeneous diseases exhibiting strong association with 
EBV. These diseases occur as a consequence of HIV immunosuppression and include CNS 
and systemic B-cell lymphomas, and primary effusion lymphomas (PELs) which can be co-
infected by KSHV (Thompson and Kurzrock 2004). Leiomyosarcomas (smooth muscle 
tumours) are not associated with EBV in immunocompetent hosts but have been strongly 
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correlated with viral infection in patients whose immune system is compromised by HIV or 
other factors. Such an association between leiomyosarcomas and EBV indicate that EBV is 
capable of infecting smooth muscle cells, a finding consistent with experimental evidence that 
the EBV receptor is present on those cells (McClain et al. 1995; Suankratay et al. 2005). 
1.6.2 EBV-associated T- and natural killer cell lymphomas 
The association of EBV with rare but specific types of T-cell and natural killer (NK)-cell 
lymphomas was completely unexpected when first identified (Jones et al. 1988; Harabuchi et 
al. 1990), given that the virus is so markedly B-lymphotropic upon in vitro exposure to human 
lymphocyte preparations. Although the mechanism by which EBV is able to access and infect 
these cell lineages in vivo is still undetermined, most evidence indicates that such infections 
are rare though when they occur, they confer a high risk of lymphoma development (Young 
and Rickinson 2004). T- and NK-cell lymphomas arising as a consequence of EBV infection 
appear highly malignant and have a poor clinical prognosis (Kanavaros et al. 1993; Harabuchi 
et al. 1996).  
1.6.3 EBV-associated epithelial cell disorders 
1.6.3.1 Oral hairy leukoplakia  
Oral hairy leukoplakia (OHL) was first described in the 1980s (Greenspan et al. 1985; 
Reichart et al. 1989) and is a benign epithelial lesion that presents on lateral and dorso-lateral 
regions of the tongue (Slots et al. 2006). OHL causes no other symptom or medical/dental 
problems, and does not usually require treatment, though antiherpesviral treatment (with 
acyclovir) may lead to remission. Histologically, OHL shows vacuolated epithelial cells and 
little or no inflammatory infiltrate in the underlying connective tissue. OHL is almost 
30 
 
Introduction 
exclusively seen in immunocompromised individuals, particularly in HIV-infected patients in 
whom it may serve as an indicator of progression to AIDS.  
Despite the well established association between EBV and OHL, the precise role that EBV 
plays in OHL development is not well understood. Both lytic and latent EBV antigens have 
been detected in lesions including EBNA1, EBNA2, EBNA-LP and LMP-1 (Sandvej et al. 
1992; Webster-Cyriaque and Raab-Traub 1998; Webster-Cyriaque et al. 2000; Walling et al. 
2004), although the consensus of opinion is that EBV does not establish a latent infection in 
the disorder. As previously mentioned, treatment of patients with acyclovir (to inhibit viral 
replication) results in significant resolution of OHL lesions. However, lesions reappear one to 
four weeks post-treatment, suggesting that viral replication is necessary for the pathogenesis 
of this disease (Walling et al. 2003). OHL lesions frequently contain multiple EBV strains 
(Walling and Raab-Traub 1994), suggesting that OHL may arise as a consequence of a 
repeated super-infection of EBV-infected cells present within differentiating epithelial layers 
(Webster-Cyriaque et al. 2000).  
Significantly, although no formal link with OHL has been established, EBV has been 
demonstrated to associate with aggressive types of oral tumours, especially in 
immunosuppressed patients (Leong et al. 2001), however research is needed to determine the 
extent to which EBV participates in oral tumourigenesis, and to understand complex and 
varying interplay between the virus and the host cell environment in different types of oral 
cancer (Slots et al. 2006). 
1.6.3.2 Nasopharyngeal Carcinoma 
Nasopharyngeal carcinoma is a distinctive type of head and neck cancer that arises from 
surface epithelium, often presenting as a neck mass with symptoms of nasal obstruction and 
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loss of hearing. NPC has a characteristic ethnic and geographic distribution, with a low 
incidence of the malignancy in Caucasians from Europe, North America and other Western 
countries (1 case per 100,000 persons per year). However, NPC represents the most common 
tumour in Southern China, accounting for 20% of all adult cancers in this region (25-30 cases 
per 100,000 persons per year) (Yu and Yuan 2002) and is particularly apparent in individuals 
of Cantonese origin (Lo et al. 2004). Incidence rates of NPC are high in individuals of 
Chinese descent irrespective of where they live, and particularly in Cantonese males, 
suggesting a genetic predisposition to the disease (Young and Murray 2003). Undifferentiated 
nasopharyngeal cancer affects mostly individuals in their mid-40s, with men two- to three-
fold more frequently affected than women (Vasef et al. 1997). Distant metastasis is the key 
contributor to NPC mortality, with thirty to sixty percent of patients with NPC eventually 
developing metastatic tumours (Spano et al. 2003). In terms of treatment strategies, NPC 
tends to be radio- and chemo-therapy sensitive, with initial treatments often encouraging. 
However, relapse and metastasis occur frequently (Spano et al. 2003; Brennan 2006). 
In 1978, the World Health Organisation (WHO) classification distinguished NPC into three 
histopathological types based on the degree of tumour differentiation: Type I – a keratinising 
squamous cell carcinoma (SCC), similar to other head and neck cancers; Type II – a non-
keratinising carcinoma; Type III – undifferentiated carcinoma (Shanmugaratnam 1978). Both 
type II and III are further characterised by the presence of a prominent cellular infiltrate and 
each type has a strong propensity to metastasise. Despite subsequent re-classification of NPC 
by the WHO in 1991, EBV researchers worldwide, rather strangely, still tend to refer to NPC 
types by the 1978 classification.  
The well-differentiated keratinising (WHO type I) NPC makes up 20% of all NPC cases, with 
the remaining cases being non-keratinising, differentiated and non-differentiated (WHO 
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Types II and III) NPC.  Prevalence of the different histological NPC types varies 
geographically, with keratinising SCC more common in Western countries, and WHO type III 
NPC accounting for more than 97% of all NPC cases in endemic regions such as Southern 
China (Marks et al. 1998). Undifferentiated NPC has a typical morphology with a prominent 
lymphocytic infiltrate. The interactions between tumour cells and these infiltrating 
lymphocytes is proposed to be critical in tumour propagation (Young and Rickinson 2004), 
with type II and III NPC being distinguished from other SCCs through their universal 
association with EBV.  
The EBV-associated, undifferentiated form of NPC (WHO type III) shows the most 
consistent worldwide association with EBV. A link between EBV and undifferentiated NPC 
was suggested as early as 1966 on the grounds of serological studies (Henle and Henle 1970), 
and was later substantiated by the demonstration of EBV DNA in the tumour cells of NPCs 
through in situ hybridisation (zur Hausen et al. 1970). Subsequently, Southern blot 
hybridisation of DNA from NPC tissues revealed the monoclonal nature of the resident viral 
genomes, indicating that EBV infection occurs prior to clonal expansion of malignant cell 
populations (Raab-Traub and Flynn 1986). EBV has since been found to be associated with 
virtually all cases of undifferentiated NPC, despite its strong tropism for B lymphocytes 
(Young et al. 1988; Niedobitek et al. 1992). Further, it has been demonstrated that tumour-
derived EBV DNA load in pre- and post-treatment patient serum was a good indicator of 
overall survival and chances of relapse (Chan et al. 2002). Association of EBV with more 
differentiated (types I and II) of NPC is not well established. Although EBV DNA has been 
detected (albeit at low copy number) in SCC biopsies by Southern blotting (Raab-Traub et al. 
1987), it remains possible that the DNA detected in this study may have originated from B 
lymphocytic infiltrate. However, a more recent study detected EBER expression in the tumour 
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cells of 31 differentiated SCC biopsies using in situ hybridisation and the same study also 
reported the presence of monoclonal EBV episomes in SCC, and a pattern of viral gene 
expression reminiscent of that observed in undifferentiated NPC (Pathmanathan et al. 1995). 
Contrastingly, other studies have failed to detect EBV DNA or EBER expression by in situ 
hybridisation analysis of differentiated NPC biopsies (Niedobitek et al. 1992; Niedobitek et 
al. 1993), leading to a general school of thought that EBV infection of squamous NPC may 
occur in endemic regions, but is less likely to occur in areas of low NPC incidence (Spano et 
al. 2003). 
Despite the strong evidence outlined above indicating that EBV plays a strong etiological role 
in NPC, EBV infection itself is not sufficient to induce tumourigenesis. This point is 
highlighted by the fact that despite most of the world’s population being asymptomatically 
infected with EBV, NPC incidence is remarkably low in most regions. Experimental evidence 
reinforces such epidemiological observations, with a reservoir of EBV infection not being 
detectable in normal and low-grade nasopharyngeal pre-invasive epithelium (Pathmanathan et 
al. 1995). Extensive epidemiological studies have resulted in the identification of two 
important co-factors, other than EBV infection, in NPC pathogenesis: genetic predispositions 
and environmental cofactors. 
Environmental cofactors such as dietary components (e.g. salted fish, high in volatile 
nitrosamines) are thought to be important in the aetiology of the disease (Yu et al. 1986). 
Indeed, rats fed Cantonese-style salted fish have been observed to develop nasal cavity 
carcinoma in a dose-dependent manner (Huang et al. 1978; Yu and Yuan 2002). The 
consumption pattern of such high-risk foods is entirely consistent with the geographical 
distribution of NPC, and a decreasing trend in NPC incidence (~30%) in Hong Kong over the 
last 25 years may be attributed to the change of traditional lifestyle, particularly the avoidance 
34 
 
Introduction 
of feeding salted fish to young children (Lo et al. 2004). Other environmental co-factors such 
as exposure to dust, smoke and chemical fumes also play a role in predisposing individuals to 
NPC (Yu et al. 1986; Yu and Yuan 2002), although while the use of Chinese medicinal herbs 
and phorbol ester contamination of water supplies have been suggested to increase the risk for 
NPC by reactivating EBV infection in the host, the association of NPC with other non-dietary 
factors such as cigarette smoking or formaldehyde exposure is either weak or disputed (Raab-
Traub 2002; Lo et al. 2004). 
The development and progression of NPC is thought to involve the accumulation of multiple 
genetic changes.  Both genetic changes, such as gene amplification, deletion and mutation,  
and epigenetic changes (methylation events) are able to effect the development of NPC 
through altering the functions of genes involved in cellular processes such as proliferation, 
apoptosis, and differentiation (Lo and Huang 2002). Some interplay between genetic and 
environmental cofactors is postulated. A variant form of the cytochrome P450 enzyme, 
CYP2E1, which catalyzes the metabolic activation of low-molecular weight nitrosamines 
such as those detected in NPC-associated foods, has been identified which exhibits higher 
enzymatic activity. Chinese subjects possessing this genotype have a 2-fold increased risk of 
developing NPC (Hildesheim et al. 1995, 1997). Genome-wide analysis of NPC genetic 
alterations has been conducted, utilising a comprehensive complementary approach through 
the combination of combining comparative genomic hybridisation (CGH), array-based CGH, 
spectral karyotyping and high resolution deletion mapping on micro-dissected tumours to 
screen for allelic losses, copy number gains and specific amplifications throughout the entire 
NPC genome (Hui et al. 1999, 2002; Lo and Huang 2002; Wong et al. 2003). Such studies 
have consistently reported high frequencies of genetic loss on multiple chromosome arms, 
including 3p, 9p, 9q, 11q, 13q, 14q and 16q, with recurrent chromosomal gains observed on 
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chromosomes 1q, 3q, 8q, 12p and 12q.  Of the reported alterations, the most common were 
deletion of 3p and 9p; regions correlating with known tumour suppressor genes located on 
9p21 (p14 and p16) and 3p21.3 (RASSF1A) which have been shown to be defective due to 
promoter hypermethylation in NPC (Lo et al. 1996, 2001). Upon restoration of p16 and 
RASSF1A expression in NPC cell lines, a marked decrease in cell growth and reduction of 
soft-agar colony formation was observed, along with reduced tumourigenic potential 
following injection into athymic nude mice (Wang et al. 1999; Chow et al. 2004). Further, 
clonal cell populations with 3p and 9p deletions have been frequently detected in dysplastic 
lesions and even in histologically normal nasopharyngeal epithelia from Southern Chinese 
individuals (Chan et al. 2000, 2002a) and these deletions were observed at a higher frequency 
in high-risk Chinese populations compared with low-risk populations.  Such observations 
suggest that these deletions are critical events which occur early in the development of NPC. 
Other promoter hypermethylation events occur on tumour suppressor gene (TSG) promoters 
in NPC including those on chromosome 11q (tumour suppressor in lung cancer TSLC1), 13q 
(endothelin receptor EDNRB) and 16q (E-cadherin). Included within the significant 
amplifications of some chromosome regions are oncogenes. Such regions include 3q (PI3K 
catalytic subunit and ΔN-p63), 7p (epidermal growth factor), and 8q (c-myc). More recently, 
micro-array analysis using biopsies from patients with EBV-positive undifferentiated NPC 
and from cancer-free controls revealed down-regulation of multiple TSGs not previously 
associated with this NPC, including the ataxia telangiectasia mutated (ATM) gene, which is 
known to be mutated in a variety of other tumours (Bose et al. 2009). An analysis of all 
genetic and epigenetic changes reported in NPC is beyond the scope of this thesis, although 
suitable review articles are readily available (Lo and Huang 2002). The genetic and epigenetic 
alterations identified following the establishment of a stable EBV infection and expression of 
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viral latent genes, are proposed to mediate the malignant development of NPC from a high-
grade pre-invasive lesion to an aggressive and metastatic invasive carcinoma. This has led to 
the design of a multi-step model for the pathogenesis of NPC in which EBV infection 
provides an essential tumour-promoting function (Lo and Huang 2002).  
EBV latent gene expression in NPC tumour cells is well characterised, with numerous studies 
reporting EBV to display type II latency gene expression, similar to that observed in HL cells. 
Expression of EBNA1, LMP2A, LMP2B, EBERs and the BARTs has been consistently 
demonstrated (Young et al. 1988; Niedobitek et al. 1992; Chen et al. 1995). LMP1 expression 
has also been reported in NPC cells, however expression of this viral latent gene product is 
variable, with around 20-30% of NPC biopsies analysed found to express LMP1 (Young et al. 
1988; Niedobitek et al. 1992). LMP1 expression seems to be important in NPC, with LMP1-
negative tumours reported to have gained additional compensatory cellular gene mutations 
(Spano et al. 2003). 
1.6.3.3 Other EBV-associated lymphoepitheliomas 
Given EBV’s well established association with NPC, studies have examined a possible role 
for EBNA1 in other undifferentiated epithelial carcinomas, or lymphoepitheliomas. Although 
EBV has been detected in thymic and salivary gland tumours (Raab-Traub et al. 1991; Fujii et 
al. 1993), examination of breast lymphoepithelioma revelated no association with EBV 
(Dadmanesh et al. 2001). Further, any EBV association with these carcinomas appears to 
correlate with regions in which NPC is endemic (Raab-Traub et al. 1991; Fujii et al. 1993). 
EBV is also associated with rare NPC-like gastric lymphoepitheliomas, with 90% of cases 
showing EBV positivity (Tokunaga et al. 1993; Imai et al. 1994). 
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1.6.3.4 Gastric Carcinoma 
In addition to the fairly well established association between EBV and gastric 
lymphoepitheliomas, numerous studies have also detected EBV in some conventional gastric 
adenocarcinomas (GC), of both the intestinal and diffuse histological subtypes (Shibata and 
Weiss 1992; Tokunaga et al. 1993; Imai et al. 1994). EBV-associated GC is a distinct 
subgroup of GC which occurs worldwide without regional or racial differences, and accounts 
for around 10% of all GC cases, with around 90,000 patients worldwide estimated to develop 
this kind of stomach cancer annually (Fukayama et al. 2008). The clinical features of EBV-
associated GC include male predominance, relatively younger age and preponderant location 
in the proximal stomach. EBV-associated GC has a relatively favourable prognosis compared 
with EBV-negative GC (Fukayama et al. 2008). 
In EBV-associated GC, studies have identified that monoclonal EBV is present in an episomal 
form, without integration into the host genome, and that the infection is latent with no viral 
replication. Mono or bi-clonal EBV has been observed in the carcinoma tissues at the 
intramucosal stage; however, at the stage of submucosal invasion, and in further advanced 
carcinoma, EBV is monoclonal (Fukayama et al. 1994; Imai et al. 1994; Uozaki and 
Fukayama 2008). Therefore, EBV infection occurs at the initial or a very early stage of 
carcinoma development (Fukayama et al. 2008), suggesting that EBV plays an important 
etiological role in tumourigenesis, a suggestion that is reinforced by the differing molecular 
and pathological phenotypes of EBV-negative and EBV-positive GCs. Tissue arrays 
comparing EBV-positive and EBV-negative GC biopsies have revealed substantial 
differences between the two tumour types. EBV-positive cases have been identified as 
showing a more frequent loss of SMAD4, E-cadherin, cyclin-dependent kinase inhibitor 
p16INK4A and O-6-methylguanine methyltransferase (Lee et al. 2004).  
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Despite such notable differences in the pathology of EBV-positive and -negative GC, the 
precise role of EBV in tumourigenesis remains poorly defined. A restricted pattern of viral 
gene expression is observed in GC similar to latency I gene expression observed in BL, but 
with LMP2A expressed in addition (Fukayama et al. 1994; Imai et al. 1994; Uozaki and 
Fukayama 2008). Although the precise pathogenic role of EBV in GC is yet to be determined, 
data demonstrating the absence of EBV infection in pre-malignant gastric lesions support the 
notion that viral infection may be a relatively late event in gastric carcinogenesis but once 
infection occurs, EBV is able to drive the clonal proliferation of malignant cells (Zur Hausen 
et al. 2004). 
1.7 EBV latent gene products 
A comprehensive review of each of the EBV-encoded latent gene products is beyond the 
scope of this thesis. The following section briefly introduces EBV latent gene products less 
pertinent to this particular project, before focussing on the two latent gene products most 
relevant to this thesis: EBNA1 and the EBERs. 
1.7.1 EBNA2 and EBNA-LP 
EBNA2 and EBNA-LP are temporally the first EBV latent proteins to be detected following 
EBV infection (Murray and Young 2002). The acidic phophoprotein EBNA2, although 
lacking intrinsic DNA binding activity, is a known transcriptional activator of viral genes 
(LMP1 and LMP2) and cellular genes (CD21 and CD23) (Wang et al. 1990; Kieff and 
Rickinson 2001), and plays a critical role in cell immortalisation. The conspicuous inability of 
an EBV strain, P3HR-1, which is deleted for the last two exons of EBNA-LP and the entire 
EBNA2 gene, to transform B-cells in vitro was the first observation that indicated that 
EBNA2 made a critical contribution to cellular transformation by EBV (Rabson et al. 1982). 
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Subsequent reintroduction of EBNA2 into this strain unequivocally confirmed the role of this 
viral latent gene product in transformation (Hammerschmidt and Sugden 1989). EBNA2 is 
also known to transactivate Cp, inducing the observed switch from Wp to Cp expression early 
in B-cell infection. EBNA2-responsive promoters are not bound directly by EBNA2, but 
rather by the ubiquitous cellular DNA-binding protein RBP-Jκ, which interacts with EBNA2 
and binds the common core sequence (GTGGGAA) of EBNA2-responsive promoters 
(Grossman et al. 1994). The RBP-Jκ homologue in Drosophila is involved in signal 
transduction from the Notch receptor, a pathway that is important in cell fate determination in 
the fruit fly and has been implicated in the development of human T-cell tumours (Artavanis-
Tsakonas et al. 1995), with EBNA2 being demonstrated to be capable of functionally 
replacing the intracellular region of Notch (Sakai et al. 1998). Conversely, activated forms of 
Notch have been shown to have the ability to substitute for EBNA2 in the promotion of B-
lymphocyte transformation and the transactivation of EBNA2-regulated viral promoters 
(Hofelmayr et al. 1999; Strobl et al. 2000; Hofelmayr et al. 2001), although a recent study 
suggests differential effects of Notch and EBNA2 signalling on the proliferation and survival 
of EBV-infected B-cells (Kohlhof et al. 2009).  The oncogene c-Myc is seemingly another 
important EBNA2 target, and is significant for EBV-induced B-cell proliferation (Kaiser et al. 
1999; Zimber-Strobl et al. 1999).  
 
EBNA-LP is a nuclear protein transcribed from the 5’ leader sequences of the other EBNA 
RNAs (Kieff and Rickinson, 2001) and functions as a transcriptional co-activator with 
EBNA2 in regulating Cp and LMP1 promoters (Nitsche et al. 1997; McCann et al. 2001). The 
cooperation between EBNA2 and EBNA-LP does not seem to require direct or indirect 
complex between these two proteins (Peng et al. 2005). EBNA-LP enhancement of EBNA2 
gene transactivation is instead suggested to occur through the displacement of HDAC4 and 
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associated transcriptional repressors (Portal et al. 2006). Although detectable in the 
cytoplasm, it has recently been established that nuclear-cytoplasmic shuttling is not required 
for efficient EBNA-LP co-activation function (Ling et al. 2009). In addition to these 
transcriptional co-activation activities, EBNA-LP may play a role in the evasion of IFN-
mediated antiviral responses by EBV (Echendu and Ling 2008). Further, EBNA-LP has been 
found to interact with Rb and p53 in vitro (Szekely et al. 1993). However, EBNA-LP’s ability 
to disrupt Rb and p53 signalling pathways in vivo and promote B-cell proliferation is 
controversial (Young and Murray 2003). EBNA2 and EBNA-LP have also been previously 
demonstrated to act cooperatively to drive progression of resting B lymphocytes into the G1 
phase of the cell cycle (Sinclair et al. 1994).  
1.7.2 EBNA3 family 
The three members of the EBNA3 family, EBNA3A, 3B and 3C are encoded by genes that 
are adjacent on the viral genome. They are all hydrophilic nuclear proteins, containing heptad 
repeats of leucine, isoleucine or valine which act as dimerisation domains. Following EBV 
infection of B-lymphocytes, transcription of the EBNA3 genes occurs after EBNA2 and 
EBNA-LP. EBNA3A and EBNA3C have been demonstrated as being essential for EBV-
mediated B-cell transformation in vitro, although EBNA3B is thought to be dispensable 
(Tomkinson et al. 1993). However, EBNA3B has been shown to enhance vimentin and CD40 
expression (Silins and Sculley 1994). 
The EBNA3 family are known transcriptional regulators, with EBNA3C inducing 
upregulation of both cellular (CD21) and viral (LMP1) gene expression (Allday and Farrell 
1994), and repression of the Cp promoter (Radkov et al. 1997). This EBNA3C function is 
thought to require association with HDAC1, mSin3A and N-CoR co-repressors (Radkov et al. 
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1999; Knight et al. 2003). EBNA3C may also promote transformation through interaction 
with pRB and has also been reported to cooperate with oncogenic RAS in transforming rat 
embryo fibroblasts (Parker et al. 1996). More recently, EBNA3C has been demonstrated to 
interact with and enhance the stability of c-Myc (Bajaj et al. 2008). Further, EBNA3A and 
EBNA3C have been demonstrated to cooperate as the main determinants of the transcriptional 
down-regulation of the pro-apoptotic Bcl-2-family member Bcl-2-interacting mediator of cell 
death (Bim) in EBV-positive BL cells (Anderton et al. 2008).   
EBNA3 family proteins have also been shown to cooperate in the specific inhibition of 
EBNA2-activated transcription, through direct interaction of their amino terminus with RBP-
Jκ (Johannsen et al. 1996; Robertson et al. 1996). This suggests that EBNA2 and EBNA3 
have cooperatively evolved to precisely regulate RBP-Jκ activity and consequent expression 
from cellular and viral promoters containing RBP-Jκ binding sites (Murray and Young 2001).  
1.7.3 LMP1 
LMP1, a 63 kDa integral membrane protein, is EBV’s major transforming protein, behaving 
as a classical oncogene in rodent fibroblast transformation assays and being essential for the 
EBV-induced transformation of B-cells in vitro (Wang et al. 1985; Kaye et al. 1993). The 
pleiotropic effects of LMP1 expression in cells include the induction of cell surface adhesion 
molecules and activation antigens (Wang et al. 1990), upregulation of antiapoptotic proteins 
such as Bcl-2 and A20 (Henderson et al. 1991; Laherty et al. 1992), and stimulation of 
cytokine production (Eliopoulos et al. 1997; Eliopoulos et al. 1999). LMP1 functions as a 
constitutively active member of the tumour necrosis factor receptor (TNFR) superfamily, 
activating a number of signalling pathways in a ligand-independent manner (Gires et al. 1997; 
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Kilger et al. 1998). Further, LMP1 functionally resembles TNFR superfamily member CD40 
and is able partially to substitute for CD40 in vivo (Uchida et al. 1999).  
Structurally, LMP1 may be subdivided into three domains: (1) the N-terminal cytoplasmic 
tail, responsible for orienting and tethering of LMP1 to the plasma membrane; (2) the six 
hydrophobic transmembrane loops which are involved in self-aggregation and 
oligomerisation; (3) a long carboxy-terminal cytoplasmic region, possessing the majority of 
LMP1’s signalling capacity. Further, two distinct functional domains referred to as C-terminal 
activation regions 1 and 2 (CTAR1 and CTAR2) have been identified based upon their ability 
to activate the NF-κB pathway (Huen et al. 1995). The activation of NF-κB contributes to an 
ever expanding range of phenotypic consequences of LMP1 expression. Indeed, LMP1 has 
recently been implicated in the regulation of DNA polymerase-β through the NF-κB pathway 
(Faumont et al. 2009b) and LMP1 has been shown to transactivate transcription of the 
oncogenic microRNA miR-155 through the NF-κB pathway (Gatto et al. 2008). 
LMP1 also engages the MAP kinase cascade which results in the consequential activation of 
ERK, JNK and p38, and the stimulation of the JAK/STAT pathway (Kieser et al. 1997; 
Eliopoulos and Young 1998; Roberts and Cooper 1998; Eliopoulos et al. 1999; Gires et al. 
1999). Many of these effects are a result of the ability of TNFR-associated factors (TRAFs) to 
interact directly with CTAR1 of LMP1, or indirectly through death domain protein TRADD 
to CTAR2 of LMP1 (Kieff and Rickinson 2001). The region between CTAR1 and CTAR2 
(CTAR3) has been suggested to be responsible for the JAK/STAT pathway although this 
remains controversial, and deletion of this region has been shown to have no effect on the 
efficiency of B-cell transformation (Gires et al. 1999; Izumi et al. 1999). LMP1 also activates 
phosphatidylinositol 3-kinase (PI3K), a lipid kinase responsible for activating a diverse range 
of cellular processes in response to extracellular stimuli (Dawson et al. 2003) and induces a 
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hyperproliferative and inflammatory gene expression programme in cultured keratinocytes 
(Morris et al. 2008).  
1.7.4 LMP2 
The LMP2 gene encodes two distinct proteins of similar structure, LMP2A and LMP2B. Both 
proteins possess 12 transmembrane domains and a 27 amino acid cytoplasmic C-terminus, 
with LMP2A also having an additional 119 amino acid cytoplasmic amino-terminal domain 
(Longnecker and Kieff 1990). Neither LMP2A nor LMP2B is essential for the EBV-mediated 
transformation of B-cells in vitro (Longnecker 2000).  
The amino-terminal domain of LMP2A contains eight tyrosine residues, two of which form 
an immunoreceptor tyrosine-based activation motif (TAM) (Fruehling and Longnecker 1997), 
similar to the TAM present in the B-cell receptor (BCR) which plays a central role in the 
mediation of lymphocyte proliferation and activation of the src family of protein tyrosine 
kinases (PTKs). The LMP2A TAM has been demonstrated to be responsible for blocking 
BCR-stimulated calcium mobilisation, tyrosine phosphorylation and the activation of EBV 
lytic cycle in B-cells (Miller et al. 1995) through interacting with PTKs and negatively 
regulating their activity through depleting the plasma membrane of Src and Syk PTKs 
(Fruehling and Longnecker 1997). Other data build upon these findings, and indicate that an 
additional tyrosine residue in the LMP2A amino-terminal domain is required for efficient 
binding of src family PTKs (Fruehling et al. 1998) and that LMP2A is phosphorylated in vitro 
on serine residues by MAP kinase (Panousis and Rowe 1997). Signalling of LMP1 was 
recently demonstrated to occur preferentially through the Src family kinase Lyn, due in part to 
Lyn’s SH2 domain associating with LMP2A (Rovedo and Longnecker 2008). Further, 
LMP2A was shown to inhibit BCR-induced apoptosis and EBV reactivation in BL cell lines 
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(Fukuda and Longnecker 2005). In addition, LMP2A contains proline motifs capable of 
interacting with WW domain-containing proteins, with LMP2A found to interact with the 
Nedd4 family of ubiquitin ligases. This interaction is thought to lead to the increased turnover 
of Lyn (Ikeda et al. 2000).  
 
Although not essential for B-cell transformation, expression of LMP2A in the B-cell 
compartments of transgenic mice abrogates normal B-cell development thus allowing 
immunoglobulin-negative cells to colonise peripheral lymphoid organs. These data suggest 
that LMP2A is able to drive survival and proliferation of B-cells in the absence of BCR 
signalling (Caldwell et al. 1998), and support a role for LMP2 in the modification of the 
normal B-cell development programme to favour the maintenance of EBV latency in the bone 
marrow and prevent inappropriate activation of EBV lytic cycle (Young and Murray 2003). 
Consistent with a cell survival role, LMP2A activates the PI3K/Akt pathway in epithelial and 
B-cells, providing protection against TGFβ induced apoptosis (Fukuda and Longnecker 
2004). 
 
LMP2B is proposed to have a regulatory role in the function of LMP2A (Longnecker 2000), 
with a more precise role for LMP2B in modulating LMP2A activity having recently been 
identified. Although LMP2B lacks the N-terminus of LMP2A it is still able to aggregate in 
the plasma membrane and may directly associate with LMP2A, with this association 
preventing the recruitment of the Lyn tyrosine kinase (Rovedo and Longnecker 2007). 
 
LMP2A’s role and function in epithelial cells is quite distinct from those seen in B-cells, with 
LMP2A phosphorylation in epithelial cells not involving PTKs, but instead being dependent 
on cell interactions with the extracellular matrix (Scholle et al. 1999). LMP2A has also been 
reported to repress NF-κB and STAT signalling and to have an importance in the modulation 
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of LMP1 expression (Stewart et al. 2004). This is in contrast to studies conducted in B-cells, 
where LMP2A was found to activate NF-κB in conjunction with LMP1 through promoting 
TRAF2 expression (Guasparri et al. 2008).  
 
1.7.5 EBV-encoded BamHI A rightward transcripts (BARTs)  
The BART RNAs are a heterogeneously spliced group of RNAs transcribed rightward from 
the BamHI A region of the EBV genome. BART RNAs have been detected in the peripheral 
blood of healthy EBV carriers (Chen et al. 1999) and in all EBV-associated diseases that have 
been examined (Raab-Traub et al. 1991; Deacon et al. 1993; Sugiura et al. 1996; Tao et al. 
1998; Sugawara et al. 1999).  
The BART RNAs were originally identified by the analysis of cDNA libraries established 
from an NPC tumour (Hitt et al. 1989; Gilligan et al. 1990b). Despite extensive analysis and 
supposition that due to their presence in EBV-associated malignancies they may play some 
role in EBV-mediated tumourigenesis, the function of the BARTs remains mysterious. Prior 
to the discovery of the EBV miRNAs, some open reading frames (ORFs) in the spliced BART 
cDNAs were investigated as potential protein-coding sequences. It was demonstrated that the 
RPMS1 and A73 ORFs could be translated in vitro from the spliced BART cDNAs isolated 
from C15 NPC tumour cells (Smith et al. 2000). Subsequently, it was shown that RNAs 
covering RPMS1 and A73 ORFs represent significant portions of the BART family of 
transcripts (de Jesus et al. 2003), with biochemical activities of artificially expressed RPMS1 
and A73 proteins having been identified as having a possible role in EBV pathology (Smith et 
al. 2000; Zhang et al. 2001; de Jesus et al. 2003). RPMS1 was found to antagonise Notch1 
and/or EBNA2 transcriptional activation, through competing for binding to the RBP-Jκ 
protein (Smith et al. 2000), with A73 found to bind to the RACK1 protein (Smith et al. 2000) 
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(known to act as a scaffold in Src family kinase signalling). Despite the existence of some 
evidence of an immune response to protein products of BART RNAs in EBV-infected 
humans (Gilligan et al. 1991; Kienzle et al. 1999), neither RPMS1 nor A73 has been 
identified in a natural EBV infection, resulting in their existence in real EBV infections 
remaining a controversial issue. 
 
Although the majority of the EBV genome in C15 NPC tumour DNA is heavily methylated, 
an unmethylated region was found around the BART promoter and extended about 1 kb 
downstream, suggesting that the genome there is protected from methylation by the binding 
factors involved in the activity of the BART promoter (de Jesus et al. 2003). 
 
1.7.6 EBV-encoded microRNAs (miRNAs) 
In addition to the BART transcripts, the BART miRNAs are thought to be almost exclusively 
derived from introns prior to splicing of the BART primary transcripts (Edwards et al. 2008). 
EBV was initially reported to express five miRNAs from two separate regions of the EBV 
genome, the BamHI A (BART miRNAs) and the BamHI H (BHRFI miRNAs)  regions 
(Pfeffer et al. 2004), although subsequent analysis has revealed EBV to be capable of 
expressing up to 22 miRNAs. However, many of these are encoded in DNA missing from the 
prototypic B95.8 genome (Cai et al. 2006; Grundhoff et al. 2006). The expression patterns of 
EBV miRNAs are complex, depending upon both cell type and the overall pattern of gene 
expression. For example, in NPC cell lines, the cluster of BART miRNAs is robustly 
expressed, whereas expression is much less abundant in most B-lymphocyte derived lines 
(Cai et al. 2006). Conversely, the BHRFI cluster of miRNAs is not detected in NPC cells, but 
is expressed in B-cells which exhibit a latency III pattern of  gene expression (Xing and Kieff 
2007). An additional level of complexity arises upon the induction of lytic EBV replication, 
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which induces expression of many but not all of the EBV-encoded miRNAs (Cai et al. 2006; 
Xing and Kieff 2007).  
The importance of miRNAs in EBV infection is supported by the high degree of conservation 
of most miRNAs between rhesus lymphocryptovirus and EBV (Cai et al. 2006), although few 
functional targets have been definitively identified for EBV miRNAs. However, there is 
evidence that miRNA BART2 is able to regulate the EBV DNA polymerase gene (Barth et al. 
2008), and that miRNA BART 1-5p and 17-5p can regulate LMP1 (Lo et al. 2007). 
1.7.7 EBNA1 
EBNA1 expression is observed in all EBV-infected cells, in which its role in the maintenance 
and replication of the episomal EBV genome is achieved through sequence-specific binding 
to the plasmid origin of viral replication, OriP. EBNA1 is expressed in all forms of viral 
latency and can be detected in all EBV-associated malignancies (Kieff and Rickinson 2001). 
Given these essential roles in maintenance of the EBV genome and ensuring correct genomic 
segregation into daughter cells, it comes as no surprise that EBNA1 has been one of the most 
intensely studied viral proteins. As previously outlined, the EBV genome is maintained 
predominently as an episome in latently infected cells. Replication of this viral episome is 
synchronised with that of the host cell chromosome, ensuring maintenance of EBV in progeny 
cells (Nonoyama and Pagano 1972). For replication of the EBV genome, requirement exists 
for two viral components: the latent origin of replication, the cis-acting element OriP; and the 
trans-acting element, EBNA1, which binds OriP.  No other viral proteins are required for the 
replication of EBV in latently infected cells, a key observation in the explanation of consistent 
association of EBNA1 with viral latency and EBV-associated malignancies (Yates et al. 1984, 
1985; Lupton and Levine 1985; Reisman and Sugden 1986; Lee et al. 1999). EBNA1 is also 
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known to act as a key viral transcriptional transactivator, having been demonstrated to 
activate both Cp and LMP1 promoters (Sugden and Warren 1989; Gahn and Sugden 1995). 
Additionally, EBNA1 has been shown to negatively regulate its own expression in latency I 
through the binding of two low-affinity EBNA1 sites downstream of the transcriptional start 
site of the Qp promoter (Sample et al. 1992). The absolute requirement for EBNA1 in 
episome maintenance and viral replication has complicated the study of EBNA1’s role in the 
modulation of cellular gene transcription. Nonetheless, there is a growing body of evidence 
suggesting that EBNA1 is capable of regulating expression of cellular, as well as viral, gene 
expression and an involvement of EBNA1 in EBV-associated malignancies is postulated.  
 
1.7.7.1 EBNA1 protein structure 
EBNA1 is a multi-domain DNA binding phospho-protein of around 641 amino acids which is 
encoded by the BamHI K region of the EBV genome. Distinct individual structural domains 
of EBNA1 have been characterised and are represented in the schematic of Figure 1.2. A 
significant portion of the amino-terminal half of EBNA1 is made up of a large domain 
containing a glycine-alanine (Gly/Ala) co-polymer repeat which shows variation in size 
between EBV isolates (Kieff and Rickinson 2001). Despite its significant structural presence, 
the Gly/Ala repeat region of EBNA1 has been shown to be dispensable for EBNA1 function, 
with deletion of the region not affecting the replication and transcription functions of EBNA1 
in vitro (Yates and Camiolo 1988) or the ability of EBNA1 to immortalise B-lymphocytes 
(Lee et al. 1999). However the Gly/Ala repeat region does play an important role in evasion 
of the host immune response by EBNA1, efficiently inhibiting ubiquitin/proteasome-mediated 
degradation of EBNA1. This acts to prevent processing of EBNA1 polypeptides and 
subsequent presentation to CTLs by MHC class I molecules on the cell surface (Levitskaya et 
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al. 1997). Protection from degradation afforded by a Gly/Ala repeat is not restricted to viral 
proteins, as a minimal Gly/Ala repeat prevents the interaction of ubiquitinated IκBα with the 
proteasome (Sharipo et al. 1998).  
EBNA1 possesses a nuclear localisation signal (NLS) which is located between amino acids 
379 and 386. Nuclear import of EBNA1 may be mediated by the nuclear importin receptor 
Rch1/importin α as interaction of EBNA1 with such complexes has been identified in vitro 
(Fischer et al. 1997; Kim et al. 1997). 
Mutation of the carboxy-terminus of EBNA1 abrogates EBNA1’s ability to regulate viral 
replication and transcription (Yates and Camiolo 1988), suggesting that sequences encoded 
here are crucial for EBNA1 dimerisation and DNA binding. More recently, the crystal 
structure of the EBNA1 DNA binding domain was resolved, with two domains characterised 
(Bochkarev et al. 1996). A core domain, similar to the bovine papilloma virus E2 protein’s 
DNA binding domain was identified, along with a flanking domain which contacts DNA 
sequences. The function of EBNA1’s 34-amino-acid acidic tail, situated carboxy-terminal to 
the DNA binding/dimerisation domain, is yet to be elucidated. 
Two DNA-linking regions (amino acids 40 to 89, and 328 to 377) of EBNA1 confer the 
ability of DNA-bound EBNA1 dimers to associate with other DNA-bound EBNA1 dimers, 
thus looping out intervening sequences (Mackey et al. 1995; Leight and Sugden 2000).      
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Figure 1.2 - The 641 amino acid structure of EBNA1 from the prototypical B95.8 strain of 
EBV. The amino terminal consists of a large domain of 328 amino acids containing the gly-
ala repeat sequence, which prevents presentation of EBNA1 antigens by MHC class I 
molecules.  Two positively charged regions within EBNA1 (amino acids 40-89 and amino 
acids 328-337) are referred to as linking region 1 and 2 respectively (LR1 and LR2) and are 
involved in DNA-linking.  A nuclear localisation sequence is located between amino acids 
379-386.  Finally, the carboxy terminus encodes the sequences required for dimerisation and 
site-specific DNA-binding, in addition to a 38 amino acid acidic tail with unknown function. 
Also shown are sequences required in mediating DNA replication, segregation and 
transcriptional activation functions of EBNA1 through binding to OriP, and those involved in 
associating with human EBP2 and USP7.  Viral replication requires the DNA 
binding/dimerisation domain and redundant contributions of both the 8-67 and 325-376 
regions.  Maintenance and segregation of the viral episome requires the DNA 
binding/dimerisation domain, residues 325-376 and is stimulated by residues 8-67.  
Transcriptional activation of viral promoters requires the DNA binding/dimerisation domain, 
residues 61-83 (shown as residues 67-81 for clarity in Figure) and 325-376, and is stimulated 
by residues 8-67.  EBP2 binding is primarily mediated by amino acids 325-376 and is 
stimulated by residues 8 to 67, whereas USP7 binding requires residues 395-450. 
DNA-binding motifs (AT hooks) that are proposed to enable EBNA1 to play a direct role in 
episome segregation (Sears et al. 2004) are found between residues 33 to 89, and residues 328 
to 378. 
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1.7.7.2 Modulation of viral replication, episome segregation and transcription - OriP and 
EBNA1 
EBV DNA replication initiates within the dyad symmetry (DS) element of OriP, which 
contains four binding sites for EBNA1 (Reisman et al. 1985; Gahn and Schildkraut 1989; 
Wysokenski and Yates 1989; Niller et al. 1995), whereas the partitioning of EBV episomes 
involves EBNA1 binding to the family-of-repeats (FR) element of OriP, which contains 20 
EBNA1 binding sites (Lupton and Levine 1985; Reisman et al. 1985). EBNA1 binding to the 
FR element also enhances expression of other viral latency proteins (Reisman and Sugden 
1986; Gahn and Sugden 1995).  
EBNA1 binding to recognition sites in OriP is reasonably well understood, with the binding 
of an EBNA1-dimer to each site, and cooperative assembly on the four sites in the DS 
element  (Frappier and O'Donnell 1991; Hearing et al. 1992; Summers et al. 1996). However, 
precise mechanisms of transcriptional and DNA replication activation by EBNA1 are more 
poorly defined. EBNA1 does not possess enzymatic activity, and as such these mechanisms 
are likely to involve the recruitment of cellular proteins, including the cellular origin 
recognition complex and minichromosome maintenance complex  (Chaudhuri et al. 2001; 
Dhar et al. 2001; Schepers et al. 2001), to OriP and possibly the remodelling of EBV 
chromatin structure. EBNA1  is known to bind and destabilise nucleosomes formed on the DS 
element (Avolio-Hunter et al. 2001), presumably allowing the access of host DNA replication 
machinery to the EBV origin of replication. In addition to four EBNA1-binding sites, the 
EBV DS repeat element contains three copies of a nonameric telomere repeat sequence which 
contributes to OriP plasmid maintenance and DNA replication (Yates et al. 2000). EBNA1-
dependent binding of telomeric repeat binding factor 2 (TRF2) to these repeats has been 
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demonstrated (Deng et al. 2002), although other telomeric regulatory factors have been 
identified to bind OriP and have an inhibitory function (Deng et al. 2002; Deng et al. 2003).  
 
A substantial body of evidence supports the idea that EBNA1 is able to govern the 
partitioning of EBV episomes and FR-containing constructs, through the mediation of their 
attachment to cellular mitotic chromosomes. EBV episomes, OriP containing constructs and 
EBNA1 have all been observed to associate with condensed cellular chromosomes during 
mitosis (Grogan et al. 1983; Harris et al. 1985; Petti et al. 1990; Delecluse et al. 1993; 
Simpson et al. 1996), with the association of OriP plasmids demonstrated to be EBNA1-
dependent (Kanda et al. 2001). Further, the OriP FR element has been demonstrated to be 
responsible for efficient segregation and mitotic chromosome attachment of DNA constructs 
(Krysan et al. 1989; Kanda et al. 2001). Additionally, deletion of amino acids 325-376 of 
EBNA1 disrupts segregation of FR-containing plasmids and EBNA1 association with mitotic 
chromosomes without affecting nuclear localisation of the protein DNA replication activity 
(Shire et al. 1999; Wu et al. 2000), and functional replacement of the N-terminal half of 
EBNA1 (which mediates chromosome attachment and OriP plasmid maintenance) with 
chromosome binding sequences from histone H1 is possible (Hung et al. 2001).  
 
Evidence suggests that EBNA1 is able to achieve attachment to cellular mitotic chromosomes 
through binding (mediated by amino acids 325-376) to the human EBNA binding protein 2 
(EBP2) on chromosomes (Shire et al. 1999; Wu et al. 2000), EBP2 being a cellular nucleolus 
component which, similarly to EBNA1, coats condensed cellular chromosomes during 
mitosis. The importance of EBP2 to EBNA1-mediated partitioning of FR-containing plasmids 
has been demonstrated through the requirement for human EBP2, EBNA1 and the OriP FR 
element in a reconstituted EBV segregation system in budding yeast (Kapoor et al. 2001). 
54 
 
Introduction 
Further, it was demonstrated that human EBP2 associates with yeast mitotic chromosomes in 
a cell cycle-dependent manner, resulting in subsequent EBNA1 recruitment to these 
chromosomes (Kapoor and Frappier 2003) and the necessity for EBP2 for the proliferation of 
human cells has also been shown (Kapoor et al. 2005). However, other evidence has been 
produced which is inconsistent with this model of EBP2-EBNA1 action. The observation that 
the amino terminus of EBNA1 contains DNA-binding motifs (AT hooks) that are found in a 
family of proteins that binds scaffold-associated regions on metaphase chromosomes has led 
to the proposal of a more direct role for EBNA1 (Sears et al. 2004), which would yield 
random partitioning.  
 
The FR element of OriP also acts as an enhancer element following EBNA1 binding 
(Reisman and Sugden 1986), enhancing transcription from the Cp and LMP1 promoters 
(Sugden and Warren 1989; Gahn and Sugden 1995), although the mechanism by which this 
transcriptional enhancement is enabled is yet to be fully elucidated. Evidence suggests that 
EBNA1 domains responsible for DNA binding/dimerisation and DNA linking are required 
(Mackey and Sugden 1999; Ceccarelli and Frappier 2000; Wu et al. 2002a), however 
EBNA1’s ability to associate with cellular proteins such as EBP2 via these linking regions 
opens the possibility that recruitment of additional cellular proteins by EBNA1 may occur 
through relocation of the EBV episome to transcriptional activation centres within the 
nucleus. Here, EBNA1 may facilitate the looping out of DNA sequences, linking the OriP FR 
element with a site proximal to promoters. Similar cellular examples of such looping out of 
DNA sequences exist, for example the p53-mediated transactivation of the muscle creatine 
kinase promoter (Jackson et al. 1998). Further, dimerisation of the E2 protein of HPV16, 
which also plays a central role in the regulation of regulating viral gene expression and 
replication, has recently been demonstrated to be responsible for DNA loop formation in the 
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regulatory region of the HPV genome (Hernandez-Ramon et al. 2008). The mitochondrial 
protein, p32/TAP, has also been demonstrated to associate with EBNA1 (Wang et al. 1997a) 
and shown to be important in the mediation of transcriptional activation via the FR of OriP 
(Van Scoy et al. 2000). However, other data suggest that the EBNA1-p32 interaction may be 
non-specific (Holowaty et al. 2003b). More recently, it has been demonstrated that EBNA1 
can functionally interact with Brd4 in native and heterologous systems, that this interaction 
facilitates transcriptional activation by EBNA1 from the FR element (Lin et al. 2008), and 
that deletion of AT hook motifs within the DNA-binding domain of EBNA1 (previously 
proposed to play a role in episome segregation) decreases the transactivation ability of 
EBNA1. This finding suggests a significant transcriptional role for this DNA-binding motif 
(Singh et al. 2009). 
 
The domains of EBNA1 involved in functional processes have been elucidated (and are 
represented diagrammatically in Figure 1.2), with the three EBNA1 functions having 
overlapping but different sequence requirements. Transcriptional activation requires residues 
61 to 83 and 325 to 376 and is stimulated by residues 8 to 67; partitioning requires residues 
325 to 376 and is stimulated by residues 8 to 67; and replication involves redundant 
contributions of both the 325-to-376 and 8-to-67 regions (Yates and Camiolo 1988; 
Kirchmaier and Sugden 1997; Ceccarelli and Frappier 2000; Wu et al. 2002a). Recently, 
further mechanistic studies on EBNA1 transcriptional activation have been performed, with 
zinc shown to be necessary for residues 61-83 of EBNA1 to activate transcription, and that 
this region of EBNA1 coordinates zinc through a pair of essential cysteine residues contained 
within it. Residues 61-83 were also shown to dimerise upon coordinating zinc, revealing that 
EBNA1 contains a second dimerisation interface in its amino-terminus (Aras et al. 2009).  
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Recent work has also suggested that phosphorylation sites of EBNA1 are involved in the 
regulation of its function. Ten specific phosphorylated EBNA1 residues were identified, and a 
phosphorylation deficient mutant derivative of EBNA1 was shown to be significantly reduced 
in its ability to maintain EBV plasmids in cells and activate transcription, despite the mutant 
retaining a long half-life and nuclear translocation ability (Duellman et al. 2009).  
1.7.7.3 Viral promoter regulation of EBNA1 
EBNA1 transcription is driven from four different viral promoters in EBV-infected cells. 
These promoters are termed Cp, Wp, Qp and Fp, and are located in the BamHI-C, BamHI-W, 
BamHI-Q, and BamHI-F regions of the viral genome respectively (Kieff and Rickinson 
2001). Differential use of these promoters is observed during different latency programmes 
and lytic cycle in EBV-infected B-lymphocytes. In LCLs, where a latency III pattern of gene 
expression is seen, transcription of EBNA1 is initiated from Cp/Wp promoters, with the Qp 
promoter transcriptionally silenced. Qp activity is subject to EBNA1 autoregulatory control 
(Sample et al. 1992) along with control by multiple cellular factors, including cytokines and 
cell cycle factors, that play both positive and negative roles in regulating Qp activity (Sung et 
al. 1994; Davenport and Pagano 1999; Zhang and Pagano 1999, 2000; Liang et al. 2000). 
Preferential selection for usage of a particular EBNA1 promoter is observed in EBV-infected 
epithelial cells and EBV-associated malignancies where the established programme of latency 
varies from the latency III programme observed in LCLs. For example, EBNA1 is transcribed 
from the Qp promoter in type I and II latency programmes (BL, HL, NPC) (Kieff and 
Rickinson 2001), with silencing of the Cp/Wp promoters through methylation observed 
(Schaefer et al. 1997). During type I latency, EBNA1 transcription was initially thought to be 
driven from Fp, although this theory was based on findings in cells undergoing spontaneous 
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lytic replication (Sample et al. 1991; Schaefer et al. 1991) and subsequent analysis revealed 
EBNA1 transcription is initiated from Fp in lytically induced cells, and the Fp promoter was 
found to be localised 100-200bp upstream of Qp (Schaefer et al. 1995, 1997; Tsai et al. 1995; 
Nonkwelo et al. 1996). 
1.7.7.4 The role of EBNA1 in the modulation of cellular transcription and tumourigenesis 
Classically EBNA1 is regarded as a genome maintenance protein, though there is a growing 
body of evidence suggesting that it may contribute to the cell transforming properties of EBV. 
The role of EBNA1 in the development of EBV-associated malignancies remains 
controversial, and despite the accumulating support for its role in oncogenesis, several reports 
contradict such findings.  
In one of the first studies implicating EBNA1 in cellular transformation, targeted expression 
of EBNA1 to the B-cell compartment in two lineages of transgenic mice resulted in 
lymphomas, which were reported to be phenotypically similar to lymphomas induced by 
dysregulated c-Myc (Wilson et al. 1996). However, the results of more recent similar 
transgenic studies failed to recapitulate these findings, as observations failed to demonstrate 
an association between EBNA1 and lymphoma development (Kang et al. 2005), although an 
increased susceptibility to pulmonary adenoma was observed in EBNA1-positive FVB mice 
(Kang et al. 2008). Consistent with EBNA1 not playing a role in cellular transformation, 
another report has shown that LCLs generated with EBV deleted for EBNA1 are 
indistinguishable from their EBNA1-positive counterparts and that when these EBNA1-
deleted LCLs were injected into SCID mice, tumour growth was supported, indicating that 
EBNA1 is not mandatory for EBV’s oncogenic potential (Humme et al. 2003). However it 
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should be noted that the frequency of LCL generation achievable with EBV deleted for 
EBNA1 was much lower than the frequency attained with wild type EBV. 
Increased expression of recombination-activating genes 1 and 2 is observed in EBV-positive 
BL cells, compared with their EBV-negative counterparts, and has been demonstrated to be 
dependent on EBNA1 expression (Srinivas and Sixbey 1995), leading to the postulate that 
EBNA1 may contribute to the characteristic c-myc translocation of BL (Srinivas and Sixbey 
1995; Wilson et al. 1996). Such an oncogenic role for EBNA1 in BL is seemingly consistent 
with findings that EBNA1 is the only viral protein consistently detected in this EBV-
associated malignancy, and data which revealed that the use of a dnEBNA1 in EBV-positive 
BL lines resulted in decreased cell viability  (Kennedy et al. 2003). However, alternative 
dnEBNA1 studies, conducted this time in LCLs with a stably integrated EBV genome, failed 
to show any dnEBNA1 induced changes in viral or cellular gene expression, other than a 
slight effect on EBER expression (Kang et al. 2001). Further, studies in which EBNA1 was 
expressed in EBV-negative BL cells failed to show any effect of EBNA1 expression upon cell 
growth, tumourigenicity and apoptosis in response to a range of stimuli (Komano et al. 1998; 
Ruf et al. 1999). 
Recent studies of the role of EBNA1 in another B-cell malignancy, HL, have revealed 
induction of CD25 and CCL20, and down-regulation of transforming growth factor β (TGFβ)-
target gene PTPRK in response to EBNA1 expression, contributing to the growth and survival 
of HL cells (Baumforth et al. 2008; Flavell et al. 2008). 
The results of several other studies of EBNA1 function suggest that the protein plays a role in 
the modulation of cellular pathways involved in tumourigenesis. EBNA1 has been 
demonstrated to associate with a known suppressor of metastasis and cell migration, Nm23-
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H1, in EBV-transformed LCLs, removing the protein’s repressive effect of upon cell motility 
(Murakami et al. 2005).   Further, EBNA1 interacts with the human deubiquitinating enzyme, 
USP7 (Holowaty et al. 2003a), through amino acids 395-450 (Holowaty et al. 2003a). USP7 
is known to associate with p53, causing deubiquitination of this tumour suppressor protein 
and thus rescuing it from proteasomal degradation, ultimately leading to p53-mediated cell 
growth suppression (Li et al. 2002). As such, it is postulated that EBNA1 may contribute to 
host cell immortalisation by EBV through sequestration of USP7 and subsequent 
destabilisation of p53. 
Much evidence also exists for EBNA1 playing a tumourigenic role in epithelial cells. EBNA1 
has been observed to destabilise p53 (through USP7 interaction) and promote cell survival in 
epithelial cells (Saridakis et al. 2005), and EBNA1-expressing NPC-derived cells were 
reported to form large, highly metastatic and poorly differentiated tumours following injection 
into mice (Sheu et al. 1996). More recently, EBNA1-mediated disruption of PML nuclear 
bodies was observed in NPC cells, promoting the survival of cells with DNA damage. PML 
nuclear body disruption by EBNA1 was shown to be independent of p53, but dependent upon 
binding to cellular USP7, with EBNA1 expression leading to the impairment of several 
cellular processes (including DNA repair and apoptosis) that are PML-dependent 
(Sivachandran et al. 2008).  
In contrast to previous data, suggesting no transactivation of cellular genes or integrated viral 
genes by EBNA1in LCLs (Kang et al. 2001), EBNA1 appears to be a potent transcriptional 
regulator in nasopharyngeal cells. In findings similar to those previously mentioned in HL 
(Flavell et al. 2008), EBNA1 has been shown to regulate the TGFβ pathway negatively, 
through an increase in the turn-over of the mothers against decapentaplegic homologue 2 
(SMAD2) transcription factor. As TGFβ is a widely regarded tumour suppressor, inactivation 
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of TGFβ signalling by EBNA1 may contribute to the development and metastatic nature of 
NPC (Wood et al. 2007). EBNA1 has also been found to modulate the AP-1 transcription 
factor pathway (O'Neil et al. 2008).  
Recently, EBNA1 has been identified to bind to promoter regions of cellular genomic DNA in 
EBV-positive B-cells (Dresang et al. 2009), and although no EBNA1-dependent activation of 
reporter constructs from these promoters was observed, these findings may prove of huge 
significance in elucidating future mechanisms of EBNA1-mediated modulation of cellular 
transcription and tumourigenesis.  
1.7.8 EBERs 
In addition to the EBV latent protein complement, two small non-polyadenylated and non-
coding RNAs, EBER1 and EBER2, are detected in all forms of viral latency, and are 
frequently used as a diagnostic marker for EBV infection. The EBERs are transcribed from 
the EcoRI-J fragment of the EBV genome, and are 167 and 172 nucleotides in length 
respectively. EBERs are abundantly transcribed in latently infected cells, with up to 107 
copies of the EBERs present in each cell (Lerner et al. 1981a; Arrand and Rymo 1982; Nanbo 
and Takada 2002). However, despite their abundant and ubiquitous expression, the EBERs 
are not essential for the EBV-induced transformation of B-lymphocytes (Swaminathan et al. 
1991; Yajima et al. 2005; Wu et al. 2007).  
The EBERs are similar in size and gene organisation to two small adenovirus RNAs, VAI and 
VAII. Other similarities between EBERs and VA RNAs exist, with both being transcribed by 
RNA polymerase III (pol III) and binding the same cellular proteins. This suggests that 
EBERs and VA RNAs may perform analogous functions in infected cells. The VA RNAs 
have been shown to be critical for adenovirus replication by rescuing cells from the shutdown 
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of protein translation mediated by the cellular kinase PKR, which is induced by interferon and 
activated by double-stranded RNAs produced during replication of many viruses 
(Hovanessian 1989; Ghadge et al. 1994). Further, in vitro analysis of adenovirus mutant 
constructs, in which VA RNAs were replaced by EBERs, revealed the EBERs to be capable 
of functionally substituting for the VA RNAs (Bhat and Thimmappaya 1983; 1985). 
 
Following EBV infection of B-lymphocytes, temporally the EBERs are the last EBV latent 
gene products to be expressed (Rooney et al. 1989; Alfieri et al. 1991). Further, the P3HR-1 
virus (which is transformation defective) is able to express the EBERs in BL cells, but not 
resting B-cells, highlighting the requirement for an activated cellular environment for EBER 
expression to occur (Rooney et al. 1989). Despite being transcribed at approximately equal 
rates EBER1 is often reported as being more abundant than EBER2 in latently infected cells, 
possibly due to EBER1 possessing a longer half-life, of around 9 hours compared with 
EBER2’s half-life of less than an hour (Clarke et al. 1992; Komano et al. 1999). Indeed a 
recent study, although not addressing EBER2 half-life, estimated the half-life of EBER1 to be 
even longer, at around 25 hours (Fok et al. 2006b). A switch from latent to lytic infection is 
accompanied by a significant down-regulation of EBER transcription, and although the 
mechanism behind this down-regulation of EBER transcription is currently undetermined, 
such a switch is consistent with the absence of EBER expression in the permissive EBV 
lesion oral-hairy leucoplakia (OHL) (Gilligan et al. 1990a; Greifenegger et al. 1998).  
The EBERs are thought to localise predominantly to the nucleus, although some evidence 
suggests that they are detectable in the cytoplasm. One of the first studies to examine EBER 
localisation used in situ hybridisation assays and reported EBER expression to be confined to 
the nucleus (Howe and Steitz 1986), although a later report using more sensitive techniques 
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(confocal microscopy) suggested that the EBERs were present in the cytoplasm during some 
phases of the cell cycle, with EBER localisation varying remarkably with the phases of the 
cell cycle (Schwemmle et al. 1992). Further analysis using in situ hybridisation supported the 
notion that the EBERs are mainly nuclear, although differences in the localisation of EBER1 
and EBER2 were reported, with no colocalisation of the two molecules found, such analysis 
suggesting distinct roles for EBER1 and EBER2 (Teramoto et al. 1998). More recently, 
EBER localisation was again addressed, with the EBERs found not to shuttle out of the 
nucleus, possibly as a consequence of their failure to bind exportin 5 (Fok et al. 2006a). As 
such, it is widely accepted that the EBERs are subject to nuclear localisation, though the 
possibility of leakage to the cytoplasm should not be completely discounted.  
A high degree of secondary structure is adopted by EBER1 and EBER2, involving long stems 
and loops due to strong intra-molecular bond formation (Nanbo and Takada 2002). This 
complex structure of the EBERs enables interaction with dsRNA binding proteins that are 
thought to be important for EBER function, an observation that is supported by the high levels 
of EBER1 and EBER2 sequence conservation reported among EBV isolates (Arrand et al. 
1989). The EBERs are reportedly able to associate with four cellular proteins: (1) La antigen; 
(2) ribosomal protein L22; (3) protein kinase R (PKR); and (4) retinoic acid-inducible gene-1 
(RIG-I) (Lerner et al. 1981a; Clarke et al. 1991; Toczyski and Steitz 1991; Nanbo et al. 2002; 
Samanta et al. 2006). The EBERs are detected in ribonucleoprotein (RNP) complexes with La 
antigen using autoreactive sera from systemic lupus erythematosus patients (Lerner et al. 
1981a), with these RNP complexes also containing L22 (Toczyski and Steitz 1991). EBER 
sequestration of L22 in the nucleus has also been observed, with the EBERs preventing L22 
from being incorporated into ribosomal machinery (Toczyski et al. 1994). Although it is 
possible that EBER interactions with La and L22 may affect RNA splicing and translation, 
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the precise physiological role of the interaction between the EBERs and these cellular 
proteins remains unidentified. The association of the EBERs with two dsRNA binding 
proteins of the innate immune system, PKR and RIG-I, is well studied and of known 
significance in explaining EBER function.  
Despite not being required for EBV reactivation, replication, virion release, infectivity, viral 
gene expression and the transformation of B-lymphocytes in vitro, the EBERs have been 
demonstrated to increase transformation efficiency by approximately 100 fold and promote 
LCL growth at low cell densities (Swaminathan et al. 1991; Yajima et al. 2005; Wu et al. 
2007). It is now understood that these effects are dependent on EBER2, rather than EBER1 
expression, and are mediated in part by the enhanced secretion of IL-6 which acts as both an 
autocrine growth factor and an inhibitor of apoptosis (Wu et al. 2007). EBER expression in 
BL cells has also been demonstrated to induce tumours when cells are injected into nude 
mice. Further, EBER expression in BL cells induces anchorage-independent growth, 
resistance to apoptosis, enhanced proliferation and the secretion of type I interferon (IFN) 
along with the autocrine growth factor IL-10 (Komano et al. 1999; Kitagawa et al. 2000; Ruf 
et al. 2000, 2005; Yamamoto et al. 2000; Nanbo et al. 2002; Samanta et al 2006), with the 
secretion of these cytokines being shown to be dependent on the activation of RIG-I by the 
EBERs (Samanta et al. 2006, 2008). EBERs appear to confer resistance to apoptotic stimuli 
through binding to, and inactivation of, PKR (Ruf et al. 2005; Wang et al. 2005b). 
The biological effects of the EBERs are not restricted to lymphocytes: work with epithelial 
cells has shown that the EBERs induce the expression of insulin-like growth factor 1 (Iwakiri 
et al. 2003, 2005). Induction of the expression of these autocrine growth factors in epithelial 
cells as well as lymphocytes hints at the transforming role the EBERs may play in EBV 
pathology. Furthermore, stable expression of EBERs in immortalised nasopharyngeal 
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epithelial cells confers resistance to apoptotic stress, with EBER expression also preventing 
p38 and c-Jun phosphorylation in response to dsRNA suggesting inhibition of AP-1 (Wong et 
al. 2005). EBER expression in intestinal 407 epithelial cells has also been reported to prevent 
FAS-mediated apoptosis (Nanbo et al. 2005). However, EBER expression has been found to 
be insufficient to transform pre-malignant nasopharyngeal cells, with the EBERs failing to 
induce anchorage-independent growth or induce tumours in nude mice (Wong et al. 2005), 
although in a more recent study, high levels of EBER expression in MDCK cells (but not 
NPC-KT cells) induced growth in soft agarose (Yoshizaki et al. 2007). 
The increase in various cytokines following EBER expression (Kitagawa et al. 2000; Iwakiri 
et al. 2003, 2005; Yang et al. 2004) has been determined to be at the level of mRNA, 
implicating induction of transcription or transcript stabilisation by the EBERs, although in the 
absence of evidence for direct or indirect interaction with promoter sequences or mRNAs, a 
plausible mechanism for the action of EBERs to induce highly gene specific effects is still 
lacking (Swaminathan 2008). Supporting the idea of EBER-induced changes to cellular 
transcription, recently published data suggest a cellular transcription response to EBER2 
expression in HEK293 cells, with significant changes in patterns of gene expression observed 
(Eilebrecht et al. 2008).  
 
Cellular non-coding RNAs have increasingly come to be recognised as playing important 
regulatory roles in cellular transcription, with a recent report describing how PIP7S, a nuclear 
La-related protein, binds and stabilises 7SK RNA, which is involved in regulating 
transcriptional elongation by pol II (He et al. 2008). Some speculation exists that the EBERs 
could be viral counterparts of cellular non-coding RNAs, playing a significant part in 
regulation of a multitude of cellular functions (Swaminathan 2008).  
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1.7.8.1 Transcriptional regulation of EBER expression 
Although transcribed exclusively by RNA polymerase (pol) III, the EBER promoters contain 
a hybrid of pol II and pol III elements. A schematic of the EBERs and their transcriptional 
regulatory regions is shown in Figure 1.3, with both EBER1 and EBER2 possessing similar 
promoter regions significant for their expression including intragenic A and B blocks (typical 
of type 2, pol III promoters) (Rosa et al. 1981; Arrand and Rymo 1982), an upstream TATA 
box,  and upstream ATF-2 and Sp1 binding sites (typical pol II promoter regions) (Howe and 
Shu 1989; 1993; Felton-Edkins et al. 2006). In addition, EBER1, but not EBER2, has two E-
boxes 130bp upstream of its transcriptional start site to which c-Myc has been shown to bind 
both in vitro and in vivo (Niller et al. 2003), although the importance of these binding sites 
has been questioned by a study which demonstrated that excision of these sites had no effect 
upon EBER expression (Wensing et al. 2001). The promoter for EBER2 has been analyzed by 
testing mutated promoters in transfection assays (Howe and Shu 1989; 1993), with results 
showing that deletion of 5' sites that would be expected to bind Sp1 and ATF-2 together 
reduced transcription by more than 90%. Additionally, deleting the TATA box reduced 
expression even further and mutations in either the Sp1 or TATA box regions reduced 
expression by 80%, whereas mutating the ATF-2 site reduced expression by 50%. 
Subsequently similar experiments have been conducted to analyse the effects of disrupting the 
promoter regions upstream of EBER1, with results confirming the importance of these 
regions to EBER1 expression, and suggesting that the ATF-2 binding site is of particular 
importance. The same study revealed that the presence of OriP and EBNA1 increased EBER 
transcription two- to four-fold, but had a much smaller effect than has been observed on the 
Cp or LMP1 promoters, which are conventional RNA polymerase II promoters (Wensing et 
al. 2001).  
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Figure 1.3 - Promoter regions of EBER1 and EBER2. ‘A’ and ‘B’ denote internal A- and B-
blocks, typical of type II, pol III promoter regions to which pol III specific transcription factor 
TFIIIC binds. Upstream elements include TATA box (-23 to -28), Sp1 (-56 to -77) and ATF  
(-40 to -55) binding sites (CRE motif). Notably, EBER1, though not EBER 2 possesses a c-
Myc binding site (consisting of two E-boxes) at -149 to -130 relative to its transcriptional start 
site.  Deletion of the 5' sites that would be expected to bind Sp1 and ATF-2 together has been 
shown to reduce EBER transcription by more than 90%. Additionally, deleting the TATA box 
reduces expression even further and mutations in either the Sp1 or TATA box regions reduces 
expression by 80%, whereas mutating the ATF-2 site reduces expression by 50% (Howe and 
Shu 1989, 1993). 
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Several observations suggest that the massive expression of EBER genes in EBV-transformed 
cells is not simply due to inherent strength of the EBER promoters, but instead requires EBV-
induced changes to the cellular environment, with previous studies suggesting a strong 
influence of trans-acting factors in controlling the transcription of the EBERs. Stable 
transfection of EBER1 alone allowed maximal expression of 105 transcripts per cell, whereas 
latent infection with the EBV genome can result in 107 EBER1 transcripts per cell (Lerner et 
al. 1981b; Laing et al. 2002). Significant EBER expression only becomes apparent 36 h after 
infection, following the appearance of other EBV latent gene products (Rooney et al. 1989). 
Further, when latently infected cells switch to lytic viral replication, transcription of the 
EBERs decreases dramatically (Greifenegger et al. 1998).  
EBV-induced changes to the cellular environment that appear to contribute to achieving high 
levels of EBER expression have recently been identified and described (Felton-Edkins et al. 
2006). EBV was shown to induce the cellular transcription factors TFIIIB and TFIIIC 
(leading to induction of general cellular pol III-mediated transcription) and the typical pol II 
transcription factor ATF-2, that enhance expression of EBER1 and EBER2. Cellular factors 
seemingly induced by EBV and involved in the transcription of the EBERs (pol III 
transcription, ATF-2, c-Myc) are discussed more fully later in this introductory section. 
Methylation, or rather hypomethylation, has also recently been shown to play a possible role 
in EBER regulation. CpG-methylation is known, in most cases, to block the activity of pol II 
transcribed promoters, and although the role of DNA methylation in the regulation of pol III 
transcribed promoters is less clear, a recent study found that in vitro methylation of EBER1 
and EBER2 promoters blocked the binding of c-Myc and ATF-2 to the 5’ regions of these 
genes, silencing their expression (Banati et al. 2008). This is significant as the EBER locus is 
invariably hypomethylated in cell lines, with the tight binding of nuclear proteins and 
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constitutive transcription proposed to keep the EBER locus methylation free, even in NPC 
cells that carry otherwise highly methylated episomes (Minarovits et al. 1992). These data 
also seem to confirm further the importance of typical pol II promoter regions upstream of 
EBER1 and EBER2. 
EBV copy number may also play a role in determining levels of EBER expression. This topic 
is addressed in Chapter 3.  
1.7.8.1.1 RNA polymerase III transcription 
The EBERs, and other viral non-coding RNAs (e.g. adenovirus VA RNAs), are transcribed 
exclusively by pol III, meaning an understanding of pol III transcription, and its links with 
cancer and viral infection, is critical in appreciating the role of pol III in expression of these 
abundantly expressed viral gene products.   
 Archaea and prokaryotes utilise just a single RNA polymerase in the transcription of their 
genes, but in eukoryotes this cellular transcription is divided between three RNA 
polymerases, pol I, pol II and pol III. All protein-encoding genes, along with many genes for 
non-coding RNAs are transcribed by pol II, with pol I and III specialised to the exclusive 
expression of non-coding RNAs. Despite this restriction, pols I and III are known to 
contribute up to 80% of all nuclear transcription in rapidly proliferating cells (White 2008). 
Pol I is unique among the nuclear RNA polymerases in transcribing only one set of genes: the 
large, tandemly repeated, ribosomal RNA (rRNA) genes, and thus in having to recognise a 
single promoter structure. Pol II promoters can be divided into a core region, defined as the 
minimal region capable of directing transcription in vitro, and a regulatory region. The 
regulatory regions are highly varied in structure, which reflects the highly varied synthesis 
patterns of cellular proteins and the need for exquisite and complex regulation of these 
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patterns. Comprehensive reviews of the complexities of pol II transcription are available 
(Orphanides et al. 1996; Woychik and Hampsey 2002; Juven-Gershon et al. 2008). 
Pol III promoters are more varied in structure than the uniform RNA polymerase I promoters, 
though not as diverse as the RNA polymerase II promoters. They have been divided into three 
main types (see Figure 1.4), two of which are gene-internal and generally TATA-less (types 1 
and 2), and one of which is gene-external and contains a TATA box. EBERs can be 
characterised as having elements typical of both type 2 and 3 pol III promoter types, with 
additional typical pol II transcription factor binding elements also present. The cellular 7SL 
genes have an upstream promoter arrangement similar to the EBER genes, as well as 
important internal promoter sequences (Ullu and Weiner 1985; Kleinert et al. 1988; Howe and 
Shu 1993; Muller and Benecke 1999).  
The promoters of pol III templates that are located within the transcribed region are bound 
directly by TFIIIC, a large complex of six subunits, TFIIIC-220, -110, -102, -90, -63 and the 
newly characterised (Dumay-Odelot et al. 2007) TFIIIC-35. By contrast, the type 1 internal 
promoters (exclusive to the 5S rRNA gene) are recognised by a polypeptide called TFIIIA 
that provides a binding site for TFIIIC. TFIIIC functions to recruit TFIIIB, a complex 
composed of the TATA-binding protein (TBP) and the Brf1 and Bdp1 polypeptides, which is 
responsible for the subsequent recruitment of pol III and its positioning over the transcription 
start site. Pol III itself has 17 subunits and is the largest RNA polymerase known (White 
2008). A comprehensive review of pol III recruitment to its target promoters is available 
(Schramm and Hernandez 2002), and provides insight into the mechanistic complexities and 
variations of pol III recruitment to each promoter type. Recent data have addressed pol III 
recruitment in vivo, and provide support for the in vitro models previously described (Kenneth 
et al. 2008). 
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RNA polymerase III is dedicated to the transcription of an eclectic collection of genes whose 
main common features are that they encode structural or catalytic RNAs and that they are 
invariably shorter than 400bp, a length limit consistent with the elongation properties of pol 
III, which recognises a simple T-residue run as a termination signal (Schramm and Hernandez 
2002). Pol III products include transfer RNAs (tRNA), 5S rRNA, and 7SL RNA, which is 
needed to insert proteins into membranes as part of the signal recognition particle.  Further 
products include the U6, MRP and H1 RNAs, required to process mRNA, rRNA and tRNA, 
respectively (Dieci et al. 2007). Pol III also synthesises 7SK, Alu and B2 RNAs, which can 
regulate pol II transcription and have been implicated in the expression of a subset of human 
miRNAs (White 2008). 
Pol III products are aberrantly over-expressed in a broad variety of cancers. In 1974, 
hyperactivity of pol III in mice with cancer was observed, in the first such report associating 
increased pol III activity and cancer (Schwartz et al. 1974). Subsequently, abnormally high 
levels of pol III products have been observed in a wide variety of transformed cell types, 
including human ovarian carcinomas (Winter et al. 2000), with one study reporting elevated 
levels of 7SL RNA samples from 19 types of cancer (Chen et al. 1997). Such compelling data 
make a strong association between aberrant expression of pol III transcripts and cellular 
transformation (White 2004).  
The molecular mechanisms that result in increased polIII output in transformed cells and 
cancers can be classified into three general categories: (1) release from repression by tumour 
suppressors; (2) activation by oncogene products; and (3) increased expression of pol III-
associated transcription factors (Marshall and White 2008). Multiple mechanisms may 
contribute to an overall increase in pol III activity in any given cancer.  
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Figure 1.4 – Adapted from Felton-Edkins et al. (2006). Summary of the promoter types 
employed by pol III. The arrow indicates the transcription start site, with PSE denoting 
proximal sequence element and CRE denoting cAMP-response element. A schematic of the 
EBER promoter type is included for comparison. Type 1 and 2 promoters possess only 
internal transcription factor finding sites, with type 1 promoters consisting of A- and C-
blocks, and type 2 promoters consisting of A- and B-blocks. Conversely, type 3 promoters 
consist entirely of promoter binding sites upstream of the transcriptional start site, with a PSE 
and TATA box constituting such a promoter type. 
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Release from tumour suppressor genes may be the most common mechanism by which pol III 
activity is increased in cancers, given that it involves tumour suppressors such as PTEN, p53 
and Rb, whose activities are known to be reduced in a large proportion of malignancies. 
PTEN is able to inhibit pol III transcription through its lipid phosphatase activity, 
counteracting signalling through the PI3K pathway (Woiwode et al. 2008). TFIIIB is also a 
target for p53, Rb, and Rb-like proteins RBL1 and RBL2, which bind it directly and prevent it 
from recruiting pol III to promoters (Chesnokov et al. 1996; Sutcliffe et al. 1999; Sutcliffe et 
al. 2000; Crighton et al. 2003; Hirsch et al. 2004). Other tumour suppressor genes are crucial 
in mediating the binding of both p53 and Rb to TFIIIB (Scott et al. 2001; Morton et al. 2007), 
and TFIIIB is also known to be bound and repressed by Maf1 (Willis and Moir 2007; 
Goodfellow et al. 2008), which although yet to be defined as a tumour suppressor, is known 
to inhibit anchorage-independent growth in glioblastoma cells (Johnson et al. 2007). 
TFIIIB is also regulated by a variety of oncogenic proteins which are able to stimulate, rather 
than repress, its activity. Many oncogenic proteins are able to affect TFIIIB through the 
subversion of negative regulation imposed by Rb and/or p53 (Marshall and White 2008); for 
example the  HPV oncoproteins E6 and E7 have been demonstrated to stimulate pol III 
transcription through the inactivation of p53 and the Rb family respectively (Sutcliffe et al. 
1999; Stein et al. 2002). Ras, Raf, PI3K and Akt operate through oncogenic signalling 
pathways which are able to alter the phosphorylation state of pol III machinery (Wang et al. 
1995; Chesnokov et al. 1996; Felton-Edkins et al. 2003), and c-Myc acts directly on TFIIIB 
stimulating its activity through a physical and genetic interaction  (Gomez-Roman et al. 
2003). Induction of c-Myc increases target occupancy by both TFIIIB and pol III, an effect 
that correlates with localised acetylation of histone H3, a modification that is associated with 
active transcription (Kenneth et al. 2007). Recently published data suggest that pol III 
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induction makes a significant contribution to c-Myc-mediated cell transformation (Johnson et 
al. 2008). 
Over-expression of pol III transcription machinery was first observed for TFIIIC, which has 
been found to be increased in culture following infection or transformation by several DNA 
tumour viruses, including adenovirus, SV40 virus and EBV (Hoeffler et al. 1988; Larminie et 
al. 1999; Felton-Edkins and White 2002; Felton-Edkins et al. 2006). Further, levels of TFIIIC 
have been demonstrated to be abnormally elevated in both NPC (Dr JR Arrand, personal 
communication) and human ovarian carcinomas (Winter et al. 2000). This is not a response to 
altered proliferation, as TFIIIC levels are not influenced by growth factors or cell cycle arrest 
(Winter et al. 2000; Scott et al. 2001). Over-expression of TFIIIB subunits has also been 
found in human cervical and colon carcinomas, and can be induced in culture by oncogenic 
viruses (such as EBV, and the X oncoprotein of HBV), and the cellular oncoprotein Ras 
(Wang et al. 1995; Johnson et al. 2003; Daly et al. 2005; Felton-Edkins et al. 2006). Further, 
other virus-encoded proteins such as HTLV-1 tax protein, have been shown to activate 
cellular pol III transcribed genes (Gottesfeld et al. 1996) with others, such as Influenza A 
virus matrix protein 1, known to interact with pol III machinery components (Huang et al. 
2009).  
 In recent years, evidence linking aberrant pol III activity to cancer (outlined above) has 
strengthened considerably, with data now suggesting that increased pol III transcription is 
capable of, and necessary for, promotion of proliferation and oncogenic transformation in 
some cellular contexts (Johnson et al. 2008; Marshall et al. 2008). These findings, although in 
need of confirmation in terms of their generality, are of huge significance and interest, 
especially given the well established role of oncogenic viruses in pol III dysregulation.  
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1.7.8.1.2 c-Myc: An EBER-associated cellular transcription factor 
The c-Myc proto-oncogene is one of the most frequently activated oncogenes and is estimated 
to be involved in 20% of all human cancers (Dang 1999; Nesbit et al. 1999). Deregulation of 
c-Myc expression occurs in cancers through chromosomal translocation, viral insertions, 
amplification, deletions, insertions, and/or mutation of cis-elements (Meyer and Penn 2008). 
A comprehensive review of the biology of c-Myc is beyond the scope of this thesis, though 
such reviews are readily available (Meyer and Penn 2008). However, it is important to 
introduce at least certain aspects of c-Myc biology, given that c-Myc has been demonstrated 
to bind upstream of the EBER1 transcriptional start site in vitro and in vivo (Niller et al. 
2003). The brief introduction to c-Myc that follows is based around its role as a 
transcriptional activator, and the regulation of its expression and activity. 
In the late 1980s, strong evidence was produced to suggest that c-Myc was able to function as 
a regulator of gene transcription (Luscher and Eisenman 1990; Marcu et al. 1992), being both 
a positive and negative regulator of cellular gene expression. Sequence-specific DNA binding 
and transcriptional activity of c-Myc were revealed through the characterisation of two 
important domains of the protein: the leucine zipper (LZ) domain (Landschulz et al. 1988) 
and the helix-loop-helix (HLH) domain (Murre et al. 1989), with both these regions found to 
be essential for c-Myc-mediated cellular transformation (Stone et al. 1987; Dang et al. 1989). 
Direct transcriptional activity of c-Myc was then demonstrated (Kato et al. 1990) before DNA 
binding of c-Myc was formally observed (Blackwell et al. 1990; Prendergast and Ziff 1991). 
Subsequently, c-Myc’s partner protein, the ubiquitously expressed Max, was identified, with 
c-Myc-Max heterodimers demonstrated to bind a CACGTG E-box motif with high affinity 
(Blackwood and Eisenman 1991), and c-Myc-Max heterodimerisation was shown to be 
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essential for c-Myc transformation (Amati et al. 1993). Although c-Myc appears dedicated to 
Max, Max itself is able to bind other members of the Mxd family through the LHL-LZ region 
(Ayer et al. 1993), with these interactions providing a mechanism of functional regulation of 
c-Myc (Billin and Ayer 2006; Nair and Burley 2006; Wahlstrom and Henriksson 2007).  
Recent estimates suggest that c-Myc could regulate as many as 15% of all genes in the human 
genome (Dang et al. 2006), by utilising a multitude of mechanisms, including recruitment of 
histone acetylases, chromatin modulating proteins, basal transcriptional factors and DNA 
methyltransferase  (McMahon et al. 1998; Cheng et al. 1999; Eberhardy and Farnham 2002; 
Fernandez et al. 2003; Kanazawa et al. 2003; O'Connell et al. 2003; Orian et al. 2003; Brenner 
et al. 2005). c-Myc targets can therefore be classified into distinct subgroups whose regulation 
may involve some or all mechanisms through which c-Myc affects transcription, with the cis-
regulatory modules for individual subgroups likely to contain binding sites for other specific 
transcription factors which cooperate with c-Myc (Dang et al. 2006). 
The identification of the Mxd family of proteins has allowed further insight into the protein 
interactions that regulate c-Myc’s transcriptional function. When bound to Max, Mad (and 
other family members) bind consensus E-box sequences and compete for binding with c- 
Myc/Max heterodimers. Mad/Max dimers repress transcription through the recruitment of the 
chromatin-modifying co-repressor complex (which contains Sin3, N-CoR, and the class I 
histone deacetylases HDAC1 and 2) to the promoters of target genes, resulting in 
deacetylation of histone tails and a closed chromatin conformation which prevents the 
transcriptional activation that occurs through E-boxes (Ayer et al. 1995; Alland et al. 1997). 
In contrast to the ubiquitous expression of Max, Mad proteins are induced during terminal 
differentiation (Ayer and Eisenman 1993), and consistent with these data, chromatin 
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immunoprecipitation (ChIP) experiments have revealed a switch from c-Myc-Max binding to 
Mad-Max binding during cellular differentiation (Bouchard et al. 2001; Xu et al. 2001).  
c-Myc is also able to inhibit transcription through direct interference with other factors known 
to activate gene expression. For example, c-Myc binds to and interferes with the 
transcriptional activator Miz-1, thereby causing trans-repression of specific Miz-1 target 
genes (Wanzel et al. 2003; Wu et al. 2003). 
The search for physiological and pathological c-Myc target genes has intensified significantly 
in recent years, with searches evolving from hypothesis-driven, low throughput studies of 
candidate c-Myc target genes, to high throughput microarray technologies for the discovery of 
c-Myc responsive genes (O'Connell et al. 2003). Despite these impressive advances, much 
work must yet be undertaken to achieve a complete understanding of c-Myc responsive genes 
and how they relate to tumourigenesis. c-Myc responsive genes that are reported consistently 
in different cell types, systems and species can be identified from the c-Myc target gene 
database (http://www.myccancergene.org). Although c-Myc is thought to influence up to 
about 15% of genes and despite the functional range of specific genes altered, c-Myc affects 
specific classes of genes involved in cellular metabolism, protein biosynthesis, cell cycle 
regulation, cell adhesion, apoptosis, intercellular signalling (such as angiogenesis) and the 
cytoskeleton (Dang et al. 2006). c-Myc has also been implicated in regulation of pols I and 
III, thus influencing genes involved in ribosome biogenesis and protein synthesis. c-Myc 
binds TFIIIB, directly activating pol III transcription, with ChIP experiments verifying that c-
Myc directly binds the pol III-transcribed tRNA and 5S rRNA genes (Gomez-Roman et al. 
2003). Significantly, recent data demonstrate that transformation by c-Myc can be 
compromised by blocking pol III transcriptional induction (Johnson et al. 2008). Interestingly, 
recent data generated in Drosophila, using a dMyc (homologue of c-Myc) mutant unable to 
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interact with Max, revealed that Max-independent stimulation of pol III transcription 
occurred, and that despite a loss of influence upon pol I and II transcription, this dMyc mutant 
retained substantial biological activity (Steiger et al. 2008). The extent to which pol III 
regulation can account for the biological activity of dMyc in Max-depleted flies remains to be 
determined, but no other Max-independent targets have yet been identified (Kenneth and 
White 2009). Further non-coding cellular RNAs, miRNAs, are regulated by c-Myc. Several 
loci that encode miRNAs are bound by c-Myc in vivo (O'Donnell et al. 2005; Chang et al. 
2008), with studies identifying c-Myc promoter binding as leading to the repression of 
miRNAs whose expression can reduce tumourigenesis (Chang et al. 2008), and c-Myc-
mediated induction of miRNAs that are able to stimulate tumour angiogenesis (Dews et al. 
2006). 
The expression and activity of c-Myc is tightly regulated in non-transformed cells and 
designed to respond quickly to proliferative cues from the extracellular signals. Initial studies 
of c-Myc established a direct link between mitogenic stimulation of quiescent cultured cells 
and a rapid induction of mRNA encoding c-Myc, with maximal mRNA levels of this 
immediate early response gene being reached within 2 hours of mitogen treatment where 
protein synthesis was inhibited (Kelly et al. 1983). Further, mRNA encoding c-Myc, and c-
Myc protein have both been demonstrated to possess short half-lives (Dani et al. 1984; Hann 
and Eisenman 1984), and anti-proliferative signals trigger a rapid down-regulation of c-Myc 
expression (Campisi et al. 1984; Gonda and Metcalf 1984; Lachman and Skoultchi 1984; 
Dean et al. 1986). A multitude of signal transduction pathways and numerous transcriptional 
and post-translational regulatory mechanisms have evolved to tightly control c-Myc 
expression. Evidence that deregulation of c-Myc mRNA expression is able to drive cancer 
development has been demonstrated through the use of transgenic mouse models (Adams et 
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al. 1985; Leder et al. 1986). The c-Myc promoter is a point of convergence for multiple 
signalling cascades involved in transcriptional regulation of c-Myc, and comprehensive 
reviews of the c-Myc promoter region have recently been published (Levens 2008; Wierstra 
and Alves 2008). Dysregulation of c-Myc transcription can occur directly and indirectly, 
resulting in cellular proliferation and transformation (Roussel et al. 1991; Afar et al. 1994; 
Barone and Courtneidge 1995; He et al. 1998; Oster et al. 2002; Cheng et al. 2006; Weng et 
al. 2006). In addition to dysregulation of transcription, c-Myc mRNA turnover is also altered 
by an array of signals, adding a further layer of complexity to the regulation of c-Myc mRNA 
levels (Jones and Cole 1987; Bernstein et al. 1992). Post-transcriptional modification of c-
Myc occurs through phosphorylation events. Research has focussed on the phosphorylation of 
two specific residues of the c-Myc protein, Thr58 and Ser62. These residues are important for 
transformation and regulate both c-Myc stability and activity (Hann 2006; Vervoorts et al. 
2006). Proliferative stimuli activate specific kinases that phosphorylate Ser62, increasing the 
stability of c-Myc. Phospho-Ser62 is subsequently able to act as a platform for 
phosphorylation of Thr58 by glycogen synthase kinase 3 (GSK-3), enabling the tumour 
suppressor FBW7 to bind leading to the direct ubiquitination of c-Myc and consequent 
proteasomal degradation. Additional mechanisms of c-Myc regulation have also been 
identified including the discovery of a short form of c-Myc, arising from variation in 
translational initiation sites (Spotts et al. 1997), and cap-independent translation of c-Myc 
(Cobbold et al. 2008). 
Significantly, recently published data suggest c-Myc (along with NF-κB) is one of the two 
main transcription factors responsible for the phenotype, growth pattern, and biological 
properties of cells driven into proliferation by EBV, with c-Myc shown to be activated in the 
latency III programme of EBV-immortalised B-cells (Faumont et al. 2009a). Interaction of 
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EBV and c-Myc growth programmes in BL has been outlined in the previous section 
discussing EBV-associated malignancies (1.6.1), and the influence of a variety of oncogenic 
viruses on c-Myc is discussed in Chapter 4.  
 1.7.8.1.3 ATF-2  
ATF-2 is postulated to play a significant role in EBER regulation, given that mutation of the 
ATF-2 binding sites upstream of EBER1 and EBER2 has been demonstrated significantly to 
reduce levels of EBER expression (Howe and Shu 1989; 1993; Wensing et al. 2001). 
The ATF/CREB family of proteins consists of sixteen cellular stress-responsive transcription 
factors, divided into six subgroups according to their sequence similarity (Hai and Hartman 
2001). These proteins all share common features, including the bZIP element, which enables 
homo- and hetero-dimerisation and binding to specific DNA sequences (Hai et al. 1989). As 
with c-Myc, a comprehensive review of ATF-2 is beyond the scope of this work, however 
suitable review articles are available (Vlahopoulos et al. 2008). 
The ATF-2 promoter contains Sp1 elements and a CRE-like element in the region -50 to +90, 
relative to the ATF-2 gene’s transcriptional start site. These regions are important for basal 
promoter activity. However activation of ATF-2 is achieved through post-translational 
modifications upon stress stimuli. In unstimulated cells, ATF-2 is maintained in a 
transcriptionally inactive form by intramolecular interactions between its own activation 
domain and its bZIP domain (Li and Green 1996). In response to stress stimuli, ATF-2 is 
phosphorylated by multiple cell signalling pathways at amino acids Thr69 and Thr71. 
Phosphorylated ATF-2 forms dimers that bind to specific DNA sequences on target gene 
promoters, activating their expression (Gupta et al. 1995; Livingstone et al. 1995; Ouwens et 
al. 2002). ATF-2 is able to form homodimers or selective heterodimers with other members of 
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the ATF/CREB family and Fos/Jun family, with these dimers preferentially binding the 8-
base palindromic CRE (cAMP Responsive Element) consensus sequence TGTACGTCA 
promoters (Hai et al. 1989), although ATF-2 has been shown to bind other elements, 
including the AP-1 element (De Cesare et al. 1995; Song et al. 2006).  
Activated ATF-2 complexes stimulate a broad spectrum of targets that are implicated in 
cancer including cell cycle molecules such as cyclin D1 (Beier et al. 1999), invasion related 
molecules such as matrix metalloproteinase 2 (MMP2) which is able to degrade components 
of the extracellular matrix (Song et al. 2006), cytokines such as IL-8 (Eliopoulos et al. 1999), 
cell adhesion molecules such as E-selectin (Read et al. 1997), and anti-apoptotic factor Bcl-2 
(Ma et al. 2007). 
The c-Jun transcription factor is an unusual target of ATF-2, as it is both a target and a co-
operator of ATF-2. c-Jun is another bZIP protein, which belongs to the Jun protein family, 
and through its bZIP domain it forms either dimers with other members of the Jun family (c-
Jun–JunB, c-Jun–JunD heterodimers), as well as heterodimers with Fos family members. The 
dimers that Jun members form are called AP-1 proteins and bind to the AP-1 element located 
in numerous genes. AP-1 has been subject to comprehensive review (Shaulian and Karin 
2002; Hess et al. 2004). 
A fine-tuned network of interacting bZIP proteins (including ATF-2) is involved in response 
to cellular stress stimuli. Interactions between ATF-2 and bZIP proteins involve: (1) 
regulation of other bZIP proteins’ transcription; (2) antagonism with other bZIP monomers 
for selective dimer formation; (3) antagonism between bZIP dimers for binding to the same 
responsive element; (4) co-operation between bZIP dimers for binding to the same responsive 
element; and (5) selection of the responsive element according to the overall cellular bZIP 
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content (Vlahopoulos et al. 2008). Deregulation of these interactions leads to alterations in 
cellular processes such as proliferation, differentiation and apoptosis, resulting in the 
acquisition of cancerous characteristics. Given that ATF-2 is implicated in each of these types 
of interaction affecting target gene regulation, it can be regarded as a major cell fate 
modulator. 
Through the described interactions with other bZIP proteins, ATF-2 has been clearly 
identified as playing a role in oncogenesis, with in vitro studies in human cancer cell lines, as 
well as in situ studies revealing a well documented activation of ATF-2 in several cancer 
types (Vlahopoulos et al. 2008). Phosphorylated ATF-2 is overexpressed in benign prostatic 
hyperplasia and, more intensely, in prostate tumours, suggesting that ATF-2 enhances 
survival and cell proliferation, promoting cancer progression (Ricote et al. 2006). Further, 
reduced levels of ATF-2 have been demonstrated to predispose mice to mammary tumours 
(Maekawa et al. 2007). ATF-2 also has been implicated in differentiation-related cell-cycle 
arrest and apoptosis in several leukaemia cell lines (Wu et al. 2002b; Wang et al. 2005a) and 
is proposed to play a role in central nervous system tumours (Tindberg et al. 2000), 
melanomas (Berger et al. 2003), lung cancer (Woo et al. 2002), hepatic cancer (Zhao et al. 
2005) and NPC (O'Neil et al. 2008). Further, transgenic mouse studies have provided in vivo 
evidence linking ATF-2 and skin cancer development (Cho et al. 2004).  
1.8 Aims and Objectives 
Although the precise mechanisms by which EBERs may function in oncogenesis are not yet 
resolved, it is clear that EBERs are an important component of the EBV latent gene 
complement. The EBERs are the most abundant viral latent gene products. However, 
precisely how EBV is able to exploit the well defined cellular transcriptional mechanisms by 
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which the EBERs are transcribed is yet to be fully elucidated. Previously EBV has been 
demonstrated to induce transcription factors associated with EBER expression, including pol 
III transcription factors and ATF-2. Thus, the main aim of this study was to further increase 
understanding of how high levels of EBER expression are achieved by EBV, with much of 
the work being conducted in an epithelial cell background. High levels of EBER expression 
are thought to be crucial for oncogenic activity of EBERs in epithelial cells, with a recent 
study suggesting that high, but not low, levels of EBER expression could cause MDCK cells 
to form colonies in soft agar (Yoshizaki et al. 2007). 
Initial studies in the project involve assessing the relationship between EBV copy number and 
levels of gene expression, to examine if high levels of EBER expression could be explained 
simply by multiple copies of EBER template being present in the form of multiple EBV 
episomes per cell. Previous evidence suggests that there may be a correlation between EBV 
copy number and rate of EBER transcription, albeit in a very small scale study (Metzenberg 
1989), although other evidence suggests that the levels of expression of other EBV latent gene 
products do not correlate with genomic copy number (Metzenberg 1989; 1990; Sternas et al. 
1990). 
Subsequently, this project focuses on an investigation of the possibility that the ubiquitously 
expressed EBV latent protein EBNA1 plays a role in the induction of EBER-associated 
cellular transcription factors, and ultimately influences levels of EBER expression in in vitro 
cell line models derived from epithelial cell carcinomas. As previously discussed, 
observations suggest that high expression levels of EBER genes in EBV-transformed cells is 
not simply due to inherent strength of the EBER promoters, suggesting a strong influence of 
trans-acting factors in controlling the transcription of the EBERs (Lerner et al. 1981a; Rooney 
et al. 1989; Greifenegger et al. 1998; Laing et al. 2002). Given previous reports of EBNA1 
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being able to induce the transcription of cellular genes, including some of those involved in 
EBER expression (Wood et al. 2007; O'Neil et al. 2008), the role of EBNA1 as a trans-acting 
factor in EBER regulation is fully investigated, and given the reported EBNA1-mediated 
transcriptional induction of cellular genes, EBNA1 promoter binding studies are conducted. 
Such studies allow mechanistic analysis of EBNA1 function, particularly in terms of 
regulation of cellular EBER-associated transcription factors.  
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Chapter 2 – Materials and Methods 
 
2.1 Molecular cloning 
 
2.1.1 Plasmids 
The commonly used cloning vector pUC19 was obtained from New England Biolabs. It 
contains an ampicillin resistance cassette. UC refers to the University in which it was created 
(University of California).  
 
The plasmid pOTEII HUMPU-GFP was obtained from Dr JR Arrand. It contains OriP and 
cassettes that express EBNA1 and GFP. It also expresses the puromycin resistance cassette 
described by Chen and Arrand (2003).   
 
The pUC19 Puro plasmid was generated by excising the puromycin resistance cassette from 
pOTEII HUMPU-GFP with SalI and inserting at the SalI site of pUC19 (as detailed in 
Chapter 4). 
 
pEcoRI-J and BamHI-X (Arrand et al. 1981) containing, respectively, the EBV EcoRI-J and 
BamHI-X fragments of EBV DNA were obtained from Dr JR Arrand. 
 
The pUC19-EBERs plasmid was generated by inserting the 1kb SacI – EcoRI subfragment 
from the EcoRI-J fragment within pEcoRI-J into the corresponding sites of pUC19. 
Subsequently, the puromycin resistance cassette from pOTEII HUMPU-GFP was inserted at 
the SalI site (as detailed in Chapter 4). 
 
For generation of pUC19-Puro-EBERs-ΔX, the X-box c-Myc binding site was excised from 
the pUC19-EBERs plasmid using SacI and PmlI, excising bases -352 to -125 relative to the 
EBER1 transcriptional start site (as detailed in Chapter 4). 
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The common cloning vector pSG5 is a high copy number eukaryotic expression vector and 
was obtained from Stratagene UK.  
 
The EBNA1 expression plasmid pSG5-EBNA1 (Sample et al. 1992) was obtained from Dr J 
Sample.  
 
The c-Myc reporter plasmid pX-CMVp-Luc plasmid and its respective control plasmid p-
CMVp-Luc (Niller et al. 2003) were obtained from Dr H-H Niller.  
 
The Renilla luciferase reporter plasmid (pRL-TK) was obtained from Promega. 
 
The AP-1 reporter plasmid pAP1-Luc was obtained from BD Biosciences. pTAL-Luc is a 
commonly used control for studying putative enhancers that are inserted upstream of the 
luciferase reporter gene and was obtained from Clontech.  
 
The dominant-negative EBNA1 expression vector EBNA1-M1 (Marechal et al. 1999) was 
obtained from Dr J-C Nicolas. 
 
To generate the c-MycER expression plasmid, a plasmid containing a functionally-inducible 
c-Myc gene (a fusion between the hormone binding domain of the oestrogen receptor and c-
Myc) (Littlewood et al. 1995) was obtained from Dr. C Tselepis. An EcoRI fragment 
containing the fusion (c-MycER) was ligated into pcDNA3.1/zeo (Invitrogen).  
 
Vectors expressing shRNA directed against c-Myc (pGIPZ 152051) and ATF-2 (pLKO.1 
13713) were both obtained from OpenBiosystems, as was the non-silencing pGIPZ shRNA 
control (RHS4348). 
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The plasmid backbone for HaloCHIP cloning (pFC14K) was obtained from Promega. For the 
plasmid map, see Figure 5.11.  
 
The cloning vector pCR8-TOPO was obtained from Invitrogen. pCR8-TOPO contains a 
topoisomerase cloning site, spectinomycin resistance cassette and sequencing priming sites to 
allow easy sequencing of PCR-derived inserts. A plasmid map is available online 
(http://tools.invitrogen.com/content/sfs/vectors/pcr8gwtopo_map.pdf).   
 
2.1.2 Solutions 
L-Broth (LB): 10g L-broth base (Gibco) was dissolved in 500ml SDW and was sterilised by 
autoclaving. 
 
Agar plates: 7.5g Agar was dissolved in 500ml of LB before autoclaving.  Agar was melted 
prior to use and allowed to cool to approximately 50oC before adding any antibiotic.  Plates 
were poured and once set were inverted and stored at 4oC until use. 
Ampicillin: 100mg/ml stock was prepared in SDW, sterilised through a 0.45μm filter and 
stored as 5ml aliquots at -20oC. The working concentration of ampicillin in plates and media 
was 100μg/ml.  
 
Kanamycin: 100mg/ml stock was prepared in SDW, sterilised through a 0.45μm filter and 
stored as 2ml aliquots at -20oC. The working concentration of kanamycin in plates and media 
was 30μg/ml. 
 
2.1.3 Restriction endonuclease digestion 
For a typical restriction endonuclease digestion reaction, 5μg of purified DNA was digested in 
a total volume of 20μl with the appropriate restriction enzymes and buffers (Roche 
Diagnostics, Germany; New England Biolabs, UK; Promega, UK). Briefly, a reaction 
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consisted of 2µl of 10x BSA stock (10mg/ml), 2µl of 10x restriction enzyme buffer, 1µl of 
each restriction enzyme (typically 10 Units) and nuclease-free water up to a final volume of 
20µl. The reaction mixture was incubated for 1.5 hours at 37ºC water bath and if required, 
reactions were stopped by heating the sample at 65°C for 20 minutes. Digested DNA was 
analysed by agarose gel electrophoresis. 
2.1.4 Ligation of DNA insert into vectors  
Ligation reactions were carried out using T4 DNA ligase (Promega, UK). Vector  and insert 
DNA were added, typically in a ratio of 1:3 (vector:insert, DNA totalling 0.2µg), to a total 
volume of 20μl, consisting of 2μl 10x T4 ligase buffer, 1μl T4 ligase and sterile water up to a 
final volume of 20μl. The reaction was incubated at 16ºC overnight to allow ligation to occur.  
 
2.1.5 Bacterial transformation of competent cells 
5µl of ligation reaction (Section 2.1.4) was used to transform 100µl DH5α competent or 
Top10 F supercompetent cells (Invitrogen, UK) in a 1.5ml microcentrifuge tube. Competent 
cells, having been stored at -80°C, were thawed on ice before the addition of ligation reaction 
DNA. Cells were gently mixed with the ligation reaction, avoiding pipetting up and down, 
incubated on ice for 30 minutes, heat shocked for 60 seconds at 42ºC and then immediately 
transferred onto ice and incubated for a minimum of 5 minutes. 250μl of LB (Section 2.1.2.) 
was added to cells before incubation at 37ºC for 1 hour in an orbital incubator. The complete 
transformed cell mixture was then spread onto LB-agar plates (see Section 2.1.2) with 
100µg/ml ampicillin or 30µg/ml kanamycin where required. Plates were inverted and 
incubated at 37º C overnight before examination of the plates for drug-resistant colonies the 
following day.  
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2.1.6 Isolation of DNA from bacterial cultures  
 
2.1.6.1 Mini-preps 
Colonies present on bacterial transformation plates were picked with a sterilised pipette tip 
and incubated in 3ml LB supplemented with the required antibiotic for 16 hours at 37oC in an 
orbital shaker. To extract plasmid DNA, 1.5ml of the bacterial culture was processed with the 
Qiagen Mini-prep kit according to the manufacturer’s protocol (Qiagen, UK). DNA was 
stored at 4°C until subsequent screening by restriction digestion.  
2.1.6.2 Maxi-preps 
To produce abundant amounts of plasmid DNA, 500μl of screened and validated mini-prep 
culture was incubated at 37oC for 16 hours with 300ml LB supplemented with the required 
antibiotic. The culture was pelleted before lysis and plasmid DNA was recovered using the 
Quiagen Maxi-prep kit. The manufacturer’s protocol was followed precisely and pelleted, 
purified plasmid DNA was resuspended in TE buffer (10mM Tris-HCl pH 8, 1mM EDTA). 
DNA concentration was determined using a NanoDrop 1000 spectrophotometer (Thermo 
Scientific) and diluted to a stock concentration of 1μg/μl before storage at -20°C.  
 
2.1.7 Preparation of glycerol stocks of plasmid-expressing bacteria 
Following maxiprep propagation (described above), aliquots of culture were taken for the 
preparation of glycerol stocks. These were generated by thoroughly mixing 800μl of liquid 
culture with 200μl sterile glycerol and stored at -80oC 
 
2.1.8 DNA Sequencing 
DNA sequencing was performed for the identification of insert DNA and to check for any 
possible mutations and rearrangements introduced during PCR amplification or cloning. 
Sequencing was performed using a well-established protocol. Briefly, for each sample PCR 
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reactions were set up in duplicate containing 100ng DNA, 2µl Ready Reaction Premix 
(Applied Biosystems),  2µl Big Dye sequencing buffer (Applied Biosystems) and 3.2pmol 
(1µl)  appropriate primer. These reactions were adjusted to 20μl with nuclease-free PCR 
grade water. PCR reactions were carried out in a thermocycler with the following conditions: 
 
96°C for 1min 
96°C for 10secs 
50°C for 5secs  x 25 cycles 
60°C for 4mins 
4°C HOLD  
 
PCR reactions were subsequently cleaned up in the following manner. 2µl of 125mM EDTA 
was added to each reaction along with 2µl of 3M sodium acetate and 50µl of 100% ethanol. 
Tubes were mixed by inverting 5 times before incubation at room temperature for 15 minutes 
and subsequent centrifugation at 4°C (45 minutes at 2000g) to pellet the PCR product. 
Supernatant was carefully aspirated and 70μl of 70% ethanol was added to each pellet to wash 
the DNA before centrifugation at 4°C (1650g for 15 minutes) to pellet the DNA once more. 
Supernatant was aspirated before pellets were air dried at 37°C for 30 minutes. HiDi 
formamide buffer (Applied Biosystems) was used to resuspend the dry pellets (10μl per 
sample) and samples were then stored at 4°C until use. 
 
Samples were loaded into a 96 well plate before the plate was itself loaded into the 3130xl 
Genetic Analyzer sequencing machine (Applied Biosystems). Samples were run using 
instrument protocol ‘standard sequence’ and analysis protocol ‘3100POP6_BDTv3kB’. Data 
were collected and analysed using Chromas Version 1.45 
(http://www.technelysium.com.au/chromas14x.html). Where 2 sequences were compared for 
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homology, following Chromas analysis, the NCBI website sequence alignment tool was 
utilised (http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi).  
 
2.2 Tissue culture 
 
2.2.1 Tissue culture media 
RPMI 1640 liquid (1x) supplemented with 2mM L-Glutamine and adjusted to pH 7.0 was 
purchased in sterile 500ml bottles from GIBCO (Invitrogen, UK) and stored at 4°C until use. 
 
2.2.2 Tissue culture reagents 
Foetal bovine serum (FBS) of South American origin, pre-screened for mycoplasma and 
viruses, was purchased in sterile 500ml bottles from GIBCO (Invitrogen, UK) and aliquoted 
into 50ml aliquots before storage at -20°C. 
 
Ciprofloxacin solution was purchased from Bayer. Filter sterilisation was carried out before 
use at 2.5ml/500ml media.  
 
Geneticin (G418) powder was purchased from Sigma-Aldrich. 5g was dissolved in 100ml 
sterile distilled water before filter sterilisation and storage in 5ml aliquots at 4°C.  
Penicillin/streptomycin (pen/strep) solution (10,000 units/ml penicillin-G and 10mg/ml 
streptomycin) were purchased from Sigma-Aldrich and filter sterilised before use at 
2.5ml/500ml media. 
 
Acyclovir powder was purchased from Sigma-Aldrich, and used to supplement culture 
medium at a concentration of 200μM. 
 
1 x Trypsin solution (containing 2.5g/L trypsin (0.25%) and 0.38g/L EDTA) was purchased in 
100ml sterile bottles from GIBCO (Invitrogen, UK). 10ml aliquots were stored at -20°C.  
93 
 
Materials and Methods 
Phosphate buffered saline (PBS) tablets were purchased from Oxoid Ltd. To produce PBS 
solution (8g/L NaCl, 0.2g/L KCl, 1.15g/L Na2HPO4, 0.2g/L KH2PO4), 10 tablets were 
dissolved in 1L of distilled H2O. Aliquots of 500ml were sterilised by autoclaving for 10 
minutes at 115°C.  
 
2.2.3 Cell lines 
Ad/AH cells are derived from a nasopharyngeal adenocarcinoma. 
 
AGS cells are a gastric carcinoma derived cell line. 
 
Hone-1 cells are an NPC derived line that were originally EBV-positive but lost the viral 
genome during culture.  
 
X50-7 is an LCL expressing the full array of EBV latent genes. 
 
Other LCLs used in obtaining copy number/EBER expression data (See Chapter 3) were 
generated within the University of Birmingham and were kind donations from various 
members of University of Birmingham staff.  
 
Akata rEBV is a Japanese BL-derived line latently infected with an Akata strain of EBV 
which has a neomycin resistance cassette to allow selection of stably infected cells (Shimizu 
et al. 1996). Unlike most EBV-positive BL lines, Akata retains the type I latency pattern.  
 
Akata BL is a sub clone of the EBV-positive line which has lost the virus through limited 
dilution in culture (Shimizu et al. 1994). 
 
BJAB is an EBV-negative BL-derived line 
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Ad/AH-rEBV is an Ad/AH cell line stably infected with an Akata strain of EBV which has a 
neomycin resistance cassette to allow selection of stably infected cells. This line was kindly 
provided by Dr VHJ Wood (Stewart et al. 2004). 
 
Ad/AH-, AGS- and Hone-1-EBNA1 and -neomycin (neo) control lines were kindly provided 
by Dr. VHJ Wood, and were generated by transfection of an EBNA1, or neo control, plasmid 
into the parental lines followed by drug selection and isolation of individual clones (Wood et 
al. 2007).  
 
Ad/AH-neo and -EBNA1-c-MycER lines were kindly provided by Dr. CW Dawson, and were 
generated by transfection of the c-MycER plasmid into Ad/AH neo or EBNA1 lines, followed 
by drug selection and isolation of individual clones.  
 
Ad/AH-Puro and –Puro-EBERs lines were generated by transfection of pUC19-Puro or 
pUC19-Puro-EBERs plasmids (generation of these plasmids is described in Chapter 4) into 
Ad/AH parental cells, followed by drug selection with puromycin. Polyclonal populations of 
cells were generated. 
 
Ad/AH-Puro-EBERs-∆X lines were generated by transfection of pUC19-Puro-EBERs-∆X 
plasmid (generation of these plasmids is described in Chapter 4) into Ad/AH parental cells, 
followed by drug selection with puromycin. Polyclonal populations of cells were generated. 
 
2.2.4 Culture conditions 
All B-cell lines were maintained in RPMI 1640 supplemented with 10% FBS, ciprofloxacin 
and pen/strep. For experiments where it was necessary to prevent lytic outgrowth of virus, 
cells were maintained in culture media supplemented with acyclovir for a minimum of 2 
weeks prior to harvest. Ad/AH, AGS and Hone-1 lines were maintained in RPMI 1640 
95 
 
Materials and Methods 
supplemented with 5% FBS, ciprofloxacin and pen/strep. To ensure viral genome 
maintenance, Akata rEBV cells were drug selected at 600μg/ml G418 and Ad/AH-rEBV cells 
were drug selected at 400μg/ml G418. Maintenance of EBNA1 expression in Ad/AH and 
AGS lines was achieved by drug selecting at 400μg/ml G418, Hone-1 lines were selected at 
200μg/ml G418. c-MycER plasmid maintenance in Ad/AH-neo and -EBNA1 cells was 
ensured by drug selection at 62.5μg/ml zeocin (Invitrogen, UK).  
 
2.2.5 Maintenance of cell lines 
All cell lines were maintained at 37°C in incubators supplied with 5% CO2.  
Adherent cells (Ad/AH, AGS, Hone-1) were grown in 75cm2 tissue culture flasks purchased 
from Iwaki. Upon reaching 90-95% confluence, spent media were removed before washing 
with PBS solution. 4ml of 1X trypsin was added and cells were subsequently incubated at 
37°C for 5 to 10 minutes to allow cell detachment from the adherent flask surface.  To 
neutralise the trypsin reaction, 10ml of RPMI 1640 supplemented with 5% FBS was added 
before centrifugation of cells at 1500rpm for 5 minutes to pellet cells. Cell pellets were 
resuspended in 10ml of RPMI 1640 supplemented with 5% FBS, and 2ml of cell suspension 
was taken into a fresh 75cm2 flask to achieve a 1 in 5 dilution of original cell numbers. 18ml 
of RPMI 1640 supplemented with 5% FBS was added and drug selection was applied if 
required.  
 
Non-adherent cells (Akata, LCLs) were grown in 25cm2 tissue culture flasks purchased from 
Iwaki. Lines were maintained in 10ml of growth medium, with cells being passaged twice 
weekly by removal of 8ml cell suspension and replacement with 8ml fresh complete growth 
medium to achieve a 1 in 5 dilution of original cell numbers. At each passage, drug selection 
was applied if necessary.  
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Cell suspensions of both adherent and non-adherent cells were used to perform 
haemocytometer counts and the required volumes added to the appropriate vessel for 
experiments. 
 
2.2.6 Cryopreservation 
For both adherent and non-adherent lines, cell suspensions were pelleted as described in 
Section 2.2.5. Pellets were resuspended in 1ml of freezing solution (complete growth 
medium, FBS and DMSO in a 5:4:1 ratio) and 1ml cell suspensions were added to cryovials 
(Nunc). Cryovials were transferred to a Mr Frosty (Nalgene) before storage at -80°C to enable 
gradual freezing. Cryovials were transferred to the gas phase of a liquid nitrogen freezer (-
140°C) 24 hours later for long term storage. 
Cells cryopreserved in the above manner were revived by rapid thawing at 37°C following 
which cell suspensions were transferred to a Universal tube (Sterilin, UK) and appropriate 
complete growth medium was added in a dropwise manner. Suspensions were seeded into 
tissue culture flasks as described in Section 2.2.5 following a 5 minute incubation at room 
temperature. If required, drug selection was applied 48 hours post-revival.  
 
2.2.7 Crystal Violet staining 
To assess cell viability following drug selection, crystal violet staining was used. Cells were 
plated into 6 well plates and grown to 80% confluence before drug selection for an 
appropriate amount of time (typically between 24 and 72 hours). Subsequently, cells were 
washed with 1x PBS, before fixing with 4% paraformaldehyde (PFA) at room temperature for 
5 minutes. Following fixation, cells were washed three times with PBS before addition of 
0.05% crystal violet solution. Cells were stained for 30 minutes before several washes with 
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distilled water to remove excess crystal violet solution, and subsequent inversion and drying. 
At this point, cells were examined by microscopy and photographed. 
 
2.3 Immunofluorescence (IF) staining  
 
Adherent cells were trypsinised and counted as described in Section 2.2.5. Cells (1x104) were 
seeded onto sterile Teflon coated slides (Henley) and left to adhere for 48 to 72 hours in 
150mm culture dishes. Desiccation was prevented by the addition of PBS solution to the 
culture dishes. Once adherent, cells were washed with PBS before fixation in 4% PFA pH 7.4 
for 10 minutes. Following fixation, cells were again washed in PBS and permeabilised in 
0.5% Triton X-100 for 5 minutes. After a further PBS wash, cells were treated with 50μl of 
20% heat inactivated goat serum (HINGS) diluted in PBS in a humidified chamber for a 
minimum of 1 hour in order to prevent non-specific antibodybinding. Primary antibodies 
diluted in 20% HINGS to a working concentration (see Table 2.1) were then applied to cells 
and incubated overnight at 4°C. Slides were washed 3 times in PBS with gentle agitation 
before the area around the wells was dried using filter paper (Whatman, UK). Alexa Fluor 
secondary antibody (Molecular Probes), of corresponding species to the primary antibody, 
conjugated to a 594nm (red) fluorochrome was diluted 1 in 1000 in 20% HINGS and applied 
to slides at room temperature for an hour in the dark. Slides were washed 3 times more in 
PBS before mounting using DABCO pH 8.6 (90ml glycerol, 10ml PBS, 2.5g DABCO ((1,4-
diazabicyclo[2.2.2]octane) powder, Sigma-Aldrich). Cells were stored in the dark at -20°C for 
a minimum of 24 hours to reduce background staining prior to visualisation by fluorescence 
microscopy. To control for background staining, cells were stained with secondary antibody 
alone, with the primary antibody incubation step being replaced with extended blocking with 
20% HINGS. 
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2.4 Immunoblotting 
 
2.4.1 Sample preparation 
Once ready for harvest, cells were washed once in PBS and lysed in 100-500μl RIPA buffer 
(25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 
depending on the size of the tissue culture vessel and the confluence of cells. Collection of 
cell lysates was achieved using cell scrapers (Sarstedt, Germany) and samples were 
transferred to pre-chilled 1.5ml microcentrifuge tubes on ice before sonication of samples to 
ensure disruption of cellular components and full cell lysis. Concentration of protein in 
samples was determined using a commercial protein assay kit (Biorad 500-0112). Briefly, 5μl 
of Bovine Serum Albumin (BSA) protein standards prepared in sterile distilled water (SDW) 
(0, 0.1, 0.2, 0.5, 1 and 2μg/μl) and 5μl sample diluted 1 in 5 using sterile H2O were aliquoted, 
in triplicate, into a 96 well microtitre plate. 25μl of reagent A followed by 200μl of reagent B 
were added to each well and incubated for 2min at room temperature with gentle shaking. The 
absorbance of the samples was then read on a BioTek automated microtitre plate reader at 
620nm. The values obtained were used to construct a standard curve for the BSA standards 
from which the sample protein concentrations were determined. Depending on the abundance 
of the protein being examined, and the quality of specific primary antibody, 30-100μg of 
protein lysate was used for immunoblotting. Samples were prepared for loading by diluting 
1:3 in Laemmli loading buffer (250mM Tris-HCl pH 6.8, 8% w/v SDS, 40% glycerol, 0.05% 
w/v bromophenol blue, 10% β-mercaptoethanol). Diluted samples were heated to 95°C for 5 
mins to denature samples before being chilled immediately on ice. Cooled samples were 
centrifuged briefly to pellet cell debris before loading on to SDS-polyacrylamide gels.  
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2.4.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using the Mini-PROTEAN 3 electrophoresis kit (Bio-Rad, UK). 
To achieve optimum fractionation, gels were cast containing a percentage of acrylamide best 
suited to the molecular weight of the protein subject to analysis. Typical gels contained a 
mixture of an appropriate percentage (v/v) of acrylamide stock solution (30% w/v acrylamide 
and 0.8% v/v bis-acrylamide) (Bio-Rad, UK), 25% v/v resolving buffer (1.5M Tris-HCl pH 
8.8, 0.4% w/v SDS and 0.24% v/v TEMED) and distilled H2O  which was added last to adjust 
the mixture to the required volume. Polymerisation was catalysed by the addition of 20% 
ammonium persulphate (APS) to a final concentration of 0.1%, prior to filling of the gel 
cassettes. Surface air bubbles were removed by overlaying the solution with 100% ethanol, 
which was subsequently rinsed away with SDW before blotting paper was used to absorb any 
excess moisture. Once the resolving gel was fully polymerised, a stacking gel consisting of 
4% acrylamide and 50% v/v stacking buffer (0.75M Tris-HCl pH 6.8, 0.2% w/v SDS and 
0.12% v/v TEMED) adjusted to the required volume using distilled H2O was prepared. 20% 
APS was added to a final concentration of 0.15% to catalyse polymerisation before gel combs 
were carefully inserted. Once the gel was fully set, gel combs were removed and the gels were 
placed into an electrophoresis tank and submerged in running buffer (30g Tris, 144g glycine 
and 10g SDS in 10L distilled H2O). Protein samples were loaded alongside molecular weight 
rainbow marker (Amersham) and electrophoresis was carried out at 130V until the dye front 
had reached the bottom of the gel. 
 
2.4.3 Protein transfer and immunoblotting 
Once resolved by electrophoresis, proteins were transfered to a nitrocellulose membrane using 
the Mini Trans-blot wet transfer system (Bio-Rad, UK). The gel and transfer membrane were 
placed between two sponges and filter papers, soaked in transfer buffer (30g Tris, 144g 
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glycine, 2L methanol and 8L distilled H2O) and pressed to remove any air bubbles. This 
sandwich was then placed into a transfer kit filled with transfer buffer before transfers were 
conducted at 90V on ice for 90 minutes.  
 
Following complete transfer of proteins, membranes were soaked in either 5% BSA in Tris-
buffered saline (TBS)-Tween (20mM Tris-HCl, pH7.4, 500mM NaCl, 0.05% Tween-20) or 
5% skimmed milk in TBS-Tween depending on the nature of the primary antibody to be used. 
5% BSA was used to block non-specific interactions for all phospho-specific antibodies, with 
5% skimmed milk being used for all total protein-specific antibodies. Blocking was 
performed with agitation overnight at 4°C or for an hour at room temperature. Following this 
blocking step, membranes were transferred to the relevant blocking buffer containing the 
appropriate concentration (Table 2.1) of primary antibody and incubated with agitation 
overnight at 4°C. Blots were then washed three times in TBS-Tween at room temperature 
with agitation before incubation with the relevant HRP-conjugated secondary antibody (Table 
2.1) in 5% skimimed milk blocking buffer at room temperature with agitation for an hour. 
Blots were washed as before then incubated with ECL reagents (1:1 ratio of reagents 1 and 2) 
which allow detection of protein-antibody conjugated complexes (Amersham). Visualisation 
of these complexes was achieved by wrapping blots in Saran Wrap, and exposing to X-ray 
film (Amersham). The X-ray film was developed using an automated film processor (X-
Ograph Ltd).  
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Table 2.1 Antibodies used for immunoblotting (WB) and immunofluorescence (IF) 
Protein 
 
 
Primary antibody Species Applic-
ation 
Dilution Secondary 
antibody & 
dilution 
β Actin β actin 
Sigma-Aldrich (A5441) 
Mouse WB 
 
1:20000 1:1000 Anti-
Mouse HRP 
Total 
Akt 
Akt Cell Signaling 
Technology (9272) 
Rabbit WB 1:500 1:1000 Anti-
Rabbit HRP 
Total 
ATF-2 
ATF-2 Santa Cruz 
Biotechnology (sc-242) 
Mouse WB, IF 1:1000 for 
WB, 1:250 
for IF 
1:1000 Anti-
Mouse HRP for 
WB, 1:1000 Anti-
Mouse 594 for IF 
pATF-2 
(Thr 
69/71) 
Phospho-ATF-2 
(Thr69/71) Cell 
Signaling Technology  
(9225) 
Rabbit WB, IF 1:1000 for 
WB, 1:250 
for IF 
1:1000 Anti-
Rabbit HRP for 
WB, 1:1000 Anti-
Rabbit 594 for IF 
c-Jun c-Jun  
Cell Signaling 
Technology (19162) 
Rabbit WB 1:1000 1:1000 Anti-
Rabbit HRP 
c-Myc c-Myc Santa Cruz 
Biotechnology (sc-40) 
Mouse WB 1:750 1:1000 Anti-
Mouse HRP 
pATF2 
(Thr71) 
Phospho-ATF-2 (Thr71) 
Cell Signaling 
Technology  (9221) 
Rabbit WB 1:1000 1:1000 Anti-
Rabbit HRP 
EBNA1 
 
A.M. (Young et al. 1988) Human 
serum 
WB 1:200 1:8000 Protein A 
HRP 
EBNA1 
 
R4 (gift from Dr Lori 
Frappier) 
Rabbit IF 1:1000 1:1000 Anti-
Rabbit 594 
Total 
ERK 
P44/42 MAPK Cell 
Signaling Technology 
(9102) 
Rabbit WB 1:1000 1:1000 Anti-
Rabbit HRP 
pERK Phospho-p44/42 MAPK 
Cell Signaling 
Technology (9101) 
Rabbit WB 1:500 1:1000 Anti-
Rabbit HRP 
Total 
GSK3β 
GSK-3β Santa Cruz 
Biotechnology (sc-
81462) 
Mouse WB 1:1000 1:1000 Anti-
Mouse HRP 
pGSK3β Phospho-GSK-3β (Ser9) 
Cell Signaling 
Technology (9336) 
Rabbit WB 1:500 1:1000 Anti-
Rabbit HRP 
HaloTag Anti-HaloTag® pAb 
Promega (G9281) 
Rabbit WB 1:1000 1:1000 Anti-
Rabbit HRP 
Sp1 Sp1 Santa Cruz 
Biotechnology  
(sc-59) 
Rabbit WB 1:500 1:1000 Anti-
Rabbit HRP 
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Table 2.1 ctd Antibodies used for immunoblotting (WB) and immunofluorescence (IF) 
Protein 
 
 
Primary antibody Species Applic-
ation 
Dilution Secondary 
antibody & 
dilution 
TFIIIC 
110 
4286 (Felton Edkins et 
al. 2006) 
Rabbit 
serum 
WB 1:1000 1:1000 Anti-
Rabbit HRP 
TFIIIC 
102 
3238 (Felton Edkins et 
al. 2006) 
Rabbit 
serum 
WB 1:1000 1:1000 Anti-
Rabbit HRP 
TFIIIC 
90  
1898-64 (Felton Edkins 
et al. 2006) 
Rabbit 
serum 
WB 1:1000 1:1000 Anti-
Rabbit HRP 
Tubulin Santa Cruz 
Biotechnology (sc-8035) 
Rabbit WB 1:500 1:1000 Anti-
Rabbit HRP 
USP7 USP7 Bethyl Labs (BL-
851) 
Rabbit WB 1:1000 1:1000 Anti-
Rabbit HRP 
 
2.5 Electromobility shift assays (EMSA) 
 
2.5.1 Nuclear and cytosolic protein extracts 
Epithelial cells were grown in 10cm2 dishes and harvested once cells were 80-90% confluent. 
Nuclear and cytosolic protein extractions were then conducted using the NE-PER Nuclear and 
Cytoplasmic Extraction kit (Pierce) following the manufacturer’s instructions. Briefly, cells 
were harvested from 10cm2 dishes by addition of 100µl ice-cold CERI (Cytosolic Extraction 
Reagent I) and scraping into pre-chilled microcentrifuge tubes, stored on ice. To each sample, 
5.5µl CERII was added before mixing by vortex and storing on ice. To pellet the nuclear 
fraction, samples were centrifuged at 16,000g for 5 minutes, and the supernatant consisting of 
the cytosolic fraction was transferred to a fresh microcentrifuge tube and stored at -80°C until 
use. The pellet containing cell nuclei was resuspended in 50µl of NER reagent and this 
suspension was stored on ice for 40 minutes. Within this 40 minute incubation, samples were 
vortexed every 10 minutes (at highest setting for 15 seconds) to break nuclei open. 
Subsequent centrifugation of samples (16,000g for 10 minutes) pelleted nuclear membrane 
fragments with the nuclear protein fraction (supernatant) being removed and placed in a fresh 
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microcentrifuge tube and stored at -80°C until use. Protein concentrations were determined as 
previously described (Section 2.4.1). 
 
2.5.2 Casting of native polyacrylamide gels 
Preparation of native polyacrylamide gels (native-PAGE)  used 13.3ml of 30% w/v 
acrylamide (Bio-Rad), 44ml of 1x TBE (10.8g Tris, 4.5g boric acid 0.74g EDTA in 1L 
distilled H2O), 22.7ml of distilled H2O and 45μl of TEMED. Polymerisation was initiated by 
addition of 450µl of 20% APS before addition of the gel mixture to novex cassettes 
(Invitrogen, UK) and careful insertion of a gel comb. Once cast, gels were wrapped in 1X 
TBE soaked paper towels and Saran Wrap and stored at 4°C until use. 
  
2.5.3 Preparation of EMSA probes 
Oligonucleotides end-labelled with an IRDye-700 (MWG-Biotech) infrared dye were diluted 
to 100pmol/µl with PCR grade H2O. 5μl of the sense and anti-sense oligonucleotides for each 
probe set were mixed with 90μl of restriction buffer B (Roche). Probes were annealed by 
incubation for 10 minutes in a hot-block at 95ºC before the hot-block was turned off, with 
samples being allowed to cool to room temperature in the hot-block overnight. Subsequently, 
annealed probes were removed from the heating block and placed in the dark at -20ºC. 
Oligonucleotide sequences are provided in Table 2.2. 
 
Table 2.2 Oligonucleotides used for EMSA. 
Probe Oligonucleotide sequence 
c-Myc X-Box 
wild type 
Sense 
5’- CGACCGCGCCACCAGATGGCACACGTGGGGGAAAT -3’ 
Antisense 
3’ - GCTGGCGCGGTGGTCTACCGTGTGCACCCCCTTTA -5’ 
c-Myc X-Box 
MUTANT 
Sense 
5’ - CGACCGCGCCACCAGAGAGCACACGGAGGGGAAAT- 3’ 
Antisense 
3’ - GCTGGCGCGGTGGTCTCTCGTGTGCCTCCCCTTTA - 5’ 
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2.5.4 EMSA binding reactions and visualisation 
The following binding reaction master mix was prepared for n+2 samples: 2µl 10x binding 
buffer, 2µl 25mM DTT containing 2.5% Tween, 1µl polyI.dC (1µg/µl), 1µl annealed EMSA 
probe. 6μl of master mix was added per sample together with 5μg of nuclear extract before 
total volume adjustment to 20μl with PCR grade H2O. Samples were gently mixed and 
incubated in the dark for 20 minutes to allow protein-DNA complexes to form before addition 
of 2µl DNA loading buffer (0.025g bromophenol blue, 0.025g Xylene Cyanol FF and 6ml 
glycerol made up to 20ml with H2O) to each sample. After gentle mixing, samples were 
loaded onto pre-cast native-PAGE gels which had been subject to electrophoresis for 30 
minutes at 70V in 0.5X TBE prior to loading in order to remove gel contaminants. Gel 
electrophoresis was subsequently conducted in the dark at 70V for 1-2 hours depending on 
dye front progression before detection of protein-DNA complexes using the Odyssey Infrared 
imaging system (Li-Cor biosciences). The IR scanner was set to 700nm to detect IRDye-700 
labelled probes, and offset focus was set to 2.5mm to account for gel and plate thickness.  
 
2.6 Nucleic acid transfection of mammalian cells 
 
Liposome transfection of eukaryotic cells was conducted using lipofectamine reagent 
(Invitrogen, UK). TurboFect reagent (Fermentas) was also used to tranfect cells in some 
instances. TurboFect in vitro transfection reagent is a sterile solution of a proprietary cationic 
polymer in water. The polymer forms compact, stable, positively charged complexes with 
DNA. These complexes protect DNA from degradation and facilitate gene delivery into 
eukaryotic cells. Both methods of transfection frequently resulted in a transfection efficiency 
of between 50% and 80% in epithelial cells. 
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Examples of transfection volumes given below were scaled up or down based on guidelines 
provided by reagent manufacturers depending on the size of tissue culture vessel used.  
 
2.6.1 Lipofectamine reagent transfection of epithelial cells 
The efficiency of transfection using lipofectamine reagent was enhanced by the addition of 
plus reagent (Invitrogen, UK). This additional reagent allows DNA to pre-complex before the 
addition of the lipofectamine reagent. Briefly, for 6-well plates, cells were seeded at a density 
of 2-3x105 and allowed to adhere for 48 hours. As such, on the day of transfection, cells were 
approximately 70-90% confluent. Amounts of DNA transfected varied as was required 
experimentally, but typically, 1μg DNA was diluted in 100μl serum-free and antibiotic-free 
Opti-MEM (Invitrogen, UK) before the addition of 6μl plus reagent. DNA complexes were 
allowed to form by incubation at room temperature for 15 minutes. Meanwhile, 4μl 
lipofectamine was diluted in 800μl serum-free and antibiotic-free Opti-MEM. Following 
DNA complex formation, the diluted lipofectamine reagent was added, and a 15 minute 
incubation at room temperature allowed liposome formation. Cells to be transfected were 
washed once in serum-free and antibiotic-free Opti-MEM before the addition of the 900μl 
transfection mix. The mix was applied dropwise and plates were gently swirled to ensure even 
distribution of complexes before transfer to a 37°C incubator for 3 hours. Subsequently, wells 
were topped up with antibiotic-free Opti-MEM, supplemented with 10% FBS (2ml per well). 
Cells were fed 24 hours post transfection with appropriate complete growth medium and 
subsequently harvested at necessary time points.  
 
2.6.2 TurboFect reagent transfection of epithelial cells 
The transfection protocol for TurboFect reagent resembled the method used for liposome 
transfection, however incubation steps varied slightly to allow effective transfection of DNA. 
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Briefly, for 6-well plates, cells were seeded at a density of 2-3x105 and allowed to adhere for 
48 hours. As such, on the day of transfection, cells were approximately 70-90% confluent. 
Amounts of DNA transfected varied as was required experimentally, but typically, 2μg DNA 
was diluted in 400μl serum-free and antibiotic-free Opti-MEM before the addition of 6μl 
TurboFect reagent. Transfection mixtures were left for 20 minutes to allow the TurboFect 
polymer to form compact, stable, positively charged complexes with DNA. During this 20 
minute incubation, cells were washed once with serum-free and antibiotic-free Opti-MEM 
before 600μl of serum-free and antibiotic-free Opti-MEM was added to each well. Following 
complex formation, the transfection mix was added to the 600μl Opti-MEM in each well. The 
mix was applied dropwise and plates were gently swirled to ensure even distribution of 
complexes before transfer to a 37°C incubator for 3 hours. Subsequently, wells were topped 
up with antibiotic-free Opti-MEM, supplemented with 10% FBS (2ml per well). Cells were 
fed 24 hours post transfection with appropriate complete growth medium and subsequently 
harvested at necessary time points. 
 
2.7 Luciferase reporter assays 
 
The Dual-Luciferase Reporter Assay System (Promega, UK) was used to conduct reporter 
assays. This system allows the activities of both firefly (Photinus pyralis) and Renilla (Renilla 
reniformis) luciferases to be measured from the same sample since the luciferases possess 
different emission wavelengths. Renilla activity was used to provide an internal control for 
cell viability and transfection efficiency, whereas firefly luciferase was measured to assess the 
activity of the experimental factor of interest.  
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Transfection of cells was conducted using the lipofectamine protocol described in Section 
2.6.1. Cells were co-transfected with 0.5µg of firefly reporter plasmid DNA (test promoter or 
empty vector to account for background luminescence) and 0.5µg of Renilla plasmid DNA. 
Harvest of cells typically occurred 48 hours post transfection. Cells were lysed in 500μl 
passive lysis buffer (Promega, UK), with complete lysis and homogenisation of samples being 
achieved through vigorous pipetting. 20μl of each homogenised sample was loaded in 
triplicate into a 96 well plate. To determine luciferase activity, 50μl LARII (Promega, UK) 
was added to each sample and the firefly luciferase activity was immediately measured using 
a Victor plate reader (Wallac, USA). Quenching of firefly activity and stimulation of Renilla 
activity was achieved by addition of 50μl Stop and Glo reagent (Promega, UK) to each 
sample. Renilla activity was immediately measured following this addition using a Victor 
plate reader.  
 
Firefly luciferase activity was normalised against Renilla luciferase activity for each sample 
and luciferase activity from an appropriate firefly control plasmid was deducted to account for 
background luminescence. Reporter plasmids and their control vectors are listed in Table 2.3.  
 
Table 2.3 Luciferase reporter and control constructs. 
 Test plasmid Control plasmid 
Renilla luciferase p-RL-TK  N/A 
c-Myc reporter pX-CMVp-Luc  p-CMVp-Luc  
AP-1 reporter pAP1-Luc  pTAL-LUC 
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2.8 RNA extractions 
 
RNA extractions were conducted using the EZ-RNA isolation kit (Geneflow, UK). Guidelines 
given by the manufacturer were followed accurately to extract RNA and the following given 
volumes were scaled up or down depending on the volume of the tissue culture vessel used in 
each experiment. Cells were grown to a confluence of 70-90% before harvesting. For a 10cm2 
dish, cells were harvested by lysis in 500μl of denaturing solution. Cells were scraped and 
collected into 1.5ml microcentrifuge tubes and incubated at room temperature for 5 minutes to 
ensure cell lysis. Subsequently, an equal volume of denaturing solution (500μl) was added 
and the sample mixed by vigorous vortexing for 15 seconds. Samples were left at room 
temperature for 10 minutes before centrifugation at 4°C (12,000rpm for 15 minutes) to 
separate the aqueous phase from the organic phase and interphase. The aqueous phase was 
then removed into a clean microcentrifuge tube and 500μl isopropanol was added to 
precipitate RNA. Precipitation occurred at -20°C overnight. Precipitated RNA was pelleted by 
centrifugation at 4°C (12,000rpm for 10 minutes) before the pellet was washed in 75% 
ethanol. RNA was repelleted by brief centrifugation and the ethanol carefully aspirated. The 
pellet was air dried before resuspension in PCR grade nuclease-free water. RNA 
concentration was determined using a NanoDrop 1000 spectrophotometer (Thermo Scientific) 
and samples diluted to 0.5µg/µl before storage at -80°C until used.  
 
2.9 DNA extractions 
 
Total DNA was extracted from cultured cells using the DNeasy spin column kit (Qiagen). 
Manufacturer’s instructions were followed precisely following pelleting of cells by 
centrifugation and resuspension in PBS and proteinase K-mediated lysis (addition of 20 µl of 
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600 mAU/ml proteinase K solution). DNA concentrations were measured using a NanoDrop 
1000 spectrophotometer.  
 
2.10 Dual RNA and DNA extractions 
 
In some instances, it was necessary simultaneously to extract both RNA and DNA from the 
same samples. In these cases, the Allprep DNA/RNA mini kit (Qiagen) was used according to 
the manufacturer’s instructions.  
 
2.11 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
2.11.1 cDNA synthesis 
cDNA was generated from RNA using Superscript III reverse transcriptase (Invitrogen, UK). 
Superscript III is derived from moloney murine leukaemia virus. For each reaction, 1μg RNA 
was added to a 0.2ml PCR tube along with 0.4μg random primers (Promega, UK) and 1μl of 
10mM dNTP mix (Invitrogen, UK) and the volume adjusted to 13μl with PCR grade H2O. 
The mixture was heated to 65°C for 5 minutes to denature the dsRNA then cooled on ice. 
Once cool, 4μl of 5x first strand buffer, 1µl of 0.1M DTT, 1µl of 40 units/µl RNaseOUT 
(Invitrogen, UK) and 1µl of 200 units/µl Superscript III was added to the tube and mixed by 
pipetting. cDNA synthesis was performed in a thermal cycler under the following conditions: 
25°C for 5 minutes 
50°C for 1 hour 
70°C for 15 minutes 
The cDNA mix was then diluted 1 in 5 (by addition of 80μl PCR grade H2O) and stored at 
4°C (for short term storage) or -20°C (for long term storage).  
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2.11.2 RT-PCR  
For each RT-PCR reaction, the following components were assembled for each sample in a 
PCR tube: 5µl (50ng) diluted cDNA, 1µl 100pmol forward primer, 1µl 100pmol reverse 
primer, 25µl 2x GoTaq Green Master Mix (Promega, UK) and 18µl PCR H2O. The GoTaq 
master mix contains Taq polymerase, PCR buffer, 400µM dNTP mix, 3mM MgCl2 and DNA 
loading dye. PCR conditions consisted of an initial denaturation step (typically 5 minutes at 
95°C), followed by a varying number of cycles of the following steps:  
Denaturation – typically 30 to 60 seconds at 95°C 
Annealing – 30 to 60 seconds at specific annealing temperature (see Table 2.4)             
Extension – typically 30 to 60 seconds at 72°C 
Samples were also subjected to a final extension period of 5 to 10 minutes at 72°C before 
being held at 4°C prior to agarose gel electrophoresis (Section 2.11.3). 
 
Primers for RT-PCR were synthesised by Sigma-Aldrich and are presented in Table 2.4 along 
with specific annealing temperatures used for each primer set and the product size expected.  
 
Table 2.4 PCR primers and accompanying annealing conditions and product sizes. 
    Gene Primer oligonucleotides 5’ – 3’ Annealing 
temp (°C) 
Product 
size (bp) 
ATF-2 Forward: CACACAACTCCACAGACCCAAA 
Reverse: GGAGCCATAACGATCTGTGAAA 
55 494 
Brf1 Forward: AATTCTGTGAGCCTCTTCCGTAGTG 
Reverse: AGACCCATGCTTGTACATTCCACG 
60 95 
c-Myc Forward: AACCAGAGTTTCATCTGCGACCCG 
Reverse: TTGTGCTGATGTGTGGAGACGTGG 
53 590 
111 
 
Materials and Methods 
Table 2.4 ctd PCR primers and accompanying annealing conditions and product sizes 
* denotes sequential annealing temperatures, ** From Felton Edkins et al. 2006. 
Gene Primer oligonucleotides  5’ – 3’ Annealing 
temperature 
(°C) 
Product 
size (bp) 
EBER1 Forward: AGGACCTACGCTGCCCTAGA 
Reverse: AAAACATGCGGACCACCAGC 
55 166 
GAPDH Forward: GCCTCCTGCACCACCAACTG 
Reverse: CGACGCCTGCTTCACCACCTTCT 
52 250 
TBP** Forward: GCCAGAGTTATTTCCTGGTTT 
Reverse: CCCAGATAGCAGCACGGTAT 
52 410 
Bdp1** Forward: GCTGATAGAGATACTCCTC 
Reverse: CCAGAGACAAGAATCTTCTC 
60 293 
TFIIIC 
220** 
Forward: TCCAGCGAGACCGTCACACC 
Reverse: GGATTGAGTGTTGCTGGGCT 
62 144 
TFIIIC 
110** 
Forward: CCAGAAGGGGTCTCAAAGTCC 
Reverse: CTTTCTTCAGAGATGTCAAAGG 
62 303 
TFIIIC 
102** 
Forward: GCAGAAGTAACATCATTGGC 
Reverse: CCTACTAATGTCCGTTATCTGTGG 
61, 58, 50* 184 
TFIIIC 
90** 
Forward: AAACAGAAGTTGCTGAGTGC 
Reverse: ATGGTCAGGCGATTGTCC 
55, 62* 210 
TFIIIC 
63** 
Forward: ATGGCTTGAAGTCCTCCTCCTCC 
Reverse: CCGAGATGTTCTACCAGTTATGCG 
69, 62, 50* 300 
5S 
RNA** 
Forward: TTTACGGCCACACCACCCTG 
Reverse: AAAGCCTTCAGCACCCTGTA 
58 107 
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Table 2.4 ctd PCR primers and accompanying annealing conditions and product sizes. 
Gene Primer oligonucleotides  5’ – 3’ Annealing 
temperatur
e (°C) 
Product 
size (bp) 
7SL** 
RNA  
 
Forward: 
GTGTCCGCACTAAGTTCGGCATCAATATGG 
Reverse: 
TATTCACAGGCGCGATCCCACTACTGATC 
70 150 
tRNAtyr** 
 
Forward: 
CCTTCGATAGCTCAGCTGGTAGAGCGGAGG 
Reverse: 
CGGAATTGAACCAGCGACCTAAGGATGTCC 
65 84 
 
In some instances where increased assay sensitivity was required, semi-quantitative RT-PCR 
followed by Southern blotting was conducted. Semi-quantitative RT-PCR involved 
incrementally increasing the number of PCR cycles conducted, with samples taken at each 
cycle increment for analysis by gel electrophoresis of optimal cycle number. This analysis 
ensured samples used were in the linear range, with cycle numbers being selected where 
sufficient application had occurred, but saturation had not been reached. This ensured any 
differences in samples were observed, and were maximal. Where optimal conditions were 
attained, the gels from electrophoresis were prepared for Southern blotting. The procedures 
involved are outlined in Section 2.13.  
 
2.11.3 Agarose gel electrophoresis 
Fractionation, resolution and visualisation of PCR products were conducted on 1-2% w/v 
agarose gels, dependent on size of PCR product. Agarose powder was weighed and dissolved 
in the appropriate volume of 1x TBE by boiling in a glass conical flask. The solution was 
cooled to around 50°C before ethidium bromide was added to a final concentration of 
0.5μg/μl. The solution was subsequently poured into a sealed gel casting tray and a gel comb 
inserted. Once set, the gel was placed into a horizontal gel electrophoresis tank (Eurogentec, 
USA) and the gel comb removed. The tank was filled with 1x TBE and 20-40μl of PCR 
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product was loaded into each well alongside an appropriate DNA size marker ladder 
(Geneflow, UK). Gel electrophoresis was typically performed at 130V for 1hr prior to 
visualisation of ethidium bromide stained bands using a UV transilluminator.  
2.11.5 RT-qPCR for cellular genes 
RT-qPCR for cellular genes was performed using ready synthesised Taqman primer and 
probe (FAM labelled) mixes purchased from Applied Biosystems (see Table 2.5). Each 
multiplexed RT-qPCR reaction consisted of 5µl (50ng) of cDNA, 1µl of ABI test primers and 
probe mix, 0.5µl of huGAPDH primer and probe (VIC labelled) mix, 10µl of 2x sensimix 
(Quantace) and DEPC water to 20µl. Reactions were performed in technical triplicate and 
analysed on an ABI 7500 Fast Real-time PCR machine. Cycle threshold (Ct) values were 
obtained by determining the point at which amplification occurred above background in the 
linear range of amplification for each reaction. The test primer data were then normalised 
against the multiplexed GAPDH data to obtain the dCt values and the average determined for 
each triplicate to obtain the mean dCt. ddCt values were calculated by subtracting the control 
dCt value from the “test” dCt, before fold changes from control to test samples were 
calculated using the formula 2-ddCt. 
Table 2.5 Applied Biosystems primer and probe master mixes. 
Gene ABI QPCR Primer/Probe Reference Number 
TFIIIC220 Hs01121460_m1 
TFIIIC110 Hs01086775_m1 
TFIIIC102 Hs01066489_m1 
TFIIIC90 Hs01034271_m1 
TFIIIC63 Hs01030747_m1 
BDP1 Hs00372575_m1 
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BRF1 Hs00377388_m1 
TBP Hs00920494_m1 
2.12 Southern Blot analysis of EBV genome copy number 
 
LCLs were maintained as described in Section 2.2.5, and DNA was extracted using 
phenol/chloroform before ethanol precipitation. 
 
2.12.1 Southern Blotting Solutions 
Denaturing solution: 1.5M NaCl, 0.5M NaOH 
Neutralisation solution: 1.5M NaCl, 0.5M Tris-HCl pH7.2, 0.001M EDTA 
20 X SSC: 3M NaCl, 0.3M Sodium Citrate 
Prehybridisation solution: (For 100ml) – 70ml ddH2O, 30ml 20 X SSC, 0.5g Milk powder. 
 
2.12.2 Sample preparation 
For each LCL, 10μg of isolated DNA was digested with BamHI restriction endonuclease. 
Digested samples were run on 0.8% agarose gels (containing ethidium bromide) before UV 
visualisation of DNA to ensure DNA had migrated an adequate distance, and to assess equal 
loading of samples.   
Following visualisation, agarose gels were prepared for capillary transfer of DNA to N+ 
Hybond membrane (Amersham, UK) by soaking in denaturing solution for 30 minutes at 
room temperature with agitation. Denaturing solution was then replaced with neutralising 
solution and gels were incubated at room temperature with agitation for another 30 minutes. 
Following neutralisation a blotting platform was prepared as illustrated in Figure 2.1. Transfer 
was allowed to take place overnight before disassembly of the blotting apparatus. The nylon 
membrane was subsequently placed onto a sheet of 3mm paper soaked in 0.4M NaOH for 20 
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minutes to immobilise the transferred DNA onto the membrane, before storage in Saran Wrap 
at 4°C until use. 
Figure 2.1   
3mm paper 
Glass support 
10X SSC (1.5M NaCl, 
0.15M Na Citrate) 
Agarose Gel Hybond N+ 
3 Sheets 3mm paper
Paper Towels 
Glass Plate 
1Kg Weight 
 
2.12.3 Probe preparation 
To produce an EBV genomic DNA Southern blot probe, pBamHI-X plasmid DNA was 
digested with BamHI. This allowed gel isolation of the BamHI-X fragment of the plasmid 
which was subsequently used to generate radioactive probes. This was achieved using a 
Random Primed DNA Labelling Kit (Roche Applied Science), closely adhering to the 
manufacturer’s instructions. Briefly, 25ng linear template DNA (BamHI-X) was denatured by 
heating to 95°C for 10 minutes before being placed on ice. Subsequently dNTP mixture was 
added (containing dATP, TTP and dGTP) along with reaction buffer, Klenow enzyme and 50 
μCi [α-32P]dCTP (Redivue aqueous solution, Amersham Biosciences, UK). The reaction was 
mixed and incubated at 37°C for at least 30 minutes to allow labelling of DNA. 
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Unincorporated radiolabelled nucleotides were removed using Sephadex G-50 DNA Grade 
NICK columns (GE Healthcare), according to the manufacturer’s instructions.  
 
2.12.4 Probe hybridisation, washing and visualisation 
Membranes with immobilised DNA were incubated in prehybridisation solution (prehyb) in a 
hybridisation oven set to 68°C for 2-3 hours prior to addition of labelled probe. Immediately 
prior to addition to membranes, labelled probes were denatured for 2 minutes at 98°C. 
Denatured probes were then added to hybridisation tubes containing prehyb and membrane(s), 
and incubated overnight at 68°C to allow hybridisation of labelled probe to DNA. Following 
incubation, membranes were washed, again in a hybridisation oven at 68°C. The washes were 
carried out sequentially as follows: 
2 X 30 minute washes in 2 X SSC, 0.1% SDS 
2 X 30 minute washes in 0.2 X SSC, 0.1% SDS 
Final rinse in 1 X SSC (removes SDS which may interfere with visualisation) 
Following post-hybridisation washes, membranes were removed from hybridisation tubes and 
wrapped using Saran wrap before being placed in autoradiography cassettes. For visualisation 
and quantification, either autoradiography film was placed in the cassette with the membranes 
(for 24-48 hours, stored at -80°C) before developing and densitometry (Section 2.18).  
 
2.13 Southern blotting following semi-quantitative RT-PCR 
 
Agarose gels from electrophoresis of RT-PCR products were prepared for capillary transfer of 
DNA to N+ Hybond membrane (Amersham, UK) as previously described (Section 2.12.1).  
Preparation of probes for specific RT-PCR products was carried out by performing RT-PCR 
with the same primer sets used experimentally, using Ad/AH genomic DNA as a template. 
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Following gel electrophoresis, bands were gel isolated for use as Southern blotting probes, 
and prepared using a Random Primed DNA Labelling Kit (Roche Applied Science) as 
previously described (Section 2.12.3).   
2.14 Quantitative PCR (qPCR) for EBV genome load 
qPCR for EBV genome load was carried out using EBV-POL specific primer probe sets 
(Gallagher et al. 1999; Junying et al. 2003). To allow precise quantification of average EBV 
genome copies in each cell line, a calibration curve was prepared and results were analysed on 
the basis of this standard curve. DNA was extracted (Qiagen Allprep DNA/RNA minikit) 
from LCLs which had been maintained as described in Section 2.2.5.  
2.14.1 DNA standards 
Namalwa BL (which contains two integrated EBV genome copies per cell (Lawrence et al. 
1988)) was used as a standard to prepare a calibration curve. DNA was isolated as described 
(Section 2.9), and the concentration determined. An aliquot of DNA was subsequently 
adjusted to give a final concentration of 132ng/μl, corresponding to 40,000 EBV copies per 
μl, based on the assumption that: (a) each cell contains 6.6pg DNA and (b) each Namalwa cell 
contains 2 viral genomes. From the 40,000 EBV genome stock, serial dilutions were prepared 
and stored at 4°C until use. Stock DNA was aliquoted and stored at -20°C.  
2.14.2 PCR reaction 
qPCR for EBV genome load was carried out using primer/probe sets (given in Table 2.6) for 
the EBV POL (BALF5) gene, and the human β-2 microglobulin gene which served as an 
endogenous cellular control.  
PCR reactions were set up using the following components per 25μl reaction: 
12.5μl Taqman Universal 2X Master Mix 
2.5μl EBV POL forward primer (2μM stock) 
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2.5μl EBV POL reverse primer (2μM stock) 
1μl EBV POL FAM-labelled probe (5μM stock) 
0.5μl β-2M forward primer (3μM stock) 
0.5μl β-2M reverse primer (4μM stock) 
0.5μl β-2M VIC-labelled probe (5μM stock) 
5μl DNA template (DNA concentration 1ng-100ng/μl) 
25μl reactions were loaded into 96-well plates and analysed using ABI 7500 Fast Real-time 
PCR machine. 
Table 2.6 qPCR primer/probe sets used in analysis of EBV copy number 
Gene Forward Primer (5’-
3’) 
Reverse Primer (5’-
3’) 
Probe (5’-3’) 
EBV POL 
(BALF5) 
CTTTGGCGCGGAT
CCTC 
AGTCCTTCTTGGC
TAGTCTGTTGAC 
CATCAAGAAGCTG
CTGGCGGCC 
β-2 
microglobulin 
GGAATTGATTTGG
GAGAGCATC 
CAGGTCCTGGCTC
TACAATTTACTAA 
AGTGTGACTGGGC
AGATCCACCTTC 
 
2.14.3 Data Analysis 
Copy number quantification was achieved using calculations based on the standard curves 
generated from Namalwa BL DNA. To generate standard curves, for both β-2M and EBV 
POL, Ct Values were plotted against the log of number of EBV copies in each diluted sample. 
An example of the curves generated is shown in Figure 2.2. 
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R2 = 0.9932
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The formula from each β-2 microglobulin standard curve (line of best fit) was used, along 
with sample Ct values, to quantify the amount of β-2 microglobulin present in each individual 
sample (Ct value = X; β-2 microglobulin value = Y). The anti-log of this value was taken and 
used as each sample’s final value for β-2 microglobulin. The same procedure was applied to 
Ct values for EBV POL, using standard curves generated from the Namalwa DNA using the 
EBV POL probe. EBV POL values for each sample were made relative to β-2 microglobulin 
values (by division) to generate the average number of EBV genome copies per cell. Each 
sample was analysed in technical and biological triplicate, with average values taken.  
 
2.15 Methods of EBER detection 
 
2.15.1 In situ hybridisation staining (ISH) for EBER expression 
The presence of EBERs was detected in situ using a peptide nucleic acid (PNA), fluorescein 
isothiocyanate (FITC) labelled, fluorescent probe (Dako, Y5200) which is able to bind small 
nuclear RNA (snRNA) EBER1 and EBER2 transcripts. As for IF staining, adherent cells were 
trypsinised and counted as described in Section 2.2.5. Cells (1x104) were seeded onto sterile 
Teflon coated slides (Henley) and left to adhere for 48 to 72 hours in 150mm culture dishes, 
with desiccation prevented by the addition of PBS solution to the culture dishes. Cells were 
then washed with PBS before fixation in 4% PFA pH 7.4 for 10 minutes and immersion in 
RNase-free water multiple times. From this point, the manufacturer’s protocol for EBER ISH 
using tissue sections was faithfully followed. Slides were placed in a humidity chamber 
before the addition of Proteinase K to each well to permeabilise the cells. Following a 20 
minute incubation, cells were immersed in pure water and then 95% ethanol, before being air 
dried in the humidity chamber. A drop of either EBER PNA Probe/Fluorescein (DAKO, 
Y5200) or negative control PNA Probe/FITC (provided in DAKO kit, K5201) was applied to 
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each well of the slides before coverslips were added, and slides were incubated in a humidity 
chamber at 55°C for 90 minutes. The negative control probe allowed analysis of background 
staining in each well. Coverslips were removed before slides were immersed in Stringent 
Wash Solution (provided in DAKO kit, K5201) which had been pre-warmed to 55°C. Slides 
were incubated for 20 minutes at 55°C with constant shaking and then adjusted to room 
temperature by a 10 second immersion in TBS. Slides were replaced into the humidity 
chamber before a drop of Anti-FITC/AP (provided in DAKO kit K5201) was added to each 
well. Following incubation for 30 minutes, the antibody was tapped off and slides were 
immersed twice in TBS for 3 minutes then twice in RNase-free water for 1 minute. Having 
been placed back in the humidity chamber, a drop of substrate (provided in DAKO kit K5201) 
was added to each well prior to incubation for 30-60 minutes. At this point, slides were 
immersed in tap water for 5 minutes before mounting with coverslips and microscopy.   
 
2.15.2 Detection of EBER RNA by flow cytometry 
EBERs were also detected by flow cytometry, using the same PNA, FITC labelled, 
fluorescent probe (Dako, Y5200) that was utilised in EBER ISH (as described in Section 
2.15.1). In order to avoid ribonuclease activity, all solutions were prepared using nuclease-
free water. For each sample, approximately 2 x 106 cells were washed in PBS before 
centrifugation to pellet cells. Cells were fixed in 1ml 5% v/v acetic acid in 4% PFA before an 
aliquot of 1 x 106 cells was removed and centrifuged. After discarding the supernatant, cells 
were permeabilised at room temperature for 10 minutes in 50µl permeabilisation buffer (0.5% 
Tween 20 in 1X PBS). To ensure a formamide and buffer concentration similar to the 
hybridisation buffer that contains the EBER probe, 100µl DEPC water, 75µl formamide and 
25µl formamide buffer (100mM NaCl, 50mM Na2EDTA, 500mM Tris-HCl pH 7.5) were 
added to the cells. This step increases probe binding, and following incubation for 5 minutes 
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this equilibration step was ended by centrifugation of cells and aspiration of the supernatant. 
Subsequently, 50μL EBER PNA probe (Dako) in hybridisation buffer (10% w/v dextran 
sulphate, 10mM NaCl, 30% v/v formamide, 0.1% w/v Na4P2O7, 0.2% w/v 
polyvinylpyrrolidone, 0.2% w/v ficoll, 5mM NaEDTA, 50mM Tris-HCl pH 7.5) was added 
and probe binding was carried out at 56˚C for 1 hour before addition of 1mL permeabilisation 
buffer and incubation at 56°C for a further 10 minutes. Cells were pelleted by centrifugation, 
with unbound probe then being washed from cells by incubation at 56˚C for 30 minutes in 
1mL permeabilisation buffer. Finally cells were pelleted by centrifugation before 
resuspension in permeabilisation buffer ready for flow cytometry. The percentage of EBER-
positive cells was measured using a Beckman Coulter XL flow cytometer. Fixed cells were 
gated on forward and side scatter and the EBER expression was detected though the FITC 
channel. The threshold of detection was set at 2% for EBV-negative cells. For each sample, 
5,000 cells were counted and the percentage of positively stained cells recorded. 
 
2.15.3 Northern blot analysis of levels of EBER expression 
 
RNA was extracted (Qiagen Allprep DNA/RNA minikit) from LCLs which had been 
maintained as described in Section 2.2.5. Simultaneously DNA from the same sample was 
extracted and was used for qPCR analysis of EBV genome load. 
 
2.15.3.1 Denaturing acrylamide gel preparation 
Denaturing acrylamide (10%) gel mix (15ml – sufficient for one gel) was prepared by mixing 
7.2g Urea (Sigma-Aldrich), 1.5ml 10 X TBE, 3.75ml  40% acrylamide (acrylamide:bis 
acrylamide = 19:1) and adding nuclease-free water to a total volume of 15ml. Subsequently, 
75μl 10% APS and 15μl TEMED were added and following brief mixing, gels were poured 
into cassettes.  
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2.15.3.2 Electrophoresis and Transfer 
10μg of RNA was mixed with loading dye prior to loading. Electrophoresis was conducted in 
1 X TBE at 90V and was terminated once the dye front had migrated the full length of the gel. 
To assess the quality of samples and separation of the RNA, gels were stained with ethidium 
bromide and examined using a transilluminator before transfer. Following this assessment, 
RNA was transferred to a nylon membrane (N+ Hybond, Amersham) by electroblotting in 
0.25 X TBE buffer, at 200mA for a minimum of 90 minutes. After blotting, the membrane 
was kept damp by wrapping in Saran Wrap, before the RNA was UV crosslinked to the 
membrane using a commercial crosslinking device (120mJ burst over 30 seconds).   
 
2.15.3.3 Probe Preparation 
A plasmid containing the EcoRI-J fragment of EBV genomic DNA was digested with EcoRI 
to yield a 3kb fragment which was excised following gel electrophoresis and used to generate 
radiolabelled probe for EBERs. This was achieved using a Random Primed DNA Labelling 
Kit (Roche Applied Science), as described in Section 2.12.3. The U4 small RNA probe was 
generated by PCR amplification of the U4 gene (Forward primer 5’-
CGTGCCAATGAGGTTTATCC-3’, Reverse primer 5’- AAAATTGCCAATGCCGACTA-
3’) followed gel electrophoresis and excision of the PCR product and use of the Random 
Primed DNA Labelling Kit (Roche Applied Science), as described in Section 2.12.3. 
 
2.15.3.4 Probe hybridisation, washing and visualisation 
Probe hybridisation, washing and visualisation were carried out as described for Southern 
blotting, in Section 2.12.4.  
2.15.4 Quantitative RT-PCR for EBER1 and EBER2 
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Quantitative reverse transcription PCR (qRT-PCR) was conducted to determine the levels of 
EBER 1 and EBER2 in LCLs. This was performed on cDNA generated from RNA extracted 
as previously described (Section 2.15.3) in a gene-specific manner (Shannon Lowe et al. 
2009). 
 
2.15.4.1 DNase Treatment of RNA 
Due to the extremely sensitive nature of qRT-PCR reactions for EBER1 and EBER2, DNase 
treatment of extracted RNA was conducted to ensure no genomic DNA was present, which 
might yield false positive results. 1μg RNA was incubated with DNase and buffer (DNA-free 
kit, Ambion, UK), in a reaction of 25µl total volume, at 37°C for 30 minutes before 2.5μl stop 
solution was added to the reaction. The mixture was then centrifuged at 10,000rpm for 90 
seconds to remove the stop solution, before 20μl of the reaction was removed to a fresh 
microcentrifuge tube. 10μl of the reaction (400ng) was used per subsequent cDNA reaction. 
 
2.15.4.2 cDNA synthesis 
The 400ng of RNA was placed into a 0.5ml microcentrifuge tube and denatured by incubation 
at 90°C for 5 minutes then placed on ice. For each sample, mastermixes were prepared with 
and without Reverse Transcriptase enzyme (AMV RT, Roche), using gene specific primers 
(given in Table 2.7): 
With RT   
2μl specific DNA primer (10μM) 
2μl dNTPs 
4μl 5 x RT Buffer 
 
 
 
0.2μl RNase inhibitor 
1.3μl SDW 
0.5μl RT
Materials and Methods 
Without RT 
2μl specific DNA primer 
2μl dNTPs 
4μl 5 x RT Buffer 
 
0.2μl RNase inhibitor 
1.8μl SDW 
 
 
10μl of appropriate RT (or no RT) mix was then added to the ice cold denatured 
RNA, and the mixtures were incubated at 42°C for 1 hour before RT was inactivated 
by heating samples to 90°C for 5 minutes. cDNA samples were subsequently diluted 
to 5ng/μl by the addition of 60μl SDW.   
 
2.15.4.3 X50-7 cDNA standard curves 
Standard curves were plotted based on serial dilutions of X50-7 cDNA. From a 
starting point of 5ng/μl, cDNA samples of concentrations 1ng/μl, 200pg/μl, 40pg/μl 
and 8pg/μl were made.  
 
2.15.4.4 PCR reactions 
Separate mastermixes for both EBER1 and EBER2 were prepared for each sample. 
Example 20μl mastermix (for either EBER1 or EBER2): 
12.5μl Taq MM 
2.5μl EBER Forward Primer 
2.5μl EBER Reverse Primer 
1μl EBER probe 
0.5μl GAPDH mix (primers and probe) 
1μl DEPC water 
 
20μl of the mastermix was added to each well of a 96 well plate as required. 5μl of 
X50-7 standard or experimental sample was added to appropriate wells, before brief 
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centrifugation of plate and loading into real-time PCR analyser. Details of 
primer/probe set sequences are given in Table 2.7: 
 
Table 2.7 EBER1, EBER2 and GAPDH primer/probe and cDNA primer sets 
Assay Oligo  Sequence 5’-3’ 
EBER1 Forward TGCTAGGGAGGAGACGTGTGT 
 Reverse TGACCGAAGACGGCAGAAAG 
 Probe AGACAACCACAGACACCGTCCTCACCA 
 cDNA primer GACCACCAGCTGGTAC 
EBER2 Forward AACGCTCAGTGCGGTGCTA 
 Reverse GAATCCTGACTTGCAAATGCTCTA 
 Probe CGACCCGAGGTCAAGTCCCGG 
 cDNA primer GGACAAGCCGAATACC 
GAPDH Forward GAAGGTGAAGGTCGGAGTA 
 Reverse GAAGATGGTGATGGGATTTC 
 Probe CAAGCTTCCCGTTCTCAGCC 
 cDNA primer GATCTCGCTCCTGGAA 
 
2.15.4.5 Data Analysis 
 Levels of EBER expression were determined relative to levels of EBER1 and EBER2 
expression empirically determined in X50-7 cells. Standard curves were generated 
using serial dilutions of X50-7 cDNA for GAPDH, EBER1, and EBER2.  For each 
gene assay, Ct Values were plotted against the log of ng/µl X50-7 cDNA in each 
diluted sample. The formula from the standard curve was applied to each sample’s Ct 
value for the appropriate variable, before the anti-log of this value was taken and used 
as each sample’s unknown for the variable. EBER unknowns (EBER1 and EBER2 
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analysed separately) were then normalised against the internal GAPDH control 
unknown (by division) to generate the relative level of expression of EBER1 and 
EBER2, relative to X50-7. Each sample was analysed in both biological and technical 
triplicate, with average values being reported.  
 
2.16 Chromatin Immunoprecipitation (ChIP) 
 
ChIP was performed using a commercial kit, EZ ChIP™ (Catalog # 17-371) obtained 
from Upstate (USA). The EZ ChIP™ kit contains reagents optimised for 
immunoprecipitation of chromatin from mammalian cells including controls to ensure 
successful performance of this assay. The included positive control antibody is a 
mouse monoclonal antibody to RNA Polymerase II and detects RNA Polymerase II of 
human, mouse, rat and yeast. The negative control is Normal Mouse IgG, which 
controls for the nonspecific immunoselection of chromatin by immunoglobulins. 
Control primers and 10X PCR Buffer are included for detection of a 166 base pair 
region of the human GAPDH promoter by PCR. Not provided in the kit are specific 
antibodies to precipitate proteins of interest and appropriate isotype control 
antibodies. Antibody chEBNA1 was kindly provided by Professor Paul Lieberman 
(The Wistar Institute, Philadelphia USA) for specific immunoprecipitation of 
EBNA1, having been successfully used for this purpose previously. chEBNA1 is a 
polyclonal rabbit antibody against EBNA1. As a non-specific isotype control, a 
polyclonal rabbit antibody to E-Cadherin was used (Santa Cruz Biotechnology Inc. 
USA, H-108). Protocols followed were as given in the Upstate user guide and are 
briefly outlined below. 
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2.16.1 Buffers and solutions provided and used in the EZ-ChIP kit 
Stored at 4°C: 
Salmon Sperm DNA/Protein G Agarose, Catalog # 16-201C. One vial containing 
1.5ml packed beads with 600μg sonicated salmon sperm DNA, 1.5mg BSA and 
approximately 4.5mg recombinant Protein G. Provided as a 50% gel slurry for a final 
volume of 3ml per vial,suspended in TE buffer, pH 8.0, containing 0.05% sodium 
azide.  
ChIP Dilution Buffer, Catalog # 20-153. One vial containing 24ml of 0.01% SDS, 
1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl, pH 8.1, 167mM NaCl. 
Low Salt Immune Complex Wash Buffer, Catalog # 20-154. One vial containing 
24ml of 0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 150mM 
NaCl. 
High Salt Immune Complex Wash Buffer, Catalog # 20-155. One vial containing 
24ml of 0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 500mM 
NaCl. 
LiCl Immune Complex Wash Buffer, Catalog # 20-156. One vial containing 24ml of 
0.25M LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid (sodium salt), 1mM EDTA, 
10mM Tris, pH 8.1. 
TE Buffer, Catalog # 20-157. Two vials, each containing 24ml of 10mM Tris-HCl, 
1mM EDTA, pH 8.0. 
0.5M EDTA, Catalog # 20-158. One vial containing 250μl of 0.5M EDTA, pH 8.0. 
5M NaCl, Catalog # 20-159. One vial containing 500μl of 5M NaCl. 
SDS Lysis Buffer, Catalog # 20-163. One vial containing 10ml of 1% SDS, 10mM 
EDTA, 50mM Tris, pH 8.1. 
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 1M Tris-HCl, pH 6.5, Catalog # 20-160. One vial containing 500μl of 1M Tris-HCl, 
pH 6.5. 
10X Glycine, Catalog # 20-282. One vial containing 24ml of 1.25M Glycine. 
10X PBS, Catalog # 20-281. One vial containing 24ml of 10X PBS. 
 
Stored at -20°C: 
Protease Inhibitor Cocktail II, Catalog # 20-283. Two vials, each containing 110μl of 
200X Protease Inhibitor Cocktail II in DMSO. 
RNase A, Catalog # 20-297. One vial containing 45μl of 10mg/ml RNase A in sterile 
water. 
Proteinase K, Catalog # 20-298. One vial containing 60μl of 10mg/ml Proteinase K in 
10mM Tris-HCl, pH 8.0, 10mM CaCl2. 
1M NaHCO3, Catalog # 20-296. One vial containing 500μl of 1M NaHCO3. 
10X PCR Buffer, Catalog # 20-295. One vial containing 200μl of 750mM Tris-HCl, 
pH 8.8, 200mM (NH4)2SO4, 0.1% Tween®-20, 25mM MgCl2. 
 
2.16.2 In vivo cross-linking and lysis 
Adherent epithelial cells were grown in 10cm2 dishes to a confluence of ~80-90% 
before in vivo cross-linking with formaldehyde. 270μl of freshly prepared 37.5% 
formaldehyde was added to the 10ml growth medium in each 10cm2 dish to give a 
final concentration of 1% formaldehyde for cross-linking. Following a gentle swirl, 
plates were incubated at room temperature for 10 minutes. Following the cross-
linking, any unreacted formaldehyde was quenched by the addition of 1ml 1.25M 
glycine. Plates were subsequently swirled and incubated at room temperature for 5 
minutes before being placed on ice, and having all media aspirated. Cells were then 
washed 3 times with 10ml ice cold PBS, before the addition of 1ml ice-cold PBS 
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containing protease inhibitors. Cells were then scraped into microcentrifuge tubes and 
spun at 700 x g for 5 minutes to pellet the cells. Supernatant was removed and 1ml 
SDS lysis buffer was used to resuspend cell pellets. Lysates were aliquoted (400μl) 
into microcentrifuge tubes and either used immediately or stored at -80°C.  
 
2.16.3 Sonication to shear DNA 
 
Prior to the immunoprecipitation (IP) step, cells require breaking open and chromatin 
within the cells must be sheared into manageable fragments. This is achieved through 
sonication of the samples. Shearing DNA to 200-1000bp in length provides a high 
degree of resolution during the detection steps at the end of the procedure. Optimal 
conditions for shearing cross-linked DNA to 200-1000bp in length are dependent on a 
number of factors. These include cell type and concentration, sonicator equipment and 
setup, power settings, and the number of pulses used. As such, the sonication 
conditions described below were determined empirically to give fragments of 200-
1000bp (see Chapter 5). The conditions outlined were applied to each set of 
experimental samples. 
 
Samples were kept on ice throughout sonication to ensure that overheating (which 
may denature chromatin) did not occur. Each 400μl sample was sheared using a 
Misonix XL2000 sonicator (Misonix, New York, USA) set to power setting 10. 10 
pulses of 10 seconds were used for each sample, with 30 seconds between each pulse 
to allow the sample to cool. Following sonication, samples were centrifuged at 12,000 
x g for 10 minutes to remove any insoluble material before a 5μl aliquot was taken 
and subjected to gel-electrophoresis to ensure fragmentation of DNA into 200-1000bp 
fragments had occurred. Each sample was then divided into 100μl aliquots 
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(containing ~2 x 106 cells), sufficient for an immunoprecipitation, and stored at -80°C 
until use. 
 
2.16.4 Immunoprecipitation of Cross-linked Protein/DNA 
All IP procedures were conducted in a temperature controlled room at 4°C. 100μl 
aliquots of sample were prepared for IP by the addition of 900μl dilution buffer. To 
pre-clear the chromatin, 60μl of Protein G Agarose (50% slurry) was added to each 
sample and samples were incubated with rotation for 1 hour at 4°C. Agarose was 
pelleted by centrifugation at 3000 x g for 1 minute and supernatant was transferred to 
a fresh microcentrifuge tube. 10μl (1%) of the supernatant was removed and saved as 
input at 4°C until the completion of the IP procedure. Immunoprecipitating antibodies 
(see Table 2.8) were subsequently added to the appropriate supernatants and samples 
were incubated overnight with rotation at 4°C. The following morning, 
antibody/antigen/DNA complexes were collected by the addition of 60μl of Protein G 
Agarose and incubated for 1 hour with rotation at 4°C. Protein G Agarose was 
pelleted by centrifugation at 3000 x g for 1 minute and the supernatant was aspirated 
and discarded. Protein G Agarose-antibody/antigen/DNA complexes were washed by 
resuspension in 1ml each of the buffers in the sequence listed below: 
Low Salt Immune Complex Wash Buffer – 1 Wash 
High Salt Immune Complex Wash Buffer – 1 Wash 
LiCl Immune Complex Wash Buffer – 1 Wash 
TE Buffer – 2 Washes 
Beads were washed by incubation with rotation for 5 minutes in each of the wash 
buffers, with Protein G Agarose-antibody/antigen/DNA complexes being pelleted 
after each wash by centrifugation at 3000 x g for 1 minute. All wash supernatants 
were carefully aspirated and then discarded.  
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Table 2.8 Antibodies used for immunoprecipitation. 
Protein 
 
 
Immuno-
precipitating 
antibody 
Species Working Concentration 
EBNA1 chEBNA1 Rabbit 7.5μl per IP 
E-Cadherin 
(chEBNA1 isotype 
control) 
E-Cad (Santa 
Cruz, H-108, 
sc7870) 
Rabbit 7.5μl (1.5μg) per IP 
RNA Polymerase II Anti-RNA 
Polymerase II 
CTD448 
Mouse 1μg per IP 
Mouse IgG Mouse IgG  Mouse 1μg per IP 
 
2.16.5 Reversal of Cross-links of Protein/DNA complexes to free DNA 
All tubes (IP samples and inputs) were supplemented with 8μl 5M NaCl and 
incubated at 65°C overnight to reverse the DNA-Protein cross-links. All samples were 
subsequently treated with RNase A for 30 minutes at 37°C before proteinase K 
digestion of remaining protein at 45°C for 2 hours.  
 
2.16.6 Purification of DNA 
DNA purification was required to remove chromatin proteins and prepare the DNA 
for detection steps. Purification was conducted using the DNA spin columns provided 
in the EZ-ChIP kit. The final volume of purified DNA eluate was ~50μl. 
 
2.16.7 DNA detection by PCR 
Immunoprecipitated-promoter region DNA was initially detected by PCR. This was 
conducted in the same manner as RT-PCR (Section 2.11.2), with the single difference 
that DNA was assayed directly, instead of cDNA being reverse-transcribed from 
cellular RNA and used as a template. Primer design was carried out (unless otherwise 
stated) for promoter regions of genes of interest. Promoter regions were identified 
using online search engines and typically primers were designed in regions up to 
500bp upstream of the transcriptional start site of the gene of interest. Bearing in mind 
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the resolution of the ChIP assay (200-1000bp), primers designed in such regions 
should comfortably detect any promoter DNA that had been precipitated. 
 
Primers for PCR were synthesised by Sigma-Aldrich and are presented in Table 2.9 
along with specific annealing temperatures used for each primer set and the product 
size produced.  
 
Table 2.9 PCR primers and accompanying annealing conditions and product sizes. 
Gene 
(promoter 
region) 
Primer oligonucleotides 5’ – 3’ Annealing 
temperature 
(°C) 
Product 
size 
(bp) 
GAPDH Forward: TACTAGCGGTTTTACGGGCG 
Reverse: 
TCGAACAGGAGGAGCAGAGAGCGA 
59 166 
ATF-2 Forward: 
CCCAAACCTCACCTAACCCGAAG 
Reverse: 
CTCGGGCGCTCATGATTGGACAA 
59 397 
c-jun Forward: 
CCCACAAGTGGGGAAACAACAA 
Reverse: 
GCTACCAGTCAACCCCTAAAAATA 
59 488 
c-myc Forward: TCCTCTCTCGCTAATCTCCGC 
Reverse: CCCTCCGTTCTTTTTCCCG 
55 117 
EBV DS 
repeat 
Forward: 
CCGTGACAGCTCATGGGGTGGGAGAT 
Reverse: 
CAATCAGAGGGGCCTGTGTAGCTACCG
59 246 
 
2.16.8 DNA detection and quantification by Real-Time quantitative PCR (qPCR) 
For increased detection sensitivity, and accurate quantitative analysis of levels of 
promoter DNA precipitated, qPCR was carried out. Samples were analysed in 
biological and technical triplicate, with an input sample, isotype control sample, and 
experimental (chEBNA1) sample being analysed (in biological and technical 
triplicate) per initial lysate. 20μl reactions were assembled using 10μl 2X Sensimix 
mastermix (Quantace Ltd), 1μl of each primer (from stock concentration of 10μM) 
and optimal probe concentrations, which were determined empirically (see Chapter 
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5). 5μl of sample DNA was used per reaction, and reactions were set up in 96 well 
plates before analysis using an ABI 7500 Fast Real-time PCR machine. Primer/Probe 
sets used for each promoter region are given in Table 2.10. 
 
Table 2.10 qPCR primer/probe sets used in ChIP analysis 
Gene 
(promoter 
region) 
Primers 5′ – 3′ 5′ FAM / 3′ TAMRA-labelled 
probe 5′ – 3′ 
c-jun Forward: 
GAGACCGCCCCTAAACTTAAGTC 
Reverse: 
CCCTTAAGGTGGCTCTGTGAA 
TTAGGCTCGCCCCCACCT
GGG 
junB Forward: 
TAACCCTCATTTCTGCTTTTTGG 
Reverse: 
AAACCCCTGAGGTACCCAGAATAC 
CCCAATGGATTGTCAGTC
CTCCTACCC 
junD Forward: 
CAGGATCCAAGCGCTTTCAG 
Reverse:  
CCCCGCGTGTGATTGC 
ACCCTCCTCTCCCCTCCCG
TCTCTT 
c-fos Forward: 
CAAGGGTAAAAAGGCGCTCTCT 
Reverse: 
ATTCGCACCTGGTTCAATGC 
CCCATCCCCCCCGACCTC
G 
fosB Forward: 
GGGATTCCCTCTGACGTCATT 
Reverse: 
GTGACGCAATTAGCCATATAAGGA 
TAGGATACCAAACAAACA
CTCCGCCG 
fra1 Forward: 
CAGTGCGCCGAGATCGA 
Reverse: 
AGGGTTACAAAAATGGTGGCATAT 
ACTCCAGCCTGGGTGACA
GAGACCC 
fra2 Forward: TCACCCGAAAGCGAGGAA 
Reverse: 
CGTTGCCAAAGATGGTCATTT 
CCCGCACTCGCGTCCTCT
AACG 
ATF-2 Forward: 
AAACCTCACCTAACCCGAAGCT 
Reverse: 
TTCCGTCACTTCCCAGCACTA 
AACGCAGCCTACTTTTAC
CCACCTCCC 
c-myc Forward: 
CCCGGGTTCCCAAAGC 
Reverse:  
CCAGACCCTCGCATTATAAAGG 
TCTCTCGCTAATCTCCGCC
CACCG 
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Table 2.10 ctd. qPCR primer/probe sets used in ChIP analysis 
Gene 
(promoter 
region) 
Primers 5′ – 3′ 5′ FAM / 3′ TAMRA-labelled 
probe 5′ – 3′ 
EBV-DS Forward: 
GCCACTGCCCTTGTGACTAAA 
Reverse: 
CCCATGAGCTGTCACGGTTT 
CACTACCCTCGTGGAATC
CTGACCCC 
GAPDH Forward: CGCCCCCGGTTTCTATAAA 
Reverse: 
GTCGAACAGGAGGAGCAGAGA 
TGAGCCCGCAGCCTCCCG 
 
Cycle threshold (Ct) values were determined by ascertaining the point at which 
amplification occurred above background in the linear range of amplification for each 
reaction. The average of each technical triplicate was taken to obtain the mean dCt 
value for each sample and ddCt values were subsequently calculated by subtracting 
the relative input sample dCt value from the respective control or experimental 
sample dCt. Data were made relative to the input samples (which had a ddCt value of 
0) by applying the formula 2-ddCt to each control and experimental sample data set (N-
fold value). Fold change from isotype control antibody to experimental antibody 
samples was calculated by simple division of these N-fold values. Statistical 
significance of fold changes was established using the Student’s t-test.  
 
2.17 HaloCHIP 
 
The HaloCHIP system (Promega UK) is a novel method which captures covalently 
formaldehyde cross-linked protein:DNA complexes from transiently transfected cells. 
It is an antibody-free system and can be regarded as a robust and efficient alternative 
to the standard chromatin immunoprecipitation system described in Section 2.16. A 
DNA-binding protein, in this instance EBNA1 (or an EBNA1 mutant), is fused to the 
HaloTag protein (which mediates a covalent interaction with a resin-based ligand) 
using standard molecular biology techniques (see Chapter 5). The recombinant 
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construct is subsequently transfected into cells for transient expression. Following 
expression of the recombinant construct, procedures are similar to that described for 
chromatin immunoprecipitation (Section 2.16). The HaloCHIP protocol is outlined 
briefly below.   
 
2.17.1 Buffers and Solutions Provided and used in HaloCHIP kit 
 
HaloCHIP™ Blocking Ligand: 5mM fluorescent TMR HaloTag® Blocking Ligand in 
DMSO (excitation: 555nm; emission: 580nm) 
HaloLink™ Resin equilibration buffer: 1X TE Buffer (pH 8.0), 0.1% IGEPAL® CA-
630 
High Salt Wash Buffer: 50mM Tris-HCl (pH 7.5), 700mM NaCl, 1% Triton® X-100, 
0.1% sodium deoxycholate, 5mM EDTA 
Lysis Buffer: 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% Triton® X-100, 0.1% 
sodium deoxycholate 
Reversal Buffer: 10mM Tris-HCl (pH 8.0), 1mM EDTA, 300mM NaCl 
TE Buffer (pH 8.0): 10mM Tris-HCl (pH 8.0), 1mM EDTA 
 
2.17.2 In vivo cross-linking and lysis 
Cells grown in 10cm2 dishes and were crosslinked with 0.75% formaldehyde 24 hours 
post transfection with recombinant constructs. At this point, cells were typically 80-
90% confluent. Other than the slightly reduced concentration of formaldehyde used, 
crosslinking procedures were identical to that given in Section 2.16.2. Following 
glycine neutralisation and several washes with ice cold PBS, each 10cm2 dish of cells 
was scraped in 2ml of PBS into 15ml tubes. Cells were centrifuged at 2000 x g for 5 
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minutes at 4°C before the supernatant was removed and cell pellets were frozen at -
80°C for at least 10 minutes (storage of cell pellets was possible at this stage of the 
procedure).  After thawing at room temperature, cells from a 10cm2 dish were 
resuspended in 700µl of ice cold lysis buffer and mixed briefly by vortexing before 
incubation on ice for 15 minutes. Mechanical disruption was then used to lyse the 
cells by passing the cells through a 25-guage needle 4-6 times.  
 
2.17.3 Sonication to shear DNA 
 
Sonication of the cells was conducted in a very similar manner to that described in 
Section 2.16.3. However, in HaloCHIP experiments, samples were sonicated in 700µl 
aliquots of lysis buffer (i.e. each 10cm2 dish was sonicated and processed as an 
individual sample). The kit manufacturer’s recommendations suggest a slightly larger 
average fragment size of DNA for these experiments. However, given the increased 
volume of aliquots in sonication, it was empirically determined that sonication 
conditions (i.e. number of pulses, sonicator power settings) should remain the same, 
or very similar to those described in Section 2.16.3.  
 
2.17.4 Capture and Release of DNA 
Sonicated samples were centrifuged at 14000 x g for 5 minutes at 4°C before careful 
aspiration of supernatant. A 30µl aliquot of supernatant was removed and retained at 
4°C until the purification steps described below and used as an “input” control in 
subsequent DNA analysis. Samples were then divided into 2 x 300µl aliquots, one 
used as a control sample and one used as the experimental sample. To the control 
sample only, 0.5µl of blocking ligand was then added (final concentration 8.3µM). 
The blocking ligand binds to the HaloTag covalent binding site, preventing 
subsequent covalent pull down of fusion proteins in the control sample.  Both control 
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and experimental samples were then incubated at room temperature for 30 minutes, 
whilst being mixed using a tube rotator. During this 30 minute incubation period, 
HaloLink Resin was prepared for use: 
 
75µl resin was dispensed into two 1.5ml microcentrifuge tubes (per sample, 1 for 
control, 1 for experimental). Resin was centrifuged at 800 x g for 2 minutes and 
supernatant discarded. Resin was equilibriated by resuspension 3 times in 
equilibration buffer. Following the final suspension, buffer was aspirated just before 
the 30 minute incubation of samples was complete.  
 
The entire experimental sample was then added to one tube containing equilibrated 
resin, and the entire control sample was added to the other tube. Samples were then 
incubated with constant mixing using a tube rotator for 3 hours at room temperature. 
Samples were centrifuged at 800 x g for 2 minutes at room temperature and the 
supernatant was discarded. Finally, samples were washed sequentially for 5 minutes 
at room temperature with constant mixing on a tube rotator in 1ml of each of the 
buffers in the order stated: 
• Lysis Buffer 
• Nuclease-Free Water (2 washes) 
• High Salt Wash Buffer (15 minute incubation) 
• Nuclease-Free Water (3 washes, the final wash being incubated for 15 
minutes) 
 
2.17.5 Reversal of Cross-links of Protein/DNA complexes to free DNA 
Following removal and discard of the final wash solution, 300µl reversal buffer was 
added to each tube with the resin and mixed by gentle pipetting. Samples were then 
incubated at 65°C overnight to reverse the crosslinks. Resin was centrifuged at 800 x 
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g for 2 minutes and the supernatant containing the released DNA was transferred to a 
fresh tube.  
 
2.17.6 Purification of DNA 
Eluted DNA was purified using a commercially available DNA purification spin 
column kit (Purelink PCR Purification Kit, Invitrogen). Half the sample was purified 
per protocol, with a final elution volume of 50μl.  
 
2.17.7 DNA detection by PCR 
Purified DNA samples were analysed using PCR analysis as described in Section 
2.16.7. Primers were designed in the same manner as previously stated with the 
exception of cellular polIII transcribed genes (5S RNA, 7SL RNA, tRNAtyr). Due to 
the short length and small upstream regulatory regions of these genes, primers were 
designed within the region of the gene itself rather than 500bp upstream. TFIIIC110 
and TFIIIC220 subunit promoter primer sequences were taken from Felton-Edkins et 
al. (2006). Primers for PCR were synthesised by Sigma-Aldrich and are presented in a 
previous table (Table 2.9), and the following table (Table 2.11) along with specific 
annealing temperatures used for each primer set and the product size expected. 
 
Table 2.11 PCR primers and accompanying annealing conditions. 
Gene 
(promoter 
region) 
Primer oligonucleotides 5’ – 3’ Anneali
ng temp 
(°C) 
Produ
ct size 
(bp) 
TFIIIC220 
 
Forward: GTTTGCAGTTCCCCTGGTTAC 
Reverse: CTTCGTCCAACAACGACTCC 
58 260 
TFIIIC110 Forward: TCTCCCCTTTTTGACACTGC 
Reverse: AGGGGGAGGAGTAATTGTGG 
58 354 
TFIIIC102 Forward: CGGTTCCTTGCTCTTGCT 
Reverse: GCATCGCCTCACTTTCTT 
55 217 
TFIIIC90 Forward: GCGGGTAGGGACAAGACT 
Reverse: CCCAGACAGGCTTTAGTT 
56 217 
TFIIIC63 Forward: GCCAACACCGACAGAATA 
Reverse: CGGAGGATAATAAGACACAAA 
58 308 
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Table 2.11 ctd PCR primers and accompanying annealing conditions. 
Gene 
(promoter 
region) 
Primer oligonucleotides 5’ – 3’ Anneali
ng temp 
(°C) 
Produ
ct size 
(bp) 
5S RNA 
 
Forward: TTTACGGCCACACCACCCTG 
Reverse: AAAGCCTTCAGCACCCTGTA 
58 107 
tRNAtyr 
 
Forward: 
CCTTCGATAGCTCAGCTGGTAGAGCGGAGG 
Reverse: 
CGGAATTGAACCAGCGACCTAAGGATGTCC 
65 84 
7SL RNA  
(gene) 
Forward: 
GTGTCCGCACTAAGTTCGGCATCAATATGG 
Reverse: TATTCACAGGCGCGATCCCACTACTGATC 
70 150 
7SL RNA 
(promoter) 
Forward: CCGTGGCCTCCTCTACTTG 
Reverse: TTTACCTCGTTGCACTGCTG 
58 202 
Brf1 
 
Forward: GCAAGGAGGTCAGGCACT 
Reverse: CCTTCCACGGCTACCTCT 
58 367 
Bdp1 
 
Forward: GTTTCTTCACACCAGCATT 
Reverse: GCTACTGAGACTGGGTTA 
56 236 
TBP 
 
Forward: CGCCCCTCCTTACCTAT  
Reverse: CAATCTGTTACCTGGGTC 
55 242 
 
2.17.8 DNA detection and quantification by quantitative PCR (qPCR) 
For increased detection sensitivity, and accurate quantitative analysis of levels of 
precipitated promoter DNA, qPCR was carried out in some instances. Samples were 
analysed in biological and technical triplicate as described in Section 2.16.8.  
 
2.18 Densitometry 
 
Densitometry was conducted on autoradiograph and UV transilluminator images 
using ImageJ 1.37V. ImageJ is a public domain, Java-based imaging-processing 
program developed at the National Institutes of Health, available online 
(http://rsbweb.nih.gov/ij/). Bands were analysed in technical triplicate, normalising 
against background image levels and, if appropriate, internal controls. In all instances, 
densitometry was conducted in biological triplicate, with average results reported.  
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2.19 Statistics 
 
Statistical significance of data was established using the Student’s t-test, following 
designation of the variance of samples as either equal or unequal using an f-test.  
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Chapter 3 - EBV genome copy number and EBER expression 
 
It has previously been demonstrated that EBV-positive cell lines show significant variation in 
the average number of EBV viral episomes maintained per cell (copy number) (Metzenberg 
1989; 1990; Sternas et al. 1990; Jeon et al. 2009) and levels of EBER expression also vary 
significantly from cell line to cell line. Although differences in a multitude of cellular and 
viral factors could explain the variation in levels of EBER expression, perhaps the most 
simplistic explanation is that of EBV genomic copy number variation being directly 
responsible for fluctuations in levels of EBER expression between various cell lines, that is, 
the rate of transcription of EBERs increases monotonically with the average genome copy 
number. Assuming a constant rate of degradation of EBER expression in each cell 
background, this monotonic increase in the rate of EBER transcription based upon increase in 
EBV genome copy number would lead to increased accumulation of EBERs in cell lines with 
high average genome copy numbers. Consistent with this hypothesis, previous data have 
shown that increasing the copies of EBER genes (from 1 to 10 copies) expressed by a plasmid 
vector significantly increased levels of EBER expression (Komano et al. 1999). Further, and 
perhaps more pertinently, in a small panel of LCLs with vastly differing copy numbers, EBER 
transcription has been demonstrated to correlate with the amount of EBV genomic DNA in 
each LCL (Metzenberg 1989). However, this was a very small scale study (with only three 
LCLs of vastly differing copy number analysed), and a study of EBER transcription rate 
rather than overall levels. Therefore further investigation of the relationship between EBV 
copy number and levels of EBER expression are warranted. Preliminary attempts at such 
investigation have previously been carried out, with results appearing to agree with the 
hypothesis (Dr. JR Arrand, personal communication). This explanation of variation in levels 
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of EBER would perhaps be in line with the high levels of EBER expression that are detectable 
in EBV-infected cells, given that multiple episomal copies of the EBV genome are usually 
carried.  
This chapter further explores the relationship between the average EBV genome copy number 
maintained in a range of LCLs, and the levels of EBER expression that are observed in each 
cell line. A variety of techniques, both traditional and more modern, for detection and 
quantification of the EBV genome and EBER1 and EBER2 are employed, with the techniques 
found to be most sensitive used in an ultimate comparison between average EBV genome 
copy number and levels of EBER expression. 
 
3.1 Results 
3.1.1 Measuring average EBV genome copy number 
3.1.1.1 Southern blotting 
Initial attempts at quantification of EBV genome copy number in the panel of LCLs focused 
on Southern blotting for the EBV genome. This well-established technique for detection of 
EBV genomic DNA, using a radio-labelled BamHI-X fragment of the EBV genome is 
outlined in Section 2.15, and the results are presented in Figures 3.1 and 3.2. LCL DNA was 
quantified before equal loading of each DNA sample, as detected by ethidium bromide 
staining (Figure 3.1A). Ideally, blotting for the BamHI-X fragment would have been 
conducted in parallel with blotting for a suitable internal control, however probes to enable 
this level of standardisation were not available at the time of experimentation. Figure 3.1 is 
illustrative of results obtained in these experiments, with changes in the intensity of bands 
seen in Figure 3.1B representing variations in EBV genome copies in each LCL. No EBV 
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Figure 3.1 – Southern blotting for EBV genomic DNA using DNA extracted from a panel of 
LCLs grown in media supplemented with acyclovir to prevent lytic outgrowth of virus. (A) 
UV transilluminator image of an ethidium bromide stained agarose gel, showing a panel of 
DNA samples extracted from LCLs and digested with BamHI enzyme. Such analysis was 
utilised to assess the consistency of sample loading. (B) Autoradiogram illustrative of 
Southern blotting for EBV genomic DNA across the panel of LCL samples. A Radio-labelled 
BamHI-X fragment of the EBV genome was used to probe. The autoradiogram presented is 
representative of a 2 hour exposure.  
Figure 3.2 – Densitometric analysis of the Southern blot data presented in Figure 3.1B. The 
average value of 3 technical repeats is shown, with error bars representing the standard 
deviation of these repeats. 
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Figure 3.1 and 3.2 
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genome DNA is detected in EBV-negative cell line BJAB, with the LCL samples showing 
only slight variation in band intensity. Sample JS carries the smallest detectable EBV genome 
load, with samples DA and LMC producing the most intense bands for EBV genomic DNA. 
To quantify the results, densitometric analysis was conducted (Figure 3.2) and the data 
replicate the visual analysis of the Southern blot shown in Figure 3.1B. However, absolute 
quantification of average numbers of copies of the EBV genome is not possible in this 
instance, with results given as arbitrary units. Given the only slight variations in EBV 
genomic DNA between LCLs detectable using this method, alternative methods for EBV 
genome detection and quantification were identified that would prove to be more sensitive, 
and able to provide more exact quantification of the average EBV genomic load in each LCL. 
3.1.1.2 qPCR measurement of average EBV genomic load 
qPCR analysis of average EBV genome load in each LCL relied upon the generation of 
standard curves from DNA of known EBV genomic load. This DNA was taken from 
Namalwa BL cells, which contain two integrated EBV genome copies per cell. Based on 
assumptions outlined in Section 2.15, it was possible to perform serial dilutions to generate a 
set of DNA standards with a known number of EBV genome copies, per microlitre volume of 
sample. Using these samples of known EBV genomic copy number, standard curves were 
generated (Figure 3.3) for internal cellular control DNA (β-2 Microglobulin) and EBV 
genomic DNA (EBV POL gene) which enabled quantification of the average EBV genome 
load in each LCL from subsequent qPCR data analysis. Figure 3.4 shows the average EBV 
genome copy number found for each LCL in the panel investigated. Consistent with Southern 
blotting, EBV genomic DNA was not detected in BJAB-cells. However, in contrast to 
Southern blotting data, a large variation in average copy number is seen, ranging from less 
than 5 copies per cell, for X50-7 samples, to greater than 35 copies per cell, for NB and DA 
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Figure 3.3 – Example standard curves (Namalwa BL DNA) for (A) β2-Microglobulin and (B) 
EBV POL qPCR analysis. Ct values (average values of technical triplicates) are plotted 
against the log of each standard value. The line of best fit is included, as is the formula of the 
line, and the R2 value for each curve. Both (A) and (B) are single examples of curves that 
were generated alongside every experimental data set, with analysis of each data set being 
reliant upon a standard curve that was produced from DNA standards analysed in the same 
run. 
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Figure 3.3 
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Figure 3.4 – qPCR results indicating the average measured EBV genome load for each LCL 
across a panel of 10 LCLs, along with BJAB as an EBV-negative control. Each sample was 
tested in biological and technical triplicate, with average values presented. Error bars are 
representative of the standard deviation of biological replicates. 
Figure 3.5 – FITC FACS staining for EBERs in BJAB (both stained and unstained cells 
plotted), Namalwa BL and Raji cells. 
Figure 3.6 – Example of Northern blotting conducted for EBER1 and U4 (small RNA 
loading control). For analysis of EBER expression levels, a radio-labelled EcoRI-J fragment 
of the EBV genome was used as a probe, and a PCR product based on U4 gene template was 
radio-labelled and employed in the Northern blot analysis of U4 snRNA levels.  
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Figures 3.4 3.5 and 3.6 
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samples. This increase in the range of detected EBV genome copies reflects the greater 
sensitivity of this qPCR assay, compared with Southern blotting. 
3.1.2 EBER expression level analysis 
3.1.2.1 EBER FITC FACS staining 
FACS analysis of EBER expression was employed in an attempt to quantify levels of EBER 
expression in the panel of LCLs. Initial experiments were conducted with BJAB-cells 
(negative control), Namalwa BL cells and Raji cells. EBER1 and EBER2 are known to be 
abundant in Raji cells (Schwemmle et al. 1992), and were included as a positive control. 
Contrastingly, EBER expression in Namalwa BL cells is very low (Minarovits et al. 1992). 
This cell line was analysed to assess the sensitivity of the assay, i.e. to establish if the 
technique enabled the detection of low levels of EBER expression and the ability to detect 
small differences in EBER expression between cell lines. Results shown in Figure 3.5 reveal 
that although EBER FITC FACS staining was successful in detecting strongly EBER-positive 
Raji cells, weakly EBER-positive Namalwa BL cells were not detected as such. Indeed, the 
results for stained BJAB-cells and Namalwa BL cells are strikingly similar. EBER FITC 
FACS staining was not therefore a suitable method of EBER quantification in this instance. 
Although useful in determining the number of strongly EBER-positive cells in a population, 
the technique was not able to distinguish between a cell population with weak EBER 
expression and a cell population completely lacking EBER expression.  
3.1.2.2 Northern blotting 
EBER expression analysis by Northern blotting is a well established technique, similar in 
terms of applications and sensitivity to Southern blotting for EBV genomic DNA. Figure 3.6 
is exemplary of the quality of results obtained through use of this method. A striking aspect of 
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these results is that only a single band is detected for the EBERs. This is notable, as the radio-
labelled probe (EcoRI-J fragment of EBV genome) detects both EBER1 and EBER2. 
However, along with U4, an internal small RNA control (detected by a separate radio-labelled 
probe), only one, and not the two predicted EBER-specific bands, was detected by Northern 
blotting. This results was most probably due to insufficient resolution of RNA to allow 
detection of distinct EBER1 (167bp) and EBER2 (172bp) bands.  
Substantial variation in EBER expression was observed across the LCL panel, along with 
high levels of EBER expression in Raji samples (included as a positive control). EBERs were 
not detected in BJAB samples (negative control), although they also went undetected in 
Namalwa BL samples. This result suggests that the sensitivity of the assay is not sufficient to 
detect very low levels of EBER expression, meaning small differences in levels of EBER 
expression between LCLs in the panel may not be apparent using this method.  
Densitometric analysis of Northern blotting was conducted (Figure 3.7), allowing quantitative 
evaluation of results. EBER data were normalised to the internal cellular control (U4) and in 
agreement with qualitative analysis of the Northern blots, substantial variation in levels of 
EBER expression was apparent. However, given the lack of sensitivity of the assay 
(undetected EBER expression in Namalwa BL samples), and lack of distinction between 
EBER1 and EBER2, alternative and more sensitive methods for EBER detection and 
quantification were identified, which were able to provide more exact quantification of 
EBER1 and EBER2 expression across the LCL panel. 
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Figure 3.7 – Densitometric analysis of Northern blotting for EBER expression levels, 
normalised to U4 small RNA loading control for each sample. Each sample was analysed in 
biological triplicate (average values presented), with technical repeats of densitometry 
performed for each replicate. Error bars represent standard deviation of biological replicates 
for each cell line. 
Figure 3.8 – Example standard curves (X50-7 RNA/cDNA) used in the qRT-PCR analysis 
and quantification of EBER1 (A) and EBER2 (B) levels in panel of LCLs. Ct values are 
plotted against log of each standard with line of best fit included. Also presented are the 
formula and the R2 value for each curve. Both (A) and (B) are single examples of curves that 
were generated alongside every experimental data set, with the analysis of each data set being 
reliant upon a standard curve that was produced from cDNA standards analysed in the same 
experimental set. GAPDH standard curves were also produced and utilised in quantification 
of GAPDH as the internal cellular control. 
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Figures 3.7 and 3.8 
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3.1.2.3 qRT-PCR for EBER1 and EBER2 
qRT-PCR was used to measure accurately and sensitively the levels of EBER1 and EBER2 in 
the LCL panel. As with qPCR for EBV genome load, measurement of EBER expression was 
reliant upon data analysis based upon standard curves. In this instance cDNA generated from 
X50-7 RNA was serially diluted to generate standard curves for EBER1, EBER2 and GAPDH 
(as internal cellular control). Results reported are normalised to respective cellular GAPDH 
levels and are relative to EBER expression levels in X50-7 cells. Figure 3.8 shows example 
standard curves generated for EBER1 (Figure 3.8A) and EBER2 (Figure 3.8B) using the X50-
7 cDNA standards. qRT-PCR analysis of EBER1, EBER2 and GAPDH levels in the LCL 
panel was followed by analysis using standard curves with average results for EBER 
expression shown in Figure 3.9. Figure 3.9A illustrates the considerable variation in levels of 
EBER1 expression that was observed across the LCL panel. Variation of EBER expression 
levels is greater than that observed using Northern blotting, confirming the highly sensitive 
nature of this method of EBER detection. Validity of standard curve-based quantification of 
EBERs was established by the analysis, as an experimental sample, of the levels of EBER1 
and EBER2 in the X50-7 RNA sample. For both EBER1 and EBER2, experimental values for 
X50-7 RNA, relative to the value derived from the standard curve generated from X50-7 
RNA, were approximately 1. Figure 3.9B reveals a similar level of variation of EBER2 
expression, though variations in levels of EBER2 expression do not necessarily correlate to 
those seen for EBER1. This lack of correlation between levels of EBER1 and EBER2 
expression in a minority of samples (most notably AO and JT) is more easily assessed when 
EBER1 and EBER2 expression data are analysed together in Figure 3.9C, illustrating that 
although in many LCLs EBER1 and EBER2 are expressed at similar levels, substantially 
higher levels of EBER1 than EBER2 were detected in some samples. 
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 Figure 3.9 – qRT-PCR analysis of EBER1 (A), and EBER2 (B) levels in LCL panel. EBER1 
and EBER2 data are also presented in tandem (C) to allow comparative evaluation. Average 
results from biological and technical triplicates normalised to internal cellular control 
(GAPDH) are plotted relative to X50-7 EBER1 and EBER2 levels. Error bars are 
representative of standard deviation of biological repeats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
157 
 
Chapter 3 
 
 
 
Figure 3.9 
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3.1.3 Comparison of average EBV genome copy number and level of EBER expression 
Figure 3.10 compares the average EBV genome copy number across the panel of LCLs 
(previously presented in Figure 3.4) with the average measured levels of EBER1 and EBER2 
(previously presented in Figure 3.9) across the same panel of LCLs. From this scattergraph it 
is apparent that across this panel of 10 LCLs, there is no direct correlation between average 
EBV genome copy number and levels of EBER1 or EBER2, with no discernable trend 
connecting levels of EBER1 or EBER2 expression with EBV genome copy number. These 
data are not consistent with the hypothesis that the variation in levels of EBER expression 
across a panel of LCLs can be attributed to similar variation in EBV genome copy number 
across these cell lines.   
 
3.2 Discussion 
The above data describe the analysis of levels of EBER expression in a panel of LCLs in 
direct comparison with the average EBV genomic load per cell. Prior to this study, direct 
comparison of EBER expression and EBV copy number had not been conducted on a similar 
scale, and the results provide significant insight into the relationship between EBV genomic 
load and levels of EBER expression in LCLs.  
Although the overall aims of this thesis relate to EBER expression in epithelial cells, a panel 
of lymphoid cells was used in these experiments. LCLs are an invaluable in vitro model of 
EBV infection and were utilised here for a number of reasons. Firstly, compared with in vitro 
EBV-positive epithelial cell systems, a large range of LCLs was readily accessible for 
analysis. This allowed generation of a data set large enough confidently to draw conclusions 
from experimental data obtained. Additionally, a large range of EBV copy numbers and levels 
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Figure 3.10 – Scattergraph plotting average EBV genome copy number (X-axis) against 
relative level of EBER1 and EBER2 expression (Y-axis) in a panel of LCLs. Average EBV 
genome copy numbers and EBER1 and EBER2 data are derived from qRT-PCR analysis 
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Figure 3.10 
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of EBER expression had previously been observed in a LCL panel, with an apparent 
correlation between the two being observed in small datasets (Dr JR. Arrand, personal 
communication). Consistent with this, a previous study of the rate of EBER transcription in 
cell lines with varying EBV genome copy number revealed a correlation between these 
variables (Metzenberg 1989).  
Importantly, LCLs used in the analysis of EBV copy number were maintained in acyclovir-
containing media, preventing any lytic outgrowth of virus. Although the percentage of 
lytically infected cells within an LCL population is typically very low, this small 
subpopulation of cells can make a significant contribution to the overall EBV DNA content of 
a transformed cell line, given the 100- to 1000-fold amplification of the viral genome during 
lytic replication (Hammerschmidt and Sugden 1988). 
Southern blotting has traditionally been used in the quantification of EBV copy number in 
LCLs. However, given the lack of availability of a suitable internal control probe, and the 
very small levels of variation observed in the panel of LCLs (Figures 3.1 and 3.2) utilised in 
this experimental sample set, it was necessary to employ more sensitive techniques in analysis 
of EBV copy number. Accurate analysis of EBV genome load by qPCR has been described 
previously (Gallagher et al. 1999; Junying et al 2003) and this methodology was adapted for 
quantification of EBV copy number in the panel of LCLs. This qPCR analysis was 
substantially more sensitive than Southern blotting, as illustrated by the greater variation in 
EBV copy number results obtained using qPCR analysis (Figure 3.4). Additionally, precise 
quantification of average EBV genome copies per cell was possible, although this precision 
was heavily reliant upon the assumption that the Namalwa cells used in the generation of 
standard curves possessed two integrated copies of the EBV genome. Given that EBV 
genomes are integrated, variation in EBV copy number between cells in a Namalwa 
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population is minimal compared with cell lines where the genome is episomally maintained 
(and unequal genome segregation can occur). Confirmation that the Namalwa cells uniformly 
possessed two integrated EBV genome copies could have been conducted using fluorescence 
in situ hybridisation (FISH)  (Shannon-Lowe et al. 2009). 
Direct comparison between results obtained using Southern blotting and qPCR analysis 
reveals both consistency and inconsistency in results of differing analysis of the same cells 
lines. For instance, although using qPCR analysis, X50-7 had the lowest observed average 
EBV copy number, using Southern blotting, similar results were not obtained and comparable 
inconsistency was observed for sample HK286. However, both Southern blotting and qPCR 
copy number analysis revealed sample DA to have the highest average EBV copy number, 
and analysis by each method of several other LCLs showed comparable results.  
The levels of variation in average copy number as measured by qPCR were comparable with 
variation previously reported, with up to 10-fold differences in average EBV copy number 
being found. Previously, much higher copy number LCLs had been reported (e.g. Metzenberg 
(1990)), however such high copy number LCLs were not present in the sample set used here. 
It would be interesting to analyse such high copy number LCLs for both copy number and 
EBER expression, to elucidate if in such extreme cases high copy number consistently led to 
high levels of EBER expression.  
Analysis of EBV copy number was carried out for the average number of genome copies per 
cell. However, within an LCL population, EBV copy number heterogeneity exists due to 
occasional inequality in EBV episome segregation. As such, the average value obtained 
cannot be applied to each cell in the population, as some cells may carry many fewer 
episomes than the average number, and others many more. Assessment of LCL heterogeneity 
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for EBV genome copy number was not conducted in the panel of LCLs analysed, and it 
would be valuable to carry out FISH analysis to examine the full extent of variation in EBV 
copy number from cell to cell, within each LCL of the panel analysed by qPCR.   
Initial attempts at analysis of EBER expression levels using FACS analysis were not 
successful. As briefly discussed in the results section, this method of EBER detection was not 
able to distinguish between cell populations expressing low levels of EBERs and those where 
expression was entirely absent (Figure 3.5). However, FACS analysis of EBER expression 
remains a valuable tool in quantification of the number/percentage of EBER-positive cells 
within a population, and indeed sorting of EBER-positive populations of cells, providing 
levels of EBER expression are sufficient to be detected.  
Northern blotting analysis was successful in quantification of EBER expression levels across 
the LCL panel, although lack of resolution meant levels were determined as a single value, 
rather than separate values for EBER1 and EBER2 expression. Adaptation of experimental 
procedures may have resulted in increased resolution; however alternative (and more 
sensitive) methods of EBER detection (RT-qPCR) were employed in place of validation of 
adapted experimental procedures. Analysis of EBER levels by Northern blotting was perhaps 
more reliable than Southern blotting quantification of EBV copy numbers, given the use of 
small nuclear control U4. This allowed normalisation of data to an internal cellular control, 
meaning any discrepancies in loading were overcome. Sensitivity of Northern blotting was 
not sufficient to allow detection of EBER expression in Namalwa cells (Figures 3.6 and 3.7), 
suggesting not only that low levels of EBER could not be detected, but also that any small 
differences in EBER expression would not be quantified using this method of analysis. 
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RT-qPCR analysis of EBER expression levels proved to be accurate and sensitive, resulting in 
quantified levels of both EBER1 and EBER2 for each LCL. Data were generated using 
standard curves based upon serial dilutions of X50-7 cDNA, and as such results were relative 
to EBER expression levels in X50-7 cells. Analysis of X50-7 RNA as an experimental sample 
was conducted, with relative levels of expression of EBER1 and EBER2 found to be around 1 
(Figure 3.9), demonstrating accuracy and reliability of RT-qPCR analysis of EBER 
expression. EBER expression analysis was also more sensitive using RT-qPCR, with 
Namalwa EBER expression being detected (data not shown, levels of EBER1 were 0.06-fold 
of X50-7 levels, EBER2 levels were 0.05-fold of X50-7 RNA levels). Additional evidence of 
increased sensitivity is provided by the greater variation in results for EBER expression from 
RT-qPCR experiments, compared with Northern blotting. However, the panel of LCLs was 
not identical for both these sets of experiments, and sensitivity of Northern blotting results 
may have been diminished by the lack of separate detection of EBER1 and EBER2. 
Separate analysis of EBER1 and EBER2 levels allowed comparative evaluation of EBER1 
and EBER2 levels in individual LCLs. Previously, conflicting data have been produced from 
such evaluation, with some studies finding EBER1 expressed at higher levels than EBER2 
(e.g. Metzenberg (1989)), and others reporting EBER2 is expressed at higher levels than 
EBER1 (e.g. Jat and Arrand (1982)). Comparative evaluation of EBER1/2 levels across this 
LCL panel was also conflicting, with some samples showing substantially greater expression 
of EBER1 than EBER2 relative to X50-7 (e.g. samples AO, JT), though the majority of 
samples showed similar levels of EBER1 and EBER2 expression, again relative to X50-7. 
Given these findings, it can be concluded that the majority of LCLs in the panel express 
EBER1 and EBER2 in a similar ratio to X50-7, though this ratio is not identified. If Northern 
blotting resolution had been sufficient to allow separate detection of EBER1 and EBER2, 
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evaluation of EBER1:EBER2 expression ratio could have been conducted. Comparative 
levels of EBER1 and EBER2 expression are significant, given reports of each RNA 
possessing specific and diverse roles within EBV latent infection (Wu et al. 2007). 
As with qPCR for EBV copy number, it should be noted that average levels of EBER 
expression were analysed and that levels of EBER expression in individual cells within an 
LCL population vary. Assessment of EBER expression heterogeneity was not conducted, and 
it would be valuable to carry out ISH analysis of EBER expression to examine the full extent 
of variation in EBER levels from cell to cell within each LCL of the panel analysed by RT-
qPCR.  
RT-qPCR analysis of the levels of EBER expression in LCLs was carried out following the 
generation of gene-specific cDNA, as outlined in the methods section of this thesis (see 
Section 2.20). It should be noted that by using gene specific cDNA in the assay, the analysis 
of levels EBER expression is dependent upon the reliability of generation of specific cDNA 
for EBER1, EBER2 and GAPDH genes, as variability in the generation of any of these gene-
specific cDNAs would lead to discrepancies in the final analysis of levels of EBER 
expression.  
Ultimate comparison of EBER expression levels with average EBV copy number across the 
panel of LCLs revealed no correlation between the two variables (Figure 3.10). This finding 
conflicts with expectations from previous data illustrating increasing the number of EBER 
genes substantially increased EBER expression levels (Komano et al. 1999). However, such 
data were produced using consecutive copies of the EBER genes in a single expression 
vector, compared with multiple copies of the EBER genes carried on separate EBV episomes, 
as was the case in the analysis presented above. Previously published data had reported a 
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correlation between EBV copy number and rate of EBER transcription in a very small panel 
of LCLs (Metzenberg 1989). Data reported in this study seem to be in conflict with such 
reports, assuming equal rates of EBER degradation. Given the larger experimental sample set 
and more sensitive methods of analysis of both EBER expression and EBV copy number, 
confidence is afforded that the data presented in this chapter are reliable, and that in this panel 
of LCLs at least, no correlation between average EBV genome copy number and levels of 
EBER expression existed. This lack of correlation of EBV genome copy number and latent 
gene product expression has precedence, with previous studies having demonstrated a lack of 
correlation between levels of several EBV latent gene products and EBV copy number 
(Metzenberg 1989; 1990; Sternas et al. 1990).  
Analysis of EBER levels in comparison to EBV genomic DNA levels is of interest in clinical 
situations, given that the gold standard assay for EBV infection in tumour biopsies targets 
EBERs by in situ hybridisation in paraffin-embedded tissue sections (Gulley 2001; Gulley 
and Tang 2008). In gastric adenocarcinoma, levels of EBV DNA levels are reported generally 
to reflect EBER status (Ryan et al. 2009). However, the sensitivity of EBER staining in 
detection of EBV-positive tumours has been questioned following molecular and 
immunohistochemical assays revealing that EBV is present in some EBER-negative tumours 
(Lauritzen et al. 1994; Chen et al. 2002; Gan et al. 2002; Grinstein et al. 2002; Korabecna et 
al. 2003). Findings presented here demonstrating no direct correlation between EBV genome 
copy number and levels of EBER expression in vitro are perhaps of interest when considering 
methods of EBV detection in tumour samples.  
The lack of correlation between EBV genome copy number and levels of EBER expression 
reported in this chapter enhanced the necessity to examine other factors involved in the 
regulation of EBER expression. Given that EBV has been shown to induce EBER-associated 
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cellular transcription factors (Felton-Edkins et al. 2006), subsequent chapters examine 
mechanisms by which EBV is able to enhance EBER expression in epithelial cells, and which 
latent gene product may be responsible for induction of EBER expression during EBV latent 
infection. 
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Chapter 4 – EBNA1 induces EBER expression through EBER-associated cellular 
transcription factors 
 
Several oncogenic viruses, including EBV, have been demonstrated to stimulate RNA 
polymerase III (pol III)-mediated transcription by the induction of increased levels of pol III-
specific transcription factors (Hoeffler et al. 1988; Gottesfeld et al. 1996; Wang et al. 1997b; 
Larminie et al. 1999; Felton-Edkins and White 2002; Felton-Edkins et al. 2006), as outlined 
in Section 1.7.8.1.1. In addition, EBER-associated transcription factors c-Myc and ATF-2, 
(Figure 1.3) which are more often associated with RNA polymerase II (pol II) transcription, 
are also influenced by a number of viral factors. Adenovirus E1A associates with the 
chromatin regulator p400 promoting its interaction with c-Myc. This interplay between c-
Myc and p400 has two important consequences: (1) stabilisation of c-Myc through interfering 
with its ubiquitylation; (2) promotion of complex formation between c-Myc and p400 on c-
Myc target genes, resulting in their activation. As such, E1A is able to elicit, in part, a c-Myc-
like cellular response that contributes to adenovirus function in apoptosis and cellular 
transformation (Chakraborty and Tansey 2009). The HBV X protein has also recently been 
demonstrated to upregulate expression of c-Myc in HepG2 cells, with this upregulation in 
expression being shown to correlate with increased cell proliferation (Yang et al. 2008). The 
small T-antigen of SV40 virus has been found to inactivate protein phosphatase 2A (PP2A), 
which dephosphorylates c-Myc at Ser62 before ubiquitination, therefore exerting its 
oncogenic potential through preventing the dephosphorylation of c-Myc, resulting in its 
stabilisation (Yeh et al. 2004). Further, the HCV ARFP/F protein has been demonstrated to 
enhance the gene trans-activation activity of c-Myc, apparently by antagonising the inhibitory 
effect of c-Myc interacting protein MM-1 (Ma et al. 2008) and HPV proteins E6 and E7 have 
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both been identified as interacting with c-Myc complexes and mediating c-Myc 
transcriptional activity (McMurray and McCane 2003; Patel et al. 2004).  
Human herpesviruses are also known to influence c-Myc, in terms of both stability and 
function. KSHV’s EBNA1 homologue LANA acts to stabilise c-Myc, preventing 
phosphorylation of c-Myc at Thr58 (Bubman et al. 2007; Liu et al. 2007), and independently 
stimulates phosphorylation of c-Myc at Ser62, an event which transcriptionally activates c-
Myc (Liu et al. 2007). Further, KSHV encodes a homologue of cellular interferon regulatory 
factor vIRF-3 which has been shown to have a direct involvement in the activation of c-Myc-
mediated transcription (Lubyova et al. 2007).  
Several human tumour viruses have been demonstrated to affect ATF-2 levels and functional 
activity, and to influence the AP-1 transcription factor family. Various members of the AP-1 
and ATF/CREB families of transcription factors, including c-Jun, are targets for the 
adenovirus E1A protein. E1A stimulates transcription regulated by c-Jun/ATF-2 heterodimers 
through increasing levels of phosphorylated c-Jun (Hagmeyer et al. 1995). The core protein 
of HCV has recently been demonstrated to increase AP-1 transcription factor levels, and 
induce ATF-2 in hepatoma cell lines (Hassan et al. 2009), with the X protein of HBV also 
known to interact with ATF-2 (Zhang et al. 2006) Reoviruses are known to be capable of AP-
1 induction (Tyler et al. 2001). In human herpesviruses, early infection with KSHV has been 
demonstrated to induce several cellular transcription factors including ATF-2 and c-Jun 
(Sharma-Walia et al. 2005), whilst EBV is known to induce levels of AP-1. Firstly, LMP1 
has been demonstrated to activate c-Jun/AP-1 and ATF-2 (Kieser et al. 1997; Eliopoulos et 
al. 1999) and more recently EBNA1 has been shown to induce both the transcription of the 
genes, and activity of the proteins, of members of the AP-1 family, including ATF-2 (O'Neil 
et al. 2008). Another recent study reported increased levels of ATF-2 in EBV-infected B-
lymphocytes and epithelial cells (Felton-Edkins et al. 2006). 
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Given that EBV stimulates polIII transcription and the observation that EBERs are 
temporally the last EBV latent gene products to be expressed following EBV infection of a 
B-lymphocyte (Rooney et al. 1989; Alfieri et al. 1991), it is tempting to propose that an EBV 
latent gene product could be involved in the regulation of EBER expression through the 
induction of EBER-associated cellular transcription factors. In addition to EBNA1’s ability to 
to induce the transcription of the genes and the activity of the proteins of members of the AP-
1 family (O'Neil et al. 2008), it is also known to have transcriptional regulatory properties on 
the viral Cp, Qp and LMP1 promoters (Sugden and Warren 1989; Sample et al. 1992; Gahn 
and Sugden 1995). Further, previously published Affymetrix array analysis (Wood et al. 
2007) revealed an induction of RNA encoding the 102kd subunit of TFIIIC (TFIIIC-102) in 
response to EBNA1, indicating that this EBV latent gene product may be responsible for 
TFIIIC induction. 
This chapter explores the hypothesis that EBNA1 may be the EBV latent gene product 
involved in the regulation of both classic pol II and pol III transcription factors associated 
with EBER expression, and that expression of EBNA1 leads to increased transcription of the 
EBERs. 
4.1 Results 
4.1.1 Generation of Ad/AH-Puro and Ad/AH-Puro-EBERs cell lines 
In order to study the effect of EBNA1 upon EBER expression, cells were generated which 
expressed EBER1 and EBER2 (from their native promoters) in the absence of EBNA1, 
enabling the impact of EBNA1 expression in these cells to be investigated. To achieve this, a 
non-OriP-based system for EBER expression was required, ensuring that EBNA1 was not 
required for EBER plasmid maintenance. Such an expression vector was constructed using 
pUC19 as a plasmid backbone. It was appropriate to include a drug resistance cassette in the 
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expression vector, given the goal of generating a polyclonal population of cells that stably 
express the EBERs. The first step of the cloning procedure for this expression vector was 
insertion of a puromycin resistance cassette into pUC19. The puromycin drug resistance 
marker was chosen due to the high sensitivity of Ad/AH cells to puromycin, along with the 
consideration that expression vectors with other drug resistance cassettes would be used in 
conjunction with this expression vector in later experiments. The puromycin resistance 
cassette (1.2kb) was excised by SalI endonuclease digestion from pOTEII GFP-HUMPU 
before ligation of the insert into pUC19 vector that had been linearised with the same 
restriction endonuclease. Diagnostic cuts were used to screen miniprep DNA taken from 
bacterial colonies, with SalI acting to excise the inserted puromycin cassette, (Figure 4.1). 
The generated plasmid is subsequently referred to as pUC19-Puro. 
pUC19-Puro-EBERs plasmid was generated by insertion of the 1kb SacI-EcoRI sub-fragment 
from the EcoRI-J fragment of the EBV genome into corresponding SacI and EcoRI sites 
located within the multiple cloning site (MCS) of pUC19-Puro. Diagnostic cuts were once 
again used to screen miniprep DNA, with EcoRI and SacI endonuclease digestion yielding 
fragments of 3.9 kb and 1kb (Figure 4.2).  
Purified pUC19-Puro-EBERs plasmid DNA was subsequently transiently transfected into 
Ad/AH cells to assess EBER1 expression levels. RT-PCR analysis (Figure 4.3A) revealed 
titratable increases in the level of EBER1 expression upon transient transfection of increasing 
amounts of pUC19-Puro-EBERs into Ad/AH cells, indicative of EBER expression from the 
pUC19-Puro-EBERs vector in the absence of EBNA1. The plasmid map for pUC19-Puro-
EBERs is given in Figure 4.3B. 
Following demonstration of transient EBER expression from the pUC19-Puro-EBERs vector 
(Figure 4.3A), this construct was used to generate a polyclonal population of cells stably 
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Figure 4.1 – Restriction endonuclease analysis of pUC19-Puro construct miniprep DNA. SalI 
digestion of DNA yields 2.7Kb and 1.2Kb fragments, confirming the insertion of the 1.2Kb 
puromycin resistance cassette (from pOTEII GFP-HUMPU) into the pUC19 vector. 
Figure 4.2 – Restriction endonuclease analysis of pUC19-Puro-EBERs construct miniprep 
DNA. Digestion of plasmid DNA with SacI and EcoRI endonucleases yields fragments of 
3.9Kb and 1Kb, confirming the insertion of the EcoRI-J fragment into the pUC19-Puro 
construct. 
Figure 4.3A – RT-PCR analysis confirming the expression of EBER1 in Ad/AH parental 
cells following transient expression of pUC19-Puro-EBERs (lanes 2-5). Cells were 
transfected with increasing amounts of plasmid DNA (from 0.1µg to 1µg), with RNA harvest 
at 24 hours post-transfection, followed by cDNA synthesis and RT-PCR analysis. EcoRI-J 
plasmid (lane 6) was used as a transient control, with untransfected Ad/AH-rEBV cells 
(which stably express EBER1 at a high level) also included as a further positive control.  
Figure 4.3B (Plasmid Map) – Plasmid map detailing the significant elements of pUC19-
Puro-EBERs plasmid. EcoRI-J fragment (EBERs and upstream regulatory region) and 
puromycin resistance cassette are presented as red arrows, with accompanying text 
highlighted. 
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Figures 4.1-4.3 
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expressing EBERs. Before drug selection for a population of EBER-expressing cells, the 
appropriate concentration of puromycin with which to treat Ad/AH cells to allow selection 
was ascertained. Figure 4.4 shows crystal violet staining of Ad/AH cells following treatment 
with increasing amounts of puromycin. Results indicate that 0.5µg/ml of puromycin was 
required for complete cell death of non-drug-resistant Ad/AH cells. Following transfection of 
Ad/AH cells with 0.5µg pUC19-Puro-EBERs (or control plasmid pUC19-Puro), cells were 
left untreated for 48 hours to allow expression of the puromycin acetyl transferase (PAC) 
gene. 48 hours post-transfection, cells were treated with 0.5µg/ml puromycin for 2 weeks 
before RNA was harvested from a population of cells and RT-PCR analysis of EBER1 and 
EBER2 expression was undertaken (Figure 4.5). The Ad/AH-Puro-EBERs cell line is 
demonstrated to express stably both EBER1 and EBER2, with Ad/AH-Puro cells expressing 
neither EBER1 nor EBER2.  
As clonal selection was not employed in the generation of Ad/AH-Puro-EBERs, a polyclonal 
population of cells was present. As such, it was unclear (from RT-PCR analysis) if the 
polyclonal population of cells was highly heterogeneous for EBER expression, and contained 
few, highly EBER-positive cells, or if the population was more uniform with the majority of 
cells being weakly EBER-positive. To determine the heterogeneity of EBER expression in 
Ad/AH-Puro-EBERs cells, in situ EBER hybridisation was carried out (Figure 4.6). Panels A 
and B show in situ EBER staining in Ad/AH and Ad/AH-rEBV cells respectively. Strong 
nuclear staining for EBERs was observed in Ad/AH-rEBV cells, with only background 
staining, equivalent to staining seen with use of a negative control (sense strand) probe 
(panels E-H) seen in Ad/AH parental cells. Similar negative staining was seen in Ad/AH-
Puro cells (panel C). Panel D reveals nuclear staining for EBERs in Ad/AH-Puro-EBERs 
cells. Fairly uniform staining is seen across all cells in this population, although levels of 
EBER expression are significantly lower than those observed in Ad/AH-rEBV cells. Ad/AH- 
176 
 
Chapter 4 
Figure 4.4 – Crystal violet staining of Ad/AH parental cells treated with varying amounts of 
puromycin, ranging from 0.1µg/ml to 0.5µg/ml. Puromycin was added to growth media for 
48 hours before cell fixation with 3.5% paraformaldehyde and crystal violet staining of viable 
cells. Images are presented at 40x magnification. 
Figure 4.5 – RT-PCR analysis of EBER1 and EBER2 expression in Ad/AH cells stably 
transfected with pUC19-Puro and pUC19-Puro-EBERs constructs (following puromycin drug 
selection). No Reverse Transcriptase (No RT) control refers to RNA samples taken from 
Ad/AH-Puro-EBERs cells and subjected to standard cDNA procedures with the RT omitted 
(ensuring no cDNA is made). This cDNA-free control enables the demonstration that EBER1 
and EBER2 primers used in the PCR assay are detecting RNA products of vector plasmid 
DNA, and not the plasmid DNA template itself.  
Figure 4.6 – A-D: In situ EBER staining of Ad/AH (A), Ad/AH-rEBV (B), Ad/AH-Puro (C) 
and Ad/AH-Puro-EBERs (D) cells. E-H Negative-control probe staining of Ad/AH (E), 
Ad/AH-rEBV (F), Ad/AH-Puro (G), and Ad/AH-Puro-EBERs (H) cells. Images were 
captured at a magnification of 60X (Panels A-D) or 40X (Panels E-H). 
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Figures 4.4-4.6 
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Puro-EBERs cells are therefore characterised as a polyclonal population of cells, with stable, 
fairly homogeneous low levels of EBER expression. 
4.1.2 Analysis of RNA polymerase III transcription in EBNA1-expressing epithelial cells  
The effect of EBNA1 expression on RNA polymerase III transcription was examined using a 
panel of epithelial cells (Ad/AH, AGS and Hone-1) which stably expressed either an empty 
vector (with neomycin drug resistance - neo) or EBNA1. In some instances, rEBV-infected 
cells of these lineages were used in the analysis of EBNA1 function. Validation of EBNA1 
expression levels in cell lines was conducted using immunofluorescence staining. 
Fluorescence microscopy images are presented in Figure 4.7. 
Previously EBV has been demonstrated to induce pol III activity via enhancement of TFIIIC 
expression in both lymphoid and epithelial cells (Felton-Edkins et al. 2006), although the 
viral gene product responsible for this induction remained unidentified. Previously published 
Affymetrix array analysis (Wood et al. 2007) revealed a 2.6-fold induction of RNA encoding 
the 102kd subunit of TFIIIC (TFIIIC-102) in response to EBNA1, indicating that this EBV 
latent gene product may be responsible for TFIIIC induction. Initial studies aimed to replicate 
results previously reported (Felton-Edkins et al. 2006), and investigate the role of EBNA1 in 
the induction of EBER-associated transcription factors. Figure 4.8 shows semi-quantitative 
RT-PCR analysis (followed by Southern blotting) of levels of three cellular pol III transcripts, 
7SL RNA, 5S rRNA and tRNATyr, in Akata BL and Ad/AH EBV-negative and -positive cell 
lines, along with Ad/AH-neo and -EBNA1 cells. The data presented were generated 
following preliminary experiments which determined the linear range of PCR amplification 
for each transcript analysed. In agreement with previous data, levels of all three cellular pol 
III transcripts were increased in both epithelial and lymphoid cells infected with EBV. In 
Ad/AH-EBNA1 cells, levels of all three cellular pol III transcripts were enhanced to a similar 
level, compared with Ad/AH-neo control cells. In addition to  
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Figure 4.7 – Immunofluorescence staining for EBNA1 in epithelial cell panel: (A) Ad/AH 
Parental; (B) Ad/AH-rEBV; (C) Ad/AH-neo c.1; (D) Ad/AH-EBNA1 c.3; (E) AGS-neo; (F) 
AGS-EBNA1; (G) Hone-1-neo; (H) Hone-1-EBNA1. Images shown are at 100X 
magnification. 
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Figure 4.7 
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Figure 4.8 – Semi-quantitative RT-PCR followed by Southern blotting to analyse the levels 
of cellular pol III-transcribed genes 7SL RNA, 5S rRNA and tRNAtyr in EBV-negative and 
EBV-positive Akata BL, Ad/AH parental, Ad/AH-rEBV, Ad/AH-neo c.1 and Ad/AH-
EBNA1 c.3 cells. The cellular housekeeping gene GAPDH is included as an internal RNA 
polymerase II-transcribed control. 
Figure 4.9 – RT-PCR analysis of TFIIIC subunit (TFIIIC-220, -110, -102, -90 and -63) 
mRNA levels in Ad/AH, AGS and Hone-1 cells stably expressing EBNA1 or a neomycin 
control cassette. Levels of EBNA1 mRNA are also assessed by RT-PCR. GAPDH is included 
as an internal cellular control. 
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confirming previously reported results, these data reveal that EBNA1 may be responsible, at 
least in part, for increased expression of endogenous pol III products induced by EBV. 
Subsequent analysis of pol III transcription factors was conducted in EBNA1-expressing 
derivatives of three distinct epithelial carcinoma cell models (Ad/AH, AGS and Hone-1) to 
examine mechanisms by which EBNA1 could induce expression of cellular pol III 
transcripts. Initial studies centred on TFIIIC subunits, given that previous microarray analysis 
had revealed transcriptional induction of TFIIIC subunits in EBNA1-expressing cells (Wood 
et al. 2007) and that EBV has been demonstrated to induce pol III activity via TFIIIC 
expression (Felton-Edkins et al. 2006). RT-PCR analysis of the levels of RNA encoding the 
five TFIIIC subunits previously shown to be EBV responsive (TFIIIC-220, -110, -102, -90 
and -63) was conducted across the epithelial cell panel and results are presented in Figure 4.9. 
Transcriptional induction of TFIIIC subunits varied, but was observed for multiple subunits 
in EBNA1-expressing derivatives of each cell line, at levels similar to those previously 
observed in EBV-infected epithelial cells (Felton-Edkins et al. 2006). In each cell line, 
EBNA1 was found to raise the expression of at least two TFIIIC subunits, with induction of 
TFIIIC subunits being most pronounced in cells of the Ad/AH lineage. Analysis of the levels 
of TFIIIC subunit proteins was restricted by a lack of suitable antibodies. However, 
immunoblotting for TFIIIC-110, -102 and -90 was conducted in Ad/AH-neo and -EBNA1 
cells (Figure 4.10) and revealed induction of all three subunits in Ad/AH-EBNA1 cells. 
In contrast to the TFIIIC data, and in agreement with the array analysis of Ad/AH-neo and 
Ad/AH-EBNA1 cells (Wood et al. 2007), there was no consistent increase in the RNA 
encoding TFIIIB transcription factors Bdp1, Brf1 and TBP across epithelial cell lines 
expressing EBNA1, as shown by RT-PCR (Figure 4.11) suggesting that EBNA1 can have a 
selective effect on the expression of TFIIIC. Such data are in agreement with previously  
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Figure 4.10 – Immunoblot analysis of the levels of TFIIIC-110, -102 and -90 in Ad/AH-neo 
and EBNA1 cells. Immunoblotting for EBNA1 is also shown, with β-Actin included as a 
loading control.   
Figure 4.11 – RT-PCR analysis showing mRNA levels of TFIIIB subunits Bdp1, Brf1 and 
TBP in Ad/AH, AGS and Hone-1 cells stably expressing EBNA1 or neomycin control 
cassette. EBNA1 mRNA levels were also assessed and GAPDH was included as an internal 
cellular control. 
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Figures 4.10 and 4.11 
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published work showing that there was no consistent increase in levels of TFIIIB subunit 
mRNA across a panel of EBV-infected cells (Felton-Edkins et al. 2006).  
To examine more precisely the levels of TFIIIB and TFIIIC subunit mRNA expression in 
Ad/AH, AGS and Hone-1 cells expressing EBNA1, RT-qPCR was conducted (Figure 4.12). 
This sensitive quantitative analysis afforded further confidence in results previously obtained, 
and enabled quantification of the changes in levels of expression of TFIIIB and TFIIIC 
subunit mRNA between neo control cells and EBNA1-expressing cells. In general, results 
obtained using RT-qPCR mirrored those seen using RT-PCR analysis, with no significant 
fold-change increase in expression seen for TFIIIB subunit mRNAs in EBNA1-expressing 
cells. In AGS-EBNA1 cells, a statistically significant increase in the expression of two 
TFIIIC subunit mRNAs (TFIIIC-220 and -110) was observed, compared with AGS-neo cells. 
However, more consistent significant increases in expression of TFIIIC subunit mRNA were 
observed in both Ad/AH and Hone-1 cells expressing EBNA1. RT-qPCR analysis of Ad/AH-
EBNA1 cells revealed significantly greater levels of mRNA for all TFIIIC subunits examined 
except TFIIIC-63, a result consistent with RT-PCR analysis (Figure 4.9). Analysis of Hone-
1-EBNA1 cells revealed, without exception, significantly greater levels of mRNAs for all 
TFIIIC subunits examined. These data are not in complete agreement with RT-PCR data 
(Figure 4.9), which suggested a less consistent induction of TFIIIC subunit mRNA levels in 
EBNA1-expressing Hone-1 cells. However, given the greater sensitivity of RT-qPCR 
compared with the qualitative analysis provided by RT-PCR and the reproducibility of the 
quantitative data, it is likely that a consistent induction of all TFIIIC subunit mRNAs does 
occur in Hone-1-EBNA1 cells. It is noted that the magnitude of fold change in TFIIIC 
subunit mRNA levels is fairly low, between 1.5 and 2 in all cases. Despite this modest 
increase in expression levels, the statistical analysis revealing significance confirms the 
importance of these quantitative data in reinforcing results seen using RT-PCR analysis. 
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Figure 4.12 – RT-qPCR analysis of levels of expression of TFIIIC and TFIIIB subunit 
mRNA in Ad/AH, AGS and Hone-1 cells stably expressing EBNA1 or neomycin control 
cassette. Fold change values are between neo control cells and EBNA1-expressing cells. All 
RT-qPCR data are means of three biological replicates analysed in technical triplicate. Error 
bars represent the standard deviation in fold change between biological replicates. Asterisks 
indicate that the fold change between neo control and EBNA1 cells is statistically significant, 
as determined by the student T-test. *P≤0.05; **, P≤0.01. Also included in the figure is the 
RT-PCR analysis from Figures 4.9 and 4.11 for easy comparison of qualitative and 
quantitative data sets. 
 
 
 
 
 
 
 
 
 
 
 
 
188 
 
Chapter 4 
 
 
 
 
Figure 4.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
Chapter 4 
Consistent with data shown in Figure 4.8, induction of cellular pol III transcripts 7SL RNA, 
5S rRNA and tRNATyr was demonstrated by RT-PCR analysis in EBNA1-expressing 
derivatives of the panel of epithelial cells (Figure 4.13). Densitometric analysis of these data 
and comparative analysis of data from Felton-Edkins and co-workers confirmed that levels of 
induction in EBNA1-expressing cells, and EBV-infected cells were comparable. Increases in 
each pol III-transcribed gene from uninfected to EBV-infected cells, and from neo- to 
EBNA1-expressing cells, was measured as being between 1.5- and 2-fold in each instance. 
These data confirm the apparent downstream significance of the induction of TFIIIC subunit 
expression observed across EBNA1-expressing epithelial cell lines. 
4.1.3 Analysis of EBER-associated RNA polymerase II (pol II) transcription factors in 
EBNA1-expressing epithelial cells 
As previously discussed in the introductory section, although the EBERs are transcribed 
exclusively by pol III, the EBER promoter regions contain a hybrid of pol II and pol III 
elements. Pol II elements of EBER promoters are well characterised, and include a TATA-
box, Sp1 and ATF-2 binding sites  (Howe and Shu 1989; 1993; Felton-Edkins et al. 2006), 
and EBER1 (although not EBER2) possesses two E-boxes upstream of its transcriptional start 
site (see Figure 1.3), to which c-Myc has been demonstrated to bind (Niller et al. 2003). The 
pol II elements of EBER promoter regions have been shown by several studies to be 
necessary to allow high levels of EBER expression to occur (Howe and Shu 1989; 1993; 
Wensing et al. 2001), although some evidence suggests that the c-Myc binding site upstream 
of EBER1 is dispensable (Wensing et al. 2001). 
Having established EBNA1’s ability to affect typical cellular pol III transcription factors 
involved in EBER expression, this study went on to examine the role of EBNA1 in the  
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Figure 4.13 – RT-PCR analysis of the levels of cellular polIII-transcribed genes tRNAtyr, 5S 
rRNA and 7SL RNA in Ad/AH, AGS and Hone-1 cells stably expressing EBNA1 or a 
neomycin control cassette. EBNA1 mRNA levels were also analysed with GAPDH included 
as an internal cellular control. 
Figure 4.14 – Immunoblotting for cellular transcription factor Sp1 in Ad/AH parental, 
Ad/AH-rEBV and Ad/AH-EBNA1 cells. β-Actin is included as a loading control, and 
EBNA1 immunoblot analysis illustrates the level of EBNA1 expression in each cell line. 
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Figures 4.13 and 4.14 
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regulation of typical pol II cellular transcription factors known to be involved in the 
regulation of EBER expression.  
4.1.3.1 Sp1 
Immunoblotting analysis revealed levels of Sp1 protein were unchanged by rEBV infection 
or EBNA1 expression in Ad/AH cells (Figure 4.14), suggesting that EBNA1 does not 
influence EBER expression through Sp1 regulation.  
4.1.3.2 ATF-2 
ATF-2 has previously been identified as an EBER-associated typical pol II transcription 
factor that is upregulated in EBV-infected epithelial cells and, in addition, it is known to bind 
and activate the promoter of the gene encoding TFIIIC-220 (Felton-Edkins et al. 2006). 
Further, ATF-2 induction in EBNA1-expressing epithelial cells has been demonstrated 
(O'Neil et al. 2008). RT-PCR analysis (Figure 4.15) confirmed a robust induction of ATF-2 
mRNA in a panel of EBNA1-expressing epithelial cells. Subsequent immunoblot analysis of 
levels of total ATF-2 protein in the same panel of EBNA1-expressing cells (Figure 4.16) 
showed induction of ATF-2 protein in Ad/AH-EBNA1 and AGS-EBNA1 cells, although no 
induction of ATF-2 protein levels was observed in Hone-1-EBNA1 cells. In agreement with 
these data, immunofluorescence staining for total and dual-phosphorylated (and activated) 
ATF-2 in Ad/AH, Ad/AH-rEBV and Ad/AH-EBNA1 cells revealed robust induction in the 
levels of total and dual-phosphorylated ATF-2 in Ad/AH-EBNA1 cells (Figure 4.17), with 
levels of induction observed being at least the equivalent of those seen in Ad/AH-rEBV cells 
and similar to levels seen upon TPA treatment of Ad/AH cells. Further immunoblot analysis 
of ATF-2 levels in Ad/AH cells (Figure 4.18) revealed not only a robust increase in levels of 
total ATF-2 in Ad/AH-EBNA1 cells, but also confirmed that significant induction of mono- 
(Thr71) and dual-phosphorylated (Thr69/71) ATF-2 occurs.  
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Figure 4.15 – RT-PCR analysis of ATF-2 mRNA levels in Ad/AH, AGS and Hone-1 cells 
stably expressing EBNA1 or a neomycin control cassette. EBNA1 mRNA levels were also 
assessed and GAPDH is included as an internal cellular control. 
Figure 4.16 – Immunoblotting for total levels of ATF-2 in Ad/AH, AGS and Hone-1 cells 
stably expressing EBNA1 or neomycin control cassette. β-Actin is included as a loading 
control, with EBNA1 immunoblotting illustrative of EBNA1 levels in the cell lysates. 
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Figure 4.17 – Immunofluorescence staining for total and dual-phosphorylated ATF-2 in 
Ad/AH cells. A-D: Immunofluorescence for total ATF-2 in Ad/AH (A), Ad/AH-rEBV (B), 
Ad/AH-neo c.1 (C) and Ad/AH-EBNA1 c.3 (D) cells; E-H: Immunofluorescence for dual-
phosphorylated ATF-2 (Thr69 and Thr71) in Ad/AH (E), Ad/AH-rEBV (F), Ad/AH-EBNA1 
c.3 (G) and TPA stimulated Ad/AH (H) cells. Images shown are at a magnification of 400X.  
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Figure 4.17 
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Figure 4.18 – Immunoblot analysis of total ATF-2, mono-phosphorylated (Thr71) ATF-2 
and dual-phosphorylated (Thr69/Thr71) ATF-2 in Ad/AH-neo and Ad/AH-EBNA1 cells. β-
Actin is included as a loading control and levels of EBNA1 expression in cell lysates is also 
shown.  
Figure 4.19 – RT-PCR analysis of the level of ATF-2 mRNA in Ad/AH-rEBV cells 
following transient transfection of cells with shRNA targeted against ATF-2. Along with a 
pSG5 transfection control, a titration of shRNA against ATF-2 from 0.5µg to 2.5µg was 
transfected into Ad/AH-rEBV cells, with RNA samples taken 72 hours post transfection for 
analysis. GAPDH is included as an internal cellular control.  
Figure 4.20 - RT-PCR analysis of levels of EBER1 and EBER2, and ATF-2 mRNA in 
Ad/AH-rEBV cells following transient transfection of cells with 2.5µg shRNA targeted 
against ATF-2. Data are representative of experiments conducted in at least biological 
triplicate. 
 
 
 
 
 
 
 
 
198 
 
Chapter 4 
 
Figures 4.18-20 
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To assess the impact of EBNA1-mediated induction of ATF-2 upon EBER expression, a 
converse approach was adopted, transiently expressing shRNA against ATF-2 in Ad/AH-
rEBV cells before analysing consequential levels of EBER1 and EBER2. Figure 4.19 shows 
RT-PCR conducted following an initial titration of shRNA against ATF-2 into Ad/AH-rEBV 
cells. Reduction in levels of ATF-2 was titratable, with the greatest reduction in levels of 
ATF-2 mRNA being observed with transfection of 2.5µg of expression vector DNA. Figure 
4.20 is representative of multiple RT-PCR assays for EBER1 and EBER2 levels in Ad/AH-
rEBV cells following transient expression of 2.5µg shRNA to ATF-2. shRNA targeting ATF-
2 robustly reduced ATF-2 expression (measured as a 2-fold reduction in levels by 
densitometry) and, as a result, expression of both EBER1 and EBER2 was significantly 
diminished (by 3.5- and 3.1-fold respectively, by densitometric analysis). Such data confirm 
the importance of ATF-2 in the regulation of EBER expression in epithelial cells. 
To influence EBER expression, nuclear location of ATF-2 is necessary. To confirm increased 
levels of nuclear ATF-2, nuclear and cytosolic fractions of Ad/AH-neo and Ad/AH-EBNA1 
cell lysates were taken for immunoblot analysis, the results of which are seen in Figure 4.21. 
A clear increase in the levels of nuclear ATF-2 is observed in the Ad/AH-EBNA1 nuclear 
lysate, compared with the Ad/AH-neo nuclear lysate, with little cytosolic ATF-2 present in 
both Ad/AH-neo and Ad/AH-EBNA1 samples. 
4.1.3.3 c-Myc 
c-Myc has been shown to bind to E-box sites upstream of the EBER1 gene (Niller et al. 
2003), and through its interaction with TFIIIB, c-Myc can directly activate many cellular pol 
III-transcribed genes (Gomez-Roman et al. 2003). Further, transcriptional induction of c-Myc 
has been demonstrated in EBNA1-expressing Ad/AH cells (Wood et al. 2007). Confirmation 
of this upregulation is shown by RT-PCR analysis (Figure 4.22), with levels of c-Myc mRNA  
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Figure 4.21 – Immunoblot analysis of total levels of ATF-2 in nuclear and cytosolic extracts, 
taken from Ad/AH-neo and EBNA1 cells. Sp1 and tubulin are nuclear and cytosolic proteins 
respectively and immunoblot analysis of levels of these proteins is included to demonstrate 
successful separation of nuclear and cytosolic fractions of cell lysates. 
Figure 4.22 – RT-PCR analysis of c-myc mRNA levels in Ad/AH, AGS and Hone-1 cells 
stably expressing EBNA1 or neomycin control cassette. EBNA1 mRNA levels are also 
assessed with GAPDH included as an internal cellular control.  
Figure 4.23 – Immunoblot analysis of total levels of c-Myc in Ad/AH-neo, Ad/AH-EBNA1 
and Ad/AH-rEBV cells. β-Actin is included as a loading control and levels of EBNA1 
expression are also shown. 
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in AGS and Hone-1-neo and -EBNA1 cells also assayed. Although induction of c-Myc 
mRNA was confirmed in Ad/AH-EBNA1 cells, no such induction was observed in AGS or 
Hone-1-EBNA1 cells.  
Immunoblot analysis of c-Myc protein levels was conducted in Ad/AH-neo, Ad/AH-EBNA1 
and Ad/AH-rEBV cells (Figure 4.23). Intriguingly, despite induction of mRNA in Ad/AH-
EBNA1 cells, levels of c-Myc protein were robustly reduced in both Ad/AH-EBNA1 and 
Ad/AH-rEBV cells, compared with levels observed in Ad/AH-neo cells. 
To assess if this reduction in levels of c-Myc protein in Ad/AH-EBNA1 cells, despite an 
induction of c-Myc mRNA, corresponded to a change in c-Myc-mediated transcriptional 
activation, dual luciferase reporter assays were conducted. The results of these assays (Figure 
4.24) reveal increased transcriptional activity of c-Myc in EBNA1-expressing cells.  
Having established that the transcriptional activation capacity of c-Myc is increased in 
EBNA1-expressing cells despite a reduction in protein levels, nuclear and cytosolic fractions 
of Ad/AH, Ad/AH-rEBV and Ad/AH-EBNA1 cell lysates were taken, to assess if increases 
in c-Myc-mediated transcription could be attributed to increased nuclear localisation of c-
Myc. Figure 4.25 shows immunoblotting for c-Myc using these nuclear and cytsolic cell 
fractions, and reveals no differences in the intracellular localisation of c-Myc in Ad/AH, 
Ad/AH-rEBV and Ad/AH-EBNA1 cells. 
Given the apparent complex nature of the regulation of c-Myc activity in Ad/AH-EBNA1 
cells and c-Myc’s involvement in regulating EBER expression, Ad/AH-neo and -EBNA1 
cells stably expressing an inducible c-Myc fusion protein (c-MycER) were utilised in further 
examination of c-Myc function in EBNA1-expressing Ad/AH cells.  Immunoblot analysis 
using an antibody which detected both endogenous c-Myc and c-MycER fusion protein 
revealed that levels of both c-MycER, and endogenous c-Myc were reduced in EBNA1- 
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Figure 4.24 – Dual luciferase reporter assays conducted in Ad/AH-neo, Ad/AH-rEBV and 
Ad/AH-EBNA1 cells. Levels of c-Myc transcriptional activation activity (from X-box 
consensus sequence) are shown, relative to levels of activity observed in Ad/AH-neo cells. 
Cells transfected with c-Myc luciferase reporter plasmid and Renilla control plasmid were 
harvested 24 hours post transfection. Levels of c-Myc luciferase reporter activity were 
normalised to transfection control (Renilla) before being made relative to levels of c-Myc 
luciferase reporter activity in Ad/AH-neo cells. The results presented are means of biological 
and technical triplicates, with error bars representative of the standard deviation of biological 
repeats. 
Figure 4.25 - Immunoblot analysis for total levels of c-Myc in nuclear and cytosolic extracts, 
taken from Ad/AH-neo, Ad/AH-rEBV and EBNA1 cells. Sp1 and tubulin are nuclear and 
cytosolic proteins respectively, with immnoblotting for these proteins included to 
demonstrate successful separation of nuclear and cytosolic fractions of cell lysates.   
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expressing cells (Figure 4.26). Analysis of the transcriptional activation capacity of c-Myc 
was expanded to these cell lines, with dual-luciferase reporter assays for c-Myc-mediated 
transcriptional activation conducted following functional induction of the c-Myc fusion 
protein with 4-hydroxytamoxifen (4-OHT) (Figure 4.27). Enhanced c-Myc activity was 
observed in both neo- and EBNA1-expressing cells, with induction being considerably 
stronger in EBNA1-expressing cells compared with their neo counterparts. This is consistent 
with there being an increased transcription-enhancing activity of c-Myc in the presence of 
EBNA1. Indeed, basal levels (without 4-OHT stimulation) of c-Myc transcriptional activation 
capacity are increased 5-fold in EBNA1-expressing cells compared with neo control cells. In 
both Ad/AH-neo and -EBNA1 cells, the increase of c-Myc activity in response to 4-OHT 
treatment was titratable, with increased 4-OHT concentrations resulting in increased levels of 
c-Myc-induced transcriptional activation. 
In an attempt to uncover an explanation for the reduced levels of c-Myc protein in EBNA1-
expressing cells, proteins involved in the regulation of c-Myc protein stability were analysed 
by immunoblotting in an Ad/AH cell panel. A schematic of the regulation of c-Myc stability 
is shown in Figure 4.28. Figure 4.29 examines levels of total and phosphorylated extracellular 
signal-regulated kinases 1/2 (ERK) in untreated/stimulated samples from Ad/AH, Ad/AH-
rEBV, Ad/AH-neo and Ad/AH-EBNA1 cells. ERK is responsible for an initial (stabilising) 
phosphorylation event (Ser62) of c-Myc (Pulverer et al. 1994; Sears et al. 2000). Across all 
samples, no significant variation in levels of total ERK was demonstrated, though levels of p-
ERK were slightly increased in unstimulated Ad/AH-rEBV cells compared with other 
unstimulated cells. However, following osmotic shock, TPA stimulation, and anisomycin 
stimulation, levels of p-ERK were reduced in EBNA1-expressing cells (Ad/AH-rEBV and 
Ad/AH-EBNA1). Total levels of Akt (which phosphorylates and inactivates GSK3β) 
remained unchanged in EBNA1-expressing Ad/AH cells (Figure 4.30), though levels of total 
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Figure 4.26 – Immunoblot analysis of the levels of c-MycER (inducible c-Myc fusion 
protein) and endogenous c-Myc in Ad/AH-neo and EBNA1 cells stably expressing the c-
MycER fusion protein. β-Actin is included as a loading control and levels of EBNA1 
expression are also shown. 
Figure 4.27 – Dual luciferase reporter assays conducted following transient transfection 
(with a c-Myc luciferase reporter plasmid) of Ad/AH cells stably expressing c-MycER and 
either EBNA1 or neomycin control cassette. Cells were treated with 0nm, 250nm, 500nm or 
1000nm 4-Hydroxytamoxifen for 24 hours before cell lysis and performance of assay. Levels 
of c-Myc transcriptional activation activity (from X-box consensus sequence) are shown, 
relative to levels of activity observed in (untreated) Ad/AH-neo cells. Levels of c-Myc 
luciferase reporter activity were normalised to a transfection control (Renilla), before being 
made relative to levels of c-Myc luciferase reporter activity in untreated Ad/AH-neo cells. 
Results presented are means of biological and technical triplicates, with error bars 
representative of the standard deviation of biological repeats.  
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Figure 4.28 – Schematic of the regulation of c-Myc stability, adapted from Sears et al. 
(2000). c-Myc is phosphorylated on residue Serine-62 by ERK (the phosphorylation activity 
of ERK is controlled by Raf/MEK pathways). Subsequently, c-Myc can be phosphorylated on 
residue Threonine-59 by GSK-3, which can be inactivated by phosphorylation events 
controlled by PI3-kinase/Akt signalling pathways. Dual phosphorylated c-Myc (at Serine-62 
and Threonine-59) is subject to ubiquitination and subsequent proteasomal degradation.   
Figure 4.29 – Immunoblot analysis of the levels of expression of total and phospho-ERK1/2 
in Ad/AH, Ad/AH-rEBV, Ad/AH-neo and Ad/AH-EBNA1 cells. Cells were left untreated or 
stimulated by osmotic shock (0.2M NaCl for 20 minutes prior to harvest), TPA treatment 
(60ng/ml TPA for 16 h prior to harvest) or anisomycin treatment (50ng/ml for 1 hour prior to 
harvest). β-Actin is included as a loading control.  
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Figure 4.30 – Immunoblot analysis of the levels of total Akt, phospho- and total-GSK3β in 
Ad/AH, Ad/AH-rEBV and Ad/AH-EBNA1 cells. β-Actin is included as a loading control 
with levels of EBNA1 expression (as assessed by immunoblotting) also shown. 
Figure 4.31 – Immunoblotting for levels of c-Myc in Ad/AH-neo and Ad/AH-EBNA1 cells 
following treatment with 2 µg/ml cyclohexamide (CHX) for 0, 30, 60 and 120 minutes. 
Figure 4.32 – Fluorescence microscopy images of GFP expression in Ad/AH-rEBV cells 48h 
post transfection with shRNA against c-myc ‘152051’ (152051 expression plasmid also 
carries a GFP expression cassette which is constitutively expressed). Images show GFP 
expression following transfection of cells with 0µg, 1µg and 2µg of 152051 plasmid DNA. 
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and phospho-GSK3β were increased in EBNA1-expressing cells (Figure 4.30). c-Myc protein 
stability in Ad/AH-neo and -EBNA1 cells was assessed using cyclohexamide as an inhibitor 
of protein synthesis (Figure 4.31). These data reveal no significant reduction in the stability 
of c-Myc in Ad/AH-EBNA1 cells, compared with Ad/AH-neo cells, a result which adds no 
explanation for the decreased levels of c-Myc protein in EBNA1-expressing Ad/AH cells. 
To assess the impact of EBNA1-mediated induction of c-Myc upon EBER expression, a 
converse approach was once more adopted, with shRNA against c-Myc transiently expressed 
in Ad/AH-rEBV cells before analysis of consequential levels of EBER1 and EBER2. The 
expression plasmid (152051) encoding the shRNA against c-Myc also constitutively 
expressed GFP, and this GFP marker was used to monitor transfection efficiency and 
efficacy. Fluorescence microscopy images of Ad/AH-rEBV cells transiently transfected with 
the shRNA vector (Figure 4.32) confirm successful transfection of expression vector, with a 
high percentage of GFP positivity in cell populations transfected with 2µg of expression 
vector plasmid DNA. Figure 4.33 illustrates the effect of transiently expressing shRNA to c-
Myc in Ad/AH-rEBV cells. c-Myc mRNA levels are significantly reduced by transient 
transfection of 1µg of the expression vector, and completely ablated by transient transfection 
of 2µg of plasmid DNA. Transient transfection with 2µg of plasmid DNA was observed to be 
sufficient to significantly reduce levels of EBER1, and cause a moderate reduction in EBER2 
levels. Densitometric analysis of the data from multiple experiments revealed the reduction in 
levels of EBER1 to be approximately 1.9-fold, with EBER2 levels being reduced only 1.2-
fold. Levels of tRNATyr were also significantly reduced (2.5-fold by densitometry), a result 
which concurs with previously published data demonstrating the direct role c-Myc plays in 
upregulating cellular pol III transcription (Gomez-Roman et al. 2003). The lack of reduction 
in levels of EBER and tRNATyr expression following ablation of c-Myc expression by 
transfection of cells with 1µg of shRNA plasmid DNA is attributed to an insufficient  
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Figure 4.33 – RT-PCR analysis of the levels of EBER1, EBER2, c-myc mRNA and tRNATyr 
in Ad/AH-rEBV cells transiently transfected with pSG5, non-silencing control shRNA, or 
shRNA to c-myc. Cells were transfected with 1µg and 2µg of test plasmid with RNA 
subsequently extracted 48h post transfection, before cDNA synthesis and RT-PCR analysis 
was conducted. GAPDH is included as an internal control. 
Figure 4.34 – RT-PCR analysis of EBER1 expression levels, confirming levels of EBER1 
are equivalent in Ad/AH-Puro-EBERs and Ad/AH-neo-c-MycER-Puro-EBERs cell lines. 
GAPDH is included as an internal control. 
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reduction in levels of c-Myc protein that this level of shRNA expression resulted in, although 
this was not experimentally assessed. In parallel to anti-c-Myc shRNA experiments, non-
silencing control shRNA was also transiently expressed in Ad/AH-rEBV cells, with no 
resultant effect on levels of c-Myc mRNA, or EBER expression (Figure 4.33). 
To examine the effect of enhanced c-Myc-mediated transcriptional activation upon EBER 
expression, Ad/AH cells expressing both c-MycER and EBERs were generated by 
transfection of Ad/AH-neo-c-MycER cells with pUC19-Puro-EBERs plasmid. Following 
puromycin drug selection over a two week period, cells were assayed by RT-PCR for EBER1 
expression (Figure 4.34). Roughly equivalent levels of EBER1 are seen for Ad/AH-Puro-
EBERs cells and Ad/AH-neo-c-MycER Puro-EBERs cells, indicating successful generation 
of a population of cells, stably expressing both EBERs and c-MycER. To confirm that 
functional induction of c-MycER remained intact in these cells, dual luciferase reporter 
assays were conducted (Figure 4.35). Cells were subsequently used to evaluate the impact of 
functional induction of c-MycER on levels of EBER expression. Figure 4.36 shows RT-PCR 
analysis of levels of EBER1 and EBER2 following treatment of Ad/AH-neo-c-MycER-Puro-
EBERs cells with 4-OHT for 6, 24 and 48 hours. Although no change in EBER expression is 
observed following 6 hours of treatment, after 24 and 48 hours, levels of EBER1 and EBER2 
are both increased although levels of EBER1 are increased to a significantly greater extent 
than levels of EBER2. This result is consistent with shRNA data and is consistent with the 
observation that only EBER1 has an E-Box (c-Myc binding site) upstream of its 
transcriptional start site (Niller et al. 2003).  
4.1.4 EBNA1 expression in Ad/AH-Puro-EBERs cell line 
The data presented above confirm that EBNA1 is able to induce several factors involved in 
the regulation of EBER expression, however these experiments fail to illustrate definitively 
216 
 
Chapter 4 
Figure 4.35 - Dual luciferase reporter assay showing levels of c-Myc transcriptional 
activation activity in response to 4OHT treatment (250nM) of Ad/AH-neo-c-MycER-Puro-
EBERs cells. Results are means of biological and technical triplicates, with error bars 
representative of the standard deviation of biological repeats. 
Figure 4.36 – RT-PCR analysis of EBER1 and EBER2 levels in Ad/AH-neo-c-MycER-Puro-
EBERs cells following treatment with 250nM 4OHT for 6, 24 and 48 hours. GAPDH is 
included as an internal control. 
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that EBNA1 increases EBER expression. To address this, the effect of expressing 
physiological amounts of EBNA1 in Ad/AH-Puro-EBERs cells was analysed by RT-PCR. 
Figure 4.37 shows analysis of EBNA1, EBER1 and EBER2 levels in Ad/AH-Puro-EBERs 
cells, following titration of EBNA1 expression vector pSG5-EBNA1, with RNA having been 
extracted for analysis at 8, 24, 48 and 72 hours post transfection. Between 1ng and 5ng of 
transfected plasmid DNA was required to attain levels of EBNA1 expression observed in 
Ad/AH-rEBV cells. At each time point, levels of EBER1 and EBER2 expression were 
significantly increased by each amount of EBNA1 expressed. Physiological levels of EBNA1 
were sufficient to increase EBER expression, with increased amounts of EBNA1 expression 
not yielding any further over-expression of EBERs. The increase in levels of EBER 
expression can be attributed to EBNA1-mediated increases in levels of cellular EBER-
associated transcription factors previously described in this chapter, as demonstrated by 
increases in TFIIIC-110 and ATF-2 mRNA, and tRNAtyr (Figure 4.38A). Densitometric 
analysis of EBER expression levels in these experiments (Figure 4.38B) revealed a 2 to 2.5-
fold mediated increase in levels of EBER expression in response to EBNA1. Although levels 
of EBER expression are not increased to those seen in Ad/AH-rEBV cells, EBER expression 
is shown to be comparable to levels of expression seen in the Burkitt’s Lymphoma cell line 
Namalwa (Figure 4.39). 
4.1.5 Disruption of c-Myc regulatory region (X-box) upstream of EBER1 
Previously published data had demonstrated c-Myc binding to E-boxes contained within an 
X-box region upstream of EBER1 (Niller et al. 2003). To confirm the importance of this site 
in the regulation of EBER expression, it was excised from pUC19-Puro-EBERs utilising 
molecular cloning techniques, before levels of EBER expression in subsequently established 
cell lines were analysed. 
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Figure 4.37 – RT-PCR analysis of EBER1 and EBER2 expression levels in Ad/AH-Puro-
EBERs cells transiently transfected with pSG5-EBNA1 (titration from 1ng to 50ng) over a 72 
hour time course. RNA was harvested and analysed at 8, 24, 48 and 72 hours post 
transfection. Levels of EBNA1 expression were also measured by RT-PCR with Ad/AH-
rEBV RNA analysed (alongside 72 hour time-point data) as a positive control for EBER and 
EBNA1 expression. GAPDH is included as an internal control. 
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Figure 4.38 – (A) RT-PCR analysis of EBER-associated transcription factor mRNA levels in 
Ad/AH-Puro-EBERs cells following transient transfection with pSG5-EBNA1 (titration from 
1ng to 50ng). Levels of ATF-2 mRNA, TFIIIC110 mRNA and cellular polIII target tRNAtyr 
were analysed using RNA harvested 48 hours post transfection with EBNA1. RT-PCR 
analysis of EBER1 and EBER2 is also shown along with levels of EBNA1 mRNA and 
GAPDH as an internal control. (B) Densitometric analysis of EBER expression in (A) 
represented as fold change from EBER expression in pSG5 control transfected cells. Error 
bars indicate the standard deviation between densitometric analyses of three biological 
repeats. RT-PCR images are included for comparison.  
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Figure 4.39 – RT-PCR analysis of EBER1 and EBER2 levels in Ad/AH, Ad/AH-rEBV, 
Namalwa BL cell lines and in Ad/AH-Puro-EBERs (Ad/AH-PE) cells that had been 
transiently transfected with a pSG5 control plasmid, or a pSG5-EBNA1 expression vector. 
Levels of EBNA1 were also assayed by RT-PCR with GAPDH included as an internal 
control. 
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Using online tools (AliBaba2.1), dry analysis of the effect on transcription factor binding of 
disrupting the wild type X-box sequence was conducted (Figure 4.40). E-box sequences were 
disrupted as previously described (Jones et al. 1996; Wang et al. 2004) (changed from 
CAGATG to CAGAGA, and CACGTG to CACGGA), leading to a clear reduction in 
predicted transcription factor binding, with c-Myc and associated transcription factors no 
longer predicted to bind to the sequence. This predicted reduction in transcription factor 
binding was tested empirically by EMSA analysis (Figure 4.41). Here, in a variety of Ad/AH 
and Akata BL cells lines, levels of transcription factor binding to the mutated X-box region 
are significantly reduced compared with binding to the wild-type X-box sequence. However, 
the c-Myc specificity of this reduction in transcription factor binding remains undetermined, 
as super-shift experiments conducted to confirm specificity were unsuccessful.  
Attempts to generate the mutant sequence used in dry analysis and EMSA analysis were 
made using site-directed mutagenesis (of pUC19-Puro-EBERs). Despite considerable 
persistence attempts were not successful, and an alternative method of ablation of the E-
boxes upstream of EBER1 was employed. Figure 4.42 gives details of endonuclease digestion 
of pUC19-Puro-EBERs and ligations to generate pUC19-Puro-EBERs-ΔX. Briefly, the X-
box c-Myc binding site (containing both E-box regions) was excised from pUC19 EBERs 
plasmid using SacI and PmlI, excising bases -352 to -125 relative to the EBER1 
transcriptional start site. Dry analysis of this novel sequence (Figure 4.43) predicted ablation 
of c-Myc binding.   
pUC19-Puro-EBERs-ΔX was introduced into Ad/AH and Ad/AH-neo-c-MycER cells before 
puromycin drug treatment for two weeks to select a polyclonal population of cells, stably 
expressing the new expression vector. Subsequently, cells were screened by RT-PCR for 
EBER1 and EBER2 expression (Figures 4.44 and 4.45). Levels of EBER expression in 
Ad/AH-Puro-EBERs-ΔX and Ad/AH-neo-c-MycER-Puro-EBERs-ΔX were observed to be 
226 
 
Chapter 4 
Figure 4.40 – In silico analysis of transcription factor binding sites (using Alibaba 2.1 
http://www.gene-regulation.com/pub/programs/alibaba2/index.html?) in wild-type X-box 
sequence and mutated X-box sequence. 
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Figure 4.41 – EMSA analysis of wild-type X-box sequence and mutated X-box sequence 
binding in Ad/AH, Ad/AH-rEBV, Ad/AH-EBNA1, Ad/AH serum starved Akata EBV-
negative and Akata EBV-positive cells. 
Figure 4.42 – Sequence (partial) analysis of the construction of pUC19-Puro-EBERs-ΔX. 
pUC19-Puro-EBERs plasmid DNA was cut with SacI and PmlI, followed by blunt-end filling 
and ligation, leading to the generation of pUC19-Puro-EBERs-ΔX, relevant areas of sequence 
are shown and annotated. 
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Figure 4.43 – In silico analysis of transcription factor binding sites (using Alibaba 2.1 
http://www.gene-regulation.com/pub/programs/alibaba2/index.html?) in mutated X-box 
sequence of pUC19-Puro-EBERs-ΔX. 
Figure 4.44 – RT-PCR analysis of the levels of stable EBER1 and EBER2 expression 
following generation of Ad/AH-Puro-EBERs-ΔX cell line in comparison with level of stable 
EBER expression observed in established pUC19-Puro-EBERs cell line. GAPDH is included 
as an internal control. 
Figure 4.45 - RT-PCR analysis of the levels of stable EBER1 and EBER2 expression 
following generation of Ad/AH-neo c-MycER Puro-EBERs-ΔX cell line in comparison with 
level of stable EBER expression observed in established pUC19-Puro-EBERs cell line. 
GAPDH is included as an internal control. 
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equivalent to levels seen in Ad/AH-Puro-EBERs (albeit with a reduction in levels of EBER1 
in Ad/AH-Puro-EBERs-ΔX cells). 
The impact upon EBER expression of transient EBNA1 expression in Ad/AH-Puro-EBERs-
ΔX cells was observed through transfection of pSG5-EBNA1 into the new cell line and, in 
parallel, Ad/AH-Puro-EBERs cells, where EBER induction by EBNA1 had previously been 
observed (Figure 4.37). Figure 4.46 confirms EBER induction in Ad/AH-Puro-EBERs cells 
upon expression of EBNA1, and that an induction of EBER1 and EBER2 expression is seen 
to a similar extent in Ad/AH-Puro-EBERs-ΔX cells, following transient expression of 
EBNA1. 
Ad/AH-neo-c-MycER-Puro-EBERs-ΔX cells were treated with 4-OHT to functionally induce 
c-MycER before analysis of EBER expression by RT-PCR (Figure 4.47). Levels of EBER1 
remain almost unchanged by c-MycER induction, with slight increases in levels of EBER2 
observed after 6 and 24 hours. In comparison, in similar cells with the X-box upstream of 
EBER1 intact (Ad/AH-neo-c-MycER-Puro-EBERs) functional induction of c-MycER led to 
substantial induction of EBER1, and slight induction of EBER2 expression. Levels of EBER 
expression across the two cells lines following 24 hours of 4-OHT treatment are shown in 
Figure 4.48 for comparison. Such results suggest c-Myc influences EBER1 transcription 
through binding to upstream E-boxes, confirming the importance of these c-Myc binding 
sites in regulation of EBER expression. 
4.1.6 Dominant-negative EBNA1 studies 
As a converse of the experiments previously described (Figures 4.37 and 4.38), ablation of 
EBNA1 function through introduction and expression of dnEBNA1 (EBNA1 M1) in EBV-
infected Ad/AH cells resulted in a titratable and robust decrease in levels of both EBER1 and 
EBER2 expression (Figure 4.49). Densitometric analysis revealed reductions of 2.1-fold in 
233 
 
Chapter 4 
Figure 4.46 - RT-PCR analysing changes in EBER1 and EBER2 expression levels in 
Ad/AH-Puro-EBERs cells, and Ad/AH-Puro-EBERs-ΔX cells following transient 
transfection of these cells with pSG5-EBNA1 (titration from 2ng to 200ng plasmid DNA). 
RNA was harvested and analysed 48 hours post-transfection. Levels of EBNA1 mRNA were 
also assessed by RT-PCR and GAPDH was included as an internal control. 
Figure 4.47 - RT-PCR analysing levels of EBER1 and EBER2 expression in Ad/AH-neo-c-
MycER Puro-EBERs-ΔX cells treated with 250nM 4OHT for 6, 24 and 48 hours. GAPDH is 
included as an internal control. 
Figure 4.48 – RT-PCR comparing of levels of EBER1 and EBER2 in Ad/AH-neo-c-MycER-
Puro-EBERs cells (A) and Ad/AH-neo-c-MycER-Puro-EBERs-ΔX cells (B). Cells were left 
untreated or treated with 250nM 4OHT for 24 hours. GAPDH is included as an internal 
control. 
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Figure 4.49 – RT-PCR analysis of EBER1 and EBER2 levels in Ad/AH-rEBV cells 
transiently transfected with an expression vector expressing a dominant negative (dn) 
EBNA1 (EBNA1 M1). A titration (from 1µg to 4µg) of dnEBNA1 is presented, along with a 
pSG5 control sample. RNA was harvested for analysis 24 hours post-transfection. GAPDH is 
included as an internal control. 
Figure 4.50 – RT-PCR analysis of EBER1 and EBER2 expression in Ad/AH-Puro-EBERs 
cells transiently transfected with 10ng pSG5-EBNA1, and increasing amounts of dnEBNA1-
M1 (ranging from 10ng to 50ng). RNA was harvested for analysis 24 hours post-transfection. 
GAPDH is included as an internal control. 
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EBER1 expression, and 2.6-fold in EBER2 expression, values which are consistent with the 
previously observed induction of EBER expression levels in response to EBNA1 (Figure 
4.38B). Upon co-expression of EBNA1 and dnEBNA1 in Ad/AH-Puro-EBERs cells, it was 
possible to titrate out induction of EBER expression by EBNA1 with dnEBNA1, as 
demonstrated in Figure 4.50. These studies, combined with the induction of EBER expression 
seen following transient EBNA1 expression in Ad/AH-Puro-EBERs cells, confirm the 
significant enhancing effect of EBNA1 upon EBER expression. 
4.2 Discussion 
It has long been established that high levels of EBER expression are a feature of cells latently 
infected with EBV and in cells of EBV-associated malignancies (Arrand and Rymo 1982). 
The findings presented here provide evidence that EBNA1 plays a significant role in the 
regulation of EBER expression in epithelial cells. EBNA1 was shown to enhance levels of 
EBER expression, seemingly through induction of EBER-associated cellular transcription 
factors, illustrating its importance in the characteristic abundant expression of EBERs that is 
associated with EBV latent infection. 
4.2.1 EBNA1 enhances cellular pol III transcription 
Initial data (Figure 4.8) confirmed previous findings (Felton-Edkins et al. 2006) that like 
several other oncogenic viruses, EBV was able to increase the level of cellular pol III 
transcription, and that this increase was seen in both lymphoid and epithelial cells infected 
with EBV. Qualitative and quantitative data presented in Figures 4.9 to 4.13 reveal that 
EBNA1 is able selectively to affect TFIIIC subunit expression in epithelial cells, and that this 
may, at least in part, be responsible for the increase in expression of endogenous pol III 
products that is induced by EBV. The DNA sequences recognised by TFIIIC are the A- and 
B-block internal promoter elements found in most pol III-transcribed genes, including tRNA 
238 
 
Chapter 4 
and EBER genes, (Schramm and Hernandez 2002) and therefore the findings that EBNA1 
induces TFIIIC and cellular pol III transcription are likely to be linked. The finding that 
EBNA1 induces TFIIIC is significant in the regulation of EBER expression, as in vitro 
transcription assays have revealed induction of EBER2 expression following the 
supplementation of cell fractions with TFIIIC, and ChIP assays have provided evidence that 
TFIIIC interacts with the EBER genes in vivo (Felton-Edkins et al. 2006). Elevation of 
TFIIIC expression following EBV infection has been identified as increasing occupancy of 
cellular target genes (Felton-Edkins et al. 2006), and the data presented in this chapter 
suggest a similar increase in occupancy of cellular target genes by TFIIIC would accompany 
the EBNA1-induced increase in TFIIIC expression.  
It should be noted that although the most compelling data presented in this chapter were 
obtained using Ad/AH-EBNA1 cells (which express very high levels of EBNA1), other 
Ad/AH-EBNA1 clones were analysed in parallel (data not shown). Other clones which 
expressed lower levels of EBNA1 (closer to observed physiological levels) showed similar 
levels of induction, confirming that the EBNA1 clone used was representative, and that the 
results obtained are not attributable to over-expression of EBNA1.   
mRNA levels of TFIIIB subunits TBP, Brf1 and Bdp1 were not consistently elevated in cell 
lines transfected with the EBNA1 expression vector (Figures 4.11 and 4.12). This finding was 
in contrast to in vivo studies conducted by co-workers  which found NPC biopsies 
consistently to overexpress the mRNAs encoding TBP and Bdp1 (Dr JR. Arrand, personal 
communication). Induction of Bdp1 may contribute substantially to the high rates of pol III 
transcription that are triggered by EBV (Felton-Edkins et al. 2006) and it would be valuable 
to determine the mechanism(s) responsible for the increase in TBP and Bdp1 expression 
observed in NPC tumours, especially given in vitro transcription data revealing induction of 
EBER2 expression following supplementation of cell fractions with TFIIIB (Felton-Edkins et 
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al. 2006). It is possible that TFIIIB subunits are basally overexpressed in the cell lines that 
were examined, or that post-transcriptional regulation by EBNA1 occurs, which would 
explain the lack of induction of TFIIIB mRNAs seen in EBNA1-expressing cells. 
Alternatively, another EBV latent gene product may be responsible for the induction 
observed in vivo.  
It is noticeable that although levels of TFIIIB subunit protein Bdp1have previously been 
demonstrated to be induced following EBV infection, no consistent increase in TFIIIB 
subunit mRNA was reported (Felton-Edkins et al. 2006). It would therefore be interesting to 
examine protein levels of TFIIIB subunits in EBNA1-expressing cells, and such studies were 
attempted in this project. However the antibodies utilised in immunoblot analysis were not 
sufficiently sensitive to detect adequate protein levels in cell lysates tested.  
The significance of increased levels of cellular pol III transcription is not restricted to 
increased levels of viral transcripts such as the EBERs. It is well-established that pol III 
transcription is often deregulated in a wide range of malignant tumours and transformed cells 
(Chen et al. 1997; White 2005; Marshall et al. 2008; White 2008) and data suggest that 
increased pol III transcription is capable of promoting proliferation and oncogenic 
transformation in some cellular contexts (Johnson et al. 2008). In support of these findings, 
co-worker-conducted in vivo studies revealed induction of pol III specific transcription 
factors TFIIIB and TFIIIC at both the mRNA and protein level in NPC tumours (Dr JR. 
Arrand, personal communication). Given data revealing induction of TFIIIC subunits in 
EBNA1-expressing epithelial cells, and the association between EBV and NPC, it is tempting 
to speculate that increased TFIIIC subunit levels in NPC tumour cells could be mediated, in 
part, by EBNA1.  
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Following epithelial cell-based in vitro data presented here, and in vivo data derived by co-
workers from epithelial cell carcinomas (Dr JR. Arrand, personal communication) it would be 
valuable to assess TFIIIC and TFIIIB levels, along with levels of pol III transcription in 
EBNA1-expressing lymphoid cell lines, and to examine levels of pol III-specific transcription 
factors in EBV-associated lymphomas. This analysis would reveal whether the results 
reported here, obtained in an epithelial cell background, are applicable to a broader range of 
cell types. Such a finding would be consistent with data showing increased cellular pol III 
transcription in EBV-positive Akata BL cells (when compared with their EBV-loss 
counterparts), which express a small complement of viral latent gene products, including 
EBNA1 (Figure 4.8 and Felton-Edkins et al. (2006)).  
It may also prove valuable to assess the levels of the recently identified 35kd (Dumay-Odelot 
et al. 2007) subunit of TFIIIC in both EBV-infected and EBNA1-expressing epithelial and 
lymphoid cell lines.  
4.2.2 EBNA1 influences typical pol II EBER-associated transcription factors ATF-2 and c-
Myc 
4.2.2.1 ATF-2 
ATF-2 has been shown previously to be important for EBER expression, with deletion or 
mutation of the ATF-2 binding site upstream of EBER genes significantly impairing EBER 
expression (Howe and Shu 1989; 1993; Wensing et al. 2001). In agreement with such data, 
experiments using shRNA to ATF-2 (Figures 4.19 and 4.20) revealed levels of both EBER1 
and EBER2 were substantially reduced following knock-down of ATF-2 using shRNA. 
These experiments were novel in their reduction of ATF-2 levels directly, rather than ablation 
of binding sites upstream of EBER genes before subsequent analysis of EBER expression. 
Additionally, ATF-2 has previously been demonstrated, through the use of ChIP assays, to 
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associate with EBER promoter regions and the promoter region of TFIIIC-220 (binding the 
CRE motifs) (Felton-Edkins et al. 2006), and in combination with data presented in this 
chapter and other published data, conclusive evidence exists for the importance of ATF-2 in 
the regulation of EBER expression. 
Several previous studies have shown EBV-mediated regulation of ATF-2, though they 
conflict in their descriptions of the precise effect of EBV on ATF-2. Initial studies revealed 
that EBV triggers hyperphosphorylation of ATF-2 leading to increased activity (Kieser et al. 
1997; Eliopoulos and Young 1998; Roberts and Cooper 1998; Adamson et al. 2000; Young 
and Rickinson 2004) with increased levels of mono-phosphorylated ATF-2 being observed in 
the absence of any increase in total levels of ATF-2. Recently published data were at odds 
with such observations, demonstrating  that EBNA1 can induce an increase in total levels of 
ATF-2 (O'Neil et al. 2008). Data presented here support these recent data, with levels of 
ATF-2 mRNA shown to be increased in EBNA1-expressing Ad/AH, AGS and Hone-1 cells 
(Figure 4.15) and levels of total ATF-2 protein being induced in Ad/AH-EBNA1 and AGS-
EBNA1 cells (Figure 4.16). Additionally, in Ad/AH-EBNA1 cells, increased levels of mono- 
and dual-phosphorylated ATF-2 were observed (Figures 4.17 and 4.18) along with increased 
levels of nuclear ATF-2 (Figure 4.21). These data suggest that EBNA1 acts to increase EBER 
expression both through induction of ATF-2 transcription and the resultant increase in levels 
of dual-phosphorylated and activated ATF-2. Further, RT-qPCR data (Figure 4.12) reveal 
statistically significant increases in levels of TFIIIC220 mRNA expression in EBNA1-
expressing Ad/AH, AGS and Hone-1 cells. This induction may be, at least in part, ATF-2-
mediated given the induction of ATF-2 in EBNA1-expressing cells, and previously published 
ChIP data demonstrating an association between ATF-2 and the TFIIIC220 promoter region 
(Felton-Edkins et al. 2006).  
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That EBNA1 alone is capable of inducing an increase in total- and activated-ATF-2 stands 
out as a novel and important finding, not only in terms of enhancing EBER expression, but 
also given the various significant roles ATF-2 is known to play in an assortment of cellular 
processes (Bhoumik and Ronai 2008).  
4.2.2.2 c-Myc 
The importance of c-Myc to expression of both EBER1 and EBER2 was examined in this 
chapter through a series of experiments involving the use of the inducible c-MycER fusion 
protein, and shRNA to c-Myc in established cell systems, and newly established EBER-
expressing cell systems. 
c-Myc directly interacts with EBER genes, through binding to E-Boxes upstream of EBER1 
(Niller et al. 2003), and through its interaction with TFIIIB c-Myc can directly activate many 
pol III-transcribed genes (Gomez-Roman et al. 2003). This is consistent with the observed 
decrease in tRNA expression that accompanies c-Myc RNAi (Figure 4.33). However, EBER2 
appears to be an exception, as in contrast to EBER1, EBER2 shows little response to RNAi or 
overexpression of c-Myc, in Ad/AH cells (Figures 4.33 and 4.38). This may reflect the 
unusual promoter arrangement and factor requirements of EBER genes, which differ from 
most cellular pol III promoters (Felton-Edkins et al. 2006). By excising the short region 
upstream of EBER1 containing the E-boxes to which c-Myc has been demonstrated to bind 
(Niller et al. 2003), this study reveals that these E-Boxes are required for induction of EBER1 
by activated c-MycER (Figures 4.47 and 4.48). This contrasts with a previous report that this 
upstream region has little importance for EBER1 expression in 293 cells (Wensing et al. 
2001).  Differences between cell types may be responsible for the discrepancy. The data 
presented in this study suggest that the EBER genes show differential responsiveness to c-
Myc due to E-box DNA motifs upstream of the EBER1 promoter.  
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Despite the demonstrated importance of the E-boxes for induction of EBER1 expression 
through the functional induction of the c-MycER fusion protein, this region was dispensable 
for induction of EBER expression by transient expression of EBNA1 (Figure 4.46). Further, 
basal levels of EBER expression in Ad/AH-Puro-EBERs, Ad/AH-neo-c-MycER-Puro-
EBERs-ΔX and Ad/AH-Puro-EBERs-ΔX cell lines were roughly equivalent, again 
suggesting perhaps that although the E-boxes are critical in terms of c-Myc regulation of 
EBER expression, in the absence of such a regulatory mechanism other compensating 
mechanisms are present to allow high levels of EBER expression. 
In addition to confirming the significance of c-Myc in the regulation of EBER expression, c-
Myc levels and activity were analysed in EBNA1-expressing epithelial cells, to examine if 
EBNA1 exerted an effect on EBER expression through c-Myc. Consistent with previously 
published Affymetrix array data (Wood et al. 2007), induction of the levels of mRNA 
encoding c-Myc was observed in Ad/AH-EBNA1 cells (Figure 4.22). Growth regulated 
accumulation of c-myc mRNA has been widely reported previously (Kelly et al. 1983; 
Luscher and Eisenman 1990) however this mRNA induction was not observed in other 
EBNA1-expressing epithelial cells analysed. Further, levels of c-Myc and c-MycER protein 
were substantially reduced in EBNA1-expressing Ad/AH cells (Figures 4.23 and 4.27). This 
observation was in direct contrast to c-Myc protein levels reported in cells expressing LANA 
(KSHV’s EBNA1 homologue), where stabilisation and activation of c-Myc is observed 
(Bubman et al. 2007; Liu et al. 2007).  
Despite the observed reduction in levels of c-Myc protein, and no apparent change in the 
intracellular localisation of c-Myc (Figure 4.25), luciferase reporter assays revealed increased 
transcriptional activation activity of endogenous c-Myc and c-MycER in Ad/AH-EBNA1 
cells (Figures 4.24 and 4.27). Although it is unclear how EBNA1 may mediate this induction 
of c-Myc activity, these data suggest that EBNA1 may influence c-Myc transcription – a 
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finding which as well as impacting upon EBER expression (in particular EBER1), could have 
a global impact upon cellular gene expression, given that c-Myc has been shown to be 
involved in the regulation of 15% of all cellular genes (Dang et al. 2006). Deregulation of c-
Myc is also a common feature of a wide range of cancers, with up to 70% of human cancers 
showing deregulated expression of c-Myc (Kuttler and Mai 2006). c-Myc impacts upon a 
diverse range of pathways contributing to tumourigenesis  (for a comprehensive review of c-
Myc’s cellular impact, see (Meyer and Penn 2008), and therefore by extrapolation, EBNA1 
may play some part in c-Myc–mediated cellular changes. In addition to increased 
transcriptional activity of c-Myc in EBNA1-expressing cells having an impact upon cellular 
events, it should not be discounted that reduced levels of c-Myc in these cells may play a role 
in regulating cellular events dependent on protein:protein interactions between c-Myc and 
other crucial cellular factors. 
Preliminary studies were conducted in an attempt to explain the reduced levels of c-Myc 
observed in EBNA1-expressing cells. Precise cellular regulation of c-Myc is crucial, with 
levels of c-Myc determining, at least in part, rates of cellular proliferation and differentiation. 
c-Myc has a short half-life of around 30 minutes (Hann and Eisenman 1984; Ramsay et al. 
1986), allowing precise control of protein levels. Two key phosphorylation events regulate c-
Myc stability: Ser62 is phosphorylated by extracellular-regulated kinase 1,2 (ERK), which 
stabilises c-Myc (Pulverer et al. 1994; Sears et al. 2000), and phosphorylation of Thr58 by 
GSK3 (an event dependent on prior phosphorylation of Ser62) promotes c-Myc degradation 
through the ubiquitin/proteosome pathway (Sears et al. 2000; Gregory et al. 2003). ERK and 
p-ERK levels were assessed both basally and following stimulation across an Ad/AH cell 
panel. Analysis was conducted post-stimulation due to very low levels of detectable p-ERK 
in unstimulated cells. Significantly reduced levels of p-ERK were seen in EBNA1-expressing 
cells following all cell stimulations, suggesting that decreased amounts of stabilised c-Myc 
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(phosphorylated at Ser62) may be present in EBNA1-expressing cells. Levels of total and 
phosphorylated (inactivated) GSK3β were also assessed. Total levels of GSK3β were 
increased in EBNA1-expressing cells. However, given the greater increase of the 
phosphorylated (inactivated) form of the protein (p-GSK3β) in these cells, it would seem that 
less phosphorylation at c-Myc Thr58 may occur in EBNA1-expressing cells. Such a 
reduction would result in a reduction of ubiquitin-mediated proteosomal degradation of c-
Myc. Therefore, the reduced levels of c-Myc are seemingly not due to decreased protein 
stability in EBNA1-expressing cells, and initial protein half-life experiments seem to confirm 
this finding (Figure 4.31). However, this analysis is an indirect examination of the 
phosphorylation status of c-Myc in EBNA1-expressing cells, and it would be valuable to 
analyse levels of p-Ser62- and p-Thr58-c-Myc, especially in light of evidence that the KSHV 
encoded homologue of EBNA1, LANA, can act to regulate c-Myc stability (Bubman et al. 
2007; Liu et al. 2007). In LANA-expressing cells, inactivation of nuclear GSK-3 was shown 
to reduce phosphorylation of c-Myc at Thr58, contributing to c-Myc stabilisation by 
decreasing c-Myc ubiquitination. Further,  LANA was demonstrated to increase the levels of 
p-ERK and ERK phosphorylation of c-Myc on Ser62 (Liu et al. 2007). 
Data presented in this chapter fail to provide elucidation of the mechanisms by which c-Myc 
protein levels are reduced in EBNA1-expressing Ad/AH cells. The reduction in protein level 
is observed despite an induction of c-Myc mRNA and no discernable negative influence upon 
protein stability. Despite the reduction in levels of c-Myc protein, transcriptional activity of 
c-Myc in Ad/AH-EBNA1 cells was increased. This increase is not explained by increased 
nuclear localisation of c-Myc, or increased levels of p-ERK which phosphorylates on c-Myc 
Ser62, a modification known to increase c-Myc transcriptional activity (Liu et al. 2007).  
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E-box binding (and transcriptional activation of reporter constructs) of c-Myc is dependent 
upon formation of dimers with co-factor Max (Dang 1999; Grandori et al. 2000). Max is 
ubiquitously and constitutively expressed in cells, but is also able to form dimers with 
cellular transcription factor Mad, and these heterodimers are able to form transcriptional 
repressors on the same E-box sequence elements, antagonising c-Myc function (Foley and 
Eisenman 1999). Both c-Myc and Mad expression is tightly regulated in relation to cell 
growth. c-Myc levels are high in cells with progressive cell cycles, but decrease as cells cease 
to proliferate and differentiate. Conversely Mad expression follows the opposite pattern, 
allowing precise regulation of levels of c-Myc/Max and Mad/Max heterodimers (Sears et al. 
2000). Analysis of Max and Mad levels in EBNA1-expressing cells may prove crucial in 
determining mechanisms by which c-Myc transcription is elevated in EBNA1-expressing 
cells. Given the cellular importance of the fine balance of c-Myc levels and activity, it is no 
surprise that c-Myc regulation in EBNA1-expressing cells is complex.  EBNA1 may be 
acting to increase levels and activity of c-Myc, possibly to increase levels of EBER 
expression, but changes in other cellular factors may be resulting in the discrepancies 
observed in the data. Such changes may be necessary in order to maintain the balance of 
levels and activity of this crucial cellular protein. 
 
4.2.3 EBNA1 increases EBER expression 
Experiments with cells expressing the pUC19-Puro-EBERs vector constitute an important 
part of the analysis of EBNA1’s effect on EBER expression. It should be acknowledged that 
as the EBER genes in this vector lie downstream of the Puromycin resistance cassette and are 
transcribed in the same direction, it is possible that pol II transcripts could run through the 
EBER gene resulting in a long polycistronic RNA that would be detected by the PCR assay 
used for the EBERs. To ensure this does not occur, future analysis of this vector should 
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include PCR analysis using a forward primer designed in the Puromycin resistance cassette 
region in combination with the EBER1 reverse primer. A lack of product would demonstrate 
that no long, polycistronic RNA was produced, indicating that the EBERs were indeed being 
transcribed from their native promoters. 
Although the data indicate that EBNA1, through a variety of mechanisms can induce EBER 
expression (Figure 4.38), the levels of expression in this model system are low when 
compared with those in Ad/AH cells stably infected with EBV (Figure 4.39). This may be 
attributable to the EBER expression plasmids in the model system being maintained in an 
integrated form. In this context it is notable that the Namalwa cell line, in which EBV is 
known to be integrated at low copy number (Henderson et al. 1983), also expresses the 
EBERs at low levels (Arrand and Rymo 1982; Arrand 2000), similar to those seen in this 
model system (Figure 4.39). In the context of whole virus infection, the EBV genome is 
usually maintained as a multi-copy episome. In this scenario, transcription factor binding 
access and kinetics may be very different, given that the EBER genes are adjacent to OriP, 
within the region of unusual chromatin structure (Wensing et al. 2001). The OriP region 
(absent from the Ad/AH-Puro-EBERs cell line) is also known to be a transcriptional enhancer 
region (Sugden and Warren 1989; Gahn and Sugden 1995) and has been previously 
demonstrated to increase EBER expression by 2- to 4-fold (Wensing et al. 2001). The number 
of copies of the EBER genes integrated into the Ad/AH-Puro-EBERs cell line generated is 
unknown, though it is unlikely to reach the number of viral episomes carried by EBV-
infected Ad/AH cells.  
Further, it is of note that EBNA1 does not seem to be sufficient to induce TFIIIB subunit 
expression and it is anticipated that pol III-transcribed genes (such as the EBERs) would be 
even more highly expressed in cells in which TFIIIB was induced in addition to TFIIIC, an 
environment which is observed in EBV-infected cells (Felton-Edkins et al. 2006). 
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Previous data have demonstrated that use of a dominant negative EBNA1 in LCLs carrying 
an integrated EBV genome led to little or no effect on cellular gene expression, or indeed 
gene expression from the integrated viral genome, with exception of a slight negative effect 
upon EBER expression (Kang et al. 2001). Such reports are in agreement with data presented 
in this study, with EBNA1 being able to have only a modest impact upon EBER expression 
where EBER genes are present in an integrated form. 
Upon expressing a dominant negative EBNA1 in Ad/AH-rEBV cells, known to carry 
multiple EBV episomes, levels of EBER expression were robustly reduced (Figure 4.49). 
These experiments provide necessary converse data to complement experiments where 
EBNA1 was transiently supplied in trans, and further confirm the importance of EBNA1 in 
the mediation of EBER expression. 
The data presented in this chapter provide compelling and extensive evidence that EBNA1 is 
capable of inducing EBER expression in epithelial cells through the induction of multiple 
cellular EBER-associated transcription factors, typical of factors involved in both pol II and 
pol III transcription. Cell systems have been developed allowing the examination of the effect 
of a trans-supplied EBNA1 upon EBER expression, and extensive studies demonstrate the 
significance of the typical pol II transcription factors in the mediation of EBER expression. 
The importance of the results presented stretches beyond the goals of this project, as the 
transcription factors shown to be induced in EBNA1-expressing epithelial cells are known to 
be important in a cellular context, with deregulation of nearly all transcription factors 
discussed here having a known involvement in cellular proliferation and oncogenesis.  
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Chapter 5 – EBNA1 promoter binding studies 
 
Every biological process relies upon the coordinated expression of genes, the products of 
which act cooperatively to mediate cellular function. Therefore, understanding the processes 
underpinning the control of cellular gene expression is essential to the comprehension of 
development and disease processes. Transcriptional regulation in higher eukaryotes is 
complex, and this is exemplified by the large number of proteins which control gene 
expression; there are more than 3,000  human transcription factors, a figure which represents 
approximately 10% of all human genes (Babu et al. 2004). Further, vast areas of the genome 
participate in transcription by acting as scaffolds on which regulatory complexes are able to 
assemble (Carroll et al. 2006). 
In addition to cellular transcription factors, many virus-encoded proteins act to influence 
cellular gene expression through direct or indirect interaction with cellular promoter regions. 
Several oncogenic viruses have been shown to influence cellular transcription by such 
mechanisms, with the subsequent changes in cellular transcription contributing to the 
pathogenesis of the virus.  
A recent study has identified deregulated direct targets of the HBV X protein, with 184 gene-
targets shown to be directly deregulated (Sung et al. 2009). The roles of these target genes, 
and their relevance in cancer, was inferred through microarray database analysis, with six 
cellular pathways predicted to be significantly deregulated following HBV X protein binding 
to target-gene promoters.  
HPV protein E2 binds to chromatin in association with the cellular bromodomain protein 
Brd4, with this interaction having been shown to be important for the transcriptional function 
of all papillomaviruses (Ilves et al. 2006; McPhillips et al. 2006; Schweiger et al. 2006). 
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Further, a study has demonstrated that a portion of bovine papillomavirus-1 E2 is bound to 
transcriptionally active chromatin (Kurg et al. 2005), with a more recent report finding that 
the E2 proteins bind to the chromatin of all active promoters, in association with the cellular 
Brd4 protein (Jang et al. 2009). However, the authors report that the association does not 
affect the transcriptional activity of these promoters and postulate that E2 associates with 
these regions in order to tether and maintain the viral genome in functionally active regions 
of the nucleus.  
The adenovirus E1A protein has evolved to interact with key cellular transcription regulators 
and promoters to control cell cycle progression, cell differentiation and chromatin 
remodelling (Green et al. 2008), although there is a limited understanding of the molecular 
mechanisms and the precise roles of cellular regulatory factors involved in such viral 
processes. E1A is thought to repress cellular gene expression through interaction with two 
important cellular proteins: TATA-binding protein (TBP) and the multifunctional co-
activator and histone acetyltransferase p300. E1A accesses transcriptional co-activators such 
as p300 on specific promoters before interacting with TBP to disrupt the TBP–TATA 
complex (Boyd et al. 2002; Green et al. 2008). In support of this, a basal core promoter 
activated by tethering p300 is repressible by E1A at the promoter level (Green et al. 2008). 
HTLV-1 protein HBZ been shown to interact with other bZIP proteins, including the AP-1 
transcription factors, resulting in the modulation of their transcriptional activity (Basbous et 
al. 2003; Thebault et al. 2004; Matsumoto et al. 2005). Further, HBZ in association with 
JunD has been shown to activate the hTERT promoter and HBZ and JunD have been 
demonstrated to coexist in the same DNA-protein complex at the proximal region of hTERT 
promoter (Kuhlmann et al. 2007). 
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Several members of the EBV latent protein complement are able to alter cellular 
transcription, as outlined in the introductory section of this thesis. Notably, EBNA2 and 
EBNA3C are known to regulate viral and cellular promoters through interactions with 
cellular transcription factors (Knight et al. 2003; Palermo et al. 2008), with EBNA1 also 
having been identified as binding to promoter regions of cellular genomic DNA in EBV-
positive B-cells (Dresang et al. 2009). As EBNA1 is known to possess DNA-binding, 
protein-protein binding, and transcriptional activation activity, these findings seemingly have 
a broad cellular significance. Given the transcriptional induction of several EBER-associated 
cellular transcription factors described in Chapter 4, it was postulated that EBNA1 may be 
acting to induce cellular factors involved in EBER transcription through association with 
their promoter regions, most likely indirectly through cooperation with cellular transcription 
factors. In order to pursue this further, promoter binding experiments were performed, and 
form the basis this chapter.    
The promoter binding field of study has developed into a widely used and rapidly changing 
area of transcription biology over recent years. Considerable effort has been made to identify 
cellular transcriptional networks and to map the regions of the genome that participate in the 
control of gene expression, with an accompanying evolution of experimental techniques that 
allow analysis of cellular transcription and promoter binding. Initial efforts to unravel the 
complex nature of regulation of cellular transcription utilised nuclease protection assays, and 
in vitro DNA-binding and reporter assays, with these methodologies allowing the 
identification of regulatory elements proximal to candidate genes and identification of direct 
targets of candidate transcription factors (Massie and Mills 2008). However, in vitro 
approaches to identify transcription factor-binding sites in the genome are hampered by both 
false negatives and false positives. The in vivo appearance of binding sites is further 
controlled by the packaging of genomic DNA in chromatin, which may mask some consensus 
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binding sites and reveal others. Therefore, alternative approaches were required to map which 
sites in cellular genomic DNA transcription factors are able to bind in vivo. Chromatin 
immunoprecipitation (ChIP) enables in vivo direct and indirect binding sites for specific 
transcription factors to be identified in the context of chromatin, therefore avoiding many of 
the problems associated with in vitro approaches (Solomon et al. 1988; Orlando and Paro 
1993). ChIP can be used to investigate any target on chromatin against which it is possible to 
raise an antibody. Consequently, it has been successfully and widely utilised in the 
identification of regions of genomic DNA which associate with specific cellular transcription 
factors, cofactors, histone modifications and DNA methylation (Solomon et al. 1988; Orlando 
and Paro 1993; Weber et al. 2005). Importantly, ChIP has also been utilised in identifying the 
interaction of viral proteins with regions of cellular genomic DNA (Kuhlmann et al. 2007; 
Green et al. 2008; Jang et al. 2009; Sung et al. 2009).  
ChIP was employed in this chapter to elucidate if EBNA1 was associated with the promoter 
region DNA of some EBER-associated cellular genes (typical of pol II transcription factors) 
which had been identified as being induced by EBNA1 in the previous chapter. In addition, 
ChIP analysis was used to demonstrate an EBNA1 association with the promoter regions of 
AP-1 transcription factors, which have previously been demonstrated to be induced at mRNA 
and functional levels in EBNA1-expressing epithelial cells (O'Neil et al. 2008).  In addition, 
non-antibody based ChIP-like promoter binding (HaloCHIP) assays were used to establish 
which domains of EBNA1 may be responsible for any identified interactions with promoter 
region DNA, and to facilitate the expansion of ChIP-based promoter binding studies to an 
increased number of cellular targets, and a variety of epithelial cell lines. Further, in silico 
analysis of the promoter region DNA of transcriptionally induced genes was conducted, in 
parallel with in vitro studies of protein-protein interactions between EBNA1 and cellular 
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transcription factors, in an effort to establish the direct or indirect interaction of EBNA1 with 
promoter region DNA.  
5.1 Results 
5.1.1 Chromatin immunoprecipitation analysis of EBNA1 promoter binding 
5.1.1.1 Validation of experimental conditions and PCR primers 
To ensure specificity of downstream ChIP experimental analysis, sonication of genomic 
DNA into fragments of between 200bp and 1000bp was necessary. Figure 5.1 demonstrates 
that nine pulses of 10 seconds were sufficient to shear the majority of genomic DNA into 
fragments of the required size for downstream analysis, when using cell lysates of cell type 
and density used in subsequent ChIP experiments. It is notable that no smear of sheared DNA 
is observed in the absence of sonication, demonstrating a lack of DNA fragmentation prior to 
sonication. Cell lines used in ChIP experiments were screened by immunofluorescence 
staining for EBNA1 expression status (Figure 5.2) before experimental procedures were 
conducted. 
To enable analysis of DNA associated with EBNA1, it was first necessary to ensure 
successful precipitation of EBNA1 protein with a specific antibody. Figure 5.3 shows 
immunoblotting for EBNA1, demonstrating that EBNA1 is specifically pulled down by the 
EBNA1 antibody chEBNA1, and not by an isotype control antibody (E-Cadherin).  
Primers for the promoter regions of proposed EBNA1 target genes were designed using 
information from literature searches and online promoter databases, with all primer sets 
designed within 500bp of transcriptional start sites. Primers for the promoter region DNA of 
c-myc, ATF-2 (EBER-associated transcription factors) and c-jun (along with ATF-2, an AP-1 
subunit upregulated in EBNA1-expressing cells), as well as primers for the EBV dyad- 
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Figure 5.1 – UV transilluminator image of  an ethidium bromide stained agarose gel showing 
validation of sonication conditions for ChIP assays. 600µl of cross-linked Ad/AH-rEBV cell 
lysate (1 x 107 cells) was sonicated for an increasing number of 10 second pulses, with the 
sample kept on ice throughout and 30 second pauses between pulses. 20µl of sample was 
removed after each pulse, mixed with loading dye and subjected to gel electrophoresis. DNA 
size markers are loaded on the right-hand side of the gel, with the numbers at the top of the 
figure indicative of the number of 10 second pulses of sonication each sample was subjected 
to.   
Figure 5.2 – Immunofluorescence staining for EBNA1 (R4 antibody) in Ad/AH (A), Ad/AH-
rEBV (B), Ad/AH-neo (C) and Ad/AH-EBNA1 (D) cells.  Images presented are at 400X 
magnification and the marker bar represents 10µM.  
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Figures 5.1 and 5.2 
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Figure 5.3 – Immunoblotting for EBNA1 following immunoprecipitation of Ad/AH-rEBV 
and -EBNA1 cell lysates with chEBNA1 antibody, or isotype control antibody E-Cadherin 
(E-Cad). Also included are cell lysates as positive controls, and input samples (5% of total 
sample), taken following pre-clearing of lysates.  
Figure 5.4 – Validation of PCR primers designed for promoter regions of c-myc (A), ATF-2 
(B), and c-jun (B). PCR primers designed for the EBV DS region are also validated (B). 50ng 
of Ad/AH-rEBV DNA was used per reaction as a template.  
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Figures 5.3 and 5.4 
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symmetry repeat (EBV DS) region (EBV genomic DNA, from the OriP region, constitutively 
bound directly by EBNA1), were optimised for annealing temperature (Figure 5.4A) and 
cycle number using Ad/AH-rEBV genomic DNA as template. Optimal conditions are defined 
as those that produce clean bands following agarose gel electrophoresis (Figure 5.4). Primers 
for the promoter region of GAPDH (negative control) were provided in the commercial ChIP 
kit used and did not require validation. 
5.1.1.2 PCR analysis of ChIP DNA 
Initial analysis of DNA from ChIP experiments was PCR based. GAPDH promoter DNA was 
successfully precipitated (Figure 5.5A) by an α-Histone antibody (positive control), 
demonstrating application of optimal ChIP experimental conditions. In the absence of 
EBNA1 (in Ad/AH and Ad/AH-neo lineages), analysis of chEBNA1 ChIP samples revealed 
no enrichment (relative to isotype control samples) for any promoter region DNA that was 
analysed (Figure 5.5B), demonstrating that the chEBNA1 antibody was not sufficient for 
promoter region DNA precipitation in the absence of EBNA1. Contrastingly, in Ad/AH-
rEBV and Ad/AH-EBNA1 cells, enrichment was observed in some cases for c-jun, ATF-2 
and c-myc promoter DNA in chEBNA1 samples, when compared with isotype control 
samples (Figure 5.5B). These data suggest that EBNA1 was associated with the promoter 
region DNA of these genes at the point of formaldehyde cross-linking. GAPDH promoter 
region DNA, in this instance serving as a negative control, was not enriched in the same 
experimental samples, demonstrating specificity of promoter DNA enrichment. EBV DS 
DNA levels were assessed for each sample (Figure 5.5B), with EBV DS DNA found to be 
present only in Ad/AH-rEBV samples (as expected). In these samples, a clear enrichment of 
EBV DS DNA was seen in chEBNA1 samples, acting as a specific positive control for the 
chEBNA1 antibody, as EBNA1 is known to bind directly to EBV DS DNA in vivo (Reisman 
et al. 1985; Gahn and Schildkraut 1989; Wysokenski and Yates 1989; Niller et al. 1995).  
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Figure 5.5A - PCR analysis of GAPDH promoter DNA performed on chromatin 
immunoprecipitated DNA from Ad/AH-rEBV cross-linked cell lysate. Rabbit IgG (negative 
control) and an α-Histone antibody (positive control) were used in the immunoprecipitation. 
Input represents 5% sample taken after pre-clearing and immediately prior to 
immunoprecipitation.  
Figure 5.5B – PCR analysis of GAPDH promoter, c-jun promoter, ATF-2 promoter, c-myc 
promoter and EBV DS DNA performed on chromatin immunoprecipitated DNA from 
Ad/AH, Ad/AH-rEBV, Ad/AH-neo and Ad/AH-EBNA1 cross-linked cell lysates. E-
Cadherin (E-Cad, isotype control) and chEBNA1 antibodies were used in the 
immunoprecipitation. Input represents 5% sample taken after pre-clearing and immediately 
prior to immunoprecipitation. 
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5.1.1.3 qPCR analysis of ChIP DNA 
To allow accurate quantification of these data and to establish the statistical significance of 
the results, qPCR analysis of immunoprecipitated DNA was undertaken. qPCR primer/probe 
sets were designed in the same regions as PCR primer sets, with probe concentration for each 
primer probe set optimised for a five-fold increase in DNA concentration, as shown in Figure 
5.6. To achieve this optimisation, Ad/AH-rEBV DNA was diluted to concentrations of 1ng/µl 
and 5ng/µl, with 5µl of each these diluted DNA solutions being used in experimental 
analysis. The amount of promoter region-specific probe was varied (constant primer 
concentration) and the fold change between samples of 5ng and 25ng DNA was determined 
(Figure 5.6). Probe concentrations that resulted in the most accurate fold change were 
subsequently utilised. Where large fluctuations in experimentally determined fold change 
were observed, the selected probe concentration was further tested to ensure reliability before 
use in analysis of ChIP samples.   
Analysis of EBV DS DNA (Figure 5.7A) revealed an approximately 15-fold enrichment of 
DNA from isotype control to chEBNA1 samples, with EBV DS DNA being detectable only 
in Ad/AH-rEBV cells. No significant enrichment of GAPDH promoter DNA (from isotype 
control to chEBNA1 samples) was observed in any of the Ad/AH cell lines (Figure 5.7), 
these data again serving as an adequate negative control, demonstrating the specificity of the 
enrichment of promoter region DNA. Levels of enrichment for the promoter regions of 
EBER-associated transcription factors c-myc and ATF-2 were significantly increased 
(statistically) in Ad/AH-EBNA1 samples, compared with Ad/AH-neo samples (Figure 5.7B). 
ATF-2 promoter DNA was enriched by 7.5 fold, with c-myc promoter DNA enriched by 2.5 
fold in Ad/AH-EBNA1 chEBNA1 samples. Given the transcriptional upregulation of these 
genes in EBNA1-expressing cells (as reported in Chapter 4), these data appear significant in 
explaining EBNA1’s mechanism of EBER induction.   
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Figure 5.6 – qPCR analysis used in the optimisation of the concentration of qPCR probe to 
be used in subsequent experimental qPCR analysis of promoter regions of GAPDH, c-jun, 
junB, junD, c-fos, fosB, fra1, fra2 and ATF-2. The optimisation of the primer probe set for 
EBV DS repeat is also shown. Data are presented as calculated fold change from 5ng DNA 
samples, to 25ng DNA samples. Samples were analysed in technical triplicate, with error bars 
being representative of standard deviation between replicates. Also included for comparison 
is a bar illustrating an exact five-fold change. 
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Figure 5.6 contd 
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Figure 5.7 – qPCR analysis performed on chromatin immunoprecipitated DNA from (A) 
Ad/AH and Ad/AH-rEBV cross-linked cell lysates and , (B and C) Ad/AH-neo and Ad/AH-
EBNA1 cross-linked cell lysates: (A) Analysis of EBV DS, and GAPDH promoter DNA; (B) 
Analysis of GAPDH, c-myc and ATF-2 promoter DNA; (C) Analysis of GAPDH promoter 
DNA, and promoter DNA of AP-1 subunits c-jun, junB, junD, c-fos, fosB, fra1, fra2 and 
ATF-2. Results represent qPCR values obtained from cross-linked genomic DNA 
immunoprecipitated using an EBNA1-specific antibody (chEBNA1) normalised to values 
obtained using an isotype control antibody (E-Cadherin). All experiments were conducted in 
biological and technical triplicate, with average values presented. Error bars are 
representative of standard deviation of biological replicates. Asterisks indicate that results 
differ significantly from the control: *, P≤0.05; **≤ P,0.01. 
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Figure 5.7 
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In addition to promoter regions for which PCR analysis was carried out, qPCR analysis of the 
promoter region DNA of ATF-2 and c-jun’s fellow AP-1 family member subunits was 
conducted (Figure 5.7C). This analysis, although not connected with EBNA1’s effect upon 
EBER expression, was conducted following data being generated that revealed EBNA1 to 
induce AP-1 activity in NPC cells (O'Neil et al. 2008). Promoter region DNA of several AP-1 
family subunit members was enriched in chEBNA1 samples (Figure 5.7C). However, the 
only statistically significant enrichments (in Ad/AH-EBNA1 samples compared with Ad/AH-
neo samples) for ATF-2 (7.5-fold enrichment) and c-jun (5-fold enrichment) promoter region 
DNA.  
5.1.2 HaloCHIP analysis of EBNA1 promoter binding 
For analysis of the domain of EBNA1 responsible for promoter binding, antibody-based 
methods were deemed undesirable, due to the changes in antibody affinity for EBNA1 
mutants lacking individual or multiple domains. To overcome this problem, vectors encoding 
EBNA1 mutants fused to a tag (HaloTag, from Promega UK) were generated, enabling the 
pull-down of these fusion proteins, in a covalent, non-antibody specific manner. Following 
the generation of the panel of expression vectors encoding these Halo-EBNA1 mutants using 
molecular biology techniques, HaloCHIP experiments were conducted following transient 
expression of the mutant fusion proteins. The transient, non-antibody-dependent nature of 
these experiments also afforded expansion of promoter binding studies to multiple cell lines, 
and the analysis of a larger variety of promoter region DNA targets. 
5.1.2.1 Construction of Halo-EBNA1 mutant expression vectors 
A panel of EBNA1 mutant expression vectors was obtained. Each EBNA1 mutant (ΔGly/Ala, 
Δ8-67, Δ61-83, Δ395-450, Δ41-376, Δ325-376) maintained on a lentivirus backbone. 
Functional details of each mutant are briefly outlined, having been more fully explained 
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previously in this thesis (Section 1.77): ΔGly/Ala-EBNA1 was used as a pseudo-wild type 
version of the protein, with only Gly/Ala repeats deleted. Studies have shown lack of Gly/Ala 
repeats does not affect EBNA1 DNA segregation, replication or transcriptional activation 
activities (Yates et al. 1985). The 325–376 region of EBNA1 mediates the interaction of 
EBNA1 with cellular chromatin and is necessary for the transcriptional activation function of 
EBNA1 (Kirchmaier and Sugden 1997; Shire et al. 1999; Ceccarelli and Frappier 2000; Wu 
et al. 2000; Wu et al. 2002). Δ395–450 mutation leaves an EBNA1 protein that is fully 
functional for all of the known functions of EBNA1 (replication, segregation and 
transcriptional activation), but which fails to bind the cellular USP7 protein (Holowaty et al. 
2003). EBNA1 amino acids 8-67 have previously been shown to contribute to, though are not 
absolutely required for, EBNA1 replication, partitioning and transcriptional activation 
functions of EBNA1(Wu et al. 2002), with a Δ61-83 deletion of EBNA1residues having been 
demonstrated to lead to the elimination of transcriptional activation activity of EBNA1 (Wu 
et al. 2002). Δ41-376 EBNA1 is a gross mutant encompassing all other mutations within this 
EBNA1 mutant panel.  
To each EBNA1 mutant-encoding sequence, it was necessary to add specific restriction 
endonuclease sites to each end of the EBNA1 mutant sequence, allowing cloning into the 
expression vector pFC14K. This was achieved through PCR amplification of EBNA1 
fragments (shown in Figure 5.8) using specific primers which introduced a SgfI restriction 
site at the 5’ end of the EBNA1-encoding sequence, and a PmeI restriction site at the 3’ end 
of the EBNA1-encoding sequence. A schematic illustrating the workflow for the entire 
cloning procedure is shown in Figure 5.9, however variations from this procedure were 
necessary. Following PCR amplification of EBNA1 mutant sequences with specific 
restriction sites at 5’ and 3’ ends of the EBNA1 encoding sequence, despite considerable 
persistence, it was not possible to clone these products directly into the pFC14K vector 
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Figure 5.8 – PCR amplifications carried out with specific primers to introduce SgfI and PmlI 
restriction sites to products using a panel of EBNA1 mutants (ΔGly/Ala, Δ8-67, Δ61-83, 
Δ395-450, Δ41-376, Δ325-376) maintained on lentivirus backbones. Following optimisation 
of primer conditions (annealing temperature, extension time, etc.) successful amplification of 
the desired EBNA1 region was achieved (and is presented here). These PCR products 
possessed an SgfI binding site at the 5’ end of the EBNA1-encoding sequence, and a PmeI 
binding site at the 3’ end of the EBNA1-encoding sequence. Product sizes are given in 
brackets.  
 
Figure 5.9 – Schematic (adapted from http://www.promega.com/tbs/tm254/tm254.pdf ) 
illustrating the cloning workflow used to generate pFC14K-HaloΔEBNA1 mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
271 
 
Chapter 5 
 
 
 
 
 
Figures 5.8 and 5.9 
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following digestion with appropriate endonucleases. This failure was possibly due to 
incomplete restriction of EBNA1 mutant PCR products, with only very small overhangs each 
side of the restriction sites. To facilitate transfer to the terminal vector, EBNA1 mutants (with 
SgfI and PmeI sites) were cloned into an intermediary pCR8-TOPO vector (Invitrogen, UK) 
using a topoisomerase enzyme. Diagnostic cuts with EcoRI (Figure 5.10) were conducted to 
demonstrate successful insertion of EBNA1 mutant sequences into this vector. Each EBNA1 
mutant was subsequently fully sequenced in this vector, confirming that mutations had not 
been introduced in the PCR amplification step of cloning, and that SgfI and PmeI sites had 
been successfully installed at either end of the mutant sequence. Following PmeI and SgfI 
digestion of the pCR8-EBNA1 mutant constructs, each EBNA1-mutant insert was 
successfully cloned into the pFC14K expression vector (see Figure 5.11: plasmid map of 
pFC14K), in place of the lethal barnase gene between SgfI and EcoICRI sites (PmeI and 
EcoICRI both producing blunt ends), and in the same reading frame as the HaloTag protein, 
leading to expression of Halo-EBNA1 mutant proteins. These expression vectors were 
screened by diagnostic endonuclease digestion analysis (Figure 5.12), PCR for EBNA1 gene 
(Figure 5.13) and transient transfection of plasmid DNA into Ad/AH parental cells, to ensure 
expression of EBNA1 mutant fusion proteins (Figure 5.14).  Each Halo-EBNA1 mutant 
expression vector was analysed in this way although, for brevity, data are shown for only 
Halo-ΔGly/Ala-EBNA1. Figure 5.15 shows immunoblot analysis of expression of each Halo-
EBNA1 mutant protein following transient transfection of expression vectors into Ad/AH 
cells. HaloΔGly/Ala-EBNA1 shows very high levels of expression, with Halo-Δ395-450, -
Δ41-376 and –Δ325-376 showing similar, lower levels of expression. Expression of Halo-Δ8-
67 and –Δ61-83 is not observed, despite diagnostic endonuclease analysis and EBNA1 PCR 
analysis of plasmid DNA suggesting expression vector DNA should encode the desired 
proteins. Due to time constraints, further attempts to achieve expression of these mutants 
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Figure 5.10 – Diagnostic restriction digests of EBNA1 mutant PCR products in the pCR8 
vector. (A) ΔGly/Ala; (B) Δ 8-67, Δ61-83 and Δ325-376; (C) Δ395-450 and Δ41-376.  
Miniprep DNA was digested with EcoRI to excise the insert from pCR8 vector.  
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Figure 5.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
275 
 
Chapter 5 
Figure 5.11 – pFC14K plasmid map (can be accessed at http://www.promega.com/). TEV 
site refers to a TEV protease recognition sequence.  
Figure 5.12 – Diagnostic restriction digest of ΔGly/Ala-EBNA1 in the pFC14K vector 
(pFC14K-HaloΔGly/Ala-EBNA1). Miniprep DNA was digested with NcoI. Where the insert 
is present, 2 NcoI sites result in excision of a 665bp fragment. Where the insert is absent, the 
vector is linearised. 
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Figures 5.11 and 5.12 
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Figure 5.13 – PCR analysis using EBNA1 primers conducted using miniprep DNA 
(pFC14K-HaloΔGly/Ala-EBNA1). Presence of product demonstrates successful insertion of 
fragment into vector.  
Figure 5.14 – Immunoblot analysis of EBNA1 expression following transient expression of 
pFC14K-HaloΔGly/Ala-EBNA1 plasmid DNA in Ad/AH cells. A titration of expression 
vector DNA from 100ng to 2500ng was carried out. HaloTag-EBNA1 fusion protein is 
demonstrated to migrate at around 100kDa. Cell lysates were made 24 hours post-
transfection. Ad/AH-EBNA1 cell lysate is included as a positive control for EBNA1 
immunoblotting, and for comparison of protein size between wild-type EBNA1 and HaloTag-
EBNA1 fusion protein. 
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Figures 5.13 and 5.14 
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Figure 5.15 – Immunoblot analysis of EBNA1 expression following transient expression of 
pFC14K-HaloΔGly/Ala-, HaloΔ8-67-, HaloΔ395-450-, HaloΔ61-83-, HaloΔ41-376- and 
HaloΔ325-376-EBNA1 plasmid DNA in Ad/AH parental cells. Note lack of expression of 
HaloΔ8-67- and HaloΔ61-85-EBNA1. In each instance, cell lysates were prepared 24 hours 
post-transfection with 1µg expression vector plasmid DNA.  
Figure 5.16 – Diagnostic restriction digest (NotI digestion) confirming the insertion of 
oligonucleotide to put HaloTag in an open reading frame. The presence of a 1kb fragment 
illustrates oligonucleotide insertion, as the oligonucleotide possesses a NotI restriction site. 
The vector also possesses a single NotI site, and as such the plasmid would linearise if the 
oligonucleotide were not inserted.  
Figure 5.17 – Immunoblot analysis of HaloTag protein expression, following transient 
transfection of Ad/AH parental cells with HaloTag-only miniprep DNA to confirm HaloTag 
protein expression following oligonucleotide insertion. The HaloTag protein migrates at 
~32kDa. HaloEBNA1 transfected cell lysate is included as a positive control. 
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Figures 5.15-5.17 
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were abandoned, in favour of more extensive analysis of the successfully generated mutant 
panel. 
The panel of Halo-EBNA1 mutants used in subsequent experiments therefore consisted of 
Halo-ΔGly/Ala, -Δ395-450, -Δ41-376 and -Δ325-376 EBNA1. 
5.1.2.2 Construction and analysis of HaloTag  
An expression vector encoding just the HaloTag element of Halo-EBNA1 mutants was 
generated to as a control to ensure that data obtained from Halo-EBNA1 mutant experiments 
were attributable to the EBNA1-mutant element of fusion proteins, and not the HaloTag. 
Briefly, an oligonucleotide was designed and inserted upstream of the HaloTag encoding 
sequence in pFC14K vector, in order to put the HaloTag protein in an open reading frame. 
The oligonucleotide insert also contained a NotI restriction site to allow detection of its 
insertion by endonuclease digestion analysis (Figure 5.16). Subsequently, prospective 
HaloTag expression vectors were transiently expressed in Ad/AH cells, with cell lysates 
being screened for HaloTag expression by immunoblotting using an anti-HaloTag antibody 
(Figure 5.17). Following immunoblot analysis of HaloTag pull-down with HaloLink resin 
(Figure 5.18), HaloTag was transiently expressed in Ad/AH cells before cross-linked cell 
lysates from these cells were utilised in HaloCHIP experiments. PCR analysis of DNA from 
these experiments is shown in Figure 5.19, with no enrichment for ATF-2 or GAPDH 
promoter DNA apparent in samples where HaloTag was specifically pulled down. qPCR 
analysis of DNA showed no enrichment of GAPDH, ATF-2, c-myc or c-jun promoter region 
DNA from control to experimental samples (Figure 5.20) confirming that the HaloTag 
portion of the Halo-EBNA1 fusion protein panel did not interact with promoter region DNA 
analysed.  
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Figure 5.18 – Immunoblotting for HaloTag to confirm pull down of HaloTag protein by 
HaloLink resin. Ad/AH cells were transiently transfected with 1µg plasmid DNA before 
lysates were made 24 hours post transfection. The sample was then treated as a HaloCHIP 
sample before being mixed with loading buffer and immunoblotting analysis. ‘CON’ refers to 
samples to which blocking ligand was added (preventing covalent binding of HaloTag to 
HaloLink resin), and ‘EXP’ refers to samples to which blocking ligand was not added 
(allowing covalent binding of HaloTag to resin). 
Figure 5.19 – PCR analysis of GAPDH and ATF-2 promoter DNA performed on HaloLink 
resin-pulled down DNA from cross-linked cell lysates produced from Ad/AH cells transiently 
expressing HaloTag. ‘CON’ refers to samples to which blocking ligand was added, and 
‘EXP’ refers to samples to which blocking ligand was not added. Input represents 5% of 
sample taken post sonication of lysate.  
Figure 5.20 – qPCR analysis of GAPDH, c-jun, c-myc and ATF-2 promoter DNA performed 
on HaloLink resin-pulled down DNA from cross-linked cell lysates produced from Ad/AH 
cells transiently expressing HaloTag. Data are presented as fold increases from control 
(CON) to experimental (EXP) samples. All procedures were conducted in biological and 
technical triplicate, with average values presented. Error bars are representative of the 
standard deviations of biological replicates. 
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5.1.2.3 HaloChIP analysis of Halo-EBNA1 mutant panel 
Prior to HaloCHIP experiments using the Halo-EBNA1 mutant panel, functional validation of 
Halo-ΔGly/Ala-EBNA1 (pseudo-wild type) was conducted. Following transient expression of 
Halo-ΔGly/Ala-EBNA1 in Ad/AH cells, RT-PCR analysis of ATF-2 levels and AP-1 
luciferase reporter assays were conducted (Figure 5.21), revealing induction of ATF-2 
mRNA and AP-1 reporter activity upon expression of Halo-ΔGly/Ala-EBNA1. These 
findings confirmed the functional activity of Halo-ΔGly/Ala-EBNA1. Immunoblot analysis 
of HaloLink resin pull-down of each Halo-EBNA1 mutant fusion protein (Figure 5.22) was 
also conducted prior to HaloCHIP experiments demonstrating that equivalent levels of each 
Halo-EBNA1 mutant were pulled down by HaloLink resin under experimental conditions. 
Initial HaloCHIP experiments were conducted using Halo-ΔGly/Ala-EBNA1. PCR analysis 
of Halo-ΔGly/Ala-EBNA1-associated DNA (Figure 5.23) revealed substantial enrichment of 
ATF-2, c-myc and c-jun promoter region DNA in experimental samples (compared with 
control samples, where pull-down of Halo-ΔGly/Ala-EBNA1 was blocked). GAPDH 
promoter region DNA was included as a negative control, demonstrating experimental 
specificity of positive results. Enrichment for GAPDH promoter region DNA was not 
observed in experimental samples. These data did not provide any novel findings in terms of 
EBNA1 function, but are in agreement with results obtained using conventional ChIP 
analysis. 
PCR analysis of HaloCHIP experiments conducted using each Halo-EBNA1 mutant is shown 
in Figure 5.24. For each mutant, no enrichment of GAPDH promoter region DNA was 
observed. Enrichment of ATF-2, c-jun and c-myc promoter DNA was observed in 
experimental samples for Halo-ΔGly/Ala and Halo-Δ395-450 EBNA1 experiments, 
indicating that the Δ395-450 mutation does not affect EBNA1’s association with these 
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Figure 5.21 – Functional validation of HaloΔGly/Ala-EBNA1 in Ad/AH cells. Following 
transient transfection of Ad/AH cells with pFC14K-HaloΔGly/Ala-EBNA1: (A) RT-PCR 
was conducted analysing ATF-2 mRNA levels to confirm induction of ATF-2 transcription 
upon transient expression of 0.1µg and 0.5µg HaloΔGly/Ala-EBNA1 plasmid DNA. Levels 
of ATF-2 mRNA in Ad/AH-rEBV and Ad/AH-EBNA1 cells are included for comparison; 
(B) AP-1 dual luciferase reporter assays were conducted in Ad/AH cells transfected with 
empty vector control (pSG5) or HaloΔGly/Ala-EBNA1. Results are presented as a fold 
change in luminescence values from pSG5 control to HaloΔGly/Ala-EBNA1 samples.  
Figure 5.22 – Immunoblotting for EBNA1 to confirm that all mutant Halo-EBNA1 fusion 
proteins are successfully pulled down by HaloLink Resin. Ad/AH cells were transiently 
transfected with 1µg plasmid DNA (with exception of pFC14K-HaloΔGly/Ala-EBNA1, 
where 0.5µg was used) before lysates were made 24 hours post transfection. Samples were 
then treated as HaloCHIP samples before being mixed with loading buffer and 
immunoblotting was carried out. ‘CON’ refers to samples to which blocking ligand was 
added, and ‘EXP’ refers to samples to which blocking ligand was not added. 
Figure 5.23 – PCR analysis of HaloCHIP samples. HaloΔGlya/Ala-EBNA1 (0.5µg plasmid 
DNA transfected) was transiently expressed in Ad/AH cells which were cross-linked before 
harvest of lysates 24 hours post-transfection. PCR analysis was conducted using Halolink 
resin-pulled down DNA, with analysis of the promoter regions of GAPDH, ATF-2, c-myc 
and c-jun (as positive control) being conducted. Input sample is 5% of sample, taken post-
sonication. ‘CON’ refers to samples to which blocking ligand was added, and ‘EXP’ refers to 
samples to which blocking ligand was not added. 
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Figure 5.24 – PCR analysis of HaloCHIP samples. HaloΔGlya/Ala-EBNA1 (0.5µg plasmid 
DNA transfected) and HaloΔ395-450 EBNA1, HaloΔ41-376 EBNA1, HaloΔ325-376 
EBNA1 (1µg plasmid DNA transfected) were transiently expressed in Ad/AH cells which 
were cross-linked and harvested 24 hours post transfection. PCR analysis was conducted on 
Halolink resin-pulled down DNA for promoter regions of GAPDH, ATF-2, c-myc and c-jun 
(as positive control). Input sample is 5% of sample, taken post-sonication. ‘CON’ refers to 
samples to which blocking ligand was added, and ‘EXP’ refers to samples to which blocking 
ligand was not added. 
Figure 5.25 – qPCR analysis of HaloCHIP samples following transient expression of Halo-
EBNA1 mutants in Ad/AH cells (samples are as used in Figure 5.24). Data are presented as 
fold increases from control (CON) to experimental (EXP) samples. All procedures were 
conducted in biological and technical triplicate, with average values presented. Error bars 
represent the standard deviations of biological replicates. Asterisks (**) indicate that results 
are significantly different from the control (HaloTag only samples, figure 5.19), P≤0.01; § 
indicates that enrichment is significantly greater for this promoter region DNA than the 
observed enrichment for GAPDH promoter region DNA, P≤0.05. 
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Figures 5.24 and 5.25 
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promoter regions. In Halo-Δ41-376 experiments, no enrichment for promoter region DNA 
was observed, confirming that this gross deletion ablated EBNA1’s association with promoter 
region DNA. Halo-Δ325-376 EBNA1 experiments revealed no enrichment of c-jun and c-
myc promoter region DNA, although a slight enrichment of ATF-2 promoter DNA was 
observed. These data suggest that this region of EBNA1 is important for association with 
promoter regions of transcriptionally upregulated genes, although the slight enrichment of 
ATF-2 promoter region DNA suggests that other domains of EBNA1 may also be important 
in mediating the association of EBNA1 with this promoter region.  
qPCR analysis of HaloCHIP experiments was conducted, allowing accurate quantification of 
results and determination of the statistical significance of data (Figure 5.25). Experimental 
samples from Halo-ΔGly/Ala-EBNA1 experiments show substantial enrichment for ATF-2, 
c-jun and c-myc promoter region DNA. Levels of enrichment were significantly different 
(statistically) from enrichment for GAPDH promoter DNA, and from enrichment for 
respective promoter region DNA in HaloTag experiments. Experimental samples from Halo-
Δ395-450 EBNA1 experiments also show substantial enrichment for ATF-2, c-jun and c-myc 
promoter region DNA with levels of enrichment for each promoter region being significantly 
different (statistically) from enrichments for respective promoter regions in HaloTag 
experiments. Levels of enrichment for ATF-2 and c-jun promoter region DNA were also 
statistically significantly greater than the level of GAPDH promoter region DNA enrichment 
seen in Halo-Δ395-450 experiments. Enrichment for ATF-2, c-jun and c-myc promoter 
region DNA in experimental samples from Halo-Δ41-376 and –Δ325-376 experiments did 
not differ significantly (statistically) from GAPDH promoter region DNA enrichments, or 
levels of enrichments for respective promoter region DNA in HaloTag experiments. qPCR 
data obtained were consistent with previously described PCR analysis, providing compelling 
support for the findings based on PCR analysis. 
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5.1.2.4 Analysis of pol III transcription factor promoters 
Following confirmation of conventional ChIP results in HaloCHIP experiments and analysis 
of Halo-EBNA1 mutants, HaloCHIP assays were used to analyse a larger variety of promoter 
region DNA targets. Having previously demonstrated EBNA1-mediated induction of TFIIIC 
subunits (Chapter 4), possible EBNA1 association with promoter regions of these subunits 
was analysed, along with EBNA1 association with the promoter regions of other pol III-
related genes. 
After relevant primer design and optimisation, analysis of TFIIIC and TFIIIB subunit 
promoter region DNA was conducted in Ad/AH cells using HaloCHIP experiments 
performed following Halo-ΔGly/Ala-EBNA1 expression. Enrichment of TFIIIC-220, -110, -
102, and -90 promoter region DNA was observed in experimental samples, compared with 
control samples, indicating an association between EBNA1 and these promoter regions, 
although no apparent enrichment of TFIIIC-63 promoter region DNA (Figure 5.26) was 
observed. This is consistent with the previous finding that TFIIIC-63 was unique amongst the 
TFIIIC subunit genes in not responding to EBNA1 in Ad/AH cells. PCR analysis (using the 
same sample sets) of the promoter region DNA of TFIIIB subunits Brf1, Bdp1 and TBP 
revealed no enrichment in experimental samples (Figure 5.27), suggesting that EBNA1 does 
not associate with the promoter regions of these genes. 
DNA for several cellular pol III-transcribed genes with internal promoter regions (5S rRNA, 
7SL RNA and tRNAtyr) was not enriched in experimental samples from Halo-ΔGly/Ala-
EBNA1 experiments (Figure 5.28), indicating that EBNA1 is not present at these regions in 
vivo. As 7SL RNA has a hybrid promoter with an upstream promoter region in addition to an 
internal region, analysis of upstream promoter region DNA was also conducted, with no 
enrichment observed in experimental samples from Halo-ΔGly/Ala-EBNA1 experiments. 
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Figure 5.26 – PCR analysis of HaloΔGly/Ala-EBNA1 HaloCHIP samples in Ad/AH cells 
(samples are as used in Figure 5.24). The analysis was conducted for promoter region DNA 
of TFIIIC subunits TFIIIC-220, -110, -102, -90, -63 with GAPDH shown as negative control. 
Input sample is 5% of sample, taken post-sonication. ‘CON’ refers to samples to which 
blocking ligand was added, and ‘EXP’ refers to samples to which blocking ligand was not 
added. 
Figure 5.27 – PCR analysis of HaloΔGly/Ala-EBNA1 HaloCHIP samples in Ad/AH cells 
(samples are as used in Figure 5.24). The analysis was conducted for promoter region DNA 
of TFIIIB subunits Brf1, Bdp1 and TBP with GAPDH shown as negative control. Input 
sample is 5% of sample, taken post-sonication. ‘CON’ refers to samples to which blocking 
ligand was added, and ‘EXP’ refers to samples to which blocking ligand was not added. 
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Figures 5.26 and 5.27 
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Figure 5.28 - PCR analysis of HaloΔGly/Ala-EBNA1 HaloCHIP samples in Ad/AH cells 
(samples are as used in Figure 5.24). Analysis conducted for 5S rRNA, 7SL RNA, and 
tRNAtyr internal promoter DNA along with 7SL RNA upstream promoter region DNA with 
GAPDH shown as negative control. Input sample is 5% of sample, taken post-sonication. 
‘CON’ refers to samples to which blocking ligand was added, and ‘EXP’ refers to samples to 
which blocking ligand was not added.  
Figure 5.29 - PCR analysis of HaloCHIP samples in AGS and Hone-1 cells. HaloΔGly/Ala-
EBNA1 (0.5µg plasmid DNA transfected) was transiently expressed in AGS and Hone-1 
cells which were cross-linked and harvested 24 hours post transfection. PCR analysis was 
conducted on Halolink resin-pulled down DNA for promoter regions of GAPDH and ATF-2. 
Input sample is 5% of sample, taken post-sonication. ‘CON’ refers to samples to which 
blocking ligand was added, and ‘EXP’ refers to samples to which blocking ligand was not 
added. 
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Combined, these data indicate that EBNA1 is present at the promoters of TFIIIC subunits 
upregulated in EBNA1-expressing epithelial cells, though it is absent from the promoter 
regions of cellular pol III-transcribed genes, or pol III-specific transcription factor subunits 
which are not upregulated in Ad/AH-EBNA1 cells. This analysis supports the hypothesis that 
EBNA1 can have a selective effect on expression of TFIIIC, and that this may be responsible 
(at least in part) for the increase in expression of endogenous pol III products that is induced 
by EBV. 
5.1.2.5 HaloCHIP promoter binding analysis in AGS and Hone-1 cells 
As all EBNA1 promoter binding studies thus far were conducted in Ad/AH cells, it was 
important to expand these studies to additional epithelial carcinoma cell models. The Halo-
ΔGly/Ala-EBNA1 expression vector was transiently transfected into AGS and Hone-1 cells 
before HaloCHIP experiments were conducted and subsequent analysis of resultant DNA. 
PCR analysis (Figure 5.29) revealed no enrichment of GAPDH promoter region DNA 
(demonstrating experimental specificity in these cell lines) and modest enrichment of ATF-2 
promoter region DNA. qPCR analysis allowed the quantification of these data, and direct 
comparison with results reported in Ad/AH cells. Figure 5.30 shows enrichment of ATF-2, c-
jun and c-myc promoter region DNA in Ad/AH, AGS and Hone-1 cells, though levels of 
enrichment seen in AGS and Hone-1 cells are noticeably lower than those in Ad/AH cells. 
However, levels of enrichment for these promoter regions were significantly greater 
(statistically) than enrichment levels for GAPDH promoter region DNA in respective cell 
lines, confirming the presence of Halo-ΔGly/Ala-EBNA1 at the promoter regions of cellular 
genes upregulated in EBNA1-expressing epithelial cells.   
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Figure 5.30 - qPCR analysis of HaloCHIP samples following transient expression of 
HaloΔGly/Ala-EBNA1 in Ad/AH, AGS and Hone-1 cells (samples as used in Figure 5.29). 
Analysis was conducted for promoter region DNA of GAPDH, ATF-2, c-myc and c-jun 
genes. Asterisks indicate that enrichment for promoter DNA differs significantly from the 
enrichment of GAPDH promoter DNA for the same sample: *, P≤0.05; **, P≤0.01. 
Figure 5.31 – Immunoblot analysis of immunoprecipitation using chEBNA1 and E-Cadherin 
(isotype control) antibodies in Ad/AH-rEBV and Ad/AH-EBNA1 cells. Immunoblotting was 
conducted for EBNA1 to confirm precipitation of EBNA1, and for ATF-2 to identify possible 
EBNA1-ATF-2 interactions. In addition to immunoprecipitated samples, also included are 
Ad/AH-rEBV and Ad/AH-EBNA1 cell lysates as positive controls, and input samples (5%), 
taken following pre-clearing of lysates.  
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5.1.3 Mechanism of EBNA1 promoter binding 
Although ChIP and HaloCHIP experiments were successful in establishing an association 
between EBNA1 and the promoter regions of various transcriptionally upregulated genes, 
such experiments did not determine the nature of the interaction between EBNA1 and 
promoter region DNA. Given the pleiotropic nature of EBNA1 function, it was possible that 
EBNA1 could bind directly to DNA sequences, or that EBNA1 was interacting with other 
transcription factors present at the promoters of genes, thereby interacting indirectly with 
promoter region DNA. Sequence homology analysis of EBNA1-associated promoter regions 
revealed no significant regions of homology, suggesting that EBNA1 may be acting 
indirectly. Consistent with this, no known EBNA1 binding sites were identified in the 
promoter regions that were analysed.  
To investigate possible protein-protein interactions between EBNA1 and cellular 
transcription factors, immunoprecipitation experiments were conducted, alongside equivalent 
experiments using Halo-ΔGlya/Ala-EBNA1. Figure 5.31 reveals a possible interaction 
between EBNA1 and ATF-2, although reciprocal immunoprecipitation experiments (using 
ATF-2 antibody in the immunoprecipitation) followed by immunblotting for EBNA1 were 
not successful in confirming the interaction. However when Halo-ΔGly/Ala-EBNA1 pull-
down experiments were conducted (Figure 5.32A), along with a clear interaction between 
Halo-ΔGly/Ala-EBNA1 and USP7 (known to interact with EBNA1), an interaction between 
Halo-ΔGly/Ala-EBNA1 and ATF-2 was apparent. Such interactions between HaloTag and 
USP7 and ATF-2 were not detected (Figure 5.32B). These data suggest that EBNA1 does 
indeed interact with cellular transcription factor ATF-2, and such an interaction may be 
responsible, in some instances, for EBNA1-association with promoter regions of upregulated 
genes.  
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Figure 5.32 – Immunblot analysis of HaloLink resin-pull downs in Ad/AH cells transiently 
transfected with 5µg pFC14 K-HaloΔGly/Ala-EBNA1 (A), or 5µg pFC14K-HaloTag (B). 
Immunoblotting is conducted for ATF-2, USP7 and EBNA1. Input sample is 5% of sample, 
taken prior to HaloLink resin-pull down. ‘CON’ refers to samples to which blocking ligand 
was added, and ‘EXP’ refers to samples to which blocking ligand was not added.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
300 
 
Chapter 5 
 
 
Figure 5.32 
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5.2 Discussion 
5.2.1 ChIP analysis 
EBNA1 has previously been shown to bind to multiple sites within the human genome 
(Dresang et al. 2009) and is also known to have transcriptional regulatory properties on the 
viral Cp, Qp and LMP1 promoters (Sugden and Warren 1989; Sample et al. 1992; Gahn and 
Sugden 1995), leading to the hypothesis that EBNA1 may be associating with the promoter 
regions of genes transcriptionally induced in EBNA1-expressing cells. ChIP analysis 
provided significant mechanistic insight into EBNA1’s induction of typical pol II, EBER-
associated cellular transcription factors. Association of EBNA1 with promoter region DNA 
of both ATF-2 and c-myc (Figures 5.5 and 5.7B) was demonstrated, suggesting that EBNA1 
may be influencing EBER expression by acting directly to transcriptionally induce EBER-
associated transcription factors through association with their promoter regions.  
It is noted that promoter occupancy by EBNA1 does not necessarily directly correlate with 
the magnitude of the resulting changes in gene expression. For example, levels of ATF-2 
promoter DNA enrichment were three-fold greater than levels of c-Myc promoter DNA 
enrichment (Figure 5.7B), but corresponding variation in the magnitude of changes in gene 
expression were not observed (Chapter 4).  
The AP-1 transcription factor (a dimer comprised of members of the Jun, Fos and ATF 
families) regulates a wide variety of cellular processes, including cell growth, death and 
survival, and differentiation (Shaulian and Karin 2002). AP-1 is often activated in a variety of 
viral infections (Tyler et al. 2001; Ludwig et al. 2003; Panteva et al. 2003) including EBV 
infection (Kieser et al. 1997; Eliopoulos and Young 1998). ChIP analysis revealed that 
EBNA1 was present at the promoters of at least two AP-1 subunit genes c-jun and ATF-2, 
two AP-1 subunits for which mRNA levels are induced in EBNA1-expressing epithelial cells 
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(O'Neil et al. 2008). It is proposed that this promoter binding is the mechanism by which 
EBNA1 enhances the transcription of these two AP-1 subunits, resulting in the elevated AP-1 
activity reported in Ad/AH cells (O'Neil et al. 2008). This finding is significant given the 
variety of cellular processes in which AP-1 is involved (Shaulian and Karin 2002), and that 
AP-1 is implicated in a wide range of cancers where it impacts upon these tightly regulated 
processes and can therefore contribute to cellular transformation (Hess et al. 2004). As ChIP 
analysis revealed that JunB, JunD and FosB promoter DNA was not statistically significantly 
enriched in EBNA1-expressing cells (though there was a non-significant (statistically) four-
fold enrichment of FosB promoter region DNA) it was considered that the regulation of these 
subunits was not mediated by EBNA1 promoter binding. 
 
Controls included in ChIP experiments afford high levels of confidence in the specificity of 
results obtained. The lack of enrichment for GAPDH promoter region DNA confirmed that 
non-specific enrichment of DNA due to experimental techniques or reagents did not occur, 
and high levels of enrichment for EBV DS DNA confirmed that DNA known to be bound by 
EBNA1 in vivo (Reisman et al. 1985; Gahn and Schildkraut 1989; Wysokenski and Yates 
1989; Niller et al. 1995) was precipitated under experimental conditions. It is interesting to 
note that levels of enrichment of promoter region DNA were similar in Ad/AH-rEBV and 
Ad/AH-EBNA1 samples (Figure 5.5, and qPCR data, not shown). Ad/AH-EBNA1 cells 
express much higher levels of EBNA1 than Ad/AH-rEBV cells (Figure 5.2) and these data 
suggest that overexpression of EBNA1 in Ad/AH cells does not increase the extent of 
association with promoter regions. 
qPCR analysis of samples allowed accurate quantification of results, and increased 
sensitivity. Levels of enrichment for ATF-2 and c-myc promoter DNA appear similar when 
analysed by PCR (Figure 5.5), however upon quantitative analysis by qPCR, a three-fold 
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difference in levels of enrichment was observed. Similarly quantitative analysis of samples 
revealed enrichment for EBV DS DNA to be much greater than enrichment for any cellular 
promoter regions. These data suggest either a greater affinity of EBNA1 for EBV DS DNA, 
or differing modes of action for EBNA1 association with viral and cellular DNA.  
Experimental analysis following this thesis should also include exploration of the possibility 
that EBNA1 may directly interact with promoters of the EBER genes. Such analysis is yet to 
be conducted, due to the proximity of OriP (to which EBNA1 is known to bind) to the EBER 
genes. However, the Ad/AH-Puro-EBERs cell system established in this thesis (Chapter 4) 
could be utilised, along with transient or stable expression of EBNA1, to enable ChIP 
analysis of the EBER promoters in assessment of a possible EBNA1 interaction. 
5.2.2 HaloCHIP analysis 
To elucidate the nature of EBNA1’s interaction with cellular promoter region DNA and to 
map the domain(s) of EBNA1 involved in such interactions, it was necessary to employ a 
panel of EBNA1 mutants in promoter binding studies. Use of traditional ChIP assays was not 
suitable, given varying degrees of affinity of EBNA1 antibodies for different EBNA1 mutant 
proteins. The use of HaloTag-EBNA1 fusion proteins overcame this problem, enabling 
specific pull-down of EBNA1 mutants through covalent binding of the HaloTag to HaloLink 
resin. Not only did the use of tagged EBNA1 mutant fusion proteins allow analysis of the 
nature of previously established EBNA1 interactions with promoter region DNA in Ad/AH 
cells, the transient, non antibody-dependent nature of the experimental system facilitated 
analysis of EBNA1 promoter binding in several epithelial cell lines, and expansion of the 
range of target promoter region DNA that could be analysed.  
Initial HaloCHIP experimental analysis centred on repetition of the results of standard ChIP 
assays using the Halo-ΔGly/Ala construct, termed pseudo wild-type as deletion of the 
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Gly/Ala repeat region of EBNA1 does not affect the DNA segregation, replication or 
transcriptional activation activities of EBNA1 (Yates et al. 1985). Consistent with this, Halo-
ΔGly/Ala-EBNA1 showed functional similarity to EBNA1 in Ad/AH cells (Figure 5.21). 
HaloCHIP experiments showing enrichment for ATF-2, c-jun and c-myc promoter region 
DNA (Figures 5.23, 5.24 and 5.25) confirmed results obtained using standard ChIP methods, 
and although these data provided no additional insight into EBNA1 and its regulation of 
EBER expression, they afforded confidence in the reliability of subsequent HaloCHIP data. 
Analysis of Halo-Δ395-450 EBNA1 HaloCHIP experiments revealed enrichments (that were 
statistically significant) similar to those observed in pseudo wild-type vector experiments 
(Figures 5.24 and 5.25) , confirming that the 395-450 region of EBNA1 is not required for 
association of EBNA1 with the promoter region DNA examined. This result is consistent 
with previous work, demonstrating Δ395-450 EBNA1 to be fully functional for all known 
functions of EBNA,1 with the exception of binding cellular protein USP7 (Holowaty et al. 
2003) . Slight reductions in enrichment of c-myc promoter and c-jun promoter region DNA 
(in comparision to Halo-ΔGly/Ala-EBNA1 experiments) are attributed to conformational 
changes of EBNA1 associated with deletion of a region of protein. 
Deletion of residues 41-376 of EBNA1 removes all functional regions of EBNA1, with the 
exception of the nuclear localisation signal (NLS) and the DNA binding and dimerisation 
domain. Despite the presence of the NLS, nuclear localisation of Δ41-376 EBNA1 mutant 
has been shown to be severely reduced (Wu et al. 2002). Given this large deletion of 
functional EBNA1 regions, it was not surprising that promoter binding of Halo-Δ41-376 
EBNA1 was not observed following PCR and qPCR analysis of HaloCHIP experiments 
(Figures 5.24 and 5.25). These data, along with Tag only experiments (Figures 5.19 and 5.20) 
confirm that the EBNA1 section of fusion proteins, and not the HaloTag, is responsible for 
association with promoter region DNA in experiments where enrichment was observed. 
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Perhaps the most significant findings of Halo-EBNA1 mutant promoter binding experiments 
came from use of the Halo-Δ325-376 EBNA1 construct. PCR and qPCR analysis of DNA 
from these experiments revealed no enrichment for promoter region DNA of c-myc and c-jun 
genes, and only a slight (and not statistically significant) enrichment of ATF-2 promoter 
region DNA. Previously this deleted region of EBNA1 has been shown to be necessary for 
both transcriptional and chromosome segregation functions of EBNA1 (Kirchmaier and 
Sugden 1997; Shire et al. 1999; Ceccarelli and Frappier 2000; Wu et al. 2000; Wu et al. 
2002), adding credence to the findings reported in this study. Data presented suggest that in 
this system, the Gly-Arg-rich sequence between amino acids 325 and 376 is necessary for the 
EBNA1 association with promoter region DNA of transcriptionally induced genes. The slight 
enrichment for ATF-2 promoter region DNA contrasts with the lack of enrichment for other 
promoter region DNA, and hints at possible variation in EBNA1’s mode of action in its 
association with promoter regions. 
Given these findings it would be valuable to expand the panel of Halo-EBNA1 mutants used 
in this study. Initial steps of the cloning procedure to allow analysis of Δ8-67 and Δ61-83 
tagged EBNA1 mutants were successful (Figure 5.8), however upon transient expression of 
these vectors, Halo-Δ8-67 and –Δ61-83 EBNA1 were not detectable by immunoblotting 
(Figure 5.15). This could be due to lack of antibody recognition of the fusion proteins, 
although previous studies (using a different anti-EBNA1 antibody) were able to detect Δ8-67 
and Δ61-83 EBNA1 mutants by immunoblotting, despite a reduction in expression levels of 
EBNA1 following these deletions (Wu et al. 2002).  
Previous data (Wu et al. 2002) indicate that various EBNA1 functions have overlapping yet 
differing sequence requirements, with transcriptional activity dependent on residues 61 to 83 
and 325 to 376, and being stimulated by residues 8 to 67. Partitioning requires residues 325 to 
376 and is stimulated by residues 8 to 67, with replication involving redundant contributions 
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of both the 325 to 376, and 8 to 67 regions. As such, future analysis of the contribution of 
residues 6 to 67, and 61 to 83, to the association of EBNA1 with promoter region DNA of 
transcriptionally induced genes could prove significant.  
 
HaloCHIP experiments afforded expansion of promoter binding studies, resulting in analysis 
of EBNA1 binding to a greater number of, and greater variety of, promoter regions of 
induced genes. Most notably, mechanistic analysis of the EBNA1-mediated induction of 
TFIIIC subunits and cellular pol III transcription (as reported in Chapter 4) was enabled. In 
findings similar to those observed for EBER-associated pol II cellular transcription factors 
ATF-2 and c-Myc, induction of TFIIIC subunits in EBNA1-expressing epithelial cells was 
accompanied by a clear association of EBNA1 with the promoter region DNA of these genes 
(Figure 5.26). Interestingly, promoter region DNA of each of the four TFIIIC subunits 
induced in Ad/AH-EBNA1 cells was enriched, whilst there was no enrichment of TFIIIC-63 
promoter region DNA, TFIIIC-63 being the single TFIIIC subunit which was not found to be 
induced in Ad/AH-EBNA1 cells. These data seemingly reveal a clear correlation between 
EBNA1 promoter binding and transcriptional induction of (EBER-associated) genes. Further, 
no enrichment of TFIIIB subunit promoter region DNA was observed (Figure 5.27). These 
pol III specific transcription factor subunits were not consistently induced in EBNA1-
expressing epithelial cells. Such data build upon the evidence presented in Chapter 4, 
suggesting that EBNA1 can have a selective effect on the expression of TFIIIC. Enrichment 
of cellular pol III-transcribed genes 5S rRNA, tRNATyr and 7SL RNA (with internal promoter 
regions) was not observed, nor was enrichment of the upstream promoter region of 7SL RNA 
(Figure 5.28). These data suggest that EBNA1 enhances cellular pol III transcription through 
selective induction of TFIIIC subunits (through interaction with their promoter regions) 
rather than a direct association with pol III-transcribed genes. Whether induction of the pol 
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III-transcribed EBERs is also through such an indirect mechanism, is yet to be determined. 
Analysis of EBNA1-association with EBER genes would be valuable in establishing if a 
direct interaction of EBNA1 with the EBER genes occurs. EBNA1 is known to associate with 
the EBV genome proximal to the EBER genes by binding of OriP, with a proximal OriP 
region having been demonstrated to enhance EBER expression (Wensing et al. 2001). 
 
Promoter binding studies were expanded to two more epithelial cell lines (Figures 5.29 and 
5.30), revealing statistically significant enrichments of ATF-2, c-myc and c-jun promoter 
region DNA in AGS and Hone-1 cells transfected with Halo-ΔGly/Ala-EBNA1. However, 
levels of enrichment were notably lower in AGS and Hone-1 cells, compared with Ad/AH 
cells, suggesting either differences in experimental efficacy or varying EBNA1 function in 
individual epithelial cell lines. Nevertheless, results obtained in Ad/AH cells were replicable 
in the additional epithelial cell lines analysed, affording confidence that other promoter 
binding data obtained in Ad/AH cells is applicable to a range of cell lineages. That c-myc 
promoter region DNA was enriched in HaloCHIP experiments conducted in AGS and Hone-1 
cells is a surprising result, given the apparent lack of transcriptional induction of c-myc in 
EBNA1-expressing AGS and Hone-1 cells (Figure 4.21). However, although statistically 
significant, levels of enrichment were only around half of those observed in Ad/AH cells 
(Figure 5.30). Further, previous studies have indicated that promoter occupancy by EBNA1 
does not necessarily lead to induction of gene transcription (Dresang et al. 2009).  It would be 
valuable to expand the analysis of TFIIIC promoter binding by EBNA1 to AGS and Hone-1 
cells, and examine whether a correlation existed in these cell lines between transcriptional 
induction of TFIIIC subunits and enrichment of promoter region DNA, as was observed in 
Ad/AH cells. Further, HaloCHIP analysis of the Halo-EBNA1 mutant panel across several 
epithelial cell lines would allow comparative analysis of EBNA1’s mechanism of association 
with promoter regions in differing cell backgrounds. 
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In HaloCHIP experiments, levels of enrichment of promoter region DNA observed were 
often notably smaller than enrichment levels seen in conventional ChIP assays, especially for 
ATF-2 promoter region DNA (Figures 5.7 and 5.25). Levels of enrichment for differing 
promoter regions were more consistent in HaloCHIP experiments than ChIP assays, albeit 
generally at a lower level. This apparent reduction in enrichment levels may be attributable to 
several factors. Firstly, HaloCHIP experiments were carried out following transient 
expression of vectors, rather than in cell lines stably expressing EBNA1. Secondly, EBNA1-
fusion proteins, by their very nature, were altered and possessed a 5’ HaloTag. Although the 
HaloTag was shown not to be responsible for any interactions of the Halo-EBNA1 proteins 
(Figure 5.20) with promoter region DNA, it is possible that the HaloTag may have interfered 
(physically) with, and had a detrimental effect upon, EBNA1 promoter binding. It is also 
noted that even the pseudo-wild type Halo-EBNA1 (ΔGly/Ala) was not a complete EBNA1-
fusion protein. Although previously shown not to affect EBNA1 function (Yates et al. 1985), 
it is possible that deletion of this region may change EBNA1 protein conformation in a 
manner detrimental to the novel promoter binding abilities reported here.  
 
5.2.3 Mechanism of EBNA1 promoter binding 
 
The presence of EBNA1 at promoters of genes induced in EBNA1-expressing cells affords a 
potential mechanistic insight into EBNA1’s mode of action in enhancing expression of the 
EBERs. The nature of the interaction between EBNA1 and upregulated genes is, at present, 
undetermined. However lack of sequence homology, and the absence of any known EBNA1 
DNA binding motifs (Baer et al. 1984; Ambinder et al. 1990; Kirchmaier and Sugden 1998; 
Dresang et al. 2009) in promoters with which EBNA1 association is shown suggests that 
direct binding of EBNA1 to promoter region DNA of induced genes is unlikely. Further, 
EBV DS DNA (a region to which EBNA1 is known to bind directly in vivo (Reisman et al. 
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1985; Gahn and Schildkraut 1989; Wysokenski and Yates 1989; Niller et al. 1995)) was 
enriched to a substantially greater extent than cellular promoter region DNA assayed, 
suggesting that EBNA1’s mode of action in association with these regions of cellular DNA 
may vary from its DNA binding activity which enables direct binding to EBV DS region. It 
was therefore tempting to speculate that EBNA1’s interaction with these regions may be 
more indirect, possibly through protein-protein interactions with other transcription factors 
and to investigate this possibility, immunprecipitations using chEBNA1 antibody (previously 
used in ChIP assays) were conducted, prior to immunoblotting for two selected cellular 
transcription factors, ATF-2 and c-Jun. These transcription factors were screened for an 
association with EBNA1 given their transcriptional induction in EBNA1-expressing cells and 
the self-regulatory nature of their transcription (Vlahopoulos et al. 2008). Additionally, AP-1 
reporter activity is increased in EBNA1-expressing cells (Figure 5.21B, (O'Neil et al. 2008)), 
a phenomenon that  in theory could be mediated, in part at least, by an interaction with 
EBNA1. Furthermore, in silico analysis revealed that each cellular transcription factor, 
reported (in Chapter 4) to be induced in EBNA1-expressing epithelial cells, contains at least 
one putative AP-1 binding site upstream of it transcriptional start site. Although no 
interaction between EBNA1 and c-Jun was detectable (data not shown), a possible interaction 
between EBNA1 and ATF-2 was identified (Figure 5.31), and despite reciprocal 
immunoprecipitation experiments proving unsuccessful, Halo-EBNA1-fusion protein pull-
down experiments (Figure 5.32) confirmed the possible interaction between EBNA1 and 
ATF-2. Such data provide no evidence to support the hypothesis that any interaction between 
EBNA1 and ATF-2 occurs at the site of transcriptional activity of these proteins, however 
increased levels of nuclear ATF-2 in EBNA1-expressing cells (Figure 4.20) and the nuclear 
localisation of EBNA1 suggest that any direct interaction between these two proteins would 
be likely to occur in the nucleus. Analysis of a possible Halo-Δ325-376 EBNA1:ATF2 
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interaction could provide mechanistic insight into EBNA1’s presence at the promoters of 
transcriptionally induced genes. If such an interaction was not identified, this would provide 
evidence that interaction of this Gly-Arg-rich region of EBNA1 with ATF-2 may be 
responsible for the reported association with promoter region DNA, given the lack of 
enrichment for promoter region DNA seen in HaloCHIP experiments conducted with this 
EBNA1 mutant fusion protein (Figure 5.25).  
The concept of viral proteins interacting with cellular promoter region DNA through 
cooperation with cellular transcription factors, leading to changes in cellular transcription, 
has precedence. As described in the introduction to this chapter, proteins from HPV (Kurg et 
al. 2005), HTLV-1 (Basbous et al. 2003; Thebault et al. 2004; Matsumoto et al. 2005) and 
Adenoviruses (Boyd et al. 2002; Green et al. 2008) amongst others, are known to influence 
cellular transcription in such a manner. As such, although the hypothesis proposed here, that 
EBNA1 interacts with promoter region DNA of transcriptionally induced genes through 
interaction with cellular transcription factors, is in need of more supporting evidence, the data 
presented (in conjunction with the previous reports of viral proteins influencing cellular 
transcription in this manner) suggest that EBNA1 interacts with cellular promoter region 
DNA through interacting with cellular transcription factors. Further, given the specific 
association of EBNA1 with the promoter regions of genes induced in EBNA1-expressing 
cells, these interactions are suggested to influence cellular gene expression. EBNA1 then, 
seemingly acts to induce expression of EBERs through association with cellular promoter 
region DNA, thus influencing cellular factors connected with EBER transcription.     
 
 Final Discussion and Future Work 
 
 
 
 
 
 
 
 
Chapter 6 
 
Final Discussion and Future 
Work 
 
 
 
 
 
 
 
 
 
 
 
 
 
312 
 
 Final Discussion and Future Work 
Chapter 6 - General Discussion and Future Work 
 
EBER1 and EBER2 are detected in all forms of EBV latency and are often used as a 
diagnostic marker for cellular infection by the virus. Although the EBERs are not required for 
the transformation of resting B-cells by EBV, they have been demonstrated to increase the 
efficiency of transformation by around 100-fold (Yajima et al. 2005). Further, expression of 
the EBERs is sufficient to maintain the tumourigenic potential of the EBV-associated B-cell 
malignancy from which the virus was first isolated, BL (Komano et al. 1999). The EBERs are 
abundantly transcribed by pol III in latently infected cells, with up to 107 copies of the 
EBERs present in each cell (Lerner et al. 1981; Arrand and Rymo 1982; Nanbo and Takada 
2002).  
Although classically a B-lymphotropic virus, EBV has the capacity to enter epithelial cells 
and shows a strong association with a number of epithelial malignancies. These malignancies 
include undifferentiated NPC, which shows a 100% association with EBV infection. The 
EBERs are frequently detected in the neoplastic cells of NPC together with EBNA1, LMP2A, 
LMP2B, the BARTs and variable levels of LMP1 although, in contrast to B-cells where the 
role of the EBERs is fairly well defined, the precise role of EBERs in epithelium and NPC 
tumourigenesis remains to be elucidated. However, high levels of EBER expression have 
been demonstrated to be crucial for oncogenic activity of EBERs in epithelial cells, with 
previously published data suggesting that high, but not low, levels of EBER expression could 
cause MDCK cells to form colonies in soft agar (Yoshizaki et al. 2007). The aim of this 
thesis was, therefore, to further elucidate the mechanisms by which EBV is able to achieve 
the high levels of EBER expression that are required for oncogenic activity in epithelial cells. 
Given that EBV is maintained in epithelial and B-cells in a multi-copy episomal form, 
Chapter 3 explored the possibility that high levels of EBER expression were attributable to a 
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high copy number of the EBER genes. The hypothesis that EBV genomic copy number 
variation is directly responsible for fluctuations in levels of EBER expression between 
various cell lines was explored, with analysis conducted to establish if the expression of the 
EBERs increases monotonically with the average genome copy number across a panel of 
LCLs. Previous data, derived from plasmid-based experiments (Komano et al. 1999) and 
small-scale studies assessing the rate of EBER transcription in LCLs with varying copy 
number (Metzenberg 1989), had suggested that such a monotonic increase in levels of EBER 
expression with corresponding increases in average EBV genomic copy number may occur. 
However, the data presented provide convincing evidence that across the panel of LCLs 
analysed, no correlation between levels of EBER expression and average EBV genomic copy 
number was demonstrable. To confirm and expand upon these findings, it would be pertinent 
to conduct similar analysis across not only an extended panel of B-cells derived from several 
malignant backgrounds, but also across a panel of epithelial cells. Further, it would be 
interesting to extend the work of Metzenberg, analysing the rate of EBER transcription across 
a much larger panel of cells with varying copy number. Other pertinent experiments might 
assess the rate of EBER degradation across various cell lines to establish the consistency of 
this possible variable.  
The findings presented in Chapter 3 are consistent with previous observations which suggest 
that the abundant expression of EBER genes requires EBV-induced changes to the cellular 
environment, and with previous studies suggesting a strong influence of trans-acting factors 
in controlling the transcription of the EBERs. Indeed, EBV-induced changes to the cellular 
environment that contribute to achieving high levels of EBER expression have recently been 
identified and described (Felton-Edkins et al. 2006). The possibility of EBV latent gene 
products influencing EBER expression has previously been suggested, not least because 
following B lymphocyte infection by EBV, the EBERs are temporally the last latent gene 
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product to be expressed (Rooney et al. 1989; Alfieri et al. 1991). Given that EBNA1 is 
expressed in all forms of viral latency (and is detectable in the vast majority of EBV-
associated malignancies) and has previously been suggested to induce the transcription of 
EBER-associated cellular transcription factors ATF-2 and TFIIIC102 (Wood et al. 2007; 
O'Neil et al. 2008), the hypothesis that EBNA1 is able to influence cellular factors involved 
in the regulation of EBER expression was tested in Chapter 4. Several transcription factors, 
typical of pol II and pol III transcription, were found to be transcriptionally induced in 
EBNA1-expressing cells, seemingly confirming the hypothesis that EBNA1, at least in part, 
is responsible for mediating EBV-induced changes to the cellular environment that are 
conducive to high levels of EBER expression (Figure 6.1).  
The EBER-associated cellular transcription factors shown to be induced by EBV-infection in 
this study have also been demonstrated to be induced by several other oncogenic viruses in 
disparate other studies, which are outlined in the introductory Chapter of this thesis. Given 
the variety of evolutionarily distinct viruses that are capable of influencing these cellular 
factors, it is likely that this influence confers a selective advantage to virus survival and/or 
replication. This raises the possibility that the increase in cellular pol III activity and 
induction of cellular transcription factors observed in EBV-positive and EBNA1-expressing 
cells has been selected for during the course of EBV evolution, rather than merely being a 
consequence of enhancing EBER expression. That pol III activation is a common response to 
the infection of cells by DNA tumour viruses, irrespective of whether such activation is 
required for viral gene expression (although activation is required for EBV expression of the 
EBERs, and adenovirus expression of VA RNAs), supports the idea that this activation has a 
selective benefit. Recent studies, which suggest that cellular pol III products including tRNA 
and 5S rRNA are needed in abundance for cells to grow and proliferate, concur with this 
notion (Johnson et al. 2008; Marshall and White 2008). However, the divergence and variety  
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Figure 6.1 – Simplified schematic summarizing findings of thesis chapters 4 and 5. EBNA1 
is proposed to indirectly (possibly through protein:protein interactions with cellular 
transcription factors (TF)) interact with the promoter regions of c-myc, ATF-2 and TFIIIC 
genes in epithelial cells. This interaction has been demonstrated to be mediated by residues 
325-376 of EBNA1 (not represented diagrammatically). The interaction of EBNA1 with 
promoter regions is proposed to enhance gene transcription, leading to increased levels of the 
EBER-associated cellular transcription factors c-myc, ATF-2 and TFIIIC. These transcription 
factors are known to interact with specific regulatory regions both upstream and downstream 
of the transcriptional start sites of EBER1 and EBER2, and have been demonstrated to be of 
significance in allowing high levels of EBER expression to occur. It is proposed that by 
enhancing levels of these EBER-associated cellular transcription factors, EBNA1 is able to 
increase levels of EBER expression. Further, EBNA1 may be directly interacting with the 
EBER genes, though this analysis was not carried out in this body of work.  
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of EBER-associated cellular transcription factors demonstrated to be induced by EBNA1 in 
Chapter 4 support the concept that EBV has specifically evolved multiple mechanisms to 
ensure abundant expression of the EBERs, and that the selective advantages produced may 
only have occurred as side-effects, albeit side-effects which are highly beneficial to virus 
survival.  
Although general pol III-mediated transcription was demonstrated to be elevated in EBNA1-
expressing cells, and EBNA1 was shown specifically to induce TFIIIC subunits in a range of 
cell lines, EBNA1’s inability to induce levels of TFIIIB subunits, which are known to be 
over-expressed in NPC tumours (Dr JR. Arrand, personal communication), and limiting for 
transcription from type 2 pol III promoters (similar to EBER promoter regions), leaves the 
model of EBNA1’s precise mode of action incomplete. Previous data have also revealed an 
individual TFIIIB subunit, Bdp1, to be induced in EBV-infected cells and limiting for pol III 
transcription (Felton-Edkins et al. 2006), a result at odds with the apparent lack of induction 
in EBNA1-expressing cells presented in Chapter 4. However, although very well 
characterised in the yeast Saccharomyces cerevisiae, the full picture of the multiple levels of 
regulation of pol III transcription is in the process of being fully defined in mammalian cells. 
For instance, in S. cerevisiae, Maf1 is an essential mediator of pol III repression in response 
to starvation and it has recently been shown that a Maf1 orthologue is also used to restrain 
pol III activity in mouse and human cells (Goodfellow et al. 2008). This study also revealed 
Maf1 to interact with pol III and associated transcription factor TFIIIB in mammalian cells, 
and, as in yeast, Maf1 was demonstrated to be phosphorylated in a serum-sensitive manner in 
vivo. This conservation of activity between yeast and mammals suggests a fundamental 
importance for the role of Maf1 in controlling pol III transcriptional activity. Given its role in 
regulation of TFIIIB, and the lack of increase in subunits of TFIIB in EBNA1-expressing 
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cells (despite an overall increase in levels of cellular pol III transcription), it is conceivable 
that EBNA1 may be acting on pol III activity through intermediaries such as Maf1.  
Also presented in Chapter 4 are data revealing that EBNA1 acts to increase the transcriptional 
activation activity of c-Myc, despite a reduction in levels of c-Myc protein in EBNA1-
expressing cells. These data hint at another possible method of EBNA1 acting to increase pol 
III transcription through an intermediary cellular factor, as c-Myc is known to directly 
activate pol III transcription (Oskarsson and Trumpp 2005). Indeed, endogenous c-Myc 
interacts with tRNA and 5S rRNA genes in vivo, and forms a stable association with 
endogenous TFIIIB (Felton-Edkins et al. 2003; Gomez-Roman et al. 2003). Moreover, 
scanning ChIP assays suggest that c-Myc co-localises with TFIIIB in the vicinity of 
transcriptional start sites, and has been demonstrated to recruit cellular cofactors TRRAP and 
GCN5 to tRNA and 5S rRNA genes leading to an increased gene occupancy by TFIIIB in 
response to c-Myc activity followed by recruitment of pol III (Kenneth et al. 2007). Such data 
provide possible mechanisms by which EBNA1 may be able to enhance the activity of 
TFIIIB to activate pol III transcription without inducing the expression of TFIIIB subunits, 
although it must be noted that c-Myc is not recruited to pol III genes by binding to E-box 
sites, and this recruitment forms the basis of the c-Myc transcriptional activation data in 
Chapter 4. Further, TFIIIB levels are known to be increased in tumours, suggesting that 
EBNA1 is only in part responsible for the increases seen in cellular pol III transcription in 
EBV-infected cells.  
Nevertheless, EBNA1 is seemingly capable of overcoming the lack of TFIIIB induction, 
given the increase in transcription of cellular pol III transcripts and the EBERs in EBNA1-
expressing cells. Other cellular regulators of pol III transcription are PTEN, which represses 
pol III activity by targeting TFIIIB (Woiwode et al. 2008), and p53, which inhibits pol III 
transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB (Crighton et al. 
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2003). It is conceivable that EBNA1 may be able to reduce the inhibitory action of such 
cellular proteins on TFIIIB activity to compensate of the lack of induction of TFIIIB 
subunits, and studies of the effect of EBNA1 expression upon other cellular factors involved 
in the regulation of pol III transcription could prove significant.  
Other interesting future analyses that may elucidate the extent of EBV and EBNA1 
involvement in the regulation of pol III transcription, and the significance of this involvement 
in tumourigenesis, might include investigation of a possible role of EBV and EBNA1 in post-
transcriptional regulation of pol III products. For example, the RNA methyltransferase Misu 
(NSUN2), which is a c-Myc target gene, has been demonstrated to methylate pol III products, 
and by doing so mediates Myc-induced cell proliferation and growth (Frye and Watt 2006). 
Given its upregulation in tumours, Misu would be another possible target gene for EBV and 
EBNA1-mediated oncogenesis, especially given Misu’s status as a c-Myc target gene. The 
significance of Misu in regulating c-Myc-mediated cell cycle progression was confirmed 
recently, upon publication of data which suggest that via Misu, c-Myc promotes proliferation 
by stabilising the mitotic spindle in fast-dividing cells (Hussain et al. 2009).  
The data presented in Chapter 5 offer a mechanistic insight into EBNA1’s mode of action in 
inducing EBER-associated cellular transcription factors. Speculatively, it seems that EBNA1 
is acting not through direct DNA-binding, but by interacting with other transcription factors 
present at promoter regions, possibly including ATF-2. Confirmation of this precise mode of 
action is essential in future studies, as is elucidation of a full range of transcription factors 
that associate with EBNA1, assuming that EBNA1 is interacting with promoter region DNA 
indirectly in this manner. To this end, ChIP-on-CHIP studies would be useful, not only in 
determining the possible broad range of cellular targets which EBNA1 may influence through 
interacting with promoter regions, but also in elucidating common themes in such promoter 
regions which may provide hints as to which transcription factors EBNA1 may be acting 
320 
 
 Final Discussion and Future Work 
through. A recently published study has carried out such ChIP-CHIP analysis on EBNA1 in 
an LCL (Dresang et al. 2009). The study identified 247 promoters in the human genome to be 
candidates for EBNA1 binding, although only 2 of these promoters contained the previously 
defined (Ambinder et al. 1990) EBNA1 DNA-binding sequence. Dresang and co-workers 
therefore generated a new EBNA1 DNA-binding consensus with increased degeneracy and 
found 54 of the 247 candidate promoters to contain this new degenerate sequence. However, 
EMSA analysis using an EBNA1 protein derivative of a subset of the 193 promoters not 
containing any consensus revealed a shift in all promoters tested, suggesting direct binding of 
DNA by EBNA1 whether a DNA-binding site for EBNA1 was predicted or not. However, 
the authors found that EBNA1 did not alter the expression of a reporter gene placed 
downstream of tested cellular promoters to which it binds, although the authors note that it is 
not clear if these data accurately reflect the ability of EBNA1 to regulate genes. Interestingly, 
the genes reported to be associated with the 247 candidate promoters identified (Dresang et 
al. 2009, supplementary information) do not include any identified in this thesis. However it 
should be noted that the ChIP analysis was conducted using B-cell nuclear lysates (rather 
than epithelial cell whole cell lysates) and was carried out using a different EBNA1 antibody.  
Promoter regions found to be associated with EBNA1 in this thesis do not contain an EBNA1 
binding site, either the EBNA1 binding motif previously detailed (Ambinder et al. 1990), or 
the degenerate consensus proposed by Dresang and co-workers. Future ChIP-CHIP analysis 
under conditions used in this thesis would provide an interesting comparison with the 
analysis recently reported (Dresang et al. 2009), which does not seem to consider the 
possibility of EBNA1 acting upon promoter regions in an indirect manner.  
 Previous similar studies have been performed in analysis of other DNA tumour virus gene 
products. Notably, this year Sung and co-workers have been successful in identifying 
deregulated targets of the Hepatitis B virus (HBV) X protein through chip-based chromatin 
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immunoprecipitation (ChIP-CHIP) in combination with expression microarray profiling. 184 
gene targets were identified as being directly deregulated by HBV X protein, and 144 
transcription factors interacting with HBV X protein were computationally inferred, before 
experimental validation was conducted confirming that HBV X protein interacts with a 
selection of the predicted transcription factors and the promoters of the deregulated target 
genes of these transcription factors (Sung et al. 2009). A similar study to identify deregulated 
targets of EBNA1 could serve to confirm the findings presented here, identify more EBNA1 
cellular targets, and uncover cellular transcription factors with which EBNA1 interacts to 
exert its cellular influence. 
Experimental analysis following on from this thesis could also include exploration of the 
possibility that EBNA1 may directly interact with promoters of the EBER genes. Such 
analysis is yet to be conducted, possibly due to the proximity of OriP (to which EBNA1 is 
known to bind) to the EBER genes. However, the Ad/AH-Puro-EBERs cell system 
established in this thesis could be utilised, along with transient or stable expression of 
EBNA1, to enable ChIP analysis of the EBER promoters in assessment of a possible EBNA1 
interaction. It would also be valuable to assess the expression of a wider range of cellular pol 
III transcripts in EBNA1-expressing cells, as although EBV was previously demonstrated to 
induce the expression of a variety of endogenous pol III transcripts, no type 3 promoter 
products previously examined (U6, 7SK, and MRP RNA) showed evidence of induction 
(Felton-Edkins et al. 2006). Analysis of such transcripts in EBNA1-expressing cells would 
allow determination of the selectivity of the stimulatory effect of EBNA1 on pol III-
transcribed genes. As pol III-transcribed genes with type 3 promoters do not require TFIIIC 
for recruitment of the transcription complex (Schramm and Hernandez 2002), it is speculated 
that the expression of such transcripts would not be enhanced in EBNA1-expressing cells.  
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In summary, data presented in this thesis have shed new light onto the mechanisms of the 
regulation of EBER expression, which allow the EBERs to be expressed in such abundance. 
Data have confirmed that EBV-infection induces a change in the cellular environment, with 
the latent gene product EBNA1 acting at the promoters of cellular factors involved in EBER-
expression to induce a cellular environment conducive to expression of the EBERs. Many of 
the cellular factors influenced by EBNA1 have oncogenic potential, increasing the 
significance of the findings presented beyond that of enhanced expression of virus-encoded 
oncogenic RNAs. As such, the data contribute to the growing weight of evidence that 
suggests that EBNA1 plays a role in EBV-mediated tumourigenesis.  
Further, recently published data have suggested that the EBER promoters are able to drive the 
expression of shRNA fusion transcripts, with siRNAs processed from these fusion transcripts 
specifically and effectively able to inhibit expression of homologous reporter or endogenous 
genes in various types of cells (Choy et al. 2008). These findings suggest that the EBER 
promoters may be effective in driving the intracellular expression of shRNAs for effective 
silencing of target genes in mammalian cells and particularly, in EBV-infected cells. If such 
techniques are to be employed in the future, the data presented in this thesis would provide 
valuable insight into the regulation of EBER promoters, and may prove valuable in allowing 
maximum efficacy of possible therapeutic shRNAs.  
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